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	Summary	
Oxygen is a key molecule for aerobic life. Eukaryotes have evolved towards an aerobic 
metabolism which has allowed them to adapt to a plethora of environments and to develop into 
multicellular systems. The proper distribution of oxygen inside the organism is vital for tissue 
function and its decreased availability, termed hypoxia, can compromise the survival of the 
organism. Cells, tissues and organs have developed a series of molecular responses in order to adapt 
to hypoxia.  
Mitochondria are the main oxygen consumers in most eukaryotic cells and also a major 
source of production of reactive oxygen species (ROS) that can be used by the cells to trigger redox 
cell signaling processes. There has been a long debate on whether cells respond to hypoxia by 
increasing ROS production and their involvement in different responses to hypoxia. Since 
superoxide anion is the first ROS formed from oxygen reduction by the mitochondrial electron 
transport chain (ETC), we have focused on its specific detection in acute hypoxia. We have 
observed that superoxide anion production by the mitochondria is increased in the first minutes of 
hypoxia and that it decreases thereafter, reaching basal levels before one hour of hypoxia, what we 
have called a hypoxic superoxide ‘burst’. In order to dissect the mechanism triggering this response, 
we have studied the role of different mitochondrial ETC complexes and ion transporters in the 
production of the hypoxic superoxide burst. We observe that complex I, complex III and the 
mitochondrial sodium/calcium exchanger (NCLX) are necessary for hypoxic ROS production, and 
that there could be a chain of events among them. Mitochondrial complex I (CI) undergoes 
‘deactivation’ in acute hypoxia; this was inversely proportional to the oxygen concentration and 
could switch its activity to a sodium/proton antiporter. CI deactivation is necessary for the 
enhancement of mitochondrial sodium/calcium exchange through NCLX, which in turn promoted 
depolarization of the mitochondrial inner membrane. Mitochondrial sodium/calcium exchange is 
necessary for superoxide production in which complex III would be involved, although the exact 
source of superoxide has not been determined.  
We have been able to observe the implication of NCLX in a variety of experimental 
settings, in which NCLX inhibition alter different responses to hypoxia, such as activation of the 
HIF pathway and hypoxic pulmonary vasoconstriction. We have assessed that this mechanism 
operates also in neurons and brain tissue and that treatment with a NCLX inhibitor diminishes cell 
death in a model of stroke, probably by reducing oxidative damage. These results open a new 
window in mitochondrial redox biology research due to the involvement of complex I deactivation 
and NCLX in superoxide production, which could also have therapeutic implications. 
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Resumen	
El oxígeno es una molécula clave para la vida aeróbica. Los organismos eucariotas han 
evolucionado hacia un metabolismo aeróbico que les ha permitido adaptarse a una plétora de 
ambientes y desarrollarse como sistemas multicelulares. La adecuada distribución del oxígeno 
dentro del organismo es vital para la función tisular y la disminución de sus disponibilidad, 
denominada hipoxia, puede comprometer la supervivencia del organismo. Las células, los tejidos y 
los órganos han desarrollado una serie de respuestas moleculares que permiten su adaptación a la 
hipoxia. 
Las mitocondrias son los principales consumidores de oxígeno en muchas células 
eucariotas y son también una de las principales fuentes de producción de especies reactivas de 
oxígeno (ROS) que pueden usar las células para promover procesos de señalización celular redox. 
Se ha generado un prolongado debate sobre si las células responden a la hipoxia incrementando la 
producción de ROS y su implicación en las diferentes respuestas a la hipoxia. Dado que el anión 
superóxido es la primera ROS formada a partir de la reducción del oxígeno por la cadena de 
transporte electrónico (ETC) mitocondrial, nos hemos centrado en su detección específica en 
hipoxia aguda. Hemos observado que se incrementa la producción de anión superóxido en las 
mitocondrias en los primeros minutos de hipoxia, disminuyendo posteriormente hasta llegar a 
niveles basales antes de una hora de hipoxia, lo que hemos llamado un ‘estallido’ de superóxido en 
hipoxia. Para diseccionar el mecanismo que desencadena esta respuesta, hemos estudiado el papel 
de distintos complejos de la ETC y trasportadores mitocondriales de iones. Observamos que el 
complejo I, el complejo III y el intercambiador sodio/calcio mitocondrial (NCLX) son necesarios 
para la producción de ROS en hipoxia, y que puede haber una cadena de eventos entre ellos. El 
complejo I (CI) mitocondrial se desactiva en hipoxia aguda, de manera inversamente proporcional a 
la concentración de oxígeno, y puede cambiar su actividad a la de antiportador sodio/protón. La 
desactivación de CI es necesaria para activar el intercambio sodio/calcio a través de NCLX, lo que 
a su vez promueve la despolarización de la membrana mitocondrial interna. El intercambio 
sodio/calcio en la mitocondria es necesario para la producción de superóxido, en lo que está 
implicado el complejo III, si bien al fuente exacta de superóxido no se ha determinado. 
Hemos podido observar la implicación de NCLX en una variedad de escenarios 
experimentales, en los que la inhibición de NCLX altera diferentes respuestas a la hipoxia, como la 
activación de la ruta de HIF y la vasoconstricción pulmonar hipóxica. Hemos comprobado que este 
mecanismo funciona también en neuronas y tejido cerebral, y que el tratamiento con un inhibidor 
de NCLX reduce la muerte celular en un modelo de ictus, probablemente disminuyendo el daño 
oxidativo. Estos resultados abren una nueva ventana en la biología redox mitocondrial debido a la 
implicación de la desactivación del complejo I y de NCLX en la producción de superóxido, l que 
puede tener también implicaciones terapéuticas. 
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1	Introduction	
1.1 Hypoxia 
Oxygen is vital for eukaryotic life. In animals the correct respiratory system function is 
coupled to the precise delivery of oxygen by the circulatory system to organs, tissues and cells. 
However, occasionally oxygen supply is inefficient what can lead to cellular dysfunction and, 
eventually to cell death. Hypoxaemia is caused by abnormally low levels of oxygen in blood, 
frequently caused by respiratory disorders. This situation, as well as other localized factors, can lead 
to reduced local oxygen availability for cells within a tissue, which is known as hypoxia.  
Hypoxia is present in many pathological situations. In cancer, the incorrect development of 
blood vessels into the solid body of the tumour creates hypoxic areas (Nagy et al., 2009). In 
ischemia an inappropriate blood flow through the vessels translates into lower oxygen supply 
(Reimer et al., 1977). Depending on the disorder and the tissue involved, the changes triggered by 
hypoxia in disease lead to cellular dysfunction or adaptation and, eventually to cell death or survival. 
However, there are physiological conditions where hypoxia is present and even necessary. In the 
course of embryo development there are situations where hypoxia is present and its role is crucial 
for the viability and correct maturation of tissues (Dunwoodie, 2009). Also, thymus is a hypoxic 
organ and thymocyte development and survival is linked to hypoxia (Hale et al., 2002). On the 
other hand, ventilatory response (i.e. due to increased physical activity) is modulated by sensing 
acute changes in oxygen concentration in blood by specialized organs such as the carotid body 
(Weir et al., 2005).  
1.1.1 Adaptation to hypoxia 
In response to hypoxia there are adaptations that can be exerted at the cellular, organ or 
organism level. This can be through long- or short-term mechanisms, depending on the cell type 
and the duration of hypoxia. 
Long-term adaptation to hypoxia in mammals is mainly mediated by the activation of the 
hypoxia inducible factors (HIFs), heterodimeric transcription factors composed of a constitutively 
expressed subunit (HIF-β, also called aryl hydrocarbon receptor nuclear translocator, ARNT), and 
an oxygen -dependent HIF-α subunit (Semenza, 2007). There are three homologs of HIF-α (HIF-1 
α, HIF-2α or EPAS-1, and HIF-3α), that are continuously degraded in normoxia through a 
mechanism mediated by a family of HIF prolyl hydroxylases (EGLNs or PHDs) which carry out an 
oxygen-dependent hydroxylation (Kaelin and Ratcliffe, 2008, Li et al., 2006, Schofield and Ratcliffe, 
2004, Chowdhury et al., 2016). Hydroxylation in specific Pro residues of the α subunit (e.g. Pro 402 
and 564 in HIF-1α) is necessary for its ubiquitination triggered by binding to the E3 ubiquitin ligase 
Von-Hippel Lindau protein (pVHL) and subsequent degradation by the 26S proteasome. EGLN 
activity becomes suppressed in hypoxia, inhibiting VHL-dependent ubiquitination and degradation, 
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in this way allowing HIF- stabilization (Maxwell et al., 1999). This subunit then heterodimerizes 
with HIF-β and translocates into the nucleus, where it interacts with coactivators such as  P300 and 
CBP which are required for binding to specific sequence features in the promoter region of the 
target genes, known as hypoxic response elements (HRE) (Freedman et al., 2002). Once the protein 
complex is bound to the HRE the hypoxic transcriptional programme starts, being able to induce 
more than 200 genes and to repress (by indirect mechanisms requiring other factors still under 
discovery) many other genes (Semenza, 2007, Kaelin and Ratcliffe, 2008). Hydroxylation of a 
specific Asn residue (e.g. Asn 803 in HIF-α) by the factor inhibiting HIF 1 (FIH-1), another 
oxygen-dependent reaction inhibited in hypoxia, impedes the interaction with P300 and 
transactivation of HIF transcriptional activity (Hewitson et al., 2002). The newly transcribed genes 
are related to metabolic adaptation to hypoxia which shift the metabolism from aerobic to 
anaerobic pathways (Tello et al., 2011, Fukuda et al., 2007, Soro-Arnaiz et al., 2016, Chen et al., 
2001). Angiogenesis is also induced to develop blood vessel through the hypoxic area and irrigate 
them (Fraisl et al., 2009, Carmeliet, 2005). Also, it modulates the coordinated removal of unneeded 
structures such as mitochondria in order to provide of energy and anabolites during oxygen 
deprivation and finally determining cell fate (Zhang et al., 2008), among other processes. 
Less known responses to long-term hypoxia involve the activity of iron response proteins 
(IRPs) in mammals. IRPs are RNA-binding proteins which bind to mRNA untranslated regions 
(UTRs) in which a specific sequence is present, the iron response element (IRE). The functional 
effect depends on the localization of the IRE (Rouault, 2006). In ferritin mRNA, IRP binding to 
the IRE in the 5’-UTR blocks its translation, while IRP binding to the IRE in the 3’ UTR of TfR1 
mRNA enhances its translation (Schneider and Leibold, 2003). IRP family is composed by two 
members, whose better known function is to regulate the transcription of a number of genes 
involved in the iron homeostasis. IRP1 is the cytosolic aconitase without enzymatic activity. In 
normoxia, IRP1 without the iron-sulphur cluster behaves as an mRNA-binding protein and in 
hypoxia its iron-sulphur cluster is recomposed, activating its aconitase activity by a yet unknown 
mechanism (Rouault, 2006). IRP2 is a structurally different protein that is ubiquitinated and 
degraded in normal conditions by the F-box/LRR-repeat protein 5 (FBXL5). FBXL5 is an 
hemerythrin-containing protein which senses oxygen and iron availability. Thus, in hypoxia or iron 
deprivation FBXL5 deactivates its IRP2-unbiquitinase function and ubiquitinates and targets itself 
to degradation, letting IRP2 to stabilize (Salahudeen et al., 2009, Vashisht et al., 2009). 
On the other hand, acute oxygen sensing involves the rapid adaptation of tissues and 
organisms to sudden decreases in oxygen availability. Specialized organs or tissues such as the 
carotid body, pulmonary arteries, ductus arteriosus, adrenal medulla or neuroepithelial bodies in the 
lung drive specific adaptations to acute hypoxia that have been long studied. The carotid body is a 
cluster of chemoreceptor and supporting cells located near the bifurcation of the carotid artery 
which are involved in oxygen sensing and hypoxia-related whole-body response. The 
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chemoreceptor cells or glomus cells are the sensing units. Hypoxia promotes the depolarization of 
these cells through the blockage of potassium currents. This depolarization allows the opening of 
voltage-gated calcium channels what causes the exocytosis of vesicles filled with neurotransmitters 
to sensory nerve fibres that activate the respiratory centre in the brain, driving hyperventilation 
(Weir et al., 2005, López-Barneo et al., 2016, López-Barneo et al., 2009, Lahiri et al., 2006). It has 
been recently shown that mitochondrial complex I is involved in the inhibition of the potassium 
currents through NADH or reactive oxygen species (ROS) signalling (Fernandez-Agüera et al., 
2015). Acute responses to hypoxia also occur in pulmonary arteries (PA), which contract upon 
hypoxia and let the blood to redistribute to more oxygenated areas of the lung. Smooth muscle cells 
are the cell type involved in oxygen sensing and contraction. Potassium channels are also blocked 
by hypoxia, causing depolarization and calcium entry via voltage-gated calcium channels, leading to 
vasoconstriction (Sweeney and Yuan, 2000, Weir and Olschewski, 2006). In this case, NADPH 
oxidases (NOXs) have been involved in the blockage of potassium currents (Frazziano et al., 2011), 
and NOXs activation is dominated by ceramide production through neutral sphingomyelinase 
(nSMase) (Cogolludo et al., 2009, Moreno et al., 2014a). Interestingly, mitochondria have been also 
involved in this pathway through the production of ROS which would activate nSMase in hypoxia, 
triggering the downstream signalling cascade (Moreno et al., 2014a). 
1.2 Reactive oxygen species (ROS) in physiology and disease 
1.2.1 ROS, definition and species 
Reactive oxygen species (ROS) are oxygen products which are produced through the 
incomplete reduction of oxygen. Superoxide anion is the ROS formed by a one-electron reduction 
of oxygen; its half-life is as short as 2x105 M-1s-1 (Kalyanaraman, 2013), what makes superoxide 
particularly difficult to detect (Kalyanaraman et al., 2017). It is not a powerful oxidant, and its effect 
on protein thiols is mainly limited to disruption of iron-sulfur clusters; in this regard, mitochondrial 
aconitase inactivation has been a classical hallmark of mitochondrial superoxide production 
(Fridovich, 1995, Gardner and Fridovich, 1991). Superoxide dismutates spontaneously or by the 
action of cytosolic or mitochondrial superoxide dismutases (Cu,Zn-SOD or Mn-SOD respectively) 
(Liochev and Fridovich, 2007), producing a reduced form, hydrogen peroxide, and an oxidized 
form, water. Hydrogen peroxide half-life is quite greater than that of its predecessor, 103-104 M-1s-1 
(Kalyanaraman, 2013), it can cross biological membranes and reversibly oxidize thiols within Cys 
residues in proteins (Izquierdo-Álvarez and Martínez-Ruiz, 2011, Bindoli et al., 2008). The latter 
capacity has been a useful tool for nature to design molecular sensors of hydrogen peroxide such as 
peroxiredoxins; likewise several laboratories have developed different fluorescent proteins capable 
of detecting hydrogen peroxide through reversible oxidation of critical, sensitive thiols in their 
structure (Belousov et al., 2006, Ermakova et al., 2014, Hanson et al., 2004, Germond et al., 2016). 
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All together, these features make hydrogen peroxide the most easily detectable ROS and the best 
known. A one-electron reduction of hydrogen peroxide forms hydroxyl radical, a reaction that can 
be catalysed by the oxidation of Fe2+ into Fe3+ in the so-called Fenton reaction (Kalyanaraman, 
2013). Hydroxyl radical is probably the most toxic ROS due to the initiation of radical chain 
reactions (Bokare and Choi, 2014). It is worth mentioning the very fast reaction of superoxide with 
nitric oxide to form peroxynitrite, with a rate comparable to that of diffusion, 4-6x109 M-1s-1 
(Kalyanaraman, 2013, Beckman and Koppenol, 1996). Although peroxynitrite is well known as an 
inducer of tyrosine nitration, it is a peroxide and as such it is a very effective two-electron oxidant 
of thiols and boronate-based probes. Also, it can modify iron-sulphur clusters (Keyer and Imlay, 
1997). 
1.2.2 Oxidative stress vs ROS signalling  
ROS have been long considered harmful species from which cells had to make up defences 
and indeed, many pathological scenarios involve the massive production of ROS. In this situation, 
cell components such as proteins, lipids and nucleic acids become oxidized, worsening the cell fate. 
Lipid oxidation is normally linked to malfunction of membrane-associated enzymes and generation 
of toxic species potentially interfering in signalling events (Stark, 2005). Nucleic acid oxidation 
readily occurs in guanine residues in comparison to the other bases which is converted into 8-
hydroxyguanine. This kind of stress is common in cancer disease since it can help transformation of 
the cell (Chao et al., 2013, Zheng et al., 2014). However, proteins under oxidative stress can be 
modified in several residues, such as Cys, Met or Tyr. Sulphonylation, methionine sulphoxidation 
and tyrosine nitration are the most common oxidative modifications in Cys, Met or Tyr residues 
when ROS production is exacerbated (Sies, 2015). These modifications can lead to malfunction of 
the protein, but in some cases they are involved in the development of cellular responses to 
oxidative stress. Oxidative stress has been involved in many diseases (Gorlach et al., 2015, Olmez 
and Ozyurt, 2012, Chandel and Tuveson, 2014, Surmeier et al., 2012, Chaturvedi and Flint Beal, 
2013). 
Lesser ROS amounts or time of production lead to signalling. The best known signalling 
ROS is hydrogen peroxide which has been related to many cellular pathways, such as laminar shear 
stress (Breton-Romero and Lamas, 2013, Breton-Romero and Lamas, 2014) or immune response 
(Lang et al., 2013, Hernansanz-Agustín et al., 2013). The capacity of this ROS to signal is 
performed by reversible thiol oxidation by which enzyme activity or protein function can be 
modulated (Martinez-Ruiz and Lamas, 2004, Izquierdo-Álvarez et al., 2012, Martinez-Ruiz et al., 
2013).  
Since ROS are constantly produced it is crucial for the cell to buffer them. In this way, 
there is a robust antioxidant system capable to quenching increases in ROS production. Redox 
homeostasis is based in the balance between production by ROS sources and buffering of ROS by 
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the antioxidant system. Indeed, variations in the level of antioxidant capacity can make a ROS 
signal harmful or ameliorate situations of oxidative stress which would normally be fateful (Nickel 
et al., 2015, Navarro et al., 2012). 
1.2.3 ROS sources 
There are many ROS sources in the cell, ranging from cytosolic to intermembrane enzymes 
or even captured into organelles. Its function and dysfunction is linked to physiological and 
pathological processes. 
NADPH oxidases (NOXs) are membrane-associated protein complexes which catalyse the 
oxidation of NADPH to NADP+ and produce ROS. There are seven members in its family (i.e. 
NOX1-5 and DuOX1-2) which produce superoxide with the exception of NOX4 which is a 
hydrogen peroxide generator (Breton-Romero and Lamas, 2013, Brown and Griendling, 2009, 
Lambeth, 2004, Nauseef, 2014). Phagosome-associated NOXs in macrophages and neutrophils 
activate in order to kill the phagocyted microorganisms, contributing to the immune response to 
infection (Lambeth, 2004). Plasma membrane NOXs are rather related to signalling, including 
among their targets protein kinase C (PKC) or every member of the mitogen activated protein 
kinases (MAPK) (Breton-Romero and Lamas, 2014, Brown and Griendling, 2009). NOX members 
such as NOX4 are linked to adaptive processes that are vital for endothelial function, such as the 
response to laminar shear stress (Sanchez-Gomez et al., 2015) and can also be found in the 
endoplasmic reticulum or the nucleus (Brown and Griendling, 2009). 
Xanthine oxidase is a cytosolic enzyme which catalyses the oxygen-dependent oxidation of 
hypoxanthine and xanthine into xanthine and uric acid, respectively (Ardan et al., 2004). As by-
product it produces hydrogen peroxide or superoxide (Galbusera et al., 2006), being the production 
of the latter associated with myocardial failure (Duncan et al., 2005, Stull et al., 2004, Kittleson and 
Hare, 2005). Xanthine and hypoxanthine are well known purine derivatives accumulating in 
ischemic conditions (Harmsen et al., 1981, Chouchani et al., 2014). Reappearance of oxygen in 
reperfusion promotes their rapid catalysis by xanthine oxidase what generates large amounts of 
ROS, contributing to cell death and tissue damage (Linas et al., 1990). 
A large family of monooxygenases metabolize a wide range of substrates, including 
steroids, lipids and xenobiotics (Holmstrom and Finkel, 2014). These heme-containing proteins 
must tightly control the oxygen transfer to the substrate, otherwise ROS can be produced (Zangar 
et al., 2004, Hrycay and Bandiera, 2015). High amounts of substrates, instability or functional or 
transcriptional regulation balance the production of ROS by this enzyme (Zangar et al., 2004). 
Cyclooxygenases (COX), lipoxygenases (LOX) and uncoupled nitric oxide synthases 
(NOS) are also ROS sources. COX is responsible for the conversion of free arachidonic acid into 
prostaglandin. However, it can also produce superoxide under stress, such as in brain injury 
(Kulkarni and Armstead, 2000). LOX catalyses the conversion of polyunsaturated fatty acids into 
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hydroperoxy fatty acids by the incorporation of an oxygen molecule (Glickman and Klinman, 
1996). It was reported that LOX produced superoxide in the presence of NADPH (Roy et al., 
1994) which was found a physiologically relevant source in skeletal muscle (Zuo et al., 2004). NOS 
catalyses the production of nitric oxide from L-arginine. Upon depletion of its cofactors or 
substrates, NOS can produce superoxide (Luo et al., 2014), although S-glutathionylation can also 
uncouple its activity and promote ROS production (Xia, 2007, Chen et al., 2010). 
Mitochondria are a well-known source of ROS and are considered the largest ROS 
producers. There are at least eleven ROS sources in the organelle (Brand, 2016) which are located 
in the mitochondrial matrix and the inner mitochondrial membrane (IMM). In the mitochondrial 
matrix 2-oxoglutarate dehydrogenase and pyruvate dehydrogenase reversibly catalyse the 
decarboxylation of 2-oxoglutarate and pyruvate into succinyl-CoA and acetyl-CoA, respectively. 
Both enzymes reduce NAD+ into NADH and produce carbon dioxide (CO2). Superoxide and 
hydrogen peroxide is produced by both the forward and reverse reactions, being the latter the main 
contributor (Ambrus et al., 2015). However, the main sources of superoxide in the mitochondria 
are in the electron transport chain (ETC). The ETC is the principal consumer of oxygen in the cell 
and a constant current of electrons flow through its complexes could derive in large production of 
ROS (see below). Therefore a tight coupling in the electron transfer between cofactors and 
complexes prevents it, probably through the formation of supercomplexes (Maranzana et al., 2013, 
Wu et al., 2016, Gu et al., 2016, Letts et al., 2016).  
1.2.4 ROS detection 
ROS are generally difficult to measure due to their short half-life and low specificity of the 
probes available. There exist several approaches to measure the different ROS in cellular and whole 
body systems. Well-known examples of low-specificity probes are dichlorofluorescein (DCF) and 
CellROX fluorescent probes. DCF has been widely used to measure ROS production in cell culture 
given its easy manipulation and useful excitation/emission spectra. However, it reacts with many 
substrates in the cell, ranging from NAD+ to nitric oxide or practically any ROS or RNS.  
To measure superoxide a well-known tool is the aconitase activity assay since iron-sulphur 
clusters are labile upon superoxide treatment (Missirlis et al., 2003, Outten, 2007). It can also 
discern between superoxide released to the mitochondrial matrix or to the cytosol, since there exist 
a cytosolic and mitochondrial isoforms of aconitase. Also, it can be assayed from in vivo samples. 
However, this activity can also be inhibited by peroxynitrite (Keyer and Imlay, 1997, Castro et al., 
1994), making this technique unspecific for superoxide detection. Currently, the most commonly 
used tool for its detection is the fluorescent probe dihidroethidium (DHE) which becomes 
fluorescent in a reaction with superoxide or by binding with nucleic acids. The specific product of 
DHE reaction with superoxide hidroxyethidium (2-OH-E) can be detected by fluorescent high 
performance liquid chromatography (HPLC), in which the 2-OH-E is separated from the DNA 
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oxidized form ehtidium (Eth), or by confocal microscopy since 2-OH-E has different spectral 
properties than 2-OH-E (Zielonka et al., 2009, Zhao et al., 2005). Although the exact chemistry of 
this reaction is not known, the specificity for superoxide detection is acknowledged. Furthermore, 
there exist mitochondrial targeted versions which allow the detection of superoxide in this 
organelle. The targeting of is performing by attaching the lipophilic cation triphenylphosphonium 
(TPP+) to the DHE molecule, rendering the mitochondrial version of DHE, Mito-HE (Robinson 
et al., 2006). Importantly, since TPP+ attraction to the mitochondria relies in its positive charge and 
its accumulation to the mitochondria in the mitochondrial membrane potential (ΔΨmt), changes in 
fluorescence could be due to differences in superoxide production or in ΔΨmt. Spin trap-based 
approaches have been also used to detect superoxide, however their specificity and low resolution 
early discarded this approach (Finkelstein et al., 1980). 
Hydrogen peroxide is the most studied ROS given its role in cell signalling. However, there 
are a few reliable tools to measure it. Fluorescent proteins such as Hyper or RhoGFP are 
ratiometric probes which base their sensitivity in specific Cys residues (Guzman et al., 2010, 
Belousov et al., 2006). In the presence of hydrogen peroxide these Cys residues become oxidized 
and promote a conformational change in the protein. This, in turn, translates into a shift the 
absorption spectra of the proteins. These proteins can be expressed in live tissues allowing in situ 
ROS detection in vivo and can also be targeted to any cell compartment (Guzman et al., 2010). 
However, since its detection properties are based on thiol oxidation, nitrosylation or other 
peroxides such as peroxynitrite can modulate the spectral properties of the proteins. Boronate, a 
group of organic compounds react with hydrogen peroxide and peroxynitrite, and this feature has 
been exploited to detect it. Boronate has been linked to a fluorescent moiety which is converted 
from a weakly fluorescent to strongly fluorescent product upon oxidation (Miller et al., 2005, 
Zielonka et al., 2012). Furthermore, boronate probes have also been used to detect mitochondrial 
hydrogen peroxide in vivo. A linked TPP+ moiety targets the arylboronate (i.e. MitoB) to the 
mitochondria. Accumulation of the probe and oxidation into its phenol product (i.e. MitoP) can be 
detected by mass spectrometry and then the ratio MitoB/MitoP be calculated (Cocheme et al., 
2012). In this case, the calculation of MitoB/MitoP avoids the possible ΔΨmt-dependent artefact. 
Peroxyredoxin is a hydrogen peroxide scavenger which has oxidizable Cys residues. Upon oxidation 
peroxyredoxin dimerizes through a disulphur bridge and only after re-reduction of the critical thiols 
becomes a monomer again (Riquier et al., 2014, Knoops et al., 2011). This can be easily detected 
and given its specificity and reversibility is becoming increasingly used to measure hydrogen 
peroxide levels. 
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1.3 Mitochondrial signalling 
1.3.1 Mitochondrial oxidative phosphorylation  
Mitochondria are cellular organelles present in all eukaryotes. They are large ellipsoidal 
organelles which are connected to each other forming a network inside the cell. They are composed 
of an outer mitochondrial membrane (OMM) and an inner mitochondrial membrane (IMM), the 
space between both membranes is the intermembrane space (IMS) and the area inside the IMM is 
the mitochondrial matrix. The IMM is folded  into the OMM forming crest-like structures called 
crista which are of vital importance for the correct function of the mitochondria (Cogliati et al., 
2013). The OMM lipid composition is similar to the rest of the membranes, being closer to the 
endoplasmic reticulum membranes. In contrast, the IMM can be considered a special type of 
membrane in the cell due to its high protein/lipid ratio which confers special properties to the 
organelle, such as osmoresistance, high impermeability to ions or large capacity to regulate the 
transport of molecules (E.A., 2014, Nelson and Cox, 2012, Comte et al., 1976). Mitochondria 
perform many tasks, ranging from cellular signalling to the production of reducing equivalents for 
the antioxidant defence or contribution to anabolic pathways (Hernansanz-Agustín et al., 2014, 
Quijano et al., 2016, Soro-Arnaiz et al., 2016). However, the main function of mitochondria is the 
production stable energy molecules through the electron transport chain (ETC).  
ETC use oxygen as the final electron acceptor, generating water and driving the production 
of the high-energy molecule ATP through oxidative phosphorylation (OXPHOS). The OXPHOS 
system is composed by mitochondrial complexes which couple the electron flow to the transport of 
proton ions across the mitochondrial inner membrane (complexes I-IV).  The resulting proton 
gradient generates an electrical and pH difference (mitochondrial membrane potential (ΔΨmt) and 
mitochondrial proton gradient (ΔpH) respectively) between the mitochondrial matrix and the IMS, 
whose combination composes the so-called proton motive force (Δµmt). The energy stored in Δµmt 
is used by the ATPase (complex V) to phosphorylate ADP in a gradient-favoured proton-
translocation step, producing ATP. The electrons needed for this process come mainly from the 
tricarboxylic acid (TCA) cycle in which reducing equivalents such as NADH and FADH2 are 
formed from substrates such as pyruvate, isocitrate, α-ketoglutarate or malate, and succinate, 
respectively. The OXPHOS is branched at the starting point since complex I or NADH-
ubiquinone oxidoreductase exclusively oxidizes NADH and complex II or succinate dehydrogenase 
performs only succinate oxidation. Complex I catalyses the oxidation of NADH at its flavin-
mononucleotide group (FMN) together with the reduction of ubiquinone to ubiquinol in its 
respective ubiquinone binding site (Q-site). The energy obtained in this reaction drives a series of 
conformational changes which translate into the translocation of four protons (Vinothkumar et al., 
2014, Sazanov, 2015, Hirst and Roessler, 2016, Fiedorczuk et al., 2016, Zickermann et al., 2015). 
NADH-ubiquinone oxidoreduction reaction is reversible and can reduce NAD+ through ubiquinol 
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oxidation and the pumping of four protons back into the mitochondrial matrix (Drose and Brandt, 
2012). The electron transfer and proton pumping is performed by 14 ‘core’ subunits of the complex 
which are conserved from bacteria to mammals (Vinothkumar et al., 2014, Letts et al., 2016). In 
mammals there are 30 ‘supernumerary’ subunits which account for assembly and function of 
complex I (Stroud et al., 2016). Importantly, complex I can exist in two catalytic distinct forms, an 
active state in which it behaves as a reversible oxidoreductase, and a deactive form which is 
characterised for being catalytically inactive, exposing the Cys 39 of its ND3 subunit and behaving 
as a sodium/proton antiporter (Grivennikova et al., 2003, Drose et al., 2016, Babot et al., 2014, 
Grivennikova et al., 2001, Grivennikova et al., 1997, Galkin et al., 2008, Galkin et al., 2009, Roberts 
and Hirst, 2012).  
Both complexes I and II reduce ubiquinone into ubiquinol which then transfers its two 
electrons to complex III or ubiquinol-cytochrome C oxidoreductase by means of the Q cycle. 
Complex III has two ubiquinone binding sites, Qo (i.e. outer) and Qi (i.e. inner). ubiquinol binds to 
the Qo site and donates one electron to Rieske iron-sulphur protein (RISP) which then reduces 
cytochrome c1 and subsequently cytochrome c. The second electron is used to reduce another 
ubiquinone through hemes bL and bH to form a semiquinone radical at the Qi site. A second cycle is 
needed to completely reduce the semiquinone to ubiquinol in the Qi site (Zhang et al., 1998, Crofts 
et al., 1999). Complex III pumps two proton for every cycle performed, moving a total of four 
protons into the IMS (Iwata et al., 1998, Xia et al., 1997, Crofts et al., 2006). Cytochrome c reduces 
complex IV or cytochrome c oxidase which finally reduces oxygen into water in a reaction coupled 
to the pumping of four protons (Sazanov, 2015). 
1.3.2 Mitochondrial cation gradients 
One important consequence of the ΔΨmt formation is the attraction of low molecular 
weight-positive charged ions. Therefore the IMM also contains channels and exchangers for ion 
management whose function is coupled to the OXPHOS engine (Nicholls, 2008). For example, the 
sodium/proton exchanger (NHE) extrudes sodium from the matrix into the intermembrane space, 
translocating proton back into the matrix (Donoso et al., 1992, Jung et al., 1992, Nicholls, 2010). 
This activity is exerted by the canonical mitochondrial NHE (mNHE), but also by the deactive 
form of mitochondrial complex I (Roberts and Hirst, 2012). This exchange is electroneutral, but 
decreases the ΔpHmt. Uptake of sodium into mitochondria is largely mediated by the mitochondrial 
sodium/calcium exchanger (mNCX), also known as NCLX (sodium/calcium/lithium exchanger) 
due to its sensitivity to lithium (Palty et al., 2010, Poburko and Demaurex, 2012, Murphy and 
Eisner, 2009). NCLX imports three sodium ions into the mitochondrial matrix in exchange for one 
calcium ions, thus generating electrical charge movement across the membrane, i.e. exerting 
electrogenic activity, since there is a net gain of positive charges in the mitochondrial matrix (Baysal 
et al., 1994, Cortassa et al., 2003, Dash and Beard, 2008, Jung et al., 1992, Kim and Matsuoka, 
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2008). Of note, it has been shown that the extrusion of mitochondrial calcium is mainly performed 
by NCLX versus other antiporters, such as Letm1 (see below) (Jiang et al., 2009). 
Calcium enters the mitochondria through the mitochondrial calcium uniporter (MCU) in a 
ΔΨmt-dependent manner (De Marchi et al., 2014, Baughman et al., 2011, Oxenoid et al., 2016). This 
has important implications since calcium is able increase the activity of several enzymes of the TCA 
cycle, such as 2-oxoglutarate dehydrogenase and its handling is coupled to OXPHOS function 
through ΔΨmt axis (Pan et al., 2013, Cox and Matlib, 1993). Calcium can also enter the 
mitochondria by an electrogenic exchange (1 calcium: 1 proton) (Poburko and Demaurex, 2012). 
This reversible activity was proposed to be carried out by the leucine zipper and EF-hand 
containing transmembrane protein (Letm1) which was also reported to be ruthenium red-sensitive 
(Jiang et al., 2009). However, it is still to be proven whether this observation better fits with a 
potassium/proton antiporter (Nowikovsky et al., 2004).  
Potassium movement across IMM is a rather slow process and has been shown to be 
performed by a potassium/proton exchanger (KHE) (Poburko and Demaurex, 2012, Bernardi, 
1999). KHE is mainly related to the maintenance of mitochondrial volume and becomes activated 
upon organelle swelling and mitochondrial matrix alkalinisation (Beavis and Garlid, 1990, Garlid, 
1980, Garlid and Paucek, 2003). 
It is important to note that there is scarce data about regulation of these channels and 
exchangers. Only the molecular identity of MCU and Letm1 has been discovered (De Marchi et al., 
2014, Baughman et al., 2011, Oxenoid et al., 2016). Only one essential protein of NCLX has been 
found so far and the identification of its complete composition remains obscure (Palty et al., 2010). 
There is no clue about what gene is encoding for NHE or KHE protein(s). In addition, the 
discovery of these is quite recent and there are not many studies relating their expression or 
regulation to physiological processes or pathophysiology. However, it is known that altered ion 
homeostasis occur in a bunch of disorders such as neurodegenerative diseases (Chan et al., 2007) 
ischemia (Tanonaka et al., 2012) or ischemia/reperfusion (Kalogeris et al., 2012). 
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Figure 1.1 Cation transporters and OXPHOS complexes in the mitochondrial inner membrane and 
their effect on ΔΨmt and ΔpHmt. OXPHOS complexes I, III and IV pump protons across the IMM 
increasing Δµmt. Cation transporters are grouped in blue. Mitochondrial calcium uniporter (MCU) allows 
calcium entry in the matrix, whereas it is extruded by NCLX in exchange of sodium in a ratio 1:3. 
Sodium/proton exchange by NHE can be performed by the canonical NHE (mNHE) or the deactive form 
of complex I. Potassium/proton antiporter (KHE) and NHE activities couple ion homeostasis to the 
activity of the ETC. 
1.3.3 Mitochondrial cation homeostasis in health and disease 
Mitochondrial cation regulation is important for cellular ion-dependent processes, such as 
regulation of action potentials or energy homeostasis. Cardiac pacemaker cells trigger their own 
action potential when a certain threshold is reached and do not need external stimulation, which is 
called automaticity. Cytosolic calcium, together with sodium and potassium oscillate which 
translates in membrane potential depolarization and repolarization cycles (Baruscotti et al., 2005). It 
was shown that HL-1 cardiomyocytes develop automaticity and that it could be modulated by 
NCLX, since inhibition of its expression translated in slower cycles (Takeuchi et al., 2013). In 
addition, TCA cycle enzymes activity such as 2-oxoglutarate dehydrogenase is enhanced by MCU-
dependent calcium uptake (Wan et al., 1989, Tarasov et al., 2012)and this activation is abolished by 
NCLX-dependent sodium influx (Cox and Matlib, 1993). Activation of TCA cycle turnover could 
be a key event in episodes of high energy requirement, such as increases in heart workload. 
Therefore, raise in cytosolic sodium concentrations could affect TCA cycle activation in physiology 
and disease. Importantly, beyond certain threshold mitochondrial calcium can promote the opening 
 22 
 
of the mitochondrial permeability transition pore (mPTP) (Wong et al., 2012, Bernardi and Di Lisa, 
2015). This reversible augmentation of the IMM permeability has been linked to dimerization of the 
complex V which would form the actual pore, turning its function from an energy conserving to an 
energy dissipating device (Giorgio et al., 2013, Bernardi and Di Lisa, 2015). Therefore, 
mitochondrial calcium homeostasis must be tightly controlled since variations in its mitochondrial 
concentration can change the cell fate from cell survival to death. 
Besides, the impact of sodium overload in mitochondrial-related dysfunctions has been 
widely studied in plants (Miller et al., 2010); however it is not the case of animals, despite it has 
been linked to several pathophysiological processes (Brocker et al., 2012). Cytosolic sodium burden 
can occur through environmental sodium overload or dysregulation of sodium channels. The best 
known hyperosmotic environment are inflammatory niches where osmotic stress has been linked to 
mitochondrial dysfunction and oxidative damage (Brocker et al., 2012). Of note, inflammatory areas 
become rapidly hypoxic and develop hypoxic adaptive response (Eltzschig and Carmeliet, 2011). 
Sodium overload is a hallmark of ischemic myocytes and it has been related to ischemic and 
ischemia/reperfusion injury (Tanonaka et al., 2012, Kohlhaas et al., 2010), in which mitochondria 
are directly involved (Chouchani et al., 2014, Chouchani et al., 2013). In addition, mutations in 
channels taking over sodium homeostasis are connected to neurological diseases whose pathology 
rely on mitochondrial function and its progression has been associated with hypoxic adaptation 
(Requejo-Aguilar et al., 2014). Therefore, sodium overload is a common signature of several 
diseases in which hypoxia is involved; however, how it alters mitochondrial function and hypoxic 
adaptation has not been studied, despite it has a potential big impact in diseases where sodium 
overload and hypoxia are present. 
1.3.4 Mitochondrial ROS production by the ETC 
As by-products of the incomplete reduction of oxygen a series of ROS are formed from 
during respiration (Turrens, 2003, Murphy, 2009). Superoxide can be produced by OXPHOS at the 
level of the first three complexes of the system. Complex III-dependent superoxide production 
relies on high ΔΨmt and can be inhibited by Qo blockers such as myxothiazol or stigmatellin, but 
not by Qi blockers such as antimycin A (Drose and Brandt, 2012). This is most probably because 
superoxide production by complex III is based on semiquinone radical formation, since inhibition 
of Qi would render a free semiquinone per every oxidized ubiquinol, whereas inhibition of Qo 
would keep the ubiquinone fully reduced (Bleier and Drose, 2013, Lanciano et al., 2013). In the 
presence of the complex II substrate succinate and the inhibitors rotenone and myxothiazol 
(complex I and III respectively), superoxide formation by complex II can be detected (Drose, 
2013). However, the major superoxide producer in the mitochondria is complex I and can produce 
superoxide both by forward or reverse reactions. The elder is only possible when Q-site inhibitors 
of complex I, such as rotenone, are applied in the presence of NADH (Drose and Brandt, 2012). 
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Whether superoxide is produced at the FMN or at the Q-site was a matter of debate, but later 
shown to occur at the FMN after full reduction of the iron-sulphur clusters in hydrophilic arm of 
complex I (Pryde and Hirst, 2011, Treberg et al., 2011, Drose and Brandt, 2012). The reverse 
electron transport (RET) occurs only in the exclusive presence of succinate which is necessary to 
create a high ubiquinol/ubiquinone ratio which overcomes catalytic turnover of complex III 
(Vinogradov and Grivennikova, 2005). Since ubiquinol, the enzymatic product of complex I is 
enormously increased, the law of mass action makes this complex to catalyse the reverse reaction 
pumping four protons back to the mitochondrial matrix and reducing NAD+ into NADH. This is 
why RET requires mitochondrial hyperpolarisation (Drose and Brandt, 2012). In this mechanism 
superoxide is produced at the level of the FMN. Therefore, RET is inhibited by Q-site or FMN 
inhibitors of complex I (e.g. rotenone and diphenyleneiodonium (DPI), respectively) as well as by 
uncouplers (e.g. carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; FCCP)(Drose and Brandt, 
2012, Hirst et al., 2008)).  
(1) (2) (3)
Figure 1.2 Mechanisms of superoxide production by the ETC. (1) RET requires the accumulation of 
large amounts of succinate which reduce the ubiquinone pool. Since complex I pumps protons back to the 
matrix it needs a highly hyperpolarized mitochondria. This reaction produces superoxide anion in the 
mitochondrial matrix. (2) In the forward reaction blockage of complex I by Q-site inhibitors such as 
rotenone do not allow transfer of electrons to ubiquinone. This translates into the reduction of oxygen at 
the FMN site of complex I. (3) Q-cycle through complex III drives the electron transfer through the 
complex. Inhibition of complex III or some physiological situations trigger the production of superoxide 
by means of uncomplete oxidation of ubiquinol and formation of semiquinone radicals. 
 
Mitochondrial ROS are implied in many pathological scenarios (Gorlach et al., 2015) such as stroke 
(Olmez and Ozyurt, 2012), cancer (Chandel and Tuveson, 2014), Parkinson´s (Guzman et al., 
2010), Alzheimer´s or cardiovascular diseases (Chaturvedi and Flint Beal, 2013), and its 
overproduction may contribute to the progression of the disease. However, it is acknowledged that 
mitochondrial ROS also act as second messengers in cell signalling processes in a variety of 
physiological conditions such as wound healing, thermogenesis or oxygen sensing (Nathan, 2003, 
Sena and Chandel, 2012, Hamanaka and Chandel, 2010, Muliyil and Narasimha, 2014, Chouchani et 
al., 2016, Moreno et al., 2014a), among others. Furthermore, some cell types such as endothelial 
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cells base their energy supply on glycolysis and not in OXPHOS, turning mitochondria into rather 
signalling organelles (Quintero et al., 2006).  
1.3.5 The paradox of ROS in hypoxia 
It has been proposed that ROS increase in hypoxia and that the main source is the 
mitochondria. However, since ROS are products of the oxygen reduction this is chemically difficult 
to explain and the fact that there grown discrepant results in the literature made these results to be 
hardly debated. The main controversy about mitochondrial ROS production in hypoxia arose from 
the unspecificity of the fluorescent probes used, that the protocols included reoxygenation of the 
samples and the application of antioxidants which also impact on other processes in redox biology 
and metabolism (Chandel et al., 1998, Chandel et al., 2000). Several reports have confirmed hypoxic 
ROS production in cells exposed to hypoxia while recording the fluorescent signal from HSP-
FRET or roGFP (Robin et al., 2007, Guzy et al., 2005, Iwase et al., 2007, Waypa et al., 2010, 
Desireddi et al., 2010 (reviewed in {Guzy, 2006 #211, Schumacker, 2011, Guzy and Schumacker, 
2006a). Both thiol-based protein sensors are oxidized by hydrogen peroxide, although oxidation by 
other intracellular  such as peroxynitrite or nitric oxide cannot be ruled out. Furthermore, 
intracellular superoxide, which is the primary ROS produced from oxygen has been measured by 
different groups giving different results. Chua et al added the superoxide probe DHE after 3 hours 
of hypoxia, observing no change in fluorescence intensity and they concluded that there was not a 
change in ROS production in hypoxia (Chua et al., 2010). On the other hand, Quintero et al used 
the same probe but incubated it with the cells for the first 60 minutes of hypoxia and showed an 
increased superoxide production (Quintero et al., 2006).   These studies are apparently discrepant, 
but the difference in the results may hide a differential production of superoxide over time, since 
the incubation times differed. Importantly, there is no study showing the dynamics of superoxide 
production upon lowering oxygen availability. Understanding the time course of superoxide 
production will help us to bring together the contradictory results in the literature. 
As the role of mitochondria in ROS production in hypoxia has been suggested, several 
groups have also tried to measure it in isolated mitochondria, also with controversial results 
(Hoffman and Brookes, 2009, Hoffman et al., 2007, Korde et al., 2011). Whereas Hoffman et al 
showed that ROS production in hypoxia was proportional to oxygen concentration, Korde and 
colleagues observed the opposite. Interestingly, they both used Mannitol-sucrose based buffer as 
extraction and working solutions, being the main difference the presence or absence of 10 mM 
sodium chloride, respectively. As mentioned earlier, the principal effect of sodium on mitochondria 
is to activate NCLX, what depletes calcium from the mitochondrial compartment (Poburko and 
Demaurex, 2012, Hoffman et al., 2007). Thus, ion homeostasis and, specifically, NCLX function 
could be implied in the production of ROS during hypoxia. 
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1.3.6 Mitochondrial ROS in the hypoxic adaptation 
Although it is clear since many years ago that ROS contribute to HIF-α stabilization 
(Gerald et al., 2004), it is not the case of hypoxic ROS production. ROS-related HIF-α stabilization 
has been linked to oxidative stress and disorders, such as Parkinson´s disease (Requejo-Aguilar et 
al., 2014), cancer (Galanis et al., 2008) or inflammation (Mittal et al., 2014). However, although it 
has been proposed that hypoxia-induced ROS production contributes to PHD inhibition and HIF-
 stabilization (Moreno et al., 2014a, Chandel et al., 1998, Chandel et al., 2000, Guzy et al., 2005, 
Brunelle et al., 2005, Mansfield et al., 2005) (reviewed in (Guzy and Schumacker, 2006a, Hamanaka 
and Chandel, 2010)), most of the approaches made so far include the alteration of OXPHOS and 
potential artefacts in oxygen gradients (Hagen et al., 2003). Notably, the use of targeted antioxidant 
proteins to the mitochondria and the observation that ETC-derived ROS are necessary for hypoxic 
HIF-α stabilization in vivo have reinforced this hypothesis (Hamanaka et al., 2016, Sabharwal et al., 
2013). 
Acute oxygen sensing was elderly linked to oxygen sensors in the plasma membrane 
(López-Barneo and Castellano, 2005). Recently mitochondrial ROS have been implied in this 
response (Fernandez-Agüera et al., 2015). In the case of glomus cells of carotid body, it has been 
shown by genetic ablation of the complex I ‘core’ subunit NDUFS2 or pharmacological inhibition 
with rotenone, that complex I activity is essential for the acute response to hypoxia specifically. 
Whether it is complex I-derived NADH, ROS or both what triggers the stimulus is yet to be 
defined (Fernandez-Agüera et al., 2015). However, it is possible that small variations in oxygen 
availability translate tiny increases in ROS production which given the proximity of mitochondria 
with the plasma membrane, could affect potassium currents by reversibly oxidizing critical thiols 
and thus blocking the channels. HPV was also shown to be a mitochondrial ROS dependent acute-
adaptation which could be abolished by rotenone or myxothiazol treatment (Moreno et al., 2014a). 
In this case, mitochondrial ROS serve as an initiator signal for the activation of another ROS 
source, the NADPH oxidases which modulate potassium current activity (Moreno et al., 2014a, 
Cogolludo et al., 2009). Now, given that mitochondria are not as close as in the carotid body it 
could be that this amplification system is necessary for thiol modification of the potassium currents. 
From all the above examples, it is clear that mitochondrial ROS play a central role in long 
and short term hypoxic adaptation. However, although the molecular actors start to be discerned 
there is not a clear frame of the molecules involved. Since hypoxic adaptation is related to many 
physiological processes and diseases it is of vital importance to identify the actors and the pathways 
implicated on it. 
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2	Objectives	
 
- Ascertain whether there is increased superoxide production in acute hypoxia, studying the 
time course of production of superoxide and other ROS production in cells during the 
transition from normoxia to hypoxia. 
- Investigate the possible mechanism of hypoxic ROS production and search for the 
molecular players involved, especially components of the mitochondrial electron transport 
chain and mitochondrial ion exchangers. 
- Study the involvement of this hypoxic ROS production in adaptive response to hypoxia 
(hypoxic pulmonary vasoconstriction, activation of the HIF pathway). 
- Evaluate the usefulness of molecular interventions that abolish the superoxide burst to 
mitigate ischemic damage in a murine model of stroke induced by photoactivated 
thrombus formation.  
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3	Materials	and	methods	
3.1 Antibodies 
Table 1. Antibodies used showing the target protein, epitope, manufacturer, catalogue number, host 
species, clonality and working dilution from stock. Clonal: Clonality, Mono: monoclonal, Poly: 
polyclonal. 
Protein Epitope / 
attachment 
Manufacturer Catalog 
number 
Host Clonal Dilution
Primary antibodies 
Prohibitin-1  C-term Abgent AJ1656a Rabbit Mono IF: 1:1000 
HIF-1α  R&D Systems MAB1536 Mouse Mono WB: 1:500 
NCLX  Aviva S.B. ARP44042
_P050 
Rabbit Poly WB: 1:1000 
NDUFS4  Abcam ab87399 Mouse Mono WB: 1:1000 
NDUFS2  Abcam ab110249 Mouse Mono WB: 1:4000 
RISP  Abcam ab14746 Mouse Mono WB: 1:1000 
NDUFB6  Proteintech 16037-1-ap Rabbit Poly WB: 1:2000 
UQCRC1  Abcam ab110252 Mouse Mono WB: 1:2000 
α-tubulin  Sigma-Aldrich T6199 Mouse Mono WB: 1:1000 
PINK1  Santa Cruz sc-33796 Rabbit Poly WB: 1:200 
Secondary antibodies 
Rabbit 
IgG/HRP 
HRP 
conjugated 
GE Heathcare NA934V Donkey Poly WB: 1:1000 
mouse 
Ig/HRP 
HRP 
conjugated 
Dako p0260 Rabbit Poly WB: 1:1000 
Rabbit 
IgG/Dylight 
488 
Dylight488 
conjugated 
Thermo 35552 
 
Goat Poly IF: 1:50 
3.2 Animals, cell culture and transfection 
All animal experiments were performed following the Guide for the Care and Use of 
Laboratory Animals and were previously approved by the institutional ethics committee of the 
Universidad Autónoma de Madrid or the Universidad Complutense de Madrid, Spain, according to 
the European guidelines for the use and care of animals for research in accordance with the 
European Union Directive 2010/63/UE of 22 September 2010 and with the Spanish Real Decreto 
53/2013 of 1 February 2013 . Animal management was performed by our collaborators (see below). 
All efforts were made to minimize the number of animals used and their suffering. 
Bovine aortic endothelial cells (BAECs) were obtained from aortas donated by a local 
slaughterhouse and isolated as previously described (Navarro-Antolin et al., 2000). BAECs were 
cultured at 37 °C in RPMI 1640 (which contains 133 mM sodium and 5.3 mM potassium) 
supplemented with 15% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 100 
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μg/mL streptomycin. . Human umbilical vein endothelial cells (HUVECs) were isolated as 
previously described (Muñoz et al., 1996) and cultured in Medium 199 supplemented with 20% 
heat-inactivated fetal bovine serum (FBS), 16 U/ml heparin, 100 mg/L ECGF (endothelial cell 
growth factor), 20 mM HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid),100 U/mL 
penicillin and 100 μg/mL streptomycin. For BAECs and HUVECs, dishes were treated with 0.02% 
gelatine for 30 min at 37ºC, which was removed before plating. BAECs were used between 
passages 3 to 9 and HUVECs between passages 3 to 7. Endothelial morphology was assessed by 
visual inspection and by Western blot for endothelial nitric oxide synthase. 
 EA.hy926 cells were provided by Dr. Cora-Jean S. Edgell (UNC, NC, USA) and were 
cultured at 37 °C in Dulbecco´s Modified Eagle Medium (DMEM; which contains 155 mM sodium 
and 5.4 mM potassium) supplemented with  hypoxanthine, aminopterin and thymidine (HAT 
supplement 50x), 10% heat-inactivated FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 
HeLa and human lilver cancer (HepG2) cells were cultured at 37 °C in DMEM 
supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 
ρ0L929 cells (mtDNA-less cells derived from L929 cells), and their control  ρ+ 
transmitochondrial cybrids,  TmC57BL/6J (herein called C57; generated by transferring functional 
mitochondria from platelets to ρ0L929 cells) were generated (Moreno-Loshuertos et al., 2006) and 
kindly provided by the group of Dr. José Antonio Enríquez (CNIC, Spain). They were cultured at 
37 ºC in DMEM supplemented with 5% heat-inactivated FBS, 100 U/ml, penicillin and 100 μg/mL 
streptomycin. ρ0L929 cells were also supplemented with 50 μg/mL uridine. 
HK-2 cells (kindly provided by Dr. María José Calzada, UAM & Instituto de Investigación 
Sanitaria Princesa, Madrid, Spain) were cultured at 37 °C in DMEM F-12-GlutaMAX supplemented 
with 10% heat-inactivated FBS, 100 U/mL penicillin and 100 μg/mL streptomycin, and 0.1% 
Insulin-Transferrin-Selenium-X solution. 
Cardiomyocytes were isolated, in a collaboration with Dr. Anna Bogdanova´s group, from 
Wistar rat pups 2-3 days after birth as previously described (Rothen-Rutishauser et al., 1998). The 
cells were seeded on collagen-coated 6-well plates, supplemented with maintenance medium 
containing 1/5 part of M199 medium and 4/5 parts of the medium containing (mM): 116 NaCl, 
32.1 NaHCO3, 1 NaH2PO4 (pH 7.2), 0.8 MgSO4, 5.5 Glucose, 1.8 CaCl2, supplemented with 1% 
horse serum, penicillin, streptomycin and 2% glutamine. Cells were used within 5 days after the 
isolation. 
Rat pulmonary artery smooth muscle cells (PASMCs) from Wistar rats were isolated as 
previously described (Moreno et al., 2014a) and cultured in DMEM supplemented with 10% FBS, 
1.1 g/l pyruvate, 1% non-essential amino acids, 100 µg/ml streptomycin and 100 U/ml penicillin. 
Rat PASMCs were used within passages 2-3. 
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Immortalized mouse hippocampal cells (HT22 cell line) were cultured at 37 °C in DMEM 
supplemented with 10% heat-inactivated FBS, 20 mM HEPES, 100 U/mL penicillin and 100 
μg/mL streptomycin. 
Transfection of 30 nM siRNA or 0.25 µg C199S pHyPer-Myto (mitosypHer) vector DNA 
per 0.8 cm2 well was carried out using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer´s instructions. In PASMCs, 10 nM siRNA was transfected using Lipofectamine RNA 
iMAX (Invitrogen) according to the manufacturer’s instructions; in parallel experiments, siRNA 
efficiency was measured by RT-PCR using commercially available primers (TaqMan Gene 
Expression Assay Rn01481405_m1, Applied Biosystems). Experiments were carried out 48 to 72 h 
after transfection.  
3.3 siRNA preparation 
Scramble siRNA (siSCR) was purchased from Santa Cruz Biotechnology, except for rat 
siNCLX for which specific siSCR was used (see below). Double-strand siRNA were purchased as 
follows: 
Table 2. siRNA sense chain used showing the target mRNA and species, manufacturer and sequence. 
Target Manufacturer Sequence/Catalogue number 
Bovine NCLX Dharmacon AGCGGCCACUCAACUGCCU 
Bovine NDUFS4 Integrated DNA Technologies GCUGCCGUUUCCGUUUCCAAGGUUUTT 
Bovine NDUFS2 Integrated DNA Technologies TCGGACAGTCGACATTGGGATT 
Bovine RISP Integrated DNA Technologies CCAAGAAUGUCGUCUCUCAGUUUTT 
Bovine PINK1 Integrated DNA Technologies GGCUGCUAAUGUGCUUCAUUU 
Human NCLX Dharmacon AACGGCCACUCAACUGUCU 
Rat NCLX OriGene SR504963 
siSCR (rat NCLX) OriGene SR30004 
3.4 Fluorescence microscopy in fixed cells and quantification 
Cells were seeded a day before experimentation on glass coverslips. For treatments in 
hypoxia, all the solutions were pre-equilibrated to hypoxic conditions before use; in some 
experiments, 1 mM Tiron (4,5-dihydroxy-1,3-benzene disulfonic acid), 1 µM carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP), 100 mM sodium chloride, 30 mM lithium chloride, 5 
mM potassium chloride, 25 mM glucose, 5 mM G/M (2.5 mM glutamine, plus 2.5 mM 
dimethylmalate), 5 mM dimethylsuccinate (DMS), 120 mM D-sorbitol, 120 mM N-methyl-D-
glucamine (NMDG), 1 µM rotenone´, 1 µM antimycin A, 1 µM myxothiazol or 10 µM 7-chloro-5-
(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one (CGP-37157) was added 30 min 
before experimentation and maintained during the experiment. Plated cells were introduced in an 
Invivo2 400 or Invivo2 200 workstation (Ruskinn) set at 1% oxygen (2% oxygen when stated), 5% 
CO2, 37 ºC, and incubated for the indicated times (0, 15, 30, 45 and 60 min) in new medium, 
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washed three times with Hank´s Balanced Salt Solution with calcium /Mg2+ (HBSS+Ca/Mg) and 
incubated with 5 µM mito-hydroethidine (Mito-HE; 3.33 or 10 µM when stated) or 5 µM 
dihydroethidium (DHE) for 10 min, or with 10 µM 5(6)-carboxy-2',7'-dichlorofluorescein diacetate 
(CDCFDA) for 15 min (all probes in HBSS+Ca/Mg), in darkness. After incubation, excess of 
probe was washed three times with HBSS+Ca/Mg, the cells were fixed by adding 4% 
paraformaldehyde (PFA), and incubated in darkness at 4 ºC for 15 min. After fixation, wells were 
again washed three times with HBSS+Ca/Mg and coverslips placed on slides. In normoxic cells, 
medium was also changed for new normoxic medium, and treated as hypoxic cells, but in a 
standard cell incubator. When normoxia was set at 7% oxygen, the cells were placed in an Invivo2 
200 workstation (Ruskinn) at 7% oxygen, 5% CO2, 37 ºC, incubated overnight and treated in the 
same chamber or transferred to the Invivo2 400 chamber for 1% oxygen hypoxia as above. 
Antimycin A was added to a final concentration of 10 µM onto normoxic cells 30 min before and 
during incubation with the probe.  
Three images per coverslip were taken in a Leica DMR fluorescence microscope with a 63x 
objective, using the following excitation/emission filter pairs: 546-12/560 for DHE and Mito-HE, 
480-40/505 for CDCFDA. The images (three images per each coverslip; the number of 
independent experiments is described in the figure legends) were quantified using Image J software. 
The quantification consisted on setting the same threshold for all the images and obtaining the 
mean value from the histogram of each image. This mean value of the three images from the same 
coverslip was then averaged and the obtained number was treated as one replicate.  
Significance of the hypoxia-induced changes was analysed by ANOVA (analysis of 
variance) for normoxic and all the hypoxic time groups, and intergroup comparison was done by 
the multiple comparison test (Dunnett posteriori test with respect to the normoxia group). The 
change of fluorescence with the time in hypoxia was evaluated by linear trend test of all the hypoxia 
groups (Armitage, 2012). Homoscedasticity was tested with Levene´s test and normality with 
Shapiro-Wilk test. Appropriate transformation was done to perform the analysis in case of no 
normal distribution. When no transformation gave normal distribution (as in Figure 4.1d), non-
parametric tests were used: differences among normoxic and all the hypoxic time groups were 
analysed with the Kruskal-Wallis test and intergroup comparison was done with the Mann-Whitney 
test with respect to the normoxia group; the change of fluorescence with the time in hypoxia was 
evaluated by non-linear trend test of all the hypoxia groups. These analyses were performed using 
Stata version 11 software and R version 2.15.2, by the Methodology Unit of the Instituto de 
Investigación Sanitaria Princesa (Madrid, Spain). 
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3.5 Detection of intracellular calcium, sodium, ROS and mitochondrial 
membrane potential by live imaging fluorescence microscopy 
These experiments were carried out at the Department of Physiology of the University of 
Zürich, using a Leica DM 16000B fluorescence microscope equipped with a Leica DFC360FX 
camera, an automated stage for live imaging and a thermostated hypoxic cabinet.  
Cells were seeded in 6-well plates one day before experimentation. Plated cells were washed 
three times with HBSS+Ca/Mg and incubated with 30 nM tetramethylrhodamine methyl ester 
(TMRM), 1 µM Fluo-4AM, 10 µM CoroNa Green AM, Mito-HE, DHE or 10 µM 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (CDCFDA) for 20 min at 37 ºC in the dark. In some 
experiments 1 µM FCCP, 100 mM sodium chloride, 30 mM lithium chloride, 5 mM potassium 
chloride or 10 µM CGP-37157 were also added and maintained during the experiment. CDCFDA, 
CoroNa Green AM and Fluo-4AM were then washed out and new HBSS+Ca/Mg was added. For 
Fluo-4AM imaging, cells were further incubated for 30 min at 37ºC in the dark to allow complete 
de-esterification of the probe. After this time, the plate was placed into the microscope. The planes 
were focused for image capture, and images were taken with a 20x objective every 2 min during 40 
min. Normoxia experiments started and ended at 20% oxygen and 5% CO2, whereas hypoxia 
experiments started at 20% oxygen and 5% CO2 and then were switched to 2% oxygen and 5% 
CO2 after 2 min. The gas mixture stably equilibrated at 2% oxygen after 1 min. The 
excitation/emission filter pairs used were as follows: 546-12/560 for Mito-HE and DHE and 
TMRM, and 480-40/505 for CDCFDA, Fluo-4AM and CoroNa Green AM. Three independent 
experiments were performed for each condition.  
For mitochondrial membrane potential controls, 12.5 µM oligomycin or 1 µM FCCP were 
added prior to focusing the planes.  
Images were quantified with Leica Las-AF software or Image J. Two different routines 
were used to quantify the fluorescence. The “line method” was applied with the Leica Las-AF 
software and was based on the creation of a linear region of interest (ROI) crossing an individual 
cell. Four ROIs were created in each experiment and condition, and the mean fluorescence of each 
ROI for the cycles 0, 5, 10, 15 and 20 was collected. The “circular method” was applied with image 
J. For each experiment and condition, four ROIs surrounding individual cells were created and the 
maximum peak value of all the cycles was collected for each ROI. Three independent experiments 
were performed for each condition. In DHE or Mito-HE experiments, the linear method was 
applied but the lines were created on non-nuclear regions of different cells (to avoid measuring 
nuclear binding of Mito-HE and DHE). 
The rate of fluorescence for each replicate was estimated by linear regression of the data 
for all the ROI and time points. Differences of the mean of the rates of fluorescence were analysed 
by the Student t test. Homoscedasticity was tested with Levene´s test and normality with Shapiro-
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Wilk test. Appropriate transformation was done to perform the analysis in case of no 
homoscedasticity or no normal distribution. These statistical analyses were performed using G-stat 
version 2.0.1 software. 
Treatment effect was analysed with GEE (generalized estimating equations method) with 
gaussian family and identity link function (Hardin and Hilbe, 2012). Variability of statistics derived 
from time observations was analysed with independent and autoregressive of order one -AR(1)- 
correlation structures (Hardin and Hilbe, 2012). However, only the independent correlation 
structure is showed for the within-subject correlation, because it was the most parsimonious model 
(p-value and coefficient were similar between the two structures, therefore the statistical 
independence of observations could be assumed). This independent correlation structure is equal to 
simple regression models. When the response variables were not normally distributed appropriate 
transformations were used. These analyses were performed using Stata version 12 software by the 
Methodology Unit of the Instituto de Investigación Sanitaria Princesa (Madrid, Spain). 
3.6 Detection of intracellular calcium, sodium, hydrogen peroxide and 
intramitochondrial hydrogen peroxide, calcium, pH and colocalization 
by live imaging confocal microscopy 
These experiments were carried out in the Hospital de La Princesa, using a Leica SP-5 
confocal microscope, with an automated stage for live imaging and a thermostated hypoxic cabinet 
To detect intracellular calcium and sodium, cells were seeded one day before 
experimentation, washed three times with HBSS+Ca/Mg and incubated with 1 µM Fluo-4AM or 5 
µM CoroNa Green AM for 30 min at 37 ºC in the dark. In some experiments, 10 µM CGP-37157, 
1 µM rotenone, 1 µM antimycin A, 1 µM myxothiazol, 10 µM KCN or 10 µM ethyl-isopropyl 
amiloride (EIPA) were also added and maintained during the rest of the experiment. CoroNa 
Green AM and Fluo-4AM were then washed out and new HBSS+Ca/Mg plus 25 mM glucose was 
added. For Fluo-4AM imaging, cells were further incubated for 30 min at 37ºC in the dark to allow 
complete de-esterification of the probe. After this time, the plate was placed into the microscope. 
The planes were focused for each sample and images were taken with a 20x objective every 2 min 
during 40 min. Normoxia experiments started and ended at 20% oxygen and 5% CO2, whereas 
hypoxia experiments started at 20% oxygen and 5% CO2 and then were switched to 1% oxygen and 
5% CO2 after 2 min. The gas mixture stably equilibrated at 1% oxygen after 1 min. Loaded cells 
were excited with a Ar/Kr laser using the 496 nm line. Fluorescence emission of Fluo-4AM and 
CoroNa Green was detected in 500-575 nm range.  
To detect intramitochondrial pH, cells were transfected with the ratiometric probe 
mitosypHer in 8-well plates two days before the experiment. The same protocol as above was used, 
except that the objective was 63x and imaging time was 30 min, with 7 cycles of 5 min. Excitation 
was performed with a 405 diode laser for 405 nm line and Ar/Kr  for 488 nm line and fluorescent 
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emission was recorded at 515-535 nm range. To assess mitochondrial colocalization of the probe 
transfected cells were incubated with 25 nM MitoTracker CMTMRos for 20 minutes at 37 ºC in 
HBSS+Ca/Mg in the dark, washed again three times with HBSS+Ca/Mg and fixed with 4% PFA; 
samples were excited with an Ar/Kr laser using the 488 nm line mitosypHer and a He/Ne laser 
using the 543 nm line for MitoTracker. Fluorescence emission of mitosypHer was detected in 515-
535 nm range and MitoTracker in 575-590 nm range. 30 µM NaOH and 8 mM of HCl were used as 
controls of basification and acidification, respectively.  
For hydrogen peroxide detection, BAECs were transfected with the non-targeted or 
mitochondrial targeted version of HyPer following the same procedure for live imaging as with 
mitosypHer. 2 mM DTT and 30 µM of antimycin A were used as controls for thiol reduction and 
oxidation, respectively. 
For intramitochondrial calcium detection a mitochondrial targeted version of the Pericam-
based probe GEM-GECO, kindly provided by Prof. Jorgina Satrústegui (CBMSO, UAM, Madrid), 
was used. Samples were excited with an Ar laser using the 405 nm line. Fluorescence emission of 
the fluorescent protein was detected in 475-495 nm range for the cyan fluorescent protein (CFP) 
and 515-555 nm range for the yellow fluorescence protein (YFP), and then the ratio CFP/YFP was 
calculated. Histamine 10 µM was used as a control for mitochondrial calcium overload.  
Images were quantified with ImageJ software using the circular method of quantification. 
Three or four independent experiments were performed for each condition.  
The rate of variation for each replicate was estimated by linear regression of the data for all 
the ROI and time points. The differences of mean of the replicate rates were analyzed by the 
Student t test (as indicated in figure legends).  
3.7 Mitochondrial localization of Mito-HE by confocal microscopy 
 Cells were seeded a day before experimentation on glass coverslips. Plated cells were 
washed three times with HBSS+Ca/Mg and incubated with 5 µM mito-hydroethidine (Mito-HE, 
also called MitoSOX) for 10 min in darkness. After incubation, excess of probe was washed three 
times with HBSS+Ca/Mg, the cells were fixed by adding 4% PFA, and incubated in darkness at RT 
for 10 min. After fixation, wells were again washed with HBSS+Ca/Mg and cells permeabilized 
with 0.5 % Triton X-100 in PBS for 10 min at RT. Blocking solution, consisting in Tris-NaCl 
blocking buffer (TNB; 11096176001; Roche Diagnosis) in PBS, was added for 20 min at 37 ºC and 
antibody against prohibitin-1 C-term was incubated for 1 h at 37 ºC. Coverslips were washed three 
times with 0.1 % Tween-20 in PBS (PBS-T) and incubated with DyLightTM-488-labeled goat anti-
rabbit secondary antibody for 30 min at 37ºC. Cells were washed three times with PBS-T and one 
with distilled water, and coverslips mounted in slides. Tri-color Z stacks were generated using Leica 
SP-5 confocal microscope. Samples were excited with Ar/Kr laser using the 488 nm line and a 
second diode laser fitted with 561 nm line. Fluorescence emission was taken using the spectral 
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capability of the SP-5 according to manufacturer’s instrucions. For 3-dimensional analysis, stacks 
were projected using the 3D project tool of Image J software. 
3.8 Measurement of superoxide formation with high performance liquid 
chromatography (HPLC) analysis 
These experiments were part of a collaboration with Dr. Santiago Lamas´ group at the 
Centro de Biología Molecular Severo Ochoa (CBM-SO) and the HPLC analysys was performed by 
Dr. Francisco Javier Sánchez Gómez. This method separates 2-hydroxyethidium (2-OH-E), the 
specific product of the reaction of DHE with superoxide, from other by-products such as ethidium 
(Eth). 
 Cells were seeded a day before experimentation in 60 mm diameter plates. For hypoxia 
treatments, plated cells were introduced in an Invivo2 400 workstation (Ruskinn) set at 1% oxygen, 
5% CO2, 37 ºC, and incubated for the indicated times (0, 15, 30, 45 and 60 min) in pre-hypoxic 
medium, washed three times with pre-hypoxic HBSS+Ca/Mg and incubated with 5 µM 
dihydroethidium (DHE) for 10 min (in pre-hypoxic HBSS+Ca/Mg solution), in the darkness. After 
incubation, excess of probe was washed once with pre-hypoxic PBS and cells lysed with 0.1% of 
Triton X-100, and frozen overnight at -80 ºC. Homogenates were thawed on ice and 100 µl 
transferred into a new tube. 1-butanol (250 µl) was added to the lysate, vortexed for 1 minute, 
centrifuged during 3 minutes at maximum speed and the upper alcoholic phase was recovered and 
dried. The desiccated fraction was resuspended in 100 µl HPLC-grade water and vortexed. An 
HPLC 2695 separation module from Waters was used to load and separate 50 µl of the samples in a 
“Mediterranean Sea” C18 column using acetonitrile 10 %-TFA 0.1 % and acetonitrile 100 %-TFA 
0.1 % as mobile phases. Fluorescence of the samples was detected by a W474 module at 490 nm 
excitation wavelength and 560 nm emission wavelengths. The peak area corresponding to 2-OH-E 
formation was quantified and corrected with the protein concentration of the sample (determined 
by the BCA assay).  
Significance of the hypoxia-induced changes was analysed by ANOVA (analysis of 
variance) for normoxic and all the hypoxic time groups, and intergroup comparison was done by 
the multiple comparison test (Dunnett posteriori test with respect to the normoxia group). The 
change of fluorescence with the time in hypoxia was evaluated by linear trend test of all the hypoxia 
groups (Armitage, 2012). Homoscedasticity was tested with Levene´s test and normality with 
Shapiro-Wilk test. All analyses were performed using Stata version 11 software and R version 
2.15.2, by the Methodology Unit of the Instituto de Investigación Sanitaria Princesa (Madrid, 
Spain). Three or four independent experiments were performed for each condition. 
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3.9 Extraction method for evaluating HIF-1α stabilization and target 
gene expression 
For hypoxic stabilization of HIF-1α resolved by western blot or quantitative real time PCR 
of mRNA extracted from hypoxic samples , cells or hippocampal slices were placed into an Invivo2 
400 workstation or an Invivo2 200 workstation (Ruskinn) set at 1% oxygen, 5% CO2, 37 ºC and 
incubated for 4 (western blot) or 6 (PCR) hours in normoxia, hypoxia or dimethyloxalylglycine 
(DMOG). Cells or hippocampal slices were taken out of the hypoxia chamber on ice, washed in 
ice-cold PBS and lysed in Laemmli buffer or Trizol Reagent. 
3.10 Western blot analysis 
Protein samples were extracted with non-reducing Laemmli buffer without bromophenol 
blue and quantified by the BCA assay. Laemmli buffer composition was 50 mM Tris-HCl pH 7.6, 2 
mM ethylenediaminetetraacetic acid (EDTA), 1% sodium dodecyl sulphate (SDS) and 10% 
glycerol. After addition of 0.02% bromophenol blue and 5% 2-mercaptoethanol, extracts were then 
loaded and separated in 10% standard polyacrylamide gel electrophoresis, and transferred to 
nitrocellulose membranes. In the case of BN-PAGE gels (see below), they were transferred to 
polyvinylidene difluoride (PVDF) membranes. Membranes were blocked for 30 min with blocking 
buffer (5% non-fat milk powder in PBS + 1% Tween). All antibodies where diluted in washing 
buffer (PBS + 1% Tween; 4 ºC), with the exception of anti-HIF-1α which was diluted in blocking 
buffer. After overnight incubation for primary antibodies, membranes were washed with washing 
buffer for 30 min several times and further incubated with species-specific secondary antibodies 
labeled with horseradish peroxidase (HRP) in washing buffer for 1 hour. Subsequently, membranes 
were washed for further 30 min in washing buffer. HRP substrate and enhancer (Thermo Scientific 
SuperSignal West Femto; Catalogue number 34095) were added and chemiluminiscence visualized 
on a digital luminescent image analyzer (Fujifilm LAS-4000). 
Images were quantified using ImageQuant TL7.0 software, applying a rolling ball method 
for subtracting the background and with supervised band detection and quantitation. Each band 
was quantified and relativized by its corresponding loading control (i.e. tubulin) and the ratio was 
then plotted in histograms. 
3.11 Quantitative real time PCR 
Total RNA was extracted from HUVECs or HeLa using Trizol reagent (Vitro) following 
the manufacturer´s instructions. The amount of RNA was quantified on Nanodrop ND-1000 
spectrophotometer (Thermo) and a control quality performed in a 2100 Bioanalyzer (Agilent 
Technologies) and 0.5 µg was reverse-transcribed (Gene Amp Gold RNA PCR Core Kit; Applied 
Biosystems) following manufacturer´s instructions. The PCR was performed with Gotaq qPCR 
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Master Mix (Promega) or Power SYBR Green PCR Master Mix (Applied Biosystems) with 1 µL of 
cDNA and specific primer pairs (Table S1). β-actin mRNA was measured as an internal sample 
control. Hypoxanthine-guanine phosphoribosyltransferase (HRPT) and 28S ribosome subunit were 
used as internal controls. Two reactions were performed for each condition and gene tested in each 
independent experiment.  
The threshold cycle value (CT) is the number of the cycle in which the fluorescence 
produced in the reaction overcomes the fluorescence threshold. The fluorescence threshold was 
automatically set by the software as ten standard deviations above the mean fluorescence generated 
during the baseline cycles. CT for the two duplicates was averaged only if the difference between 
them was not greater than 0.5, otherwise the experiment were discarded. The resulting value was 
expressed as fold change vs normoxia, relativized to β-actin and plotted as mean ± s.e.m of at least 
three replicates.  
Table 3. Specific primers pairs used showing the target forward and reverse sequences. 
  Forward Reverse 
HIF1-α 5´-AGCCGAGGAAGAACTATGAACATAA-3´ 5´-GTGGCCTGTGCAGTGCAA-3´ 
HIF2-α 5´-CAATCAGCTTCCTGCGAACA-3´ 5´-TTCGGCTTCGGACTCGTTT-3´ 
PDK1 5´-GTGGTTTATGTACCATCCCATCTCT-3´ 5´-TCCATAGTGGCTCTCATTGCAT-3´ 
GLUT1 5´-TCAACCGCAACGAGGAGAA-3´ 5´-CTGTCCCGCGCAGCTT-3´ 
BNIP3 5´-TCAAGTCGGCCGGAAAATAT-3´ 5´-GCGCTTCGGGTGTTTAAAGA-3´ 
Β-actin 5´-GGCACCCAGCACAATGAAG-3´ 5´-CCGATCCACACGGAGTACTTG-3´ 
3.12 Measurement of cellular oxygen consumption 
Oxygen consumption rate (OCR) in cell culture was measured using an XF24 Extracellular 
Flux Analyzer (Seahorse Bioscience). BAECs, 6x104 per well (6-7 wells per treatment for each 
independent experiment) were plated one day before the experiment. Cells were preincubated with 
unbuffered DMEM (155.462 mM sodium and 5.366 mM potassium) supplemented with 25 mM 
glucose, 1 mM pyruvate, and 2 mM glutamine for 1 h at 37 °C in an incubator without CO2 
regulation. OCR measurements were programmed with successive injections of unbuffered 
DMEM, 5 µg/mL oligomycin, 300 nM FCCP, and 1 µM rotenone plus 1 µM antimycin A. DMSO 
or 10 µM CGP-37157 were added before starting the measurements. In experiments using silenced 
cells, as proliferation and cell growth may vary after plating, protein concentration from each 
condition (i.e. all the wells from the same condition in the same plate were mixed) was quantified 
by the BCA assay to normalise the OCR. Calculations of OCR and associated parameters were 
performed following the manufacturer´s instructions. After measuring basal respiration, oligomycin 
was added to inhibit respiration (by blocking complex V), therefore, the amount of oxygen used to 
produce ATP by OXPHOS is estimated from the difference with basal oxygen consumption (i.e. 
coupling efficiency). FCCP uncouples OXPHOS by translocating proton from intermembrane 
space to matrix, thus maximizing electron flux through the ETC, giving the maximal respiration 
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rate. This treatment provides information about the stored energy in mitochondria that a cell could 
use in an energetic crisis (i.e. reserve capacity). Antimycin A and rotenone block complexes III and 
I, respectively, consequently inhibiting electron flux through the ETC and eliminating any proton 
translocation, therefore, the leftover value is non-mitochondrial respiration, i.e. the oxygen 
consumed by other enzymes in the cell. Ultimately, proton leak is calculated from the remaining 
respiration after oligomycin addition less the non-mitochondrial respiration, giving the respiration 
due to the proton translocation due to other molecules than complex V. 
3.13 Simultaneous measurement of oxygen consumption and hydrogen 
peroxide in isolated mitochondria 
OCR in intact isolated mitochondria was performed in the Mitochondrial Biology Unit 
(Cambridge, United Kingdom) and measured using an Oxygraph-2k (O2k, OROBOROS 
Instruments, Innsbruck, Austria) and combined with the Fluorescence-Sensor Green of the O2k-
Fluo LED2-Module for hydrogen peroxide measurement. Experiments were carried out in 
potassium chloride medium (120 mM potassium plus 1 mM EGTA) in two parallel chambers. 
Before experiment 500 µg of rat heart mitochondria, 10 µM amplex red, 1mg/ml SOD, 1 mg/ml 
HRP, 10 mg/ml bovine serum albumin (BSA) were added. 5mM glutamate and 5 mM malate (GM) 
addition at the beginning of the experiment acted as a mitochondrial-NADH generating system 
(state 2), 2.5 mM ADP was added to couple respiration (state 3) followed by the addition of 10 mM 
succinate to study complex II contribution to the total oxygen consumption or hydrogen peroxide 
production. 
3.14 Submitochondrial particles (SMPs) isolation and blue native 
polyacrylamide gel electrophoresis (BN-PAGE)  
This procedure was performed before BN-PAGE or detection of ND3 by fluorescent 
labelling. BAECs or HepG2 cells were plated in one 100 mm-diameter dish for each condition. 
Each plate washed twice in ice-cold PBS, scraped off the plate and centrifuged for 5 min 600 g at 
4ºC. Hippocampal slices were washed and disaggregated in ice-cold PBS and centrifuged for 5 min 
at 600 g at 4ºC. To obtain SMPs, cells were resuspended in 200 µL of PBS, mixed with 200 µL of 8 
mg/mL of pure digitonin and incubated for 10 min in ice. After this, 1 mL PBS was added and the 
samples were centrifuged 5 min at 10,000 g, 4ºC. The resulting pellet of SMPs was washed and 
resuspended in 100 µL of 1.5 M aminocaproic acid, 50 mM Bis-Tris/HCl pH 7.0. Protein 
concentration was quantified by BCA assay. SMPs were centrifuged 2 min at 13,500 g at 4ºC and 
the pellet was resuspended at 10 µg/µL with 1.5 M aminocaproic acid, 50 mM Bis-Tris/HCl pH 
7.0. SMPs were solubilized with 4 g/g digitonin, incubated 5 min in ice and centrifuged 30 min 
16,000 g at 4ºC.  
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For BN-PAGE analysis supernatants were collected and mixed with sample buffer 
(Coommassie brilliant blue G-250 5% in 1 M aminocaproic acid solution). For each sample, 100-
150 µg was loaded and run on a 3-20% gradient BN-PAGE gel as described elsewhere (Schagger, 
1995, Schagger and von Jagow, 1991). Gel transfer was performed onto PVDF membranes, which 
were then washed with methanol for 3 min before western blotting. 
3.15 Fluorescent labelling of ND3 Cys-39 from isolated mitochondrial 
membranes 
For cell extracts and ex vivo samples, the same procedure previously described for SMP 
preparation was used. For in vivo samples, brain mitochondria isolation was performed using the 
Mitochondrial Isolation Kit for tissue (ab110168; Abcam) according to the manufacturer’s protocol. 
Briefly, brain tissue was washed and minced in Isolation Buffer and cells were disrupted using a 
Dounce tissue grinder pestle (Sigma). Then, homogenized tissue was centrifuged at 1,000 g for 10 
minutes at 4 °C and the supernatant was centrifuged at 12,000 g for 15 minutes at 4 °C, giving the 
enriched mitochondria and cytosol fractions in the pellet and the supernatant, respectively.  
SMP or mitochondrial protein amount was determined by the BCA assay and then proteins 
were solubilized with 4 g/g digitonin, incubated 5 min in ice and centrifuged 30 min at 16,000 g, 
4ºC. Samples from cell cultures were split into two parts, one part was incubated at 37 ºC for 60 
min to fully deactivate complex I and the other part was kept on ice. Samples were then incubated 
with Bodipy-TMR C5-maleimide (Invitrogen) for 20 min at 15 ºC in the dark; then, 1 mM cysteine 
was added and the samples were further incubated for 5 min. After this time, the samples were 
precipitated twice with acetone, centrifuged at 9,500 g for 10 min at 4 ºC in the dark, and the 
resulting pellet was resuspended in non-reducing Laemmli loading buffer. For each sample, 100 µg 
was loaded onto 10% Tricine-SDS-PAGE gels as previously described (Schagger and von Jagow, 
1991). Total protein staining was performed with Sypro Ruby (Invitrogen) following the 
manufacturers’ instructions. The images corresponding to Bodipy-TMR C5-maleimide fluorescence 
were obtained with Cy3 settings (excitation with green LED, emission filter 575DF20) and the total 
protein by Sypro with a UV transiluminator and 605DF40 filter, using a digital fluorescent image 
analyzer (Fujifilm LAS-4000). The signal of the ND3 band was quantified using ImageQuant TL7.0 
software in the two images from the same gel (Bodipy-TMR and Sypro Ruby) and the ratio of 
signals, Bodipy-TMR/Sypro Ruby, quantified for each band. 
Data were analysed one-way ANOVA followed by a Tukey’s test (when comparing 
multiple groups), as indicated in the figure legends. Values of p < 0.05 were considered to be 
statistically significant. 
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3.16 Protein mass spectrometry analysis  
These experiments were performed in collaboration with Dr. Anabel Marina´s group at the 
CBM-SO (Proteomics Unit of the CBM-SO and the IIS-IP, a member of ProteoRed-ISCIII / 
PRB2) by Nuria Sánchez-López and Laura Peláez-Aguado, in order to confirm the identity of the 
protein bands corresponding to ND3. After drying, the electrophoretic bands that migrated at the 
position expected for ND3 were cut in pieces, destained in acetonitrile:water 1:1, reduced with 10 
mM DTT for 1 h at 56 ºC, alkylated with 50 mM iodoacetamide for 1 h at room temperature (RT) 
in the dark and digested in situ with sequencing grade trypsin (Promega, Madison, WI) as described 
by Shevchenko et al(Shevchenko et al., 1996) with minor modifications. The gel pieces were shrunk 
by removing all liquid using sufficient ACN. Acetonitrile was pipetted out and the gel pieces were 
dried in a speedvac. The dried gel pieces were re-swollen in 50 mM ammonium bicarbonate pH 8.8 
(AB) with 12.5 ng/μL trypsin for 1 h in an ice-bath. The digestion buffer was removed and gels 
were covered again with AB and incubated at 37 °C for 12 h. Digestion was stopped by the 
addition of 1% TFA. Whole supernatants were dried down and then desalted onto ZipTip C18 
Pipette tips (Millipore). 
The desalted protein digest was dried, resuspended in 10 l of 0.1% formic acid and 
analyzed by RP-LC-MS/MS in an Easy-nLC II system coupled to an ion trap LTQ-Orbitrap-Velos-
Pro mass spectrometer (Thermo Scientific), as previously described (Moreno et al., 2014a) with 
minor modifications. The peptides were concentrated (on-line) by reverse phase chromatography 
using a 0.1 mm × 20 mm C18 RP precolumn (Proxeon), and then separated using a 0.075 mm x 
250 mm C18 RP column (Proxeon) operating at 0.3 μl/min. Peptides were eluted using a 240-min 
dual gradient from 5 to 25% solvent B in 180 min followed by gradient from 25 to 40% solvent B 
over 240 min (Solvent A: 0.1% formic acid in water, solvent B: 0.1% formic acid, 80% acetonitrile 
in water). ESI ionization was carried out using a Nano-bore emitters Stainless Steel ID 30 μm 
(Proxeon) interface. 
The mass spectrometer was operated in the selected MS/MS ion monitoring mode (SMIM 
mode (Jorge et al., 2007). In this mode, the LTQ-Orbitrap-Velos-Pro detector was programmed to 
perform, along the same entire gradient, a continuous sequential operation in the MS/MS mode on 
the doubly or triply charged ions corresponding to the peptide selected previously from the 
theoretical prediction.  
Peptides were detected in survey scans from 400 to 1600 amu (1 μscan), followed by ten 
data-dependent MS/MS scans (Top 10), using an isolation width of 2 u (in mass-to-charge ratio 
units), normalized collision energy of 35%, and dynamic exclusion applied during 30 sec periods. 
The Orbitrap resolution was set at 30,000. Peptide identification from raw data was carried out 
using the SEQUEST algorithm (Proteome Discoverer 1.4, Thermo Scientific). Database search was 
performed against handmade database and search against decoy database (integrated decoy 
approach) using false discovery rate (FDR) < 0.01. The following constraints were used for the 
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searches: tryptic cleavage after Arg and Lys, up to two missed cleavage sites, and tolerances of 20 
ppm for precursor ions and 0.8 Da for MS/MS fragment ions, and the searches were performed 
allowing optional Met oxidation, Cys carbamidomethylation and Cys N-ethylmaleimide 
modification.  
3.17 Measurement of pulmonary artery contraction 
These experiments were carried out by Dr. Laura Moreno, in Dr. Angel Cogolludo´s lab at 
Universidad Complutense de Madrid (UCM). Third division branches of the pulmonary arteries 
(PA) were isolated from male Wistar rats and mounted in a wire myograph. Contractile responses 
were recorded as previously reported (Moreno et al., 2014a). The chambers were filled with Krebs 
buffer containing (in mM) NaCl 118, KCl 4.75, NaHCO3 25, MgSO4 1.2, CaCl2 2.0, KH2PO4 1.2 
and glucose 11, maintained at 37 °C and aerated with 21% oxygen -5% CO2-74% N2 gas (pO2 17-
19 kPa). After an equilibration period of 30 min, PA (internal diameter 300-400 µm) were distended 
to a resting tension corresponding to a transmural pressure of 2.66 kPa. Preparations were initially 
stimulated by raising the potassium concentration of the buffer (to 80 mM) in exchange for sodium. 
Vessels were washed three times and allowed to recover. Then, each vessel was exposed to two 
hypoxic challenges (95% N2-5% CO2; pO2 = 2.6-3.3 kPa), the second one after 40 min incubation 
with vehicle (control) or CGP-37157 (30 µM). The steady state contraction is the force of 
contraction 10 min after peak contraction. Both were measured and relativized to the first hypoxic 
challenge. 
Data were analysed using one-way ANOVA followed by a Bonferroni’s test. Values of p < 
0.05 were considered to be statistically significant 
3.18 Preparation of mouse hippocampal slices 
These experiments were part of a collaboration with Dr. Manuela G. López´s group and 
were performed by Dr. Elisa Navarro. Three-month-old C57BL/6 mice were anesthetized with 
1.5% isoflurane in oxygen under spontaneous respiration, then decapitated and forebrains were 
rapidly removed from the skull and placed into ice-cold Krebs bicarbonate dissection buffer (pH 
7.4), containing (in mM): NaCl 120, KCl 2, CaCl2 0.5, NaHCO3 26, MgSO4 10, KH2PO4 1.18, 
glucose 11 and sucrose 200. The hippocampi were dissected, and slices (250-µm thick) were 
prepared using a McIlwain Tissue Chopper. Then, the slices were transferred to vials containing 
sucrose-free dissection buffer to allow tissue recovery from slicing trauma before experimentation 
(equilibration period). Both solutions were gassed with 5% CO2 at least 30 minutes before use to 
ensure pH 7.4.  
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3.19 Detection of superoxide in hippocampal slices by confocal 
microscopy  
For treatments in hypoxia, all solutions were pre-equilibrated to hypoxic conditions before 
use; when necessary, 10 µM CGP-37157 or 10 µM antimycin A was added 30 min before the 
experiment and maintained during the rest of the procedure. Hippocampal slices were placed into 
an Invivo2 400 workstation (Ruskinn) set at 1% oxygen, 5% CO2, 37 ºC, and incubated for 30 min 
in fresh sucrose-free dissection buffer, washed three times with HBSS+Ca/Mg and incubated with 
5 µM DHE for 10 min in the dark. After incubation, excess probe was removed by three washes in 
HBSS+Ca/Mg, slices were fixed with 4% PFA, and incubated in the dark at 4 ºC for 15 min. After 
fixation, wells were again washed three times with HBSS+Ca/Mg and the slices placed on slides 
with coverslips on top. For normoxic treatments, medium was changed for fresh normoxic 
medium, and treated as above, but in a standard cell incubator. Images of CA1 region of 
hippocampal slices were taken with a Leica SP-5 confocal microscope with a 40x objective. Samples 
were excited with an Ar/Kr laser using the 488 nm line for OHE and 496 nm line for E. 
Fluorescence emission of 2-OH-E was detected at 560-570 nm and Eth at 570-600 nm following 
previously-reported methods (Zhao et al., 2005). Three-dimensional image stacks were processed 
using ImageJ software. For each stack, the mean fluorescence from the CA1 region of each 
condition was obtained and the background substracted,. The value from of two hippocampal slices 
in every condition was promediated in each independent experiment.  
Data were analysed using one-way ANOVA followed by a Bonferroni’s test (when 
comparing multiple groups). Values of p < 0.05 were considered to be statistically significant. 
3.20 In vivo photothrombotic stroke 
These experiments were part of a collaboration with Dr. Manuela G. López´s group and 
were performed by Dr. Javier Egea and Dr. Esther Parada. Three-month-old male C57BL/6 mice 
(30-35 g) were anesthetized with 1.5% isoflurane in oxygen under spontaneous respiration. Mice 
were then placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) and 
physiological temperature (37 ± 0.5 ºC) was maintained by a servo-controlled rectal probe heating 
pad (Cibertec, Madrid, Spain). A small incision in the midline was made and, after removal of the 
periosteum, bregma and lambda points were identified. A cold light (Zeiss KL 1500 LCD, Jena, 
Germany) was centred using a micromanipulator at 0.2 mm posterior and 1.5 mm lateral to bregma 
on the right side using a fibre optic bundle of 2 mm in diameter. One milligram of the 
photosensitive dye Rose Bengal (Sigma Aldrich, St. Louis, MO, USA) dissolved in sterile saline (0.1 
mL) was injected intraperitoneally (i.p.). and 5 min later the brains were illuminated during 20 min. 
After completion of the surgical procedures, the incision was sutured and the mice were allowed to 
recover for 24 h. Animals were randomly distributed into 2 groups (Jahan and Vinuela, 2009): 
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control (treated with vehicle) and CGP-37157 30 mg/kg. CGP-37157 was dissolved in Tween 80 
and diluted with 5x volume of NaCl 0.9% and was administered i.p. 5 min after photothrombotic 
stroke induction. 
Twenty-four hours after stroke induction, mice were anesthetized and sacrificed by 
decapitation and brains were quickly removed. Then, coronal sections of 1-mm-thickness were cut 
and slices were incubated in a 2% solution of triphenyltetrazolium chloride and then fixed in a 
buffered formalin solution. Infarcted tissue was defined by the unstained area and the 
morphometric determination of cortical infarct volume was calculated by the use of an unbiased 
stereological estimator of volume based on Cavalieri's principle (Avendano et al., 1995). Data were 
analysed using Student’s unpaired t test. Values of p < 0.05 were considered to be statistically 
significant. 
3.21 Statistics 
In addition to specific statistical analyses described in each method, other data were 
analysed using Student’s unpaired t test (when comparing two groups) or by one-way ANOVA 
followed by a Bonferroni’s test (when comparing multiple groups), as indicated in the figure 
legends. Values of p < 0.05 were considered to be statistically significant. 
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4	Results	
4.1 Hypoxia produces a superoxide burst in cells 
4.1.1 Hypoxia induces a superoxide burst in the first minutes of hypoxia in 
endothelial cells 
So far, the level of ROS production in hypoxia has been debated, mostly because of 
discrepancies in the results obtained by several groups (Chua et al., 2010, Chandel et al., 1998). Such 
differences could result from the use of non-specific probes for ROS detection, reoxygenation of 
the samples and times of hypoxia studied. We aimed to determine whether reduction in oxygen 
concentration was able to induce the production of superoxide at different times of short hypoxia 
in endothelial cells. Since endothelial cells are the first cells in the vessel lumina, they could be 
important in sensing oxygen variations. In addition, since it is a rather gycolityc cell type 
mitochondria would serve as a rather signalling organelle and approaches altering mitochondrial 
homeostasis would affect drastically to their bioenergetics. 
 Dihydroethidium (DHE) reacts specifically with superoxide to produce 2-hydroxyethidium 
(2-OH-E) which can be detected by fluorescence microscopy. We have developed a method for 
measuring superoxide production analysing the 2-OH-E signal in fixed cells. As a positive control 
we used antimycin A which inhibits complex III of the OXPHOS system, increasing superoxide 
production (Turrens, 2003). Primary bovine aortic endothelial cells (BAEC) were subjected to 
hypoxia for different times, ranging from 10 to 70 min. DHE was added over the last 10 min of 
hypoxic exposure, and after that, cells were fixed in the hypoxia chamber, avoiding reoxygenation. 
The amount of 2-OH-E produced was assessed in a fluorescence microscope (Figure 4.1a-b). 
Antimycin A gave a clear signal, (not compared in the statistical test, as it was just a positive 
control). A significant increase in superoxide amount was observed within the first minutes of 
hypoxia, compared to the value in normoxia. An additional analysis of the linear trend (p 
trend(Armitage, 2012)) among the measures at different times in hypoxia showed that superoxide 
production was progressively diminished over the following hour. Similar results were obtained 
with a cell line derived from human endothelial cells, EA.hy926 (Edgell et al., 1983)(Figure 4.1c-d). 
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Figure 4.1. Superoxide detection by DHE in endothelial cells. BAECs (a, b) and EA.hy926 
cells (c, d) were incubated for 60 min in normoxia (Nx), in normoxia with antimyicin A (AA, 10 µM for 
30 min) or incubated in a hypoxia chamber at 1% oxygen with medium pre-equilibrated in the hypoxic 
condition (Hp) for 0, 15, 30, 45 or 60 min. 5 µM DHE was added for 10 min more, and cells were fixed in 
the hypoxia chamber. (a, c) Representative images showing DHE fluorescence. (b, d) Quantification of 
images from four (b) or three (d) independent experiments. (e) BAECs were treated as in (a); after DHE 
incubation cells were lysed in the hypoxia chamber, frozen and 2-OH-E amount was analyzed by HPLC 
with fluorescent detection. Data are presented as mean  s.e.m. of four independent experiments. (f) 
Quantification of three independent experiments of control BAECs (black bars) and BAECs incubated 
with 1 mM Tiron (white bars), treated as in (a). Data are presented as mean  s.e.m. * p < 0.05, ** p < 
0.01, & p = 0.0495 versus Nx (one-way ANOVA or Kruskal-Wallis). Linearity of fluoresncence intensity 
among hypoxic samples was analyzed by linear trend test. Linearity significant p trend < 0.05. a.u., 
arbitrary units. 
 
DHE oxidation measurement by fluorescence microscopy is not completely specific for 
superoxide detection, as there are other reactions that can also give fluorescent products, but 2-
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OH-E can be differentiated from ethidium and other products by HPLC analysis with fluorescent 
detection (Zhao et al., 2005). In order to confirm the results from microscopy and to 
unambiguously detect the production of superoxide, we performed HPLC analysis of cell lysates 
from BAECs subjected to hypoxia, incubated with DHE and extracted in the hypoxia chamber. 
The peak of 2-OH-E is clearly separated from the peak of ethidium (Eth), both in control 
experiments with cyclosporine A treatment (Redondo-Horcajo et al., 2010) and in hypoxia 
treatments (Figure 4.2a-b). With this methodology we also observed a transient burst of superoxide 
production during the first minutes of hypoxia (Figure 4.1e). Superoxide signal thereafter decreased, 
and did not differ from normoxic values after 45-60 min in hypoxia. These findings correlated with 
the results obtained by fluorescence microscopy (Figure 4.1a-d), confirming the specific detection 
of superoxide in our setting. In order to further confirm the superoxide burst, we aimed to inhibit it 
with specific reagents, so we treated BAECs with 1 mM Tiron before and during the hypoxic 
incubation in microscopy experiments. Tiron reacts with superoxide, and clearly abolished the 
signal from the superoxide burst in hypoxia (Figure 4.1f). 
 
 
Figure 4.2. Chromatograms from control experiments showing the separation of the peaks 
corresponding to 2-hyroxyethidium (2-OH-E) and ethidium (Eth). (a) Treatment of BAECs with 
cyclosporin A (CsA) induced superoxide anion production (Redondo-Horcajo et al., 2010), which was 
abolished by treatment with 1 mM Tiron. (b) Chromatograms from a representative experiment included 
in Figure 4.1e. Exposure of BAECs to hypoxia increased the area of 2-OH-Et peak in the first minutes, 
decreasing to normoxic values thereafter (quantified in Figure 4.1e), independently of the Eth peak.  
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Next, we wanted to assess if this superoxide burst is specific of the change in oxygen 
concentrations we have used in the experimental setting, so we performed similar experiments with 
different initial and final oxygen concentrations. First, we used a lower initial "normoxic" reference 
concentration, 7% oxygen, which could be more physiologically relevant for endothelial cells, 
maintaining the hypoxia at 1% oxygen. We observed a similar superoxide burst (Figure 4.3a). 
Similar increase in superoxide production was observed when 2% oxygen was used as hypoxia 
while ambient air was used as normoxia. In fact the amplitude of superoxide burst at 2% oxygen 
exceeded that observed at 1% oxygen (Figure 4.3b). 
In order to determine the production of other ROS (Kalyanaraman et al., 2012) that could 
be derived from the superoxide burst we used 5(6)-carboxy-2',7'-dichlorofluorescein diacetate 
(CDCFDA). BAECs incubated in hypoxia showed a burst in CDCFDA oxidation, which peaks at 
15-30 min (Figure 4.3c-d), suggesting that the superoxide burst is translated into a burst of other 
ROS such as hydrogen peroxide with a slight delay. 
 
  
Figure 4.3. The time course of ROS production varies slightly with different concentrations 
of oxygen in normoxia and hypoxia, and the probe used. (a) BAECs were treated as in Figure 1, but 
normoxia was set at 7% oxygen. (b) BAECs were treated as in Figure 1, but the hypoxia chamber was set 
at 2% oxygen and normoxia performed at atmospheric oxygen concentration. (a and b) Quantification of 
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images from three independent experiments. (c and d) BAECs were treated as in Figure 1. CDCFDA 10 
µM was added for 15 min more, and cells were fixed in the hypoxia chamber. (c) Representative images 
showing CDCFDA fluorescence. (d) Quantification of images from four independent experiments. Data 
are presented as mean  s.e.m. *** p < 0.001 versus Nx, ** p < 0.01 versus Nx, * p < 0.05 versus Nx. 
 
4.1.2 Superoxide is produced in mitochondria 
We next wanted to explore the role of mitochondria in the superoxide production induced 
in acute hypoxia. To this end, we used the mitochondria-targeted probe Mito-HE, in which a 
triphenylphosphonium (TPP+) group is linked to DHE. Mito-HE accumulates within active 
mitochondria since positively charged TPP+ drives the compound to the negatively charged 
mitochondrial matrix (Robinson et al., 2006). EA.hy926 incubated with Mito-HE during the last 10 
min of exposure to 1% oxygen showed a similar acute transient rise of superoxide production in 
response to hypoxia (Figure 4.4a-b), suggesting mitochondrial localization of superoxide 
production. Again, similar results were obtained in BAECs, where superoxide production in 
hypoxia could be even higher (Figure 4.4c-d). 
We confirmed mitochondrial targeting of Mito-HE by assessing colocalization with 
prohibitin-1, a mitochondrial protein (Nijtmans et al., 2000) (Figure 4.4e). In order to additionally 
control that Mito-HE signal was actually related with increases in superoxide production and there 
was no saturation effect in the signal, we tested different concentrations of Mito-HE, observing 
that there is a clear increase with the Mito-HE concentration (Figure 4.4f). 
A complementary approach to analyse the mitochondrial origin of the superoxide 
production came from the study of the hypoxia response in ρ0 cells, which do not have a functional 
OXPHOS due to mitochondrial DNA damage. ρ0 cells are cells treated with small amounts of 
ethidium bromide which depletes mitochondria from its DNA, leaving nuclear DNA undamaged 
(Perales-Clemente et al., 2008). Nuclear DNA expression is maintained, although there could be 
some variations dude to the long ethidium bromide exposure. Thus. ρ0 cells (ρ0L929) had their 
control cybrids with non-damaged mitochondria (TmC57BL/6J, from now on called 
C57)(Moreno-Loshuertos et al., 2006). ρ0 cells and C57 were subjected to hypoxia and DHE 
fluorescence was measured in the same conditions as with endothelial cells. C57 cells also showed a 
superoxide burst in the first minutes of hypoxia (Figure 4.4g, black bars). However, ρ0L929 cells 
showed much lower DHE signal, which does not increase with antimycin A treatment (due to the 
lack of OXPHOS); hypoxic exposure of ρ0L929 cells did not significantly affected the DHE signal 
(Figure 4.4g, white boxes). In line with the previous data these findings point to the mitochondrial 
origin of the superoxide burst that we observe in the first minutes of hypoxia. 
 56 
 
 
Figure 4.4. Hypoxic superoxide production is produced by mitochondria. EA.hy926 cells (a, 
b) and BAECs (c, d) were treated as in Figure 1. Mito-HE 5 µM was added for 10 min more, and cells 
were fixed in the hypoxia chamber. (a, c) Representative images showing Mito-HE fluorescence. (b, d) 
Quantification of images from three independent experiments. (e) BAECs were incubated with 5 µM 
Mito-HE for 10 min, fixed and immunostained with anti-prohibitin (PHB) antibody. Representative 
images show mitochondrial localization of Mito-HE. Pearson and Mander’s correlation coefficients for 
colocalization of both signals were estimated. (f) BAECs were treated as in (a), but incubated with 
different Mito-HE concentrations. Quantification of images from three independent experiments. (g) C57 
(black bars) and ρ0L929 cells (white bars) were treated as in Figure 1 and quantification shows three 
independent experiments. Data are presented as mean  s.e.m. ** p < 0.05, * p < 0.01 versus Nx. 
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4.1.3 Early hypoxic superoxide production is confirmed in living cells 
In the previous experiments the accumulation of ROS was detected for 10 (DHE) or 15 
(CDCFDA) min following 0-60 min of incubation at hypoxic or normoxic conditions. In other 
words, the cells were incubated with the probe for the same period of time in all conditions, but 
this incubation time window was opened after different times of hypoxic treatment. In order to get 
a complementary measure of ROS production in hypoxia, we monitored the rates of oxidation of 
the ROS-sensitive probes using live imaging under normoxic or hypoxic conditions. In these 
conditions, the probe is added before the beginning of the measurement, and remains throughout 
all the experiment, so the incubation time with the probe increases progressively; thus, we expect 
the fluorescent signal to accumulate over time due to the irreversible oxidative modification of the 
probes.  
Under normoxic conditions a gradual sustained increase in the oxidation signal was 
detected in BAECs using DHE, Mito-HE and CDCFDA (Figure 4.5a-c, black circles). This 
increase corresponds to the normoxic ROS production that oxidizes the probes. For assessing 
acute hypoxia, the oxygen concentration in the gas chamber around the cells in the microscope was 
changed to 2% oxygen after the first measurement at time 0. The oxidation signal of the probes 
increased more than in the cells under normoxia (Figure 4.5a-c, white circles). We calculated the 
rates of oxidation of the probes for the whole time of the experiment, which are clearly increased in 
hypoxia (Figure 4.5a-c, insets).  
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Figure 4.5. Superoxide and ROS production in acute hypoxia measured by fluorescence 
microscopy in living endothelial cells. BAEC were treated with 10 µM DHE (a), 5 µM Mito-HE (b) or 
15 µM CDCFDA (c) for 20 min and subsequently incubated in a chamber with atmospheric and 
temperature control in a fluorescence microscope, where they were maintained in normoxia for 40 min or 
placed in normoxia and switched to hypoxia (2% oxygen) for the rest of the experiment. Black circles: 
normoxia (Nx); white circles: hypoxia (Hp). Quantification of four regions for three independent 
experiments is plotted for each time as mean ± s.e.m. (Insets) Oxidation rates considering all time points 
of each replicate (n=3) are plotted as mean ± s.e.m. **p<0.01 versus Nx.  
 
Using live imaging we have also explored the hypoxia-dependent changes in the 
mitochondrial membrane potential (ΔΨmt). Mitochondrial targeting of Mito-HE is driven by ΔΨmt. 
Thus, hyperpolarization is associated with greater accumulation of Mito-HE within mitochondria 
and a concomitant increase in fluorescence which is not caused by increased superoxide formation. 
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We have measured ΔΨmt in BAECs using tetramethylrhodamine (TMRM) in non-quenching mode. 
TMRM-based probes are positive charged fluorescent molecules which are easily attracted by ΔΨmt. 
Thus, less accumulation inside the mitochondria due to depolarization would mean less fluorescent 
signal, this is so called the non-quenching mode. However, above certain concentrations (~ 50 nM) 
the accumulation of the probe drives its aggregation and quenching of the fluorescence. This 
translates into less signal upon hyperpolarization due to further aggregation of the probe and more 
fluorescence after depolarization because of its liberation from the aggregates (Perry et al., 2011). 
We confirmed non quenching mode measurement by the clear and immediate decrease in the signal 
when FCCP (which depolarizes by uncoupling OXPHOS) was added (Figure 4.6a). We also 
observed a signal increase after addition of oligomycin (which inhibits ATPase causing 
mitochondrial hyperpolarization) (Figure 4.6a). Hypoxic treatment of BAECs was associated with 
mitochondrial depolarization, while the potential was maintained or slightly increased in BAECs in 
normoxia (Figure 4.6b). Thus, oxygen production in the mitochondria of hypoxic BAECs could be 
underestimated using Mito-HE as the dye levels in depolarized hypoxic mitochondria would be 
lower than in the mitochondria of normoxic cells. 
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Figure 4.6. Mitochondrial membrane potential measurement by fluorescence microscopy in 
live untreated endothelial cells and treated with oligomycin or FCCP. (a) BAECs were treated with 
30 nM TMRM as in Figure 4.5 but only in normoxia. Oligomycin or FCCP  were added prior to image 
acquisition. Quantification of four regions for three replicates is plotted for each time as mean  s.e.m. 
Black circles: non-treated cells; white circles: FCCP treatment; black inverted triangles: oligomycin 
treatment. (b) BAECs were treated as in Figure 4.5. Black circles: normoxia (Nx); white circles: hypoxia 
(Hp). Fluorescence quantification was plotted as F/F0 in order to make clearer the comparison of Nx vs 
Hp in-time variations. 
 
We also used a model of cells in which OXPHOS is inactive to confirm the mitochondrial 
implication in the increased superoxide production in hypoxia. While C57 cells exhibit a clear 
increase in the DHE and CDCFDA signals when they are subjected to hypoxia, ρ0L929 cells do not 
have these changes when subjected to hypoxia (Figure 4.7). 
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Figure 4.7. Superoxide and ROS production in acute hypoxia measured by fluorescence 
microscopy in living ρ0 cells. C57 and ρ0L929 cells were incubated with 10 µM DHE (a) and 15 µM 
CDCFDA (b) and treated as in Figure 4.5. Black circles: C57 in normoxia (Nx C57); white circles: C57 
in hypoxia (Hp C57); black inverted triangles: ρ0L929 in normoxia (Nx ρ0L929); white triangles: ρ0L929 
in hypoxia (Hp ρ0L929). Quantification of four regions for three independent experiments is plotted for 
each time as mean ± s.e.m. (Insets) Oxidation rates considering all time points of each replicate (n=3) are 
plotted as mean ± s.e.m. **p<0.01 versus Nx. 
 
4.1.4 Superoxide burst and ROS formation in hypoxia is not specific of endothelial 
cells 
We wondered whether the hypoxia-induced superoxide burst and the increase in ROS 
production was specific to endothelial cells or a common feature for several cell types, so we 
studied it in different cell types. 
First, we carried out live imaging experiments with cultured neonatal rat cardiomyocytes. In 
line with the results obtained in endothelial cells, hypoxia triggered a significant increase in the rate 
of oxidation of DHE, Mito-HE and CDCFDA, indicating an increased production of ROS (Figure 
4.8a-c). Furthermore, depolarization of mitochondrial membrane in hypoxic cardiomyocytes was 
confirmed when monitoring the TMRM signal (Figure 4.8d), suggesting that superoxide production 
within mitochondria could be underestimated.  
We also assessed whether tumour cells could exhibit a similar response to hypoxia. HeLa 
and HK2 cells were exposed to acute hypoxia and incubated with Mito-HE at different times, and. 
the response was similar to that of endothelial cells (Figure 4.8e-f). We also confirmed by HPLC 
with fluorescent detection that the DHE probe was specifically detecting the superoxide burst in 
HeLa cells (Figure 4.8g). 
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Figure 4.8. Hypoxia produces a superoxide burst and mitochondrial depolarization in 
different cell types. (a) Primary neonatal cardiomyocytes were treated and data obtained and plotted as 
in Figure 4. HeLa (e) and HK2 cells (f) were treated as in Figure 3a. 5 µM Mito-HE was added for 10 min 
more, and cells were fixed in the hypoxia chamber. (g) HeLa cells were treated as in Figure 1e. After 
DHE incubation (5 µM DHE, 10 min) cells were lysed in the hypoxia chamber, frozen and 2-OH-E 
amount was analyzed by HPLC with fluorescent detection. Data are presented as mean  s.e.m. of three 
independent experiments. ** p < 0.01 versus Nx, * p < 0.05 versus Nx. 
 
 
These results reinforce the involvement of mitochondria in hypoxic superoxide burst, and 
suggest that this could represent a general mechanism for different cell types. 
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4.2 Complex I deactivation and mitochondrial sodium/calcium 
exchange through NCLX are necessary for hypoxic ROS production 
4.2.1 Hypoxia triggers sodium/calcium exchange via mitochondrial NCLX 
We questioned whether sodium or calcium movements between cellular compartments 
were altered during acute hypoxia. To measure cytosolic calcium (Ca2+i) and sodium (Na+i) levels, 
BAECs were loaded with Fluo-4AM or CoroNa GreenAM fluorescent probes (they become 
fluorescent after calcium or sodium binding, respectively; acetoxymethyl ester –AM– makes these 
probes cell permeant and is removed with cellular esterases) for live cell imaging and exposed to 
normoxia or hypoxia for 40 min. A clear increase in Ca2+i and a decrease in Na+i was detected in 
cells acutely exposed to hypoxia, whereas the signals in normoxic cells remained constant (Figure 
4.9a-b). We then treated BAECs with 10 µM CGP-37157 (CGP), a specific NCLX inhibitor, which 
abolished both the release of calcium into the cytosol (Figure 4.9c) and the concomitant depletion 
of cytosolic sodium (Figure 4.9d) in hypoxia-exposed cells.  
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Figure 4.9. Acute hypoxia produces variations in cytosolic calcium and sodium inhibited by 
CGP-37157. Cytosolic calcium measured with the Fluo-4AM probe (a and c) or cytosolic sodium 
measured with the CoroNa Green probe (b and d) in normoxic (Nx, ●) and hypoxic (2% oxygen; Hp, ○) 
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conditions in BAECs by live cell imaging fluorescence microscopy. (a, b) Control treatment. (c, d) 
Addition of 10 µM CGP-37157 (NCLX inhibitor). Data are represented as mean  s.e.m. of three 
independent experiments. (Photographs) Representative images of Nx and Hp times 0, 10, 20, 30 and 40 
min. (Insets in a-d) Slopes considering all the ROI and time points of each replicate (n = 3) were 
estimated by linear regression and plotted as mean  s.e.m. *** p<0.001 (Student’s t-test). 
 
Hypoxia-induced sodium/calcium exchange was not affected transfection with a scramble 
siRNA (siSCR), while it was abolished when we silenced NCLX by transfecting a siRNA specific 
for this gene (siNLCX; Figure 4.10). 
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Figure 4.10. Acute hypoxia triggers calcium and sodium exchange via NCLX. Cytosolic 
calcium (a-c) or cytosolic sodium (d-f) in normoxic (Nx, ●) and hypoxic (2% oxygen; Hp, ○) conditions 
were measured as in Figure 4.9 in BAECs by live cell imaging fluorescence microscopy. (a and d) Non-
treated controls. (b and e) Cells transfected with scramble siRNA (siSCR). (c and f) Cells transfected 
with siRNA for NCLX (siNCLX). Data are represented as mean  s.e.m. of three independent 
experiments. (Insets in a-f) Slopes considering all the ROI and time points of each replicate (n = 3) were 
estimated by linear regression and plotted as mean  s.e.m. *** p<0.001, * p < 0.05 (Student’s t-test). 
 
NCLX mediates the extrusion of one calcium in exchange for three sodium ions (Poburko 
and Demaurex, 2012) triggering an electrogenic process that is capable of modifying the 
mitochondrial membrane potential (Kim and Matsuoka, 2008). Thus, we questioned whether 
NCLX activity could take part in the mitochondrial depolarization that we have seen in acute 
hypoxia (Figure 4.6). Treatment of BAECs with CGP (Figure 4.11a-b) or NCLX gene knockdown 
(Figure 4.11c-e) inhibited mitochondrial depolarization in acute hypoxia as shown by live cell 
imaging. These findings were corroborated in primary rat cardiomyocytes (Figure 4.11f-g).  
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Figure 4.11. Inhibition of NCLX prevents hypoxic mitochondrial depolarization. BAECs (a-
b) or rat primary cardiomyocytes (f-g) untreated (a, f) or treated with 10 µM CGP-37157 (b, g) were 
subjected to normoxia (Nx, ●) or hypoxia (2% oxygen; Hp, ○) and mitochondrial membrane potential 
detected with the TMRM probe. (f-h)  Same as a-b in untreated (c), siSCR-treated (d) or siNCLX-treated 
(e) BAECs. Data are represented as mean  s.e.m. of the actual fluorescence divided by the fluorescence 
at time 0 (F/F0) of three independent experiments.  
 
Overall, these results show that in acute hypoxia NCLX alters the calcium and sodium 
concentrations in the cytosol, and is involved in the hypoxia-induced mitochondrial depolarization.  
 
4.2.2 NCLX activity is needed for ROS production in acute hypoxia 
We next explored whether NCLX participates in superoxide production in hypoxia. To do 
this, we exposed BAECs to different periods of hypoxia after which we added DHE for 10 min. 
Pre-incubation of BAECs with CGP inhibited the hypoxic burst (Figure 4.12a-b). Similar results 
were obtained in human umbilical vein endothelial cells (HUVECs) treated with CGP (Figure 
4.12c) and in BAECs after NCLX knockdown (Figure 4.12d).  
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Figure 4.12. Inhibition of NCLX prevents the superoxide burst triggered by hypoxia. (a-d) 
Detection of superoxide production by fluorescence microscopy in fixed cells. Cells were incubated for 
60 min in normoxia (Nx), for 30 min in normoxia with antimycin A (AA 10 µM) or incubated with pre-
hypoxic medium in a hypoxia chamber at 1% oxygen (Hp) for 0, 15, 30, 45 or 60 min. DHE (5 µM) was 
added for 10 min more and cells were fixed in the hypoxia chamber. BAECs (a, b) or HUVECs (c) 
without (Control) or with 10 µM CGP-37157. (d) BAECs untreated (Control), or treated with scramble 
siRNA (siSCR) or siRNA against NCLX (siNCLX). (a) Representative images showing DHE 
fluorescence in BAECs. (b-d) Data are presented as mean  s.e.m. of three independent experiments.  
 
We also performed live imaging to measure general ROS production using CDCFDA. 
BAECs treated with CGP did not show an increased DCFDA fluorescence intensity during 
hypoxia (Figure 4.13a-b).  
In addition, we used the ratiometric fluorescent protein HyPer, which is reversibly oxidized 
in cysteine residues by hydrogen peroxide or other peroxides; this oxidation alters the fluorescence 
signal, allowing it to detect changes in the redox state of the cell compartments (Belousov et al., 
2006). When we transfected BAECs with a cytosolic version of the protein, CytoHyPer, the 
oxidation signal decreased upon treatment with dithiothreitol (a thiol-reduding agent) and increased 
after mitochondrial ROS production induced by antimycin A (Figure 4.13c); this shows that the 
protein is sensing redox changes in these cells. Hypoxia induced the increase in the HyPer signal 
during the first 20 minutes of hypoxia, which decreased thereafter (Figure 4.13d), confirming the 
burst in ROS production which is reverted in longer hypoxia times. This peak in ROS production 
was abolished upon treatment with CGP (Figure 4.13e) or 1 µM rotenone (Figure 4.13f). We also 
used mitoHyPer, a HyPer version targeted to the mitochondrial matrix, obtaining similar results 
(Figure 4.13g-h). 
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Figure 4.13. Inhibition of NCLX prevents the increase in mitochondrial ROS production 
triggered by hypoxia. (a and b) Detection of ROS production by live fluorescence microscopy with 
CDCFDA. BAECs untreated (a) or treated with 10 µM CGP-37157 (b) were subjected to normoxia (Nx, 
●) or hypoxia (2% oxygen; Hp, ○). Data are presented as the mean s.e.m. of three independent 
experiments. (Insets in a and b) Slopes considering all time points of each replicate (n = 3) are plotted as 
mean s.e.m. The slope for each replicate was estimated by linear regression of the data for all the ROI 
and time points. * p<0.05 (Student’s t-test). (g-j) Detection of hydrogen peroxide by the ratiometric 
fluorescent probe CytoHyPer. (c) BAECs were transfected with CytoHyPer, treated with 2 mM of the 
thiol reducing agent DTT and with 30 µM of antimycin A (AA). (d-f) CytoHyPer transfected BAECs 
either untreated (d), treated with 10 µM CGP-37157 (e) or with 1 µM rotenone (f) were subjected to 
normoxia (Nx, ●) or hypoxia (1% oxygen; Hp, ○). (a-c) Detection of mitochondrial hydrogen peroxide by 
the ratiometric fluorescent probe Mito-HyPer. BAECs transfected with Mito-HyPer were either untreated 
(g), treated with 10 µM CGP-37157 (h) or with 1 µM rotenone (i) and subjected to normoxia (Nx, ●) or 
hypoxia (1% oxygen; Hp, ○). Data are presented as the mean s.e.m. of four independent experiments. 
n.s. non-significant difference, * p < 0.05, ** p < 0.01 (Student’s t-test). 
 
 
4.2.3 NCLX inhibition has no effect on respiration 
We next sought to determine whether NCLX inhibition impacted cellular respiration. A 
widely used approach to analyse the bioenergetic footprint in cells is the measurement of oxygen 
consumption with subsequent injections of oligomycin, FCCP and antimycin A/rotenone (BOFA 
assay; Figure 4.14a). Once basal respiration is measured, oligomycin is added to inhibit complex V, 
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blocking respiration. Therefore, the amount of oxygen used to produce ATP by OXPHOS is 
estimated from the difference with basal oxygen consumption (i.e. coupling efficiency). FCCP 
uncouples OXPHOS by making the IMM permeable to protons, thus maximizing electron flux 
through the ETC what translates into the cellular maximal respiration. This treatment provides 
information about the stored energy in mitochondria that a cell could use in an energetic crisis (i.e. 
reserve capacity). Antimycin A and rotenone block complexes III and I, respectively, and inhibit 
electron flux through the ETC. This eliminates any proton translocation through this complexes. 
Therefore, the leftover value is the non-mitochondrial respiration, i.e. the oxygen consumed by 
other enzymes in the cell. Ultimately, proton leak is the respiration due to the proton translocation 
due to other molecules than complex V, which is calculated from the remaining respiration after 
oligomycin addition less the non-mitochondrial respiration. 
  We performed BOFA analysis to evaluate the effect of CGP on oxygen consumption rate 
(OCR) and several other respiratory parameters (Figure 4.14a). CGP treatment had no effect on any 
of measured parameters (Figure 4.14a-f) and NCLX knockdown did not affect respiration in 
comparison with control (Figure 4.14g-l), except for an increase in maximal respiration, indicating a 
higher reserve capacity (Figure 4.14j).  
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Figure 4.14. Inhibition of NCLX has no effect on oxygen consumption rate (OCR). (a-f 
Oxygen consumption was measured in a Seahorse XF24 Analyzer in untreated BAECs (Control, ●) or 
BAECs treated with 10 µM CGP-37157 (CGP, ○). (g-l) Oxygen consumption in untreated BAECs 
(Control, ●), BAECs treated with scramble siRNA (siSCR, ○) or with siRNA against NCLX (siNCLX, 
▼) was measured in a Seahorse XF24 Analyzer. (a and g) OCR plots indicating the sequential addition of 
drugs: medium, 5 µg/ml oligomycin (oligom), 300 nM FCCP, 1 µM rotenone and 1 µM antimycin A 
(ant/rot). Boxes (exemplified for the control measurements) represent the calculations shown in b-f and h-
l: ( ) Basal respiration (b, h), ( ) coupling efficiency (c, i), ( ) maximal respiration, ( ) reserve 
capacity (d, j), ( ) proton leak (e, k) and ( ) non-mitochondrial respiration (f, l). Data are presented as 
mean  s.e.m. of three (a-f) or four (g-l) independent experiments.  
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4.2.4 NCLX-dependent sodium/calcium exchange is dependent on mitochondrial 
complex I, but not on complex III  
We next wanted to analyse the relationship between the induction of NCLX activity in 
acute hypoxia and the function of mitochondrial complexes. Previous reports have shown that 
mitochondrial complex III Rieske iron-sulphur protein (RISP) is necessary for ROS production in 
hypoxia (Guzy and Schumacker, 2006a, Hamanaka and Chandel, 2010, Hamanaka et al., 2016) and 
that rotenone, a well-established complex I inhibitor, can abolish it (Archer et al., 1993, Chandel et 
al., 1998). We therefore silenced the expression of key genes in complex I and complex III in 
BAECs to determine whether they were implicated in hypoxic ROS production. NDUFS2 gene 
encodes for the bovine 49 kDa core subunit of complex I whose function is related to the binding 
of ubiquinone. NDUFS4 gene encodes for the bovine 18 kDa accessory subunit of complex I, and 
is related to the stability of the complex (Stroud et al., 2016). UQCRFS1 encodes for RISP protein 
in complex III and is vital for electron transfer from ubiquinol to the rest of complex (Iwata et al., 
1998). Interference with siNUFS4, siNDUFS2 and siRISP reduced clearly the amount of each 
protein interfered (Figure 4.15a-c). We also analysed by blue native electrophoresis (BN-PAGE) the 
organization of mitochondrial complexes and supercomplexes after the interferences. NDUFS4 
knockdown destabilized most of complex I and its corresponding supercomplexes, leaving a 
subcomplex which could be complex I less the N-module as recently reported (Stroud et al., 2016); 
in contrast, the assembly of complex III and the lighter complex III containing supercomplexes 
was not affected (Figure 4.15d-e). RISP knockdown destabilized complex III-containing 
supercomplexes, while preserving a band corresponding to complex III; Western blot of complex I 
in siRISP confirmed the loss of complex III-containing supercomplexes, while the band for 
complex I was maintained assembly was not affectedtogether with the lightest complex I containing 
supercomplex (Figure 4.15d-e). 
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Figure 4.15. Complex I and complex III subunits interference. (a-c) Protein extracts from 
BAECs treated with siSCR, siNDUFS4, siRISP or siNDUFS2 were immunoblotted for NDUFS4, RISP 
or NDUFS2 proteins with tubulin as a loading control. (d and e) BN-PAGE of siSCR-treated, 
siNDUFS4-treated or siRISP-treated BAECs, revealed by western blotting with antibodies against 
NDUFB6 (complex I; d) or Core I (complex III; e).  
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Figure 4.16. Complex I or complex III deficiency or inhibition prevents hypoxic ROS 
production. (a and b) Superoxide detection by fluorescence microscopy with DHE after fixation in 
BAECs treated with siSCR (red or black), siNDUFS4 (orange), siRISP (yellow) or siNDUFS2 (white) 
and subjected to the same protocol as in Figure 1. (c) Untreated (black) or BAECs treated with 1 µM 
WB: NDUFB6
d
siSCR siNDUFS4 siRISP
BAECs e
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BAECs
WB: Core I
SC-CI
CI SC-
CIII
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rotenone (white) were subjected to the same protocol as in Figure 1. (d) Untreated (red) or BAECs treated 
with 1 µM myxothiazol (orange) or 1 µM antimycin A (yellow) were subjected to the same protocol as in 
Figure 4.1. Of note, 1 µM was added to inhibit complex III and 10 µM as the positive control.  
 
All these interventions inhibited the superoxide burst in hypoxia (Figure 4.16a-b); however, 
whereas RISP knockdown resulted in the maintenance of a low superoxide  level both in normoxia 
and hypoxia, NDUFS4 and NDUFS2 knockdown increased superoxide levels in normoxia whilst 
reducing them in hypoxia (Figure 4.16a-b). In order to assess the specificity of these interventions, 
we also used rotenone, an inhibitor of complex I (Figure 4.16c), and 1 µM antimycin A or 
myxothiazol, inhibitors of different sites of complex III (Figure 4.16d), obtaining similar results. 
We performed live imaging to evaluate whether hypoxia-induced sodium/calcium 
exchange was also perturbed in cells after knockdown of complex I and complex III subunits. 
Whereas NDUFS4 knockdown abrogated the activation of sodium/calcium exchange in hypoxia, 
RISP knockdown had no effect (Figure 4.17). In addition, the complex I inhibitor piericidin A 
abolished the sodium/calcium hypoxic exchange, in contrast to the complex III inhibitor antimycin 
A or the complex IV inhibitor potassium cyanide (KCN; Figure 4.18). 
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Figure 4.17. Complex I, but not complex III deficiency prevents hypoxic sodium/ calcium 
exchange. (a-f) Live cell imaging by confocal microscopy measuring cytosolic calcium with the Fluo-
4AM probe (a-c) or cytosolic sodium with the CoroNa Green probe (d-f) in BAECs treated with siSCR 
(a, d), siNDUFS4 (b, e) or siRISP (c, f) subjected to normoxia (Nx, ●) or hypoxia (1% oxygen; Hp, ○). 
Data are represented as mean  s.e.m. of three (d-f) or four (a-c) independent experiments. (Insets in e-j) 
Slopes considering all the ROI and time points of each replicate (n = 4 in a-c; n=3 in d-f) were estimated 
by linear regression and plotted as mean  s.e.m. * p < 0.05, ** p < 0.01 (Student’s t-test). 
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Figure 4.18. Complex I, but not complex III or complex IV inhibition prevents hypoxic 
sodium/ calcium exchange. Live cell imaging by confocal microscopy measuring cytosolic calcium with 
the Fluo-4AM  probe (a, c, e and g) or cytosolic sodium with the CoroNa Green probe (b, d, f and h) in 
BAECs non treated (a and b) or treated with piericidin A (c and d), antimycin A (e and f) or KCN (g and 
h) subjected to normoxia (Nx, ●) or hypoxia (1% oxygen; Hp, ○). Data are represented as mean  s.e.m. 
of three or four independent experiments. (Insets) Slopes considering all the ROI and time points of each 
replicate (n = 3 in a, c, e and g; n=4 in b, d, f and h) were estimated by linear regression and plotted as 
mean  s.e.m. * p<0.05, ** p<0.01 (Student’s t-test). 
 
These results demonstrate the essential role of complex I, but not other mitochondrial 
complexes, in triggering the sodium/calcium exchange in acute hypoxia. In addition, both complex 
I and complex III are necessary for hypoxic superoxide burst 
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4.2.5 PTEN-induced putative kinase 1 (PINK1) is not involved in the hypoxic 
superoxide burst 
Since PINK1 mutation has been associated with inhibition of NCLX activity (Gandhi et 
al., 2009), we silenced PINK1 (Figure 4.19a). We observed that superoxide increased in normoxia 
but hypoxia still triggered the superoxide burst (Figure 4.19b). Interestingly, both raised superoxide 
levels and hypoxic burst could be abolished by treatment with CGP (Figure 4.19b). 
 
 
 
 
 
 
 Figure 4.19. PINK1 deificiency doea 
not affect the hypoxic superoxide burst. (a) 
Protein extracts from BAECs treated with 
siSCR or siPINK1 were immunoblotted for 
PINK1 protein with tubulin as a loading control. 
(b) Superoxide detection by fluorescence 
microscopy with DHE after fixation in BAECs 
treated with siSCR (black), siPINK1 (red) or 
siPINK1 plus 10 µM CGP-37157(green) and 
subjected to the same protocol as in Figure 4.1. 
 
4.2.6 Hypoxia increases the deactive state of mitochondrial complex I  
Activation of NCLX in acute hypoxia could be mediated by the active to deactive 
transition (A/D transition) of complex I and enhancement of its NHE activity. A/D transition 
involves a conformational rearrangement of compelx I resulting in the exposure of Cys-39 within 
the bovine mitochondrial subunit ND3, among other subunits (Babot et al., 2014, Zickermann et 
al., 2015). Labelling of this thiol group with thiol-specific reagents thus constitutes a suitable marker 
for deactivation of complex I (Babot et al., 2014, Galkin et al., 2008, Roberts and Hirst, 2012). Our 
research group is expert in labelling Cys residues with fluorescent residues for their detection in 
electrophoresis techniques (Tello et al., 2009, Izquierdo-Alvarez et al., 2012, Moreno et al., 2014b), 
so we have developed a specific methodology for detecting the exposed Cys-39 residue of ND3 
using a fluorescent maleimide reagent under non-denaturing conditions.  
Using this technique, exposed cysteines in mitochondrial membrane preparations from 
cells subjected to normoxia or hypoxia were labelled with a fluorescent maleimide. The detection of 
the exposed Cys labelling was performed by running the samples in a SDS-PAGE with tricine 
buffer (Schagger, 2006) and total protein signal was stained by Sypro Ruby (Figure 4.20a-b). The 
exposed Cys signal of a protein species of approximately 10 kDa was clearly increased after thermal 
deactivation (Babot et al., 2014, Galkin et al., 2008) (Figure 4.20b, left) and, more interestingly, in 
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samples from hypoxia-treated BAECs (Figure 4.20b, bottom). Total protein amounts, detected with 
Sypro Ruby, were similar in all gel lanes (Figure 4.20b, right). In order to confirm the identity of 
this band, we digested it with trypsin and performed tandem mass spectrometry analysis (LC-
MS/MS), obtaining a fragmentation spectrum corresponding to a peptide of ND3 containing Cys-
39 (Figure 4.20e-f); according to the sequence of the protein, this is the only tryptic peptide that can 
be detected in the usual procedure with this technique.  
Quantification of the ratio of TMR/Sypro signals (exposed Cys vs total protein) for this 
band in several replicates clearly showed that Cys-39 (the only Cys of this protein) was more 
exposed after 5 min of hypoxia and was unaffected by CGP treatment in BAECs (Figure 4.20c) or 
in the hepatocyte cell line HepG2 (Figure 4.20g). Furthermore, exposure of ND3 Cys-39 was 
maintained from 5 to 30 min of hypoxia (Figure 4.20h) and increased gradually with decreasing 
oxygen tension (Figure 4.20d).  
Taken together, these results show that acute hypoxia induces the transition of complex I 
to its deactive state, exposing ND3 Cys-39, and that this occurs proportionally to the level of 
hypoxia. Furthermore, it is maintained during hypoxia and it is a conserved mechanism in other cell 
types. 
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Figure 4.20. Acute hypoxia deactivates complex I. (a-d) Fluorescent labelling of exposed Cys 
in ND3, reflecting complex I deactivation. (a) Cys-39 of ND3 remains buried in active complex I 
(yellow), while it is exposed in deactive complex I (red). Mal-Bodipy-TMR was used to label exposed 
Cys before electrophoretic protein separation. TMR fluorescence signal for the ND3 band was higher 
when complex I was deactive (grey picture). Protein amount for the same band is detected with Sypro 
Ruby staining (red picture). (b, c) Mitochondrial membranes from BAECs treated for 5 min in normoxia 
(Nx), hypoxia (1% oxygen, Hp or H5), normoxia with 10 µM CGP-37157 (NxCGP) or hypoxia with 10 
µM CGP-37157 (H5CGP) were split in two equal parts; one part was incubated for 1 hour at 37 ºC to 
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fully deactivate complex I (Deactivated), whereas the other was kept on ice (Non treated). (b) Bodipy-
TMR signal reflects exposed Cys (left) and Sypro Ruby signal detects total protein (right). Arrows ( ) 
mark the band corresponding to ND3 identified by LC-MS/MS; the lower image on the left is a more 
exposed photograph of the Bodipy-TMR signal. (c) Band corresponding to TMR-labeled ND3 was 
quantified and relativized to total ND3. (d) Same as (c) for BAECs subjected to normoxia or different 
hypoxia conditions (3% or 0.5% oxygen) for 5 min; NxD: thermal deactivation of normoxic sample. Data 
are presented as the mean  s.e.m. of six (c) or three (d) independent experiments.  (e-f) MS/MS 
identification of a peptide of bovine ND3 containing Cys-39, obtained from tryptic digestion of the band 
of a gel from experiment in figure 11b. CID fragmentation MS/MS spectrum (e) and table (f) indicating 
the assigned fragments from the b and y series. (g) ND3 Cys exposure in HepG2 cells subjected to the 
same protocol as in figure 11b-c. (h) ND3 Cys exposure in BAECs treated for 5, 15 or 30 minutes under 
hypoxia (H5, H15 and H30) or 5 min of normoxia as in figure 11b-c. Data in (c-d) are represented as 
mean  s.e.m. of three independent experiments. * p<0.05 (Student’s t-test). 
 
4.2.7 Hypoxia enhances complex I sodium/proton exchanger (NHE) activity  
It has been reported that deactive complex I can function as a NHE antiporter (Roberts 
and Hirst, 2012), so NCLX and complex I function can be coupled by this NHE. However, the 
NHE activity in the inner mitochondrial membrane is usually attributed to the canonical mNHE. 
Thus, we questioned whether mNHE or deactive complex I were involved in this response. Since 
the molecular identity of the mNHE is not known, we treated BAECs with an inhibitor of this 
antiporter 5-(N-ethyl-N-isopropyl)amiloride (EIPA) (Arias et al., 2008), or with rotenone, an 
inhibitor of complex I that inhibits also its NHE activity (Roberts and Hirst, 2012), and observed 
that sodium/calcium exchange was inhibited by rotenone, but not by EIPA (Figure 4.21), 
suggesting that canonical mNHE is not involved in the activation of NCLX. 
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Figure 4.21. Complex I inhibition, but not mNHE inhibition, abolished sodium/calcium 
exchange in acute hypoxia. Cytosolic calcium (a-c) or cytosolic sodium (d-f) measured by live confocal 
microscopy in normoxic (Nx, ●) and hypoxic (1% oxygen; Hp, ○) conditions in control (a, d), rotenone-
treated (b, e) or EIPA-treated (c-f) BAECs. (Insets) Slopes considering all the ROI and time points of 
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each replicate (n=4) were estimated by linear regression and plotted as mean  s.e.m. * p < 0.05, ** p < 
0.01, *** p < 0.001 (Student’s t-test). 
 
We measured mitochondrial matrix pH as a readout of NHE activity in BAECs transfected 
with the FRET-based mitochondrial pH indicator mitosypHer (Poburko et al., 2011). We validated 
the ability of the cytosolic version of this fluorescent protein, CytosypHer, to respond to pH 
changes (Figure 4.22a), the subcellular localization of its mitochondria-targeted version (Figure 
4.22b) and its ability to measure mitochondrial matrix acidification after incubation of cells with 
FCCP or oligomycin (Figure 4.22c). Acute hypoxia acidified the mitochondrial matrix (Figure 
4.22d) independently of CGP treatment (Figure 4.22e). Rotenone treatment abolished hypoxia-
induced acidification (Figure 4.22f). Although this approach does not exclude other mechanisms 
that could also contribute to matrix acidification, the results are compatible with the hypothesis of 
an increase in the NHE activity of complex I. 
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Figure 4.22. Mitochondrial matrix is acidifed in acute hypoxia. (a) A non-targeted version of 
sypHer was used in BAECs in order to perform an experimental control of pH change. BAECs were 
treated with two subsequent additions of 30 µM NaOH and one of 8 mM HCl. Data are represented as 
mean  s.e.m. of eight different ROIs. (b) BAECs transfected with mitosypHer were incubated with 25 
nM MitoTracker CMTMRos for 20 min and fixed. Representative images show mitochondrial 
localization of mitosypHer by confocal microscopy. Pearson and Mander’s correlation coefficients for 
colocalization of both signals were estimated. (c-f) Intramitochondrial pH measured with mitosypHer. (c) 
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488/405 signals ratio reflecting intramitochondrial pH in BAECs transfected with mitosypHer either 
untreated (No treat), or treated with 1 µM FCCP (FCCP) or with 12.5 µM oligomycin (Oligo). Data are 
represented as mean  s.e.m. of four independent experiments. * p < 0.05, *** p < 0.001 (one-way 
ANOVA). Transfected BAECs either untreated (c), treated with 10 µM CGP-37157 (d) or with 1 µM 
rotenone (e) were subjected to normoxia (Nx, ●) or hypoxia (1% oxygen; Hp, ○). Data are represented as 
mean  s.e.m. of the ratio between the fluorescence signals with excitation at 488 nm and 405 nm of four 
independent experiments. (Insets in d-f) Slopes considering all time points of each replicate (n = 4) are 
plotted as mean s.e.m. * p < 0.05, ** p < 0.01 (Student’s t-test).  
 
These results indicate that NCLX ion exchange is not mediated by the canonical NHE and 
that acidification of the mitochondrial matrix is probably due to deactive complex I  NHE activity. 
As a proof of principle, if sodium/proton exchange triggers sodium/calcium exchange and 
superoxide production in hypoxia, normoxic induction of sodium/proton exchange should imitate 
the mentioned events. Accordingly, treatment with the sodium/proton exchanger monensin 
increased intracellular calcium (Figure 4.23a) and superoxide production in normoxia (Figure 
4.23b). 
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Figure 4.23. Induced sodium/proton exchange mimics hypoxic response. (a) Live cell 
imaging by fluorescence microscopy measuring cytosolic calcium with the Fluo 4-AM probe after 
treating BAECs with 10 µM monensin for 20 min. * p<0.05 (Student’s t-test). (b) Non treated BAECs or 
treated with 10 µM monensin for 30 min were subjected to the same procedure as in Figure 4.1. Mean  
s.e.m. of at least three independent experiments. ** p < 0.01 (one-way ANOVA).
 
4.2.8 The superoxide burst is not caused by complex I reverse electron transport 
(RET) 
Since we have observed that complex I is involved in the hypoxic production of ROS by 
mitochondria, we wondered whether RET was involved. Complex I is a reversible enzyme which 
can perform the reduction of NAD+ into NADH by oxidizing ubiquinone into ubiquinol (Drose, 
2013) and translocating protons into the mitochondrial matrix. This process requires large amounts 
of ubiquinol which are normally generated from succinate, and hyperpolarized mitochondria, so 
that the electron flux through complex III is inhibited. In this process the flavin group of complex I 
can reduce large amounts of oxygen into superoxide and has been related to pathophysiological 
processes, such as ischemia/reperfusion injury (Chouchani et al., 2014).  
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Thus, given that succinate is necessary for this process, incubation of cells in media adding 
only the permeable form of succinate, dimethylsucciante (DMS), would maintain the superoxide 
burst in the transition to hypoxia. In the contrary, facilitating the forward complex I reaction by 
NADH-generating substrates such as permeable derivates of glutamate and malate (i.e. glutamine 
and dimethylmalate; GM), would inhibit it. However, in the presence of GM the superoxide burst 
resembled to the control, whereas DMS fed cells did not produce superoxide in hypoxia (Figure 
4.24a). On the other hand, since RET requires hyperpolarized mitochondria, depolarization by 
ionophores should abolish ROS production. We treated BAECs with FCCP and observed that 
there was no difference between non-treated and FCCP-treated cells by differenct approaches 
(Figure 4.24b-d).  
These results indicate that RET is not involved in hypoxic ROS production. Of note, 
hypoxic stabilization of HIF-1α was not affected by mitochondrial depolarization, which supports 
the results discarding RET as the mechanism producing ROS in hypoxia (Figure 4.24e-f). 
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Figure 4.24. Hypoxic ROS production is not due to RET. (a-b) Non treated BAECs (red or 
black) or treated with 5 mM GM (orange), 5 mM DMS (yellow) or 1 µM FCCP (white) were subjected to 
the same procedure as in Figure 4.1. (c) BAECs either non treated or treated with 1 µM FCCP were 
subjected to the same protocol as in Figure 4.5a. (e-f) BAECs untreated or treated 1µM FCCP were 
exposed for 4 hours to normoxia (Nx), normoxia with 1 mM dimethyloxalylglycine (DMOG, a positive 
control for PHD inhibition and HIF-1α stabilization) or to hypoxia (1% oxygen, Hp), proteins extracted 
and blotted against HIF-1α protein. Representative image is shown in (e) and densitometry of three 
independent experiments in (f). 
 
4.2.9 Mitochondrial calcium does not vary in hypoxia  
We don’t know any commercially available probe to measure mitochondrial sodium 
concentration. However, new Förster resonance energy transfer (FRET)-based fluorescent proteins 
such as GEM-GECO have been developed in the recent years which allow a reliable quantitative 
measurement of cellular calcium concentration (Zhao et al, 2010). Also, these proteins can be 
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targeted to specific cell compartments, such as mitochondria. We transfected BAECs with a version 
of the GEM-GECO protein targeted to the mitochondrial matrix (MitoGEM-GECO) and added 
10 µM histamine in order to release endoplasmic reticulum calcium stores. Histamine increases 
cytosolic calcium which then translates into an augmentation in mitochondrial calcium through the 
MCU (Jou et al., 1996). We observed an increase of mitochondrial calcium after 10 µM histamine 
addition (Figure 4.25a). We also incubated transfected BAECs with 10 µM CGP-37157, 1 µM of 
the MCU blocker ruthenium red or 1 µM rotenone and subjected the cells to normoxia or hypoxia. 
CGP-treated cells showed increased mitochondrial calcium, compatible with the inhibition of 
NCLX. Strikingly, we observed no change upon hypoxia in any of the conditions tested (Figure 
4.25b-e), indicating that calcium extrusion from mitochondria was probably being compensated by 
calcium refilling by a MCU-independent pathway. 
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Figure 4.25. Mitochondrial calcium does not change during hypoxia. (a) BAECs were 
transfected with MitoGEM-GECO and treated with 10 µM histamine. (b). Transfected BAECs were 
either untreated or treated with 1 µM ruthenium red 360 (a specific inhibitor of the MCU), 10 µM CGP-
37157 or 1 µM rotenone for 20 min and subsequently incubated in a chamber with atmospheric and 
temperature control in a confocal microscope, where they were maintained in normoxia for 30 min or 
placed in normoxia and switched to hypoxia (1% oxygen) for the rest of the experiment. Black circles: 
normoxia (Nx); white circles: hypoxia (Hp). Quantification of four independent experiments is plotted for 
each time as mean ± s.e.m 
 
4.2.10 Isolated mitochondria produce a burst of ROS triggered by successive 
additions of sodium chloride and calcium chloride 
As mentioned previously, two different groups which have tried to detect ROS in isolated 
mitochondria under hypoxia and obtained opposite results (Hoffman et al., 2007, Korde et al., 
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2011). In both cases, the buffers used to isolate mitochondria do not contain sodium and deplete 
calcium by the addition of a chelating agent (EDTA); the main difference was the addition or not 
of 10 mM sodium chloride in the working solutions. Hoffman et al included sodium chloride into 
the isolation buffer and to the working solutions, and detected that ROS production decreased with 
hypoxia. We reasoned that sodium addition would deplete mitochondrial calcium stores by 
activating NCLX prior to the measurements.  
As a proof of concept, if NCLX activity was necessary for ROS production by 
mitochondria, sodium addition could activate NCLX, triggering calcium extrusion and producing 
ROS in isolated mitochondria in normoxia. 
We first tested whether the addition of sodium chloride or calcium chloride was able to 
induce any change in ROS production or respiration in isolated adult rat heart mitochondria. There 
are several states in which isolated mitochondria can be maintained. Mitochondrial solutions with 
no energy source are in the so called state 1, thus oxygen is not consumed. Addition of substrates 
such as glutamate/malate (GM; donate electrons through complex I) or succinate (through 
complex II) triggers the state 2 and oxygen consumption increases. Coupling respiration with ADP 
stimulates respiratory state 3, leading to maximal respiration. State 4 is reached after all the ADP is 
converted to ATP what translates into a decrease in oxygen consumption. Finally, anoxia stops 
respiration and mitochondria fall into state 5 (Chance and Williams, 1955, Babcock and Wikstrom, 
1992).  
We performed experiments in which mitochondrial respiratory state 2 was induced by 
addition of GM. Successive additions of the specified salts or diluent (water) were performed and 
ADP added thereafter; finally, complex II-based respiration was induced by succinate add-on 
(Figure 4.26a; black circles). Successive additions of calcium chloride produced a biphasic effect om 
respiration, which increased after the two additions, and then decreased after reaching 1 mM of 
total calcium chloride concentration addition (Figure 4.26a; white bars). Notably, after addition of 
the highest calcium chloride amount, neither ADP nor succinate were able to fully couple 
respiration. Hydrogen peroxide production slightly decreased after several additions of water, 
probably due to dilution of the sample, and increased only with succinate (Figure 4.26b; black bars). 
Mitochondria treated with calcium chloride rose hydrogen peroxide levels only after reaching 1 mM 
concentration, coinciding with the decrease shown in respiration (Figure 4.26b; white bars). In 
contrast, progressive increase in sodium chloride concentration up to 15.6 mM had no effect on 
oxygen consumption or ROS (Figure 4.26c-d), indicating that sodium had no effect on any of them 
and that chloride was not responsible for the effects seen in Figure 4.26a-b.  
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Figure 4.26. Different effects of calcium and sodium additions in energized isolated 
mitochondria. (a and c) Variations in oxygen consumption induced by successive additions of calcium 
chloride (a) or sodium chloride (c) after glutamate and malate based state 2 measured by Oxygraph-2k . 
State 3 was induced by addition of ADP and contribution of complex II by succinate. (b and d) ROS 
production in calcium chloride (b) or sodium chloride (d) treated mitochondria was measured by Amplex 
Red in parallel to respiration. (e and f) Successive addition of small amounts of sodium chloride and 
calcium chloride were aded in order to activate NCLX and the effects on respiration (e) and ROS 
production (f) were measured. (g) Representative trace of ROS production with successive addition of 
small amounts of sodium chloride and calcium chloride. 
 
It has been reported that mixtures of sodium chloride and calcium chloride could activate 
NCLX in isolated energized mitochondria (Carafoli et al., 1974). 100 µM of sodium chloride ddi 
not had any effect in neither oxygen consumption nor ROS production (Figure 4.26e-f). However, 
subsequent addition of 200 µM calcium choride moderately increased respiration hydrogen 
peroxide levels (Figure 4.26e-f). Interestingly, 100 µM  calcium chloride further increased 
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respiration and produced a new burst of ROS, although less pronounced (Figure 4.26e-f).The 
production of ROS by mixtures of sodium chloride and calcium chloride generate a reversible 
induction of ROS. This is represented in Figure 4.26g which is the trace of one experimental 
replicate. Therefore, activation of NCLX by small amounts of sodium and calcium are sufficient to 
produce a burst of ROS in rat heart isolated mitochondria. 
4.3 NCLX activity is involved in hypoxic adaptation and injury 
4.3.1 Hypoxic adaptation through HIF-1 α stabilization correlates with the hypoxic 
superoxide burst, but superoxide is not the key species in this pathway 
As previously stated, hypoxic ROS production has been implicated in triggering hypoxia 
adaptation signals through the HIF pathway, mediated by HIF-α subunits stabilization (Guzy and 
Schumacker, 2006b, Hamanaka and Chandel, 2009, Guzy and Schumacker, 2006a, Hamanaka and 
Chandel, 2010). Additionally, we have recently showed that in endothelial cells there is a reversible 
oxidation in certain proteins after two hours of hypoxia, that could be implied in acute responses to 
hypoxia (Izquierdo-Álvarez et al., 2012). Indeed, it has been recently shown that PHD proteins 
respond to Cys oxidation (Briggs et al., 2016). Thus, the superoxide burst we observe could take 
part in hypoxic signals at longer times, related with the different kinetics of accumulation of 
different oxidized species.  
In order to test this, we studied HIF-1α stabilization in the systems in which we have been 
able to abolish the superoxide burst in hypoxia. First, we used ρ0 cells, as it has been published 
elsewhere for other ρ0 cells that they are not able to stabilize HIF-1α (Guzy et al., 2005, Mansfield 
et al., 2005, Chandel et al., 1998). ρ0L929 cells subjected to 4 hours of hypoxia did not stabilize 
HIF-1α as happened in the control C57 cells (Figure 4.27). However, treatment with 1 mM 
dimethyloxalylglycine (DMOG, a PHD inhibitor) stabilized the α subunit in both cell lines, 
indicating that PHDs activity was similar (Figure 4.27).  
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Figure 4.27. Hypoxic HIF-1α stabilization relies on functional mitochondria. C57 and 
ρ0L929 cells were exposed for 6 hours to normoxia (Nx), normoxia with 1 mM DMOG, a positive control 
for PHD) or to hypoxia (1% oxygen, Hp), proteins extracted and blotted against HIF-1α protein. 
Representative image is shown in (a) and densitometry of three independent experiments in (b). 
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Second, we assayed HIF-1α stabilization after NCLX inhibition. Inhibition of NCLX 
activity with CGP abolished hypoxic HIF-1α stabilization in BAECs (Figure 4.28a-b) and in 
HUVECs (Figure 4.28c-d), and a comparable effect was detected after silencing NCLX expression 
(Figure 4.28e-f). Importantly, induction of sodium/proton exchange with monensin stabilized HIF-
1α in normoxia in BAECs (Figure 4.28g-h). 
 
Figure 4.28. Inhibition of NCLX inhibits HIF-1α stabilization. HIF-1α stabilization measured 
by western blotting in BAECs (a and b) or HUVECs (c and d) treated or not with 10 µM CGP-37157 
(CGP), or BAECs untreated or treated with siSCR or siNCLX (e and f), and exposed for 4 h to normoxia 
(Nx), normoxia with 1 mM DMOG or to hypoxia (1% oxygen, Hp). Tubulin was used as a loading 
control. Representative images of at least four independent experiments are shown. Densitometries of a, c 
and e are shown in b, d and f. (g and h) HIF-1α stabilization measured by western blotting in BAECs 
either untreated, treated with 10 µM monensin (Mon) or with 1 mM DMOG for 4 h in normoxia. 
Representative image is shown in (g) and densitometry of three independent experiments in (l). 
 
We also measured expression levels of HIF target genes, such as PDK1, Glut1 and BNIP3 
by RT-PCR in HUVECs. Treatment with CGP diminished the hypoxic induction of all genes in 
comparison with non-treated cells (Figure 4.29a-c), whereas HIF-1α and HIF-2α mRNAs amounts 
did not change after treatment with CGP (Figure 4.29d-e). 
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Figure 4.29. Activation of the HIF pathway is prevented by NCLX inhibition. (a-e) 
Quantitative RT-PCR analysis of Glut1 (b), BNIP3 (c), PDK1 (d), HIF-1α (e) and HIF-2α (f) mRNAs in 
untreated (black) or 10 µM CGP-37157-treated (white) HUVECs subjected to 6 hours of normoxia (Nx), 
hypoxia (1% oxygen, Hp) or normoxia with 1 mM DMOG. Data are represented as mean s.e.m. of the 
β-actin ratio relative to normoxia for four independent experiments. * p < 0.05, ** p < 0.01 Control Hp 
versus CGP Hp of each condition (Student’s t-test). 
 
Third, we used Tiron, which abolishes the superoxide burst (Figure 4.1f). However, Tiron 
treatment in BAECs did not abolish HIF-1α stabilization in hypoxia and even increased it, both in 
normoxia and in hypoxia (Figure 4.30a-b). Measurement of CDCFDA oxidation showed that cells 
with Tiron produced equal or slightly higher signals than cells without treatment (Figure 4.30c; this 
can be related to the oxidation of superoxide due to the reaction with Tiron, producing mainly 
hydrogen peroxide, Thus, we can discard superoxide as the species directly involved in HIF-1α 
stabilization, while the increase in hydrogen peroxide could be implied in it. which can explain 
increased HIF-1 α stabilization. 
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Figure 4.30. Hypoxic HIF-1α stabilization does not depend on superoxide anion. (a and b) 
BAECs were exposed for 4 hours to normoxia (Nx), normoxia with 1 mM DMOG or to hypoxia for 2 
(Hp2H) or 4 hours (Hp4H), proteins extracted and blotted against HIF-1α protein. Representative image 
is shown in (a) and densitometry of three independent experiments in (b). (c) Control BAECs (black bars) 
and BAECs incubated with 1 mM Tiron (white bars) were treated as in Figure 2c and d. 10 µM CDCFDA 
was added for 15 min more, and cells were fixed in the hypoxia chamber. Plot shows the quantification of 
images from three independent experiments. Data are presented as mean  s.e.m. *** p < 0.001 versus 
Nx, ** p < 0.01 versus Nx, * p < 0.05 versus Nx of each condition (Dunnet post-hoc test; n = 3). 
 
4.3.2 Inhibition of NCLX inhibits the redox component of hypoxic pulmonary 
vasoconstriction (HPV) 
We wondered whether inhibition of the mechanism we have revealed, in which NCLX is 
implied in the hypoxic superoxide burst, played a role in physiological or pathological scenarios 
where hypoxia has been described to produce reactive oxygen species.  
Among the acute responses to hypoxia, HPV helps to match lung ventilation with 
perfusion by inducing a contractile response in pulmonary arteries (PA) which has been shown to 
depend on increased mitochondrial ROS (Connolly et al., 2013, Frazziano et al., 2011, Sylvester et 
al., 2012). Smooth muscle cells are the key cells implied in HPV, so we subjected rat pulmonary 
artery smooth muscle cells (PASMCs) to acute hypoxia, observing the superoxide- burst in the first 
minutes of hypoxia, which was abolished upon silencing of NCLX (Figure 4.31a-b); this confirms 
the presence of the same NCLX-dependent hypoxic response in these cells. In rat PA, exposure to 
hypoxia in the absence of pretone (precontraction) induced a rapid contractile response within 2-4 
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min (peak contraction), which then decayed and reached a plateau after 10-12 minutes (steady state 
contraction). This response resembled physiological HPV and was reproducible in successive 
treatments of the same artery (Figure 4.31c). A second challenge with hypoxia was performed in the 
absence or in the presence of CGP. In arteries treated with vehicle, the peak and steady state 
contractions of HPV were similar to those obtained during the first hypoxic challenge (Figure 
4.31c-d). By contrast, CGP treatment had no effect on the peak contraction but markedly reduced 
the steady-state component of the HPV contraction (Figure 4.31d-e). A similar inhibition was 
shown upon treatment with ROS scavengers and ETC inhibitos (Moreno et al., 2014a). Thus, 
NCLX inhibition blocks part of the HPV in PA which could be related to the abolition of the 
superoxide burst in smooth muscle cells in hypoxia. 
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Figure 4.31. Inhibition of NCLX blunts hypoxic pulmonary vasoconstriction (HPV). (a) 
Quantitative RT-PCR analysis of NCLX mRNA in PASMCs treated with siSCR or siNCLX. Data are 
presented as mean s.e.m. of the GAPDH ratio relative to siSCR-treated cells for three independent 
experiments. ** p<0.01 (Student’s t-test vs. 1). (b) PASMCs were treated with siSCR or siNCLX and 
subjected to the same procedure as in Figure 1a. Mean  s.e.m. of four independent experiments. (c-e) 
Representative traces (c and e) and average values (d) of HPV measured in rat PA. Each artery was 
exposed twice to hypoxia. The second hypoxic challenge was performed in the absence (control, c) or the 
presence of 30 M CGP-37157 (CGP; e). Data are expressed as a percentage of the first hypoxic 
contractile response, represented as mean ± s.e.m. * p < 0.05 vs control (ANOVA and Bonferroni’s test; n 
= 7-9). 
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4.3.3 Inhibition of NCLX abolishes the hypoxic response in neuronal cells and brain tissue, 
and reduces brain ischemic damage 
Since most of the preceding experiments were carried out in non-excitable cells (mainly 
primary endothelial cells), we questioned whether inhibition of NCLX activity could also be 
observed in excitable cells, such as neurons. Both the hypoxic superoxide burst and HIF-1α 
stabilization was abolished in HT22 immortalized mouse hippocampal neuronal cells treated with 
CGP (Figure 4.32a, c). To check for the specificity of the treatment, NCLX expression was silenced 
in HT22 cells, which also abolished the superoxide burst in acute hypoxia (Figure 4.32b).  
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Figure 4.32. NCLX inhibition abolishes hypoxic ROS production and HIF-1α stabilization 
in neurons. (a) Control untreated (black) and 10 µM CGP-37157-treated (CGP; white), (b) or treated 
with siSCR or siNCLX HT22 cells were subjected to the same procedure as in Figure 4.1a. Mean  s.e.m. 
of three independent experiments. On the right, protein extracts from BAECs treated with siSCR or 
siNCLX immunoblotted for NCLX protein with tubulin as a loading control. (c) HT22 cells were 
subjected to the same procedure as in Figure 4.27. Representative images and densitometry of three 
independent experiments.  
 
To further study this effect in brain tissue, we exposed isolated mouse hippocampal slices 
to acute hypoxia. After 30 min of hypoxia, complex I was deactivated, independently of the 
treatment with CGP (Figure 4.33a). However, the hypoxia-dependent increase in superoxide 
production (Figure 4.33b-c) and HIF-1α stabilization (Figure 4.33d) were selectively abolished with 
CGP. Overall, these results strongly suggest that the same mechanism operates in excitable cells 
such as neurons and in the hippocampus. 
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Figure 4.33. NCLX inhibition abolishes hypoxic ROS production and HIF-1α stabilization, 
but not complex I deactivation, in brain tissue. (a) Hippocampal slices were subjected to 30 min of 
normoxia (Nx), hypoxia (1% oxygen; H30), normoxia with 30 M CGP-37157 (NxCGP) or hypoxia with 
30 M CGP-37157 (H30CGP) and treated as in Figure 4.20b-c. Mean  s.e.m. of three independent 
experiments. (b and c) Hippocampal slices untreated (Control) or treated with 30 µM CGP-37157 (CGP) 
were incubated for 30 min in normoxia (Nx), in normoxia with antimycin A (AA 10 µM) or in hypoxia at 
1% oxygen (Hp 30-40 min). DHE (5 µM) was added for 10 min more, and slices were fixed in the 
hypoxia chamber. (b) Representative images showing DHE fluorescence. (c) Data are presented as mean 
 s.e.m. of four independent experiments. (d) Untreated or 30 µM CGP-37157-treated hippocampal slices 
were exposed for 4 hours to normoxia (Nx), normoxia with 1 mM DMOG or to hypoxia (1% oxygen, 
Hp), proteins extracted and blotted against HIF-1α protein and tubulin. Representative image and 
densitometry of four independent experiments. ** p<0.01, *** p<0.001 (Student’s t-test). 
 
Finally, we addressed whether the pharmacological inhibition of NCLX could be protective 
in an in vivo model of photothrombotic ischemic injury. The ischemic insult is caused by the 
reaction of the photosensitive dye Rose Bengal with a cold light, which induces thrombi formation 
in the brain vessels. At the end of the experiment, the infarcted area is differentiated by 
triphenyltetrazolium chloride staining. We have analysed separately the infarcterd area, the 
ipsilateral area including the penumbra region around the infarct (where there is a partial ischemia) 
and the contralateral area (the symmetric half of the brain, which remains in normoxia). Complex I 
deactivation was clearly observed in the infarcted area of mice, independently of CGP treatment 
which was less obvious but also seen in the ipsilateral area (Figure 4.34a). In contrast, CGP-treated 
mice had a significantly smaller infarct size compared with non-treated littermates (Figure 4.34b-c).  
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Figure 4.34. NCLX inhibition protects brain from ischemic damage without affecting 
complex I deactivation. Mice were subjected to photothrombotic stroke induction and treated either with 
vehicle or with 30 mg/kg of CGP-37157 5 min after illumination. (a) ND3 Cys exposure (as in Figure 
4.20b) from samples of different regions of the brain: infarct, ipsilateral (IPSI) and contralateral (Contra). 
(b and c) Brain tissue was stained with triphenyltetrazolium chloride and the infarct volume quantified. 
Data represents mean ± s.e.m. of the quantification of the infarct volume. *** p < 0.001 vs vehicle  
(Student’s t-test; n = 7).  
 
In summary, NCLX inhibition prevents the superoxide burst in hypoxia in neurons and 
neuronal tissue, independently of Complex I deactivation and lowers the infarct size in an ischemic 
injury mice model. 
 
4.4. Sodium overload alters NCLX activity and ROS production 
4.4.1 Sodium overload alters the sodium/calcium exchange in acute hypoxia 
As mentioned in the introduction, sodium overload is a common feature in diseases where 
hypoxia is present. Therefore, we wondered whether sodium overload could affect the Complex I-
NCLX-ROS pathway in the transition from normoxia to hypoxia. Since we have described most of 
this pathway in non-excitable primary endothelial cells and the measurement of Ca2+i and Na+i is 
not reliable in excitable cells due to the action potential variations (personal observation), we 
decided to study sodium overload by adding 100 mM of sodium chloride salt in BAECs culture 
medium of BAECs (i.e. doubling the normal sodium chloride concentration  in RPMI, which is 120 
mM).  
First, we analysed sodium and calcium cytosolic concentrations in the transition from 
normoxia to hypoxia by live fluorescence imaging. Increased extracellular sodium concentration 
augmented basal intracellular Na+i; (Figure 4.35a). Incubation of BAECs in hypoxia decreased Na+i, 
while in normoxia treatment it remained constant throughout all the experiment (Figure 4.35a-b). 
Sodium overload altered the hypoxic Na+i decrease (Figure 4.35a-b). Indeed, hypoxia triggered a 
Ca2+i rise which was abolished by sodium overload (Figure 4.35c-d). Of note, basal Ca2+i levels were 
higher in BAECs under sodium overload than in non-treated controls (Figure 4.35c) which suggests  
NCLX activation upon sodium overload. 
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Figure 4.35. Sodium overload alters hypoxic sodium/ calcium exchange, but not complex I 
deactivation. (a) Cytosolic sodium measured with the CoroNa Green probe or cytosolic calcium 
measured with Fluo-4AM (C) in normoxia (Nx, ●), hypoxia (2% oxygen; Hp, ○), normoxia plus 100 mM 
sodium chloride (Nx NaCl, ) or hypoxia plus 100 mM sodium chloride (Hp NaCl, ) in BAECs by live cell 
imaging fluorescence microscopy. (b and d) Slopes considering all the ROI and time points of each 
replicate (n = 3) were estimated by linear regression and plotted as mean  s.e.m. A and C are plotted in B 
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and D respectively. Untreated BAECs (e) or treated with extra 100 mM sodium chloride (f) were 
subjected to normoxia (Nx, ●) or hypoxia (2% oxygen; Hp, ○) and mitochondrial membrane potential 
detected with the TMRM probe. Data are represented as mean  s.e.m. of the actual fluorescence divided 
by the fluorescence at time 0 (F/F0) of three independent experiments. (g) Fluorescent thiol labelling and 
quantification of ND3 residue Cys39. BAECs were subjected to hypoxia or normoxia for 5 min in the 
presence or absence of further 100 mM sodium chloride. Maximal exposure of the residue was measured 
by treating the same samples at 37ºC for 60 min. Quantification shows the mean ± s.e.m. of three 
independent experiments. *** p < 0.001 (Student’s t-test; n = 3). 
 
As NCLX-mediated exchange is an electrogenic process, we also measured mitochondrial 
depolarization in acute hypoxia. Non-treated BAECs showed hypoxic mitochondrial depolarization 
(Figure 4.35e) which was inhibited by sodium overload (Figure 4.35f). Interestingly, increased 
sodium depolarized mitochondria in normoxic conditions (Figure 4.35f). This correlates well with 
overactivation of NCLX which performs an electrogenic exchange and mitochondrial 
repolarization (Kim and Matsuoka, 2008). 
We also questioned whether the dysregulation of sodium/calcium exchange by sodium 
overload was due to alteration of hypoxic complex I deactivation. Sodium overload was induced in 
BAECs before and during acute hypoxia and complex I deactivation detected through ND3 Cys39 
fluorescent labelling. We observed an increased deactivation of complex I in acute hypoxia, which 
was maintained by sodium overload (Figure 4.35g).  
NCLX is the only member in its family insensitive to potassium and blocked by lithium 
(Palty et al., 2010), thus if any other member of the sodium/calcium exchanger family was involved 
the response, it should be inhibited by increased potassium and not by lithium. We treated BAECs 
with doubled media potassium concentration (i.e. addition of 5 mM potassium chloride in the 
media over the already 5 mM present) or added 30 mM lithium chloride. Increased potassium 
diminished the raise in cytosolic calcium and had no effect on sodium decrease (Figure 4.36b,e ), in 
contrast to, lithium chloride treatment which clearly abolished both (Figure 4.36c,f).  Thus, 
sodium/calcium exchange is specifically inhibited by lithium chloride, reinforcing the hypothesis of 
the involvement of NCLX. Besides, the effect seen in the hypoxic cytosolic calcium by potassium 
may arise from alteration of plasma membrane potassium currents. 
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Figure 4.36. Alteration of NCLX activity modifies hypoxic mitochondrial sodium/ calcium 
exchange. (a-c) Cytosolic calcium measured with the Fluo-4AM probe or cytosolic sodium measured 
with Corona Green (d-f) in BAECs non treated or treated with extra 5 mM potassium chloride or 30 mM 
lithium chloride subjected to normoxia (Nx, ●) or hypoxia (2% oxygen; Hp, ○) by live cell imaging 
fluorescence microscopy. (Insets in a-f) Slopes considering all the ROI and time points of each replicate 
(n = 3) were estimated by linear regression and plotted as mean  s.e.m. 
 
We measured the variation in mitochondrial membrane potential in BAECs and observed 
that increased potassium had no effect in any of the conditions and lithium chloride inhibited 
hypoxic mitochondrial depolarization (Figure 4.37). In neonatal rat primary cardiomyocytes 
addition of 100 mM sodium chloride or 30 mM lithium chloride clearly abolished hypoxic 
mitochondrial depolarization, while addition of 5 mM potassium chloride did not affect it (Figure 
4.38). 
 
TMRM 30 mM LiCl
Time (min)
0 10 20 30 40
F/
F0
0.0
0.5
1.0
1.5
2.0
Nx 
Hp 
Time (min)
 TMRM Control
0 10 20 30 40
F
/F
0
0.0
0.5
1.0
1.5
2.0
Nx 
Hp 
a c TMRM  + 5 mM K
Time (min)
0 10 20 30 40
F/
F
0
0.0
0.5
1.0
1.5
2.0
Nx 
Hp 
b Cl
 
Figure 4.37. Alteration of NCLX activity modifies hypoxic mitochondrial depolarization. 
Untreated BAECs (a) or BAECs treated with extra 5 mM potassium chloride (b) or 30 mM lithium 
chloride (c) were subjected to the same protocol as in Figure 4.11. Data for TMRM fluorescence are 
represented as mean  s.e.m. of the actual fluorescence divided by the fluorescence at time 0 (F/F0) of 
three independent experiments. 
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Figure 4.38. Alteration of NCLX activity modifies hypoxic mitochondrial depolarization in 
cardiomyocytes. Untreated primary rat cardiomyocytes untreated (j) or treated with extra 100 mM 
sodium chloride (k), 30 mM lithium chloride (l) or extra 5 mM potassium chloride (m) were subjected to 
the same protocol as in Figure 4.11. Data for TMRM fluorescence are represented as mean  s.e.m. of the 
actual fluorescence divided by the fluorescence at time 0 (F/F0) of three independent experiments. 
 
All together, these results show that sodium overload abolishes hypoxic mitochondrial 
sodium/calcium exchange and depolarization, independently of complex I deactivation. Of note, 
excess of sodium probably pulls calcium out of mitochondria via NCLX anticipating the hypoxic 
sodium/calcium exchange.  
 
4.4.2 Sodium overload alters cellular respiration 
Since we observed that sodium overload depolarizes mitochondria we reasoned that it 
could have an effect on mitochondrial bioenergetics. Thus, we examined whether oxygen 
consumption was altered in a BOFA experiment. Basal respiration and coupling efficiency (i.e. the 
amount of oxygen used for the OXPHOS to produce ATP) were affected (Figure 4.39a-c), which 
was expected since both are directly dependent on ΔΨmt. The reserve capacity (oxygen consumed 
from the mitochondrial energy stores) of sodium-overloaded BAECs was abolished (Figure 4.39d); 
this suggests that the excess of sodium reduces TCA cycle dehydrogenases turnover, probably due 
to depletion of mitochondrial calcium through NCLX activation. Interestingly, proton leak was not 
affected by this treatment, indicating that it did not permeabilize the IMM or trigger uncoupling 
due to activation of uncoupling proteins (UCPs), mitochondrial permeability transition pore 
(mPTP) or by other means (Figure 4.39e). Intriguingly, non-mitochondrial respiration also 
decreased, suggesting that other systems using oxygen as a substrate were affected as well (Figure 
4.39f). 
The extracellular acidification rate (ECAR) is proportional to the glycolysis rate in cells. 
ECAR was higher in sodium-overloaded BAECs in comparison to control, indicating that the 
reduction in OXPHOS was compensated with an increased glycolysis (Figure 4.39g). Accordingly, 
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the glycolytic reserve (i.e. maximal glycolysis), which is obtained after oligomycin addition, was 
lower in sodium overloaded cells, suggesting that they already reached the highest glycolysis rate 
(Figure 4.39h). Strikingly, this value was negative in sodium overloaded BAECs. Sodium-dependent 
inhibition of respiration would translate in matrix acidification since sodium entry into the 
mitochondria would activate the canonical NHE. This would extrude sodium in exchange of 
protons which acidifies the matrix. Now, in response to matrix acidification and in order to 
maintain certain level of ΔΨmt, complex V could work pumping protons to the IMS. Thus, 
inhibition by oligomycin woul stop proton pumping by complex V, decreasing extramitochondrial 
and, in turn, extracellular proton content,, lowering ECAR. 
 
Basal respiration
Control NaClO
C
R
(p
m
ol
/m
in
)
a
Time (min)
O
C
R
(p
M
ol
es
/m
in
)
medium oligom FCCP ant/rot
0
40
80
120
160
Coupling efficiency Proton leak
0
10
20
30
40
50
Non-mito resp
0
20
40
60
Reserve capacity
10 20 30 40 50 60 70 80 90 100 110 120 130 140
0
50
100
150
200
250
b
Control NaCl Control NaCl Control NaClO
C
R
(p
m
ol
/m
in
)
O
C
R
(p
m
ol
/m
in
)
O
C
R
(p
m
ol
/m
in
)
O
C
R
(p
m
ol
/m
in
)
c d e f
0
20
40
60
80
100
120
120
160
Control NaCl0
40
80
Control
NaCl
Basal ECAR
Control NaCl
EC
A
R
(m
pH
/m
in
)
0
2
4
6
8
10
12
14
Glycolytic reserve
EC
A
R
(m
pH
/m
in
)
-6
-4
-2
0
2
4
6
8
Control NaCl
g h
** ** ** *
* ***
 
Figure 4.39. Sodium overload switches aerobic to anaerobic metabolism. (a-f) Oxygen 
consumption was measured in a Seahorse XF24 Analyzer in untreated BAECs (Control, ●) or BAECs 
treated with 100 mM sodium chloride added to the media (NaCl, ○). (a) OCR plots indicating the 
sequential addition of drugs: medium, 5 µg/ml oligomycin (oligom), 300 nM FCCP, 1 µM rotenone and 1 
µM antimycinA (ant/rot). Basal respiration (b), coupling efficiency (c), maximal respiration (d), reserve 
capacity, proton leak (e) and non-mitochondrial respiration (f). (g) Extracellular acidification rate 
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(ECAR) measured in untreated or BAECs treated with extra 100 mM sodium chloride. (h) ECAR 
measured after oligomycin addition, indicating the glycolytic reserve of the cells. Data are presented as 
mean  s.e.m. of three independent experiments. * p < 0.05, ** p < 0.01 , *** p < 0.001 (Student’s t-test; 
n = 4). 
 
In summary, sodium overload switches the metabolism, probably through NCLX, towards 
a rather glycolytic profile without increasing mitochondrial permeability. 
4.4.3 Hypoxic superoxide burst is altered by sodium overload 
Since mitochondrial hypoxic sodium/calcium exchange was altered by sodium overload we 
wondered whether superoxide production in hypoxia was also affected when we added extra 100 
mM sodium chloride to the cells. Non-treated BAECs generated superoxide in the first minutes of 
hypoxia, which declined to basal levels within an hour (Figure 4.40a,c). However, sodium overload 
increased superoxide production in normoxia which then diminished in hypoxia, thus rendering 
superoxide levels proportional to oxygen concentration (Figure 4.40b,d). Importantly, normoxic 
sodium overload-derived increase in superoxide was abolished by CGP-37157 (Figure 4.40b), 
indicating that NCLX is specifically required for the effect of sodium overload in normoxic ROS 
production, and suggesting again that sodium chloride addition may drive a normoxic 
sodium/calcium exchange in the mitochondria through NCLX, which affects superoxide 
production. 
In addition, we performed live imaging experiments using the fluorescent probe CDCFDA. 
Sodium overload inhibited ROS increase in hypoxia, but it raised the basal levels of ROS (Figure 
4.40e-f). Of note, sodium-overloaded BAECs did not show a decline in ROS production with 
CDCFDA in hypoxia in comparison to normoxia, probably due to irreversibility of the probe 
oxidation.  
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Figure 4.40. Sodium overload and not high osmolarity increases normoxic superoxide levels 
and abolishes the hypoxic superoxide burst. (a-d) Detection of superoxide production by fluorescence 
microscopy in fixed cells. Cells were incubated as in Figure 4.1. (a and b) Representative images 
showing DHE fluorescence in BAECs. Superoxide levels were measured in non-treated BAECs (Control) 
or with extra 100 mM sodium chloride (NaCl) (a-c), CGP-37157 or 100 mM sodium chloride plus 10 µM 
CGP-37157 (d). Data are presented as mean  s.e.m. of three independent experiments. ** p < 0.01 (one-
way ANOVA). (e and f) Detection of ROS production by live fluorescence microscopy with CDCFDA. 
(e) Untreated BAECs in normoxia (Nx, ●) or hypoxia (2% oxygen; Hp, ○), or treated with extra 100 mM 
sodium chloride in normoxia (Nx NaCl, ) or hypoxia (2% oxygen; NaCl Hp, ). (f) Slopes considering 
all time points of each replicate (n = 3) are plotted as mean s.e.m. The slope for each replicate was 
estimated by linear regression of the data for all the ROI and time points. * p<0.05 of Nx versus Hp 
(Student’s t-test). 
 
Furthermore, in order to check whether the superoxide burst was being altered via NCLX 
we treated BAECs with doubled potassium or 30 mM lithium chloride. Expectedly, whereas 
potassium addition had no effect on the superoxide burst, lithium abolished it (Figure 4.41a-b).  
The same results were obtained with the probe CDCFDA (Figure 4.41c-e). 
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Figure 4.41. Modification of NCLX activity influences hypoxic superoxide and ROS production. (a 
and b) Detection of superoxide production by fluorescence microscopy in fixed cells. Non-treated 
BAECs (Control) or treated with extra 5 mM potassium chloride (KCl) (a) or 30 mM lithium chloride (b) 
were subjected to the same protocol as in Fig. 3A. (c-e) Detection of ROS production by live fluorescence 
microscopy with DCFDA. (c) Untreated BAECs in normoxia (Nx, ●) or hypoxia (2% oxygen; Hp, ○), or 
treated with extra 5 mM potassium chloride (d) or 30 mM lithium chloride (e). (Instets in c-e) Slopes 
considering all time points of each replicate (n = 3) are plotted as mean s.e.m. The slope for each 
replicate was estimated by linear regression of the data for all the ROI and time points. Data are presented 
as the mean s.e.m. of three independent experiments. 
 
Altogether, these results show that sodium overload inverts NCLX-dependent ROS 
production in the transition from normoxia to hypoxia. Importantly, activating NCLX-dependent 
sodium/calcium exchange by sodium overload in normoxia promotes mitochondrial depolarization 
and ROS production. This supports the hypothesis of NCLX activation as a key player in 
superoxide generation by mitochondria.  
 
4.4.4 HIF-1 pathway activation in hypoxia is inhibited by sodium overload 
Since hypoxic HIF-1α stabilization has been linked to ROS production in hypoxia (Guzy et 
al., 2005, Chandel et al., 1998, Brunelle et al., 2005, Mansfield et al., 2005) and since sodium 
overload altered ROS levels both in normoxia and hypoxia, we wondered whether sodium increase 
affected HIF-1α presence in hypoxia. We observed an increase in HIF-1α stabilization in hypoxia 
and DMOG, while sodium-overloaded BAECs showed a reduced stabilization of HIF-1 α in 
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hypoxia, in contrast to DMOG-treated cells (Figure 4.42a-b). This was replicable in human 
umbilical vein endothelial cells (HUVECs) and HeLa cells (Figure 4.42c-d).  
 
 
Figure 4.42. Sodium overload abolishes HIF-1α stabilization through NCLX inactivation in several 
cell types. HIF-1α stabilization measured by western blotting in BAECs (a, b and e-h), HUVECs (c, i 
and j) and HeLa (d) treated or not with extra 100 mM sodium chloride (a-d), extra 5 mM potassium 
chloride (e, f and i) or 30 mM lithium chloride (g and j) and exposed for 4 h to normoxia (Nx), normoxia 
with 1 mM DMOG or to hypoxia (1% oxygen, Hp). Tubulin was used as a loading control. (a, c, d, e, g, i 
and j) Representative images of at least three independent experiments are shown. Densitometry of a, e 
and h is shown in b, f and h, respectively. 
 
Previous results showed that doubled potassium did not affect NCLX activity and ROS 
production, in contrast to addition of 30 mM lithium chloride. In accordance to this, hypoxic 
stabilization of HIF-1α was not affected by the former but it was in the presence of latter (Figure 
4.43a-f). 
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The amount of HIF-1α or HIF-2α mRNAs varied slighyly but not significantly between 
different conditions (Figure 4.43g-h). However, gene expression of HIF-1 targets such as PDK1, 
BNIP3 or PHD3 was induced in hypoxia, which was abolished or diminished by sodium overload 
(Figure 4.43i-k). Of note, increased sodium tended to inhibit DMOG-dependent expression of 
these genes (Figure 4.43i-k). 
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Figure 4.43. Sodium overload inhibits HIF-1α stabilization and function through NCLX in 
different cells. Quantitative RT-PCR analysis of HIF-1α (a), HIF-2α  (b), PDK1 (c), BNIP3 (d) and 
PHD3 (ke mRNAs in untreated (black) or treated with extra 100 mM sodium chloride (white) HUVECs 
subjected to 6 hours of normoxia (Nx), hypoxia (1% oxygen, Hp) or normoxia with 1 mM DMOG. Data 
are represented as mean s.e.m. of the β-actin ratio relative to normoxia for four independent 
experiments. * p < 0.05 Control Hp versus +NaCl 100 mM Hp of each condition (Student’s t-test). 
 
In summary, sodium overload decreases HIF-1α stabilization in hypoxia, which could be 
related to its effect on hypoxic ROS production through NCLX. Furthermore, HIF-1 pathway 
activity was decreased both in hypoxia and DMOG-treated cells, suggesting that sodium chloride 
addition is also altering the mechanisms of HIF-1α stabilization. 
4.4.5 The effects of sodium chloride addition are not due to osmotic stress 
The addition of extra 100 mM sodium chloride could produce an osmotic stress or change 
in ionic strength that could be the cause of the effects observed. The effects of high salinity due to 
increased sodium chloride have been widely studied in plants, where osmotic stress can also affect 
mitochondrial ROS production (Miller et al., 2010). In order to study the effects of osmolarity an 
inert osmolyte such as D-sorbitol is added. Apart from the osmolarity, the fact of introducing a 
positive charge and not the specific effect of a particular ion (e.g. Na+) can alter ion homeostasis in 
the cell and mitochondria. Therefore, an inert organic monovalent cation such as N-Methyl-D-
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glucamine (NMDG) is added to test it. Thus, we measured the superoxide burst in the presence of 
100 mM D-sorbitol or NMDG, observing that they had no effect on the superoxide burst (Figure 
4.44a-b). Indeed, we confirmed these results by checking HIF-1α stabilization upon treatment with 
100 mM D-sorbitol and observed no change in comparison to non-treated cells (Figure 4.44c-d).  
We also checked whether the effects on HIF-1α stabilization of doubling potassium 
chloride concentration (i.e. addition of 5 mM potassium gives a total of 10 mM potassium in the 
medium) or of addition of 30 mM lithium chloride were due to differences in osmolarity or 
specifically to potassium, chloride or lithium ions, by switching the concentrations. Thus, we 
increased total potassium up to 30 mM and decreased lithium chloride addition to 10 mM. Even 
with this change in the concentrations, we could still observe that potassium chloride addition had 
no effect while lithium chloride inhibited HIF-1α stabilization (Figure 4.44e-h). 
 
Figure 4.44. ROS production and HIF-1α stabilization inhibition by sodium overload is not 
due to high osmolarity or high potassium concentration. Non-treated BAECs (Control) or with extra 
100 mM D-sorbitol (a) or 100 mM N-methyl D-glucamine (NMDG) (b) were treated as in Figure 4.1. 
Data are presented as mean  s.e.m. of three independent experiments. (c-h) HIF-1α stabilization 
measured by western blotting in BAECs treated or not with 100 mM D-sorbitol (c and d), 10 mM lithium 
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chloride (e and f) or 30 mM potassium chloride (g and h) and exposed for 4 h to normoxia (Nx), 
normoxia with 1 mM DMOG or to hypoxia (1% oxygen, Hp). Tubulin was used as a loading control. (c, e 
and g) Representative images of at least three independent experiments are shown and its densitometries 
are shown in b, d and f. 
 
In summary, the effects observed with sodium overload are specifically due to this ion and 
not to osmotic stress or changes in ionic strength. Furthermore, the effects of potassium chloride 
or lithium addition are not due to differences in concentrations, but rather probably to their specific 
effects on NCLX function. 
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5	Discussion	
We have focused our research on the detection of superoxide anion in acute hypoxia and in 
the characterization of the molecular players involved in triggering its production in the 
mitochondria. We have detected superoxide anion production specifically and observed that in 
behaved as a burst in the first minutes of hypoxia. We observed that it was related to hypoxic HIF-
1α stabilization. 
Our results indicated that complex I deactivates proportionally to the level of hypoxia and 
in an acute manner. Such deactivation would preclude its activity switch to a sodium/proton 
antiporter. Complex I is needed for mitochondrial sodium/calcium exchange via NCLX and both 
are required for the superoxide burst. Hypoxic superoxide burst relies also on complex III, 
although we have not assessed its specific role. Inhibition of NCLX correlated with inhibition of 
hypoxic HIF-1α stabilization in cell culture and hippocampal slices, and with loss of steady-state 
contraction of PA. Blockage of NCLX diminished infarct size in phototrombotic ischemic injury in 
mice.  
Finally, we have also studied the influence of sodium overload in the hypoxic response and 
observed that the response is altered at the level of NCLX. 
5.1 Hypoxia produces a mitochondrial superoxide anion burst 
Using several converging methodologies that avoid re-oxygenation we have demonstrated 
that exposure of cells to acute mild hypoxia (1-2% oxygen in our culture conditions) was associated 
with a burst in superoxide production within the first minutes. Thereafter the levels of superoxide 
production in hypoxic cells reduced gradually over time. In one hour no difference in superoxide 
production could be detected between hypoxic (1% oxygen) and normoxic cells (Figure 5.1). We 
made special efforts in detecting specifically the first product of one-electron reduction of oxygen, 
superoxide anion. This allowed us to rule out other ROS sources or mechanisms producing other 
species, such as hydrogen peroxide or peroxynitrite. Our results comparing different hypoxic 
oxygen concentrations in the same experimental setting (Figures 4.1a and 4.3 b) show that at 2% 
oxygen the superoxide burst can be more intense and sustained than at 1% oxygen. This allows 
speculating that the decrease in superoxide production after some time of hypoxia could be related 
to a decrease in the oxygen availability near the mitochondria. Although most of our experiments 
have been done setting hypoxic conditions at 1% oxygen (except for Figure 4.3b and live imaging 
experiments performed in the fluorescence microscope at the University of Zürich), it will be very 
interesting to study the magnitude of the superoxide burst and downstream responses in moderate 
hypoxia. In these conditions, increased superoxide production can be a cellular signal anticipating 
the reduction in oxygen availability, triggering adaptive responses before oxygen concentration 
decreases below the threshold for inactivating key enzymes such as cytochrome c oxidase.  
 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Hypoxia produces a superoxide burst in cells. Mitochondria generate superoxide in 
the first minutes of hypoxia which decreases up to an hour.  Since discrepant literature has emerged due 
to measurements in different times, this scheme highlights the importance of time in ROS detection.  
 
Our observation of the temporal dynamics of superoxide levels in acute hypoxia resolve 
the seeming contradictory findings reported earlier, in which some groups reported increased ROS 
levels in hypoxia and others showed no increase (Mehta et al., 2008). For example, Quintero et al. 
analysed superoxide production by incubating endothelial cells with DHE for the first 60 min of 
hypoxia (3% oxygen), showing a clear increase in the fluorescence signal (Quintero et al., 2006); in 
these conditions, DHE would be oxidized by the superoxide burst that we have seen in our 
experiments. On the other hand, Chua et al. have seen no increase in DHE fluorescence when 
HEK293 cells were exposed to 1% hypoxia; however, in this case DHE was added for 30 min after 
3 h of incubation of the cells in hypoxia (Chua et al., 2010), which would not allow to detect the 
initial superoxide burst. This illustrates the importance of time in ROS measurements (Figure 5.1). 
Other studies have also shown an increase in DHE oxidation in cardiomyocytes in a model of acute 
ischemia during up to 60 min, where in addition to hypoxia nutrients were removed from the cell 
culture medium (Becker et al., 1999).  
The fact that DCFDA oxidation was maximal after 15 min of hypoxic exposure suggests 
that the superoxide burst during the first minutes of hypoxia translates into an increase in hydrogen 
peroxide or other ROS with a certain delay in time. This could be related with the different kinetics 
of accumulation of the diverse ROS, although it can be also an effect of the different probes used 
or even that the superoxide burst could trigger peroxide generation by other pathways. In line with 
this, we had performed a proteomic characterization of protein cysteine residues that were 
reversibly oxidised in endothelial cells after two hours of hypoxia (Izquierdo-Álvarez et al., 2012), 
and we have seen a peak in protein cysteine oxidation between 30 and 120 min of hypoxia 
(unpublished results). This suggests that the increase in each ROS or in their downstream effects 
may have different kinetics that could fit in a signal transduction scheme in the cell.  
O2
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Time matters… 
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We have seen a similar superoxide burst and ROS production in different cell types 
exposed to hypoxia, and using either probes distributed throughout the cell, cytosolic or 
mitochondria-targeted probes. When using ρ0 cells lacking a functional OXPHOS the superoxide 
burst was abolished; this strongly suggests that the superoxide burst in the first minutes of hypoxia 
comes from the mitochondrial OXPHOS system (Chandel et al., 1998).  
5.2 Complex I deactivation is required for ROS production in acute 
hypoxia 
We have also studied in more detail the molecular aspects triggering the hypoxic 
superoxide burst, showing that both complex I and NCLX are required. Our results  highlight the 
role of complex I responding proportionally to different levels of acute hypoxia and triggering 
hypoxic adaptation through a superoxide signal. Complex I deactivation produces a conformational 
change (Babot et al., 2014, Galkin et al., 2008, Zickermann et al., 2015) that exposes several of its 
subunits, including Cys-39 of ND3 (Galkin et al., 2008, Babot et al., 2014), and switches its activity 
to a sodium/proton exchanger, NHE (Roberts and Hirst, 2012). We show that ND3 Cys-39 
becomes more exposed in acute hypoxia in different experimental models, strongly suggesting that 
complex I deactivation is a key event in response to oxygen deprivation. We also show that the 
mitochondrial matrix is acidified in hypoxia in a complex I-dependent manner, which is compatible 
with its increased NHE activity. Increased NHE activity induces matrix acidification which is 
known to solubilize mitochondrial calcium-phosphate precipitates which would increase calcium 
concentration in the matrix, turnover of TCA cycle dehydrogenases and NADH production which 
is necessary for other processes in the cell, such as cell signalling or maintenance of the antioxidant 
defence through NADPH generation (Fernandez-Agüera et al., 2015, Nickel et al., 2015).  
However, further experimental confirmation of the complex I NHE activity would be needed. 
Besides, the specific mechanism(s) by which oxygen levels influence the conformation and activity 
of complex I, as well as other aspects such as possible oxygen binding sites or hypoxia sensing by 
complex-I partner proteins remain to be elucidated.  
It has recently been described that complex I and ROS signals are essential components of 
acute oxygen sensing by the carotid body (Fernandez-Agüera et al., 2015). In this study, the 
response to hypoxia of carotid body glomus cells lacking the ‘core’ subunit NDUFS2 was 
selectively abolished, while higher level of ROS were generated in normoxia (Fernandez-Agüera et 
al., 2015). We show here that different interventions that reduce the activity of complex I abolished 
the superoxide burst in hypoxia while increasing superoxide levels in normoxia. This underlines the 
role of complex I in mitochondrial ROS production, either in response to acute hypoxia (which can 
be used by the cell as a signal) or in chronic situations (where it can be more related to oxidative 
stress). 
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5.3 NCLX links hypoxic complex I deactivation to ROS production 
We have found that NCLX is a key element linking the primary oxygen sensing event and 
superoxide production through sodium/calcium exchange. It is well known that NCLX activity is 
linked to OXPHOS through NHE (Murphy and Eisner, 2009, Poburko and Demaurex, 2012), 
therefore activation of NHE would increase mitochondrial sodium/calcium exchange through 
NCLX. We expected that increased mitochondrial calcium extrusion by NCLX would decrease 
matrix calcium concentration, which could translate in decreased TCA cycle dehydrogenases 
turnover and NADH production (Cox and Matlib, 1993); however we observed that mitochondrial 
calcium concentration was maintained in hypoxia even in the presence of the MCU blocker 
ruthenium red (Figure 4.25). This paradox could be explained with the involvement of other 
mechanisms that could increase matrix calcium concentration, such as matrix acidification and 
solubilisation of calcium-phosphate precipitates of the mitochondrial matrix (see above).  
NCLX activity is electrogenic as it extrudes one calcium ion (Ca2+) while it imports three 
sodium cations (Na+). We have shown that hypoxia depolarizes mitochondria in an NCLX-
dependent manner, suggesting that this exchanger can regulate respiration in hypoxia, a situation 
where mitochondrial oxygen consumption and energy conversion would become inefficient. In 
accordance, enhancing NCLX activity by sodium overload decreased basal respiration. In this 
regard, studying the regulation of NCLX and its relationship with physiology and disease would be 
interesting.  
We have also correlated the activity of NCLX to the production of ROS in hypoxia. Up to 
our knowledge, this is the first description of the implication of this ion transporter in ROS 
production. This poses a new window of research since directly links mitochondrial ion 
homeostasis and redox biology. There are several tissues were this may have special importance in 
pathogenesis. This is the case of heart or brain diseases, where the correct regulation of action 
potentials govern the main function of the organ and ROS production are involved in many of 
their pathologies, such as ischemia/reperfusion injury, Parkinson´s or Alzheimer´s disease 
(Chouchani et al., 2014, Guzman et al., 2010). Therefore, dysregulation of ion homeostasis could 
impact NCLX function and ROS production by mitochondria. On the other hand, enhancement of 
NCLX function (e.g. by complex I deactivation) would translate into ROS production which could 
modify the activity of ion channels involved in brain or heart homeostasis, contributing to the 
development of the diseases. 
We cannot attribute ROS production after NCLX activation to a precise ROS source in the 
mitochondria. Our results measuring mitochondrial calcium allow to discard the modulation by 
calcium of TCA cycle dehydrogenases activity (Cox and Matlib, 1993). The intrusion of sodium into 
the mitochondrial matrix or the extrusion of calcium could have many unknown effects on 
different enzymes. We have performed experiments with ρ0 cells and uncouplers which suggested 
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that a functional OXPHOS was required for the hypoxic superoxide burst. Given that complex I 
becomes deactive in acute hypoxia and since the second major producer of superoxide in the ETC 
is complex III, it could be that this complex is involved. We have shown that lack of functional 
complex III is required for hypoxic ROS production, despite the presence of complex I. In 
addition, complex III inhibition at the Qi site promotes the production of semiquinone radical 
which is a well-known superoxide producer. Semiquinone is normally formed from ubiquinol 
oxidation. Indeed, in preliminary experiments we observed that acute hypoxia oxidized ubiquinol 
pool which was prevented by NCLX inhibition (unpublished results). These results would support 
previous findings involving complex III as superoxide producer in hypoxia (Chandel et al., 2000, 
Brunelle et al., 2005, Guzy et al., 2005). However, how NCLX activity influences complex III ROS 
production is still to be elucidated.  
We propose a model in which we connect our findings regarding the role of complex I  
deactivation and NCLX activation in response to acute hypoxia (Figure 5.2), Our results indicate 
that acute hypoxia deactivates complex I which switches to its NHE activity. We hypothesize that 
sodium extrusion through complex I mediates NCLX activation. This results in an increase in 
cytosolic calcium, a decrease in cytosolic sodium, and mitochondrial depolarization due to 
electrogenic exchange. In parallel, mitochondrial sodium/calcium exchange activation is required 
for induction of superoxide burst in hypoxic cells. Further work will be needed to pinpoint the 
precise source of superoxide production in acute hypoxia. Complex III activity is required for 
superoxide production but not for the activation of the sodium/calcium exchange. Importantly, 
activation of NCLX in energized isolated mitochondria by complex I substrates through mixtures 
of low amounts of sodium and calcium triggers ROS production, highlighting that isolated 
mitochondria are sufficient to produce ROS upon sodium/calcium exchange. 
 
Figure 5.2. Scheme of the role of complex I and NCLX in acute hypoxia. Active complex I (yellow) 
switches to its deactive conformation (red) in acute hypoxia, which enhances its sodium/proton antiporter 
activity and sodium/calcium exchange through NCLX, promoting mitochondrial depolarization as well as 
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ROS production by OXPHOS complexes, which can be a signal for hypoxic adaptation or can lead to 
ischemic injury. 
5.4 NCLX is required for ROS-dependent hypoxic adaptation and 
injury 
By exploiting the fact that NCLX inhibition abolishes the hypoxic superoxide burst 
without increasing normoxic levels, we show that this mechanism participates in different ROS-
dependent adaptations to hypoxia. First, activation of the HIF pathway is impaired when NCLX is 
inhibited, both in cultured cells and in brain tissue ex vivo; these results suggest a tight relationship 
between acute and chronic responses to hypoxia. Second, activation of the complex I-NCLX-ROS 
pathway could be a primary event in acute oxygen sensing in different cell types, which would be 
translated into specific responses in those specialized cells that have the adequate machinery to 
transduce this ROS signal into effective acute adaptations. PA could be such an example, and we 
have shown that NCLX inhibition impairs the redox-dependent component of their contraction in 
acute hypoxia, which is relevant for HPV. In this setting, the mitochondrial superoxide signal 
would be amplified and transduced to the activation of specific plasma membrane ion channels 
(Frazziano et al., 2011, Rathore et al., 2008). The carotid body can be another example, as the 
observed complex I-dependent ROS production (Fernandez-Agüera et al., 2015) could affect 
redox-dependent activity of specialized potassium channels, which could also be mediated by Cys 
oxidation of specific enzymes that transduce and/or amplify the primary signal (Yuan et al., 2015). 
The mechanism we present here may also be engaged in pathological scenarios where ROS 
production is exacerbated by hypoxia. In an in vivo model of stroke, treatment with CGP clearly 
reduced infarct volume, suggesting that it may reduce ROS production and oxidative damage, 
although a ROS-independent role of NCLX cannot be discarded.  
5.5 Sodium overload alters hypoxic response 
Finally, we have uncovered the effects of sodium overload on the complex I-NCLX-ROS 
pathway. Alterations in cytosolic sodium content could contribute to the development of diseases 
or trigger responses related to NCLX. We have observed that sodium overload increased cytosolic 
calcium, probably from mitochondria since it also caused drop in respiration which correlates well 
with lower TCA cycle dehydrogenase turnover. ROS production was also increased in normoxia in 
a NCLX-dependent manner (Figure 4.40), suggesting that enhancement of NCLX activity 
promotes mitochondrial ROS production. 
Mutations or environmental alterations in membrane sodium channels or exchangers can 
cause cytosolic sodium overload which could primarily cause an energetic crisis due to decreased 
respiration and increased ROS production (Kunzelmann et al., 2007, Brocker et al., 2012). Indeed, 
application of the sodium/potassium ATPase inhibitor ouabain leads to busted mitochondrial ATP 
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production and higher ROS levels in pancreatic islets (Kajikawa et al., 2002). Thus, mutations 
inhibiting this enzyme could also cause this phenotype. In addition, given our results with cellular 
respiration sodium overload could also explain respiratory alterations derived from phenotypic 
modifications in plasma membrane sodium channels, since accumulation of cytosolic sodium could 
trigger the extrusion of mitochondrial calcium (Kunzelmann et al., 2007, Alsuwaidi et al., 2014, 
Babsky et al., 2001). Importantly, we have observed that sodium overloaded cells cannot stabilize 
HIF-1α in hypoxia. This could have important implications since the hypoxic response in these 
mutants could vary from canonical adaptations. 
Sodium overload is present in pathological situations such as heart ischemia or 
ischemia/reperfusion and inflammation (Brocker et al., 2012, Murphy and Eisner, 2009). Since 
sodium increase in ischemia is well known to occur in cardiomyocytes (Murphy and Eisner, 2009) 
but we could not detect it in endothelial cells (see Figure 4.9 for example) we reasoned that it could 
be a cell type-specific event, suggesting possible NCLX-independent pathways controlling sodium 
content in ischemia. However, given that sodium measurement in cardiomyocytes is technically 
difficult due to the interference of the action potential (personal observation) and that we have 
performed most of our studies in endothelial cells, we decided to study the effect of sodium 
overload in endothelial cells. The divergence on cytosolic sodium variations between 
cardiomyocytes and endothelial cells could highlight differences seen in hypoxic ΔΨmt and ROS 
production (Figures 4.5 and 4.8a-d). Furthermore, given that inflammatory areas become normally 
hypoxic, whether or not there is sodium overload could lead to very different scenarios and be 
crucial for the outcome of the disease.  
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6	Conclusions 
- Different cell types increase their superoxide levels in the first minutes after being exposed 
to hypoxia, which declines during an hour approximately. This effect can be called a 
‘superoxide burst’.  
- The hypoxic superoxide burst is produced by functional mitochondria. 
- The mitochondrial sodium/calcium exchanger, NCLX, is necessary for the hypoxic 
superoxide burst.  
- Acute hypoxia triggers a sodium/calcium exchange in endothelial cells through NCLX, and 
mitochondrial complex I is necessary for this process. 
- We have developed a novel method to measure mitochondrial complex I deactivation, 
showing that complex I is deactivated in acute hypoxia in cell culture, hippocampal slices 
and  in a stroke model. 
- We propose a model for explaining how complex I deactivation and NCLX activation are 
implied in the hypoxic superoxide burst. According to this model, acute hypoxia 
deactivates complex I and enhances its sodium/proton antiporter function. This activates 
sodium/calcium exchange through NCLX, which depolarizes the mitochondrial inner 
membrane. These events lead to increased superoxide production in the mitochondria, 
probably by the electron transport chain, although the exact source still has to be 
determined. 
- NCLX inhibition can abolish several adaptations to hypoxia such as HIF-1α stabilization 
and the ‘steady-state’ component of hypoxic pulmonary vasoconstriction.  
- NCLX inhibition ameliorates brain ischemic injury in vivo in a mouse model of 
photothrombotic stroke. 
- Addition of sodium to endothelial cell cultures alters the response to hypoxia through 
modification of NCLX function. 
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7	Conclusiones	
- Diferentes tipos celulares aumentan los niveles de superóxido en los primeros minutos tras 
la exposición a hipoxia y disminuyen antes de la primera hora. A este efecto le podemos 
llamar un ‘estallido’ de superóxido. 
- El estallido hipóxico de superóxido lo producen mitocondrias funcionales. 
- El intercambiador de sodio/calcio mitochondrial (NCLX) es necesario para el estallido 
hipóxico de superóxido. 
- La hipoxia aguda dispara un intercambio de sodio/calcio en células endoteliales a través de 
NCLX, proceso en el que el complejo I mitocondrial es necesario. 
- Hemos desarrollado un nuevo método para medir la desactivación de complejo I, 
mostrando que el complejo I se desactiva en hipoxia aguda en cultivo celular, rodajas de 
hipocampo y en un modelo de ictus. 
- Proponemos un modelo que explica cómo la desactivación de complejo I y la activación de 
NCLX están implicadas en el estallido hipóxico de superóxido. De acuerdo con este 
modelo, la hipoxia aguda desactiva el complejo I e incrementa su función antiportadora 
sodio/protón. Esto activa el intercambio sodio/calcio a través de NCLX, el cual 
despolariza la membrane mitocondria interna. Estos eventos promueven un incremento en 
la producción de superóxido por parte de la mitocondria, probablemente a través de la 
cadena de transporte de electrones, aunque la fuente exacta está todavía por determinar. 
- La inhibición de NCLX puede abolir varias adaptaciones a hipoxia, tales como la 
estabilización de HIF-1α y el componente de ‘estado estable’ de la vasoconstricción 
hipóxica pulmonar. 
- La inhibición de NCLX disminuye el daño isquémico in vivo en modelos de isquemia 
cerebral fototrombótica en ratón. 
- La adición de sodio en cultivos de células endoteliales altera la respuesta a hipoxia a través 
de la modificación de la función de NCLX. 
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a b s t r a c t
Oxygen is a key molecule for cell metabolism. Eukaryotic cells sense the reduction in oxygen availability
(hypoxia) and trigger a series of cellular and systemic responses to adapt to hypoxia, including the
optimization of oxygen consumption. Many of these responses are mediated by a genetic program
induced by the hypoxia-inducible transcription factors (HIFs), regulated by a family of prolyl hydro-
xylases (PHD or EGLN) that use oxygen as a substrate producing HIF hydroxylation. In parallel to these
oxygen sensors modulating gene expression within hours, acute modulation of protein function in
response to hypoxia is known to occur within minutes. Free radicals acting as second messengers, and
oxidative posttranslational modiﬁcations, have been implied in both groups of responses. Localization
and speciation of the paradoxical increase in reactive oxygen species production in hypoxia remain
debatable. We have observed that several cell types respond to acute hypoxia with a transient increase in
superoxide production for about 10 min, probably originating in the mitochondria. This may explain in
part the apparently divergent results found by various groups that have not taken into account the time
frame of hypoxic ROS production. We propose that this acute and transient hypoxia-induced superoxide
burst may be translated into oxidative signals contributing to hypoxic adaptation and preconditioning.
& 2014 Elsevier Inc. All rights reserved.
In most metazoans, oxygen has to be distributed through the
organism to be used by cells within various organs. In several
physiological and pathophysiological scenarios, cells undergo a
decrease in the amount of available oxygen, known as hypoxia,
which induces acute and long-term cellular, local, and systemic
responses [1]. Most of the long-term responses are mediated
by the induction of over 100 genes by the hypoxia-inducible
factors (HIFs), heterodimeric transcription factors composed of a
constitutively expressed subunit (HIF-β) and an O2-dependent
HIF-α subunit. In normoxia the latter subunit is continuously
degraded through a mechanism mediated by a family of HIF prolyl
hydroxylases (EGLNs or PHDs), which carry out an O2-dependent
hydroxylation that is suppressed when oxygen concentration
decreases, allowing HIF-α stabilization [2]. Some studies revealed
that HIF-α stabilization was associated with an acute increase in
reactive oxygen species (ROS) production in hypoxia [3,4].
It has been shown that acute responses to hypoxia involve local
temporal changes in redox state due to the alterations in production
of short-lived reactive oxygen species [5–8]. However, the nature of
oxygen-sensing free radical generators, the targets of these radicals,
and the resulting changes in enzyme activity and, ﬁnally, whether
hypoxia causes a decrease or an increase in ROS production remain
a matter of debate. Hypoxia-induced ROS production has been
attributed mainly to the mitochondrial oxidative phosphorylation
system (OXPHOS) and has been proposed to contribute to PHD
inhibition and HIF-α stabilization [9–12] (reviewed in [13,14]).
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This posed a paradox, as superoxide is directly produced from
oxygen so its production rate should decrease with a decrease in
oxygen availability [13,15]. Indeed, some of these ﬁndings and
methodological approaches have been questioned [16,17] (reviewed
in [18]). However, detailed investigations conﬁrmed that increased
ROS production occurred under conditions of mild hypoxia (1–3%
O2), but not during severe hypoxia or anoxia [13,19,20].
ROS production in hypoxia has often been measured with
ﬂuorescent probes that are oxidized by different species. The main
limitation of some (if not most) of these studies is that the
ﬂuorescence measurements were performed outside the hypoxia
chamber with reoxygenation occurring during the measurements.
Several recent reports have conﬁrmed hypoxic ROS production in
cells exposed to hypoxia while recording the ﬂuorescent signal
from HSP-FRET or roGFP [5,9,21–23] (reviewed in [13,24]). Both
thiol-based protein sensors are oxidized by H2O2, although oxida-
tion by other intracellular oxidants cannot be ruled out. Super-
oxide anion is the primary ROS produced by the OXPHOS.
However, there are few reports using a speciﬁc probe for direct
measurement of this species in hypoxic cells [17,20,25] and we are
not aware of any study showing the dynamics of superoxide
production upon deoxygenation. Understanding the time course
of superoxide production will help us approach the mechanisms
underlying that response.
By using a novel proteomic method for detecting reversible
thiol oxidation (redox ﬂuorescence switch), we have recently
shown a speciﬁc pattern of proteins in which cysteine thiol
residues are reversibly oxidized when endothelial cells are sub-
jected to acute hypoxia for 2 h [8]. This suggests a role for hypoxia-
induced ROS production in cell signaling: the increased ROS levels
can produce speciﬁc oxidative posttranslational modiﬁcations that
may regulate the HIF pathway or promote other acute responses
[8]. We herein present the data on superoxide production directly
assessed in the cytosol and in the mitochondria of cells exposed to
acute hypoxic challenge, combining different techniques to avoid
potential artifacts.
Materials and methods
Cell culture
Bovine aortic endothelial cells (BAECs) were obtained from
aortas donated by a local slaughterhouse and isolated as pre-
viously described [26]. BAECs were cultured at 37 1C in RPMI 1640
supplemented with 15% heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin, and 100 μg/ml streptomycin. They were used
between passages 3 and 9; endothelial morphology was assessed
by visual inspection and by Western blot for endothelial nitric
oxide synthase.
EA.hy926 cells (kindly provided by Dr. Cora-Jean S. Edgell,
University of North Carolina, NC, USA) were cultured at 37 1C in
Dulbecco's modiﬁed Eagle medium (DMEM) supplemented with
HAT, 10% heat-inactivated FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin
HeLa cells were cultured at 37 1C in DMEM supplemented with
10% heat-inactivated FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin.
Fig. 1. Superoxide detection by DHE and ﬂuorescence microscopy in ﬁxed endothelial cells. (A, B) BAECs and (C, D) EA.hy926 cells were incubated for 60 min in normoxia
(Nx) or in normoxia with antimycin A (AA, 10 mM for 30 min) or incubated in a hypoxia chamber at 1% O2 with medium preequilibrated in the hypoxic condition (Hp) for 0,
15, 30, 45, or 60 min. 5 mM DHE was added for 10 min more, and the cells were ﬁxed in the hypoxia chamber. (A, C) Representative images showing DHE ﬂuorescence. (B, D)
Quantiﬁcation of images from four (B) or three (D) independent experiments. Data are presented as the mean 7 SEM. *p o 0.05, &p ¼ 0.0495 versus Nx.
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ρ0L929 cells (mitochondrial DNA-less cells derived from L929
cells) and their control ρþ transmitochondrial cybrids, TmC57BL/
6J (generated by transferring functional mitochondria from plate-
lets to ρ0L929 cells), were generated [27] and kindly provided by
the group of Dr. José Antonio Enríquez (CNIC, Spain). They were
cultured at 37 1C in DMEM supplemented with 5% heat-inactivated
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. ρ0L929 cells
were also supplemented with 50 μg/ml uridine.
HK-2 cells (kindly provided by Dr. María José Calzada, UAM and
Instituto de Investigación Sanitaria Princesa, Madrid, Spain) were
cultured at 37 1C in DMEM F-12–GlutaMAX supplemented with
10% heat-inactivated FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin, and 0.1% insulin–transferrin–selenium-X solution.
Cardiomyocytes were isolated from rat pups 2–3 days after
birth as previously described [28]. The cells were seeded on
collagen-coated six-well plates, supplemented with maintenance
medium containing 1 part M199 medium and 4 parts medium
containing (in mM) 116 NaCl, 32.1 NaHCO3, 1 NaH2PO4 (pH 7.2),
0.8 MgSO4, 5.5 glucose, 1.8 CaCl2, supplemented with 1% horse
serum, penicillin, streptomycin, and 2% glutamine. Cells were
maintained in cell culture incubators (95% air, 5% CO2 in gas phase,
37 1C) and used within 5 days of isolation.
Fluorescence microscopy in ﬁxed cells and quantiﬁcation
Cells were seeded a day before experimentation on glass cover-
slips. For treatments in hypoxia, all the solutions were preequili-
brated to hypoxic conditions before use; in some experiments,
1 mM Tiron (4,5-dihydroxy-1,3-benzene disulfonic acid) was added
30 min before experimentation and maintained during the rest of
the experiment. Plated cells were introduced in an Invivo2 400
workstation (Ruskinn) set at 1% O2 (2% O2 when stated), 5% CO2,
37 1C, and incubated for the indicated times (0, 15, 30, 45, and
60 min) in new medium, washed three times with Hanks’ balanced
salt solution with Ca2þ/Mg2þ (HBSS þ Ca/Mg) and incubated
with 5 mM mito-hydroethidine (Mito-HE; 3.33 or 10 mM when
stated) or 5 mM dihydroethidium (DHE) for 10 min, or with 10 mM
5(6)-carboxy-20,70-dichloroﬂuorescein diacetate (CDCFDA) for
15 min (all probes in HBSS þ Ca/Mg), in darkness. After incubation,
excess probe was washed away three times with HBSS þ Ca/Mg,
and the cells were ﬁxed by adding 4% paraformaldehyde and
incubated in darkness at 4 1C for 15 min. After ﬁxation, wells were
again washed three times with HBSS þ Ca/Mg and coverslips
placed on slides. In normoxic cells, medium was also changed for
new normoxic medium and treated as hypoxic cells, but in a
standard cell incubator. When normoxia was set at 7% O2, the cells
were placed in an Invivo2 200 workstation (Ruskinn) at 7% O2, 5%
Fig. 2. Superoxide detection by DHE and HPLC in endothelial cells. BAECs were
treated as in Fig. 1. After DHE incubation (5 mM DHE, 10 min) cells were lysed in the
hypoxia chamber and frozen, and 2-OH-E amount was analyzed by HPLC with
ﬂuorescence detection. Data are presented as the mean 7 SEM of four indepen-
dent experiments. *p o 0.05, **p o 0.01 versus Nx.
Fig. 3. Superoxide detection by DHE and ﬂuorescence microscopy in ﬁxed
endothelial cells treated with 1 mM Tiron. (A) Control BAECs and (B) BAECs
incubated with 1 mM Tiron were treated as in Fig. 1. (A, B) Representative images
showing DHE ﬂuorescence. (C) Quantiﬁcation of images from three independent
experiments. Data are presented as the mean 7 SEM. **p o 0.01 versus Nx.
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CO2, 37 1C, incubated overnight, and treated in the same chamber or
transferred to the Invivo2 400 chamber for 1% O2 hypoxia as above.
Antimycin A was added to a ﬁnal concentration of 10 mM onto
normoxic cells 30 min before and during incubation with the probe.
Three images per coverslip were taken in a Leica DMR ﬂuorescence
microscope with a 63 objective, using the following excitation/
emission ﬁlter pairs: 546-12/560 for DHE and Mito-HE, 480-40/505
for CDCFDA. The images (three images per coverslip; the number of
independent experiments is described in the ﬁgure legends) were
quantiﬁed using ImageJ software. The same threshold was set for all
the images and the mean value from the histogram was averaged
for the three images of each coverslip.
Signiﬁcance of the hypoxia-induced changes was analyzed
using analysis of variance (ANOVA) for normoxic and all the
hypoxic time groups, and intergroup comparison was done by
the multiple comparison test (Dunnett posteriori test with respect
to the normoxia group). The change in ﬂuorescence with the time
in hypoxia was evaluated by linear trend test of all the hypoxia
groups [29]. Homoscedasticity was tested with Levene's test
and normality with the Shapiro–Wilk test. Appropriate transfor-
mation was done to perform the analysis in the case of no normal
distribution. When no transformation gave normal distribut-
ion (Figs. 1D and 6D), nonparametric tests were used: differences
among normoxic and all the hypoxic time groups were analyzed
with the Kruskal–Wallis test and intergroup comparison was
done with the Mann–Whitney test with respect to the normoxia
group; the change in ﬂuorescence with the time in hypoxia
was evaluated by nonlinear trend test of all the hypoxia groups.
All analyses were performed using Stata version 11 software
and R version 2.15.2, with the help of the Methodology
Unit of the Instituto de Investigación Sanitaria Princesa (Madrid,
Spain).
Colocalization analysis of Mito-HE by confocal microscopy
Cells were seeded a day before experimentation on glass
coverslips. Plated cells were washed three times with HBSS þ
Ca/Mg and incubated with 5 mM Mito-HE for 10 min in darkness.
After incubation, excess probe was washed away three times with
HBSS þ Ca/Mg, and the cells were ﬁxed by adding 4% parafor-
maldehyde and incubated in darkness at room temperature (RT)
for 10 min. After ﬁxation, wells were again washed with HBSS þ
Ca/Mg and cells permeabilized with 0.5% Triton in phosphate-
buffered saline (PBS) for 10 min at RT. Blocking solution, consisting
in 5-thio-2-nitrobenzoic acid in PBS, was added for 20 min at
37 1C, and antibody against prohibitin-1 C-term (AJ1656a; Abgent)
was incubated for 1 h at 37 1C. Coverslips were washed three times
with 0.1% Tween 20 in PBS (PBS-T) and incubated with DyLight-
488-labeled goat anti-rabbit secondary antibody for 30 min at
37 1C. Cells were washed three times with PBS-T and once with
distilled water and coverslips mounted in slides. Tri-color Z stacks
were generated using a Leica SP-5 confocal microscope. Samples
were excited with an Ar/Kr laser using the 488 nm line and a
second diode laser ﬁtted with a 561 nm line. Fluorescence
Fig. 4. Superoxide detection by DHE in endothelial cells at different concentrations of O2 in normoxia and hypoxia. (A, B) BAECs were treated as in Fig. 1, but normoxia was
set at 7% O2. (C, D) BAECs were treated as in Fig. 1, but the hypoxia chamber was set at 2% O2 and normoxia performed at atmospheric O2 concentration. (A, C) Representative
images showing DHE ﬂuorescence. (B, D) Quantiﬁcation of images from three independent experiments. Data are presented as the mean 7 SEM. ***p o 0.001 versus Nx,
**p o 0.01 versus Nx, *p o 0.05 versus Nx.
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emission was taken using the spectral capability of the SP-5
according to the manufacturer's instructions. For three-
dimensional analysis, stacks were processed using ImageJ
software.
High-performance liquid chromatography (HPLC) analysis
Cells were seeded a day before experimentation in 60-mm-
diameter plates. For hypoxia treatments, plated cells were introduced
into an Invivo2 400 workstation (Ruskinn) set at 1% O2, 5% CO2, 37 1C,
and incubated for the indicated times (0, 15, 30, 45, and 60min)
in prehypoxic medium, washed three times with prehypoxic HBSS þ
Ca/Mg and incubated with 5 mM DHE for 10 min (in prehypoxic HBSS
þ Ca/Mg solution), in the darkness. After incubation, excess probe was
washed away once with prehypoxic PBS and cells were lysed with
0.1% Triton X-100 and frozen overnight at 80 1C. Homogenates were
thawed on ice and 100 ml was transferred into a new tube. 1-butanol
(250 ml) was added to the lysate, vortexed for 1 min, and centrifuged
for 3 min at maximum speed and the upper alcoholic phase was
recovered and dried. The desiccated fraction was resuspended in
100 ml HPLC-grade water and vortexed. An HPLC 2695 separation
module from Waters was used to load and separate 50 ml of the
samples in a Mediterranean Sea C18 column using acetonitrile 10%–
triﬂuoroacetic acid (TFA) 0.1% and acetonitrile 100%–TFA 0.1% as
mobile phases. Fluorescence of the samples was detected by a W474
module at 490 nm excitation wavelength and 560 nm emission
wavelength. The peak area corresponding to hydroxyethidium forma-
tion was quantiﬁed and corrected with the protein concentration of
the sample (determined by the BCA assay). Statistical analysis was
performed as for ﬂuorescence microscopy in ﬁxed cells (see above).
Live imaging ﬂuorescence microscopy and quantiﬁcation
Cells were seeded in six-well plates a day before experimenta-
tion. Plated cells were washed three times with HBSS þ Ca/Mg and
incubated with 5 mM Mito-HE, 10 mM DHE, 30 nM tetramethylrho-
damine methyl ester (TMRM), or 10 mM CDCFDA for 20 min at 37 1C
in darkness. After that the plate was placed in a Leica DM 16000B
ﬂuorescence microscope equipped with a Leica DFC360FX camera,
an automated stage for live imaging, and a thermostated hypoxic
cabinet. The planes were focused for image capture, and images
were taken with a 20 objective every 2 min for 40 min, providing
a total of 20 cycles. Normoxia experiments started and ended at 20%
O2 and 5% CO2, whereas hypoxia experiments started at 20% O2 and
5% CO2 and were switched to 2% O2 and 5% CO2 in cycle 2. The
excitation/emission ﬁlter pairs used were 546-12/560 for DHE,
Mito-HE, and TMRM, 480-40/505 for CDCFDA.
For mitochondrial membrane potential controls, 12.5 mM oligo-
mycin or 1 mM carbonyl cyanide-4-(triﬂuoromethoxy)phenylhy-
drazone (FCCP) were added before focusing the planes.
Images were quantiﬁed with Leica Las-AF software. Three
independent experiments were performed for each condition. For
each experiment and condition, four identical linear regions of
interest (ROIs) were created on nonnuclear regions of different cells
(to avoid measuring nuclear binding of Mito-HE and DHE). The
maximum peak value of cycles 0, 5, 10, 15, and 20 was collected for
each ROI. The oxidation rate for each replicate was estimated by
linear regression of the data for all the ROIs and time points. The
differences in the means of the replicate oxidation rates were
analyzed by the Student t test. Homoscedasticity was tested with
Levene's test and normality with the Shapiro–Wilk test. Appro-
priate transformation was done to perform the analysis in the case
of no homoscedasticity or no normal distribution. These statistical
analyses were performed using G-Stat version 2.0.1 software.
Treatment effect was analyzed with GEE (generalized estimat-
ing equations method) with Gaussian family and identity link
function [30]. Variability of statistics derived from time observa-
tions was analyzed with independent and autoregressive of
order 1 (AR1)—correlation structures [30]. However, only the
independent correlation structure is shown for the within-
subject correlation, because it was the most parsimonious model
(p value and coefﬁcient were similar between the two structures,
therefore the statistical independence of observations could be
assumed). This independent correlation structure is equal to
simple regression models. When the response variables were not
normally distributed appropriate transformations were used.
These analyses were performed using Stata version 12 software
with the help of the Methodology Unit of the Instituto de
Investigación Sanitaria Princesa (Madrid, Spain).
Western blot analysis
Protein extracts were run on 10% standard polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes.
Monoclonal anti-HIF-1α antibody (MAB1536; R&D Systems) and
monoclonal anti-α-tubulin antibody (T6199; Sigma) were used.
Antibody binding was detected by chemiluminescence with
species-speciﬁc secondary antibodies labeled with horseradish
peroxidase and visualized on a digital luminescence image analy-
zer (Fujiﬁlm LAS-4000).
Fig. 5. ROS detection by CDCFDA and ﬂuorescence microscopy in ﬁxed endothelial
cells. BAECs were treated as in Fig. 1. CDCFDA 10 mM was added for 15 min more,
and cells were ﬁxed in the hypoxia chamber. (A) Representative images showing
CDCFDA ﬂuorescence. (B) Quantiﬁcation of images from four independent experi-
ments. Data are presented as the mean 7 SEM. ***p o 0.001 versus Nx.
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Results and discussion
Hypoxia induces a superoxide burst in the ﬁrst minutes of hypoxia in
endothelial cells
We aimed to determine whether reduction in oxygen concen-
tration was able to induce the production of superoxide (O2d)
at different times. DHE reacts with superoxide to produce 2-
hydroxyethidium (2-OH-E), which can be detected by ﬂuorescence
microscopy. As a positive control we used antimycin A, which
inhibits complex III of the OXPHOS system, increasing superoxide
production [31]. Primary BAECs were subjected to hypoxia for
various times, ranging from 10 to 70 min. DHE was added over the
last 10 min of hypoxic exposure, and after that, the cells were ﬁxed
in the hypoxia chamber. The amount of 2-OH-E produced was
assessed in a ﬂuorescence microscope (Fig. 1A and B). Compared to
the measure in normoxia, a signiﬁcant increase in superoxide
production was observed within the ﬁrst minutes of hypoxia. An
additional analysis of the linear trend (p trend [29]) among the
measures at various times in hypoxia showed that superoxide
production was progressively diminished over the following hour.
Similar results were obtained with a cell line derived from human
endothelial cells, EA.hy926 [32] (Fig. 1C and D).
DHE oxidation measurement by ﬂuorescence microscopy is not
completely speciﬁc for superoxide detection, as there are other
reactions that can also give ﬂuorescent products, but 2-OH-E can
be differentiated from ethidium and other products by HPLC
analysis with ﬂuorescence detection [33]. To conﬁrm the results
from microscopy and to unambiguously detect the production of
superoxide, we performed HPLC analysis of cell lysates from BAECs
subjected to hypoxia, incubated with DHE, and extracted in the
hypoxia chamber. The peak of 2-OH-E was clearly separated from
the peak of ethidium, both in control experiments with cyclos-
porin A treatment [34] and in hypoxia treatments (Supplementary
Fig. 1). With this methodology we also observed a transient burst
of superoxide production during the ﬁrst minutes of hypoxia
(Fig. 2). Superoxide signal thereafter decreased and did not differ
from normoxic values after 45–60 min in hypoxia. These ﬁndings
correlated with the results obtained by ﬂuorescence microscopy
(Fig. 1), conﬁrming the speciﬁc detection of superoxide in our
setting.
To further conﬁrm the superoxide burst, we aimed to inhibit it
with speciﬁc reagents, so we treated BAECs with Tiron before and
during the hypoxic incubation in microscopy experiments. Tiron
reacts with superoxide, and clearly abolished the signal from the
superoxide burst in hypoxia (Fig. 3).
To assess if this superoxide burst is speciﬁc for the change in
oxygen concentrations we have used in the experimental setting,
we performed similar experiments with different initial and ﬁnal
oxygen concentrations. First, we used a lower initial "normoxic"
reference concentration, 7% O2, which could be more physiologi-
cally relevant for endothelial cells, maintaining the hypoxia at 1%
O2. We observed a similar superoxide burst (Fig. 4A and B). A
similar increase in superoxide production was observed when 2%
O2 was used as hypoxia and ambient air was used as normoxia. In
fact the amplitude of the superoxide burst at 2% O2 exceeded that
observed at 1% O2 (Fig. 4C and D).
To determine the production of H2O2 (along with ONOO and
other ROS [35]) that could be derived from the superoxide burst
we used CDCFDA. BAECs incubated in hypoxia showed a burst in
Fig. 6. Mitochondrial superoxide detection by Mito-HE and ﬂuorescence microscopy in ﬁxed endothelial cells. (A, B) EA.hy926 cells and (C, D) BAECs were treated as in Fig. 1.
Mito-HE 5 mMwas added for 10 min more, and the cells were ﬁxed in the hypoxia chamber. (A, C) Representative images showing Mito-HE ﬂuorescence. (B, D) Quantiﬁcation
of images from three independent experiments. Data are presented as the mean 7 SEM. *po 0.05, **p o 0.01, &p ¼ 0.0495 versus Nx.
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CDCFDA oxidation, which peaks at 15–30 min (Fig. 5), suggesting
that the superoxide burst is translated into a burst of other ROS
such as H2O2 with a slight delay. A similar kinetics has been
described for CDCFDA oxidation after VEGF addition, increased
under hypoxic conditions [36].
Superoxide is produced in mitochondria
We next wanted to explore the role of mitochondria in
hypoxia-induced superoxide production. To this end, we used
the mitochondria-targeted probe Mito-HE, in which a triphenyl-
phosphonium (TPPþ) group is linked to DHE. Mito-HE accumu-
lates within active mitochondria because positively charged TPPþ
drives the compound to the negatively charged mitochondrial
matrix. EA.hy926 cells incubated with Mito-HE during the last
10 min of exposure to 1% O2 showed a similar acute transient rise
in superoxide production in response to hypoxia (Fig. 6A and B),
suggesting mitochondrial localization of superoxide production.
Again, similar results were obtained in BAECs, in which superoxide
production in hypoxia could be even higher (Fig. 6C and D).
We conﬁrmed mitochondrial targeting of Mito-HE by assessing
colocalization with prohibitin-1, a mitochondrial protein
(Supplementary Fig. 2A) [37]. To additionally control that the
Mito-HE signal was actually related to increases in superoxide
production and there was no saturation effect in the signal, we
tested different concentrations of Mito-HE, observing that there is
a clear increase with the Mito-HE concentration (Supplementary
Fig. 2B).
A complementary approach to analyzing the mitochondrial
origin of the superoxide production came from the study of the
hypoxia response in ρ0 cells, which do not have a functional
OXPHOS owing to mitochondrial DNA damage. ρ0 cells (ρ0L929)
and their control cybrids with undamaged mitochondria
(TmC57BL/6J, from now on called C57) [27] were subjected to
hypoxia and DHE ﬂuorescence was measured under the same
conditions as with endothelial cells. C57 cells also showed a
superoxide burst in the ﬁrst minutes of hypoxia (Fig. 7). However,
ρ0L929 cells showed much lower DHE signal, which did not
increase with antimycin A treatment (owing to the lack of
OXPHOS); hypoxic exposure of ρ0L929 cells also did not signiﬁ-
cantly affect the DHE (Fig. 7). In line with the previous data these
ﬁndings point also to the mitochondrial origin of the superoxide
burst that we observe in the ﬁrst minutes of hypoxia.
Early hypoxic superoxide production is conﬁrmed in living cells
In the previous experiments the accumulation of ROS was
detected over the 10 or 15 min after 0–60 min of incubation under
hypoxic or normoxic conditions. To get a complementary measure
of ROS production in hypoxia, we monitored the rates of oxidation
of the ROS-sensitive probes using live imaging under normoxic or
hypoxic conditions. Under normoxic conditions a gradual sus-
tained increase in the oxidation signal was detected in BAECs
using DHE, Mito-HE, and CDCFDA (Fig. 8A–C). In these experi-
ments, the ﬂuorescent signal accumulated over time because of
the irreversible oxidative modiﬁcation of the probes. Thus, this
method allowed assessing only the change in the rate of oxidation,
which reﬂects the relative changes in differences in ROS produc-
tion, and not the differences between the time points. We
conﬁrmed a signiﬁcant increase in the rate of ROS production in
BAECs for all the three probes when cells were subjected to
hypoxia (Fig. 8A–C).
Using live imaging we also explored the oxygen-dependent
changes in the mitochondrial membrane potential. Mitochondrial
targeting of Mito-HE is driven by mitochondrial membrane
potential. Thus, hyperpolarization is associated with greater
accumulation of Mito-HE within mitochondria and a concomitant
increase in ﬂuorescence, which is not caused by increased super-
oxide formation. We measured the mitochondrial membrane
potential in BAECs using TMRM in nonquenching mode [38],
conﬁrmed by the clear and immediate decrease in the signal
when FCCP (which depolarizes the membrane by uncoupling
OXPHOS) was added and the increase after addition of oligomycin
(which inhibits ATPase, increasing the potential) (Supplementary
Fig. 3). Hypoxic treatment of BAECs was associated with mito-
chondrial depolarization, whereas the potential was maintained in
BAECs in normoxia (Fig. 8D). Thus, superoxide production in the
mitochondria of hypoxic BAECs could be underestimated using
Fig. 7. Superoxide detection by DHE and ﬂuorescence microscopy in ﬁxed C57 and
ρ0L929 cells. (A) C57 and (B) ρ0L929 cells were treated as in Fig. 1. (A, B)
Representative images showing DHE ﬂuorescence. (C) Quantiﬁcation of images
from three independent experiments. Data are presented as the mean 7 SEM. **p
o 0.05, *p o 0.01 versus Nx.
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Mito-HE, as the dye levels in depolarized hypoxic mitochondria
would be lower than in the mitochondria of normoxic cells.
Live imaging also conﬁrmed the mitochondrial implication in
the increased superoxide production in hypoxia. Whereas C57
cells exhibit a clear increase in the DHE and CDCFDA signals when
they are subjected to hypoxia, ρ0L929 cells do not show these
changes when subjected to hypoxia (Fig. 9).
Superoxide burst and ROS formation in hypoxia are not speciﬁc solely
to endothelial cells
We wondered whether the hypoxia-induced superoxide burst
and the increase in ROS production were speciﬁc to endothelial
cells or a common feature for several cell types, in addition to the
ﬁbroblasts previously shown (Figs. 7 and 9). We carried out live
imaging experiments with cultured neonatal rat cardiomyocytes.
In line with the results obtained in endothelial cells, hypoxia
triggered a signiﬁcant increase in the rate of oxidation of DHE,
Mito-HE, and CDCFDA, indicating an increased production of ROS
(Fig. 10A–C). Furthermore, depolarization of the mitochondrial
membrane in hypoxic cardiomyocytes was conﬁrmed when mon-
itoring signal intensity of TMRM (Fig. 10D), suggesting that super-
oxide production within mitochondria could be underestimated.
We also assessed whether tumor cells could exhibit a similar
response to hypoxia. HeLa and HK2 cells were exposed to acute
hypoxia and incubated with Mito-HE at different times
(Supplementary Figs. 4 and 5). The response was similar to that
of endothelial cells, thus reinforcing the involvement of mitochon-
dria in hypoxic superoxide production and suggesting that this
could represent a general mechanism for various cell types.
Superoxide burst as a regulator of HIF-1α stability
As previously stated, hypoxic ROS production has been impli-
cated in triggering hypoxia adaptation signals through the HIF
pathway, mediated by HIF-α subunit stabilization [13,14]. Addi-
tionally, we have recently shown that in endothelial cells there is a
reversible oxidation in certain proteins after 2 h of hypoxia, which
could be implied in acute responses to hypoxia [8]. Thus, the
superoxide burst we observe could take part in hypoxic signals at
longer times, related to the different kinetics of accumulation of
different oxidized species.
To test this, we studied HIF-1α stabilization in the systems in
which we have been able to abolish the superoxide burst in
hypoxia, namely ρ0 cells and treatment with Tiron. In accordance
with results published elsewhere for other ρ0 cells [3,9,10],
ρ0L929 cells did not stabilize HIF-1α in hypoxia as happened in
the control C57 cells (Fig. 11A). Contrary to our hypothesis,
Tiron treatment in BAECs did not abolish HIF-1α stabilization in
hypoxia and even increased it, both in normoxia and in hypoxia
(Fig. 11B). Measurement of CDCFDA oxidation showed that cells
with Tiron produced equal or slightly higher signals than cells
Fig. 8. Superoxide, ROS, and mitochondrial membrane potential measurement by ﬂuorescence microscopy in live endothelial cells. BAECs were incubated with (A) 10 mM
DHE, (B) 5 mM Mito-HE, (C) 15 mM CDCFDA, or (C) 30 nM TMRM for 20 min and subsequently incubated in a chamber with atmospheric and temperature control in a
ﬂuorescence microscope, where they were maintained in normoxia or subjected to 2% O2 for 40 min. Quantiﬁcation of four regions for three independent experiments is
plotted for each time as the mean 7 SEM. Black circles, normoxia (Nx); white circles, hypoxia (Hp). The p value shown corresponds to the evaluation of the treatment effect
evaluated with the GEE method with independent correlation structure. (Insets in A–C) Oxidation rates considering all time points of each replicate (n ¼ 3) are plotted as the
mean 7 SEM. **p o 0.01 versus Nx.
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without treatment (Supplementary Fig. 6); this can be related to
the reduction of superoxide due to the reaction with Tiron,
producing mainly H2O2, which can explain increased HIF-1α
stabilization.
Conclusions and future directions
Using several converging methodologies that avoid reoxygena-
tion we have demonstrated that exposure of cells to acute
mild hypoxia (1–2% O2 under our culture conditions) was asso-
ciated with a burst in superoxide production within the ﬁrst
minutes. Thereafter the levels of superoxide production in hypoxic
cells reduced gradually over time. In 1 h no difference in super-
oxide production could be detected between hypoxic (1% O2) and
normoxic cells. Our results comparing different hypoxic O2 con-
centrations in the same experimental setting (Figs. 1, 4C, and 4D)
show that at 2% O2 the superoxide burst can be slower and more
sustained than at 1% O2. These observations resolve the seeming
contradiction in the ﬁndings reported earlier. For example,
Quintero et al. [20] analyzed superoxide production by incubating
endothelial cells with DHE for the ﬁrst 60 min of hypoxia (3% O2),
showing a clear increase in the ﬂuorescence signal; under these
conditions, DHE would be oxidized by the superoxide burst that
we have seen in our experiments. On the other hand, Chua et al.
[17] saw no increase in DHE ﬂuorescence when HEK293 cells were
exposed to 1% hypoxia; but in this case DHE was added for 30 min
after 3 h of incubation of the cells in hypoxia, which would not
allow the detection of the initial superoxide burst.
Other studies have also shown an increase in DHE oxidation in
cardiomyocytes in a model of acute ischemia for up to 60 min, in
which, in addition to hypoxia, nutrients were removed from the cell
culture medium [39]. Further studies would be interesting to evaluate
the relative role of oxygen and nutrient depletion, as well as the
putative signiﬁcance of this mechanism in ischemic preconditioning.
We have seen a similar superoxide burst in different types of
cells exposed to hypoxia and using either a probe distributed
throughout the cell or a mitochondria-targeted probe. When we
used ρ0 cells, lacking a functional OXPHOS, the superoxide burst
was abolished. Although we cannot rule out that other mechan-
isms of superoxide production could be implicated, this strongly
suggests that the superoxide burst in the ﬁrst minutes of hypoxia
comes from the mitochondrial OXPHOS system, and it could be
related to an early rearrangement of oxygen distribution and the
electron transport chain throughout the system. The fact that at 2%
O2 the superoxide production seems to be more intense and
prolonged than at 1% O2 allows speculation that the decrease in
superoxide production after some time of hypoxia could be related
to a decrease in the O2 availability inside the mitochondria, which
could be delayed with respect to the O2 reduction outside the cells.
The fact that DCF oxidation was maximal after 15 min of
hypoxic exposure suggests that the superoxide burst during the
ﬁrst minutes of hypoxia translates into an increase in H2O2 or
other ROS with a certain delay in time. This could be related to the
different kinetics of accumulation of the diverse ROS, although it
can be also an effect of the different probes used or even that the
superoxide burst could trigger peroxide generation by other
pathways; a more detailed evaluation of this relationship would
deserve further investigation. The increase in protein modiﬁcation
by thiol oxidation occurs later on and was observed after 2 h of
hypoxia in endothelial cells [8]; in further experiments, we have
observed protein thiol oxidation initiating after 30 min of hypoxia
in the same setting (unpublished results). If this signal takes part
in the stabilization of a transcription factor such as HIF-α, and
accumulation of target mRNAs, this could happen at even longer
times. Our experiments studying the functional consequences of
ablating the superoxide burst on HIF-1α stabilization (Fig. 11) are
not fully conclusive. On one hand, although both the superoxide
burst and the HIF-1α stabilization were ablated in ρ0 cells, there
could be many other effects related to OXPHOS impairment that
could be taking part. On the other hand, Tiron was effective in
scavenging superoxide, but probably increased H2O2 levels, which
correlated with equal or increased HIF-1α stabilization. Thus,
further experiments would be needed to assess this, probably
with more speciﬁc interventions to inhibit the superoxide burst.
We propose that a superoxide production burst in the ﬁrst
minutes, which is translated into cell signals mediated by redox
posttranslational modiﬁcations, may result in complex responses
of the cells to hypoxia (and maybe ischemia) such as adaptation
and preconditioning. This may include the activation of the HIF
pathway and the concomitant modiﬁcation of gene expression,
although other HIF-independent responses could be triggered by
such redox-based signal. Further research in this area should take
into account not only the intensity of the hypoxic stimulus and the
cell type and context, but also the time frame of the stimuli and of
ROS production and signaling.
Fig. 9. Superoxide and ROS measurement by ﬂuorescence microscopy in live C57
and ρ0L929 cells. C57 and ρ0L929 cells were incubated with (A) 10 mM DHE and
(B) 15 mM CDCFDA and treated as in Fig. 8. Quantiﬁcation of four regions for three
independent experiments is plotted for each time as the mean 7 SEM. Black
circles, C57 in normoxia (Nx C57); white circles, C57 in hypoxia (Hp C57); black
inverted triangles, ρ0L929 in normoxia (Nx ρ0L929); white triangles, ρ0L929 in
hypoxia (Hp ρ0L929). The p value shown corresponds to the evaluation of the
treatment effect evaluated with the GEE method with independent correlation
structure. (Insets) Oxidation rates considering all time points of each replicate (n ¼
3) are plotted as the mean 7 SEM. **p o 0.01 versus Nx.
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Fig. 10. Superoxide, ROS, and mitochondrial membrane potential measurement by ﬂuorescence microscopy in live cardiomyocytes. Primary cardiomyocytes were treated
and data obtained and plotted as in Fig. 8.
Fig. 11. Immunoblot analysis of HIF-1α in C57 and ρ0L929 cells and endothelial cells
untreated or treated with 1 mM Tiron. (A) C57 and ρ0L929 cells were exposed for
6 h to normoxia (Nx), normoxia with 1 mM dimethyloxalylglycine (DMOG; a
positive control for PHD inhibition and HIF-1α stabilization), or hypoxia (1% O2,
Hp). Proteins were extracted and blotted against HIF-1α protein. Representative
image of ﬁve independent experiments. (B) BAECs were exposed for 4 h to
normoxia (Nx), normoxia with 1 mM DMOG, or hypoxia for 2 (Hp2H) or 4 h
(Hp4H). Proteins were extracted and blotted against HIF-1α protein. Representative
image of three independent experiments.
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Reactive oxygen species (ROS) are produced as a consequence of
cellular activity and they can induce modifications that damage
DNA, lipids and proteins. These alterations are usually associat-
ed with oxidative stress, whereby ROS production exceeds the
reduction capacity of the cell's antioxidant systems [1]. However,
ROS are also involved in physiological cell signaling processes in
which adequate antioxidant activities are sustained [2,3].
Due to their reactivity, cysteine residues are key targets of a
variety of oxidative post-translational modifications (OPTM).
Irreversiblemodifications such as sulfonic acid (\SO3H) forma-
tion are associated with oxidative stress, while reversible
oxidative modifications are thought to act as redox sensors in
molecular cell signaling pathways [2,4–8]. These reversible
OPTMs include sulfenic acid (\SOH) formation, S-nitrosylation
(formation of a nitrosothiol, R-SNO) and the formation of
disulfide bonds between protein cysteines (intra- or interchain
disulfides) or between protein cysteines and low molecular
mass thiols, such as glutathione (S-glutathionylation) [9,10].
There are several methods to identify proteins that are
reversibly oxidized at cysteine residues, collectively known as
the “thiol redox proteome”. These approaches are mainly based
on derivatization techniques coupled to either gel-based separa-
tion of labeled proteins or LC-based peptide separation (for recent
reviews, see [11–15]). Recently developed fluorescent derivatiza-
tionmethods can be used in conjunctionwith gel separation, and
they represent relatively accessible and affordable techniques to
process a large number of samples, which have proved effective
in analyzing thesemodifications. However, to date this technique
has mainly been used to identify proteins that are oxidized in
models of oxidative stress (provoked by adding reagents such as
diamide or H2O2), and not in physiological conditions in which
OPTM may participate in cell signaling [15]. Moreover, this
approach suffers from several technical limitations, including
difficulties in identifying the residues modified [15].
Cells and living organisms have developed several systems
to sense oxygen (O2) availability, allowing them to activate
specific adaptive responses in hypoxic conditions. Examples
include the activation of the angiogenic response through VEGF
overexpression, and the induction ofmetabolic rearrangements
to activate glycolysis and reduce oxidative phosphorylation,
thereby limiting oxygen consumption [16,17]. In metazoans,
many of these responses are mediated by transcriptional
programs activated by a set of hypoxia-inducible factors (HIFs),
transcription factors that modulate the expression of a large
number of genes and whose stability is controlled mainly by a
family of specific HIF prolyl hydroxylases (PHDs) that behave as
monooxygenases, using O2 as substrate [18,19].
Despite much debate in recent years, there is abundant
evidence that ROS production augments in hypoxic cells and
that mitochondria are the main source of these ROS. Indeed,
this increase in ROS production has been implicated in the
activation of the HIF pathway (reviewed in [20–22]). Increased
protein cysteine oxidation has been linked with the produc-
tion of ROS in hypoxia, as shown with distinct fluorescent
sensors in different cell types [23–25], including pulmonary
artery endothelial cells [26]. As the identity of the proteins
directly oxidized in hypoxia remains unknown, the use ofthiol redox proteomics methods with sufficient sensitivity to
detect differential oxidation may help identify them.
Here, we describe the use of a “redox fluorescence switch”
(RFS) to reversibly label oxidized cysteines with a fluorophore
that can subsequently be detected after two-dimensional
electrophoresis (2-DE) separation. We used this differential
thiol redox proteomics technique to evaluate cysteine oxida-
tion in endothelial cells during the acute response to hypoxia.
This is a physiological state in which ROS production does not
induce oxidative stress but contributes to cell signaling. We
identified a number of reversibly oxidized proteins that may
mediate physiological responses to hypoxia, either by signal-
ing via the HIF-induced response pathway or by promoting
acute adaptive responses to oxygen deprivation. The use of
complementary “switch” techniques allowed us to confirm
the modification of individual proteins and to overcome some
of the limitations of current methods in identifying the
residues that are specifically modified in hypoxia.2. Experimental procedures
2.1. Cell culture, treatment and extraction
EA.hy926 cells (kindly provided by Dr Cora-Jean S. Edgell, UNC,
NC, USA) were cultured at 37 °C in DMEM supplemented with
HAT, 10% heat-inactivated fetal calf serum, 100 U/mL penicil-
lin and 100 μg/mL streptomycin, in an atmosphere of 5% CO2.
Human umbilical vein endothelial cells (HUVEC) were
isolated as described previously [27] and cultured on gelatin-
coated plates at 37 °C in medium 199 supplemented with
20% heat-inactivated fetal calf serum, 100 U/mL penicillin,
100 μg/mL streptomycin and 0.5 mg/ml ECGF, in an atmo-
sphere of 5% CO2.
Hypoxia was induced for 2 h in an Invivo2 200 workstation
(Ruskinn) set at 0.5%O2, 5% CO2 and 37 °C. Cells were introduced
into the workstation, washed with pre-hypoxic physiological
serum, and pre-hypoxic medium was added prior to treatment.
After induction of hypoxia, some cells were reoxygenated for
30 min.
After treatment, the cells were washed twice with physio-
logical serum and protein extracts were obtained by incubating
at room temperature (RT) for 10 min inTENT buffer (50 mMTris
pH 7.5, 1 mM EDTA, 100 μMneocuproine, 1% Triton X-100) with
protease inhibitors and 50 mM iodoacetamide. The cell debris
was removed by centrifugation and 2% SDS was added to the
supernatant, which was incubated for an additional 30 min at
37 °C to block free thiols. Samples were aliquoted and frozen at
−80 °C, and the protein concentration was estimated by the
BCA assay (Pierce). Hypoxic samples were obtained inside the
workstation.
2.2. Redox fluorescence switch
Protein extracts (400 μg) were precipitated with acetone,
resuspended in 800 μl of TENS buffer (50 mM Tris pH 7.5,
1 mM EDTA, 100 μM neocuproine, 1% SDS) with 2.5 mM DTT
and incubated for 10 min at RT. Samples were again precip-
itated with acetone, resuspended in 800 μl of TENS buffer with
40 μMBODIPY FL N-(2-aminoethyl)maleimide (Invitrogen) and
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stopped by adding 2.5 mM DTT. After precipitating again with
acetone, the samples were resuspended in the corresponding
buffer. For analytical experiments (SDS-PAGE) the quantities
were downscaled to 25 or 50 μg of protein.
2.3. Protein electrophoresis and fluorescence detection
For SDS-PAGE the samples were resuspended in non-reducing
SDS loading buffer and they were then separated on 10%
acrylamide gels using standard protocols.
For 2-DE, samples were resuspended in 300 μl of rehydra-
tion buffer (7 M urea, 2 M thiourea, 4% CHAPS, bromophenol
blue) with 1% of the corresponding ampholytes, 2% DTT
and Destreak, and they were applied to dry IPG 17 cm strips
pH 4–7 L for overnight reswelling. Isoelectric focusing was
performed at a maximum of 50 mA per IPG strip in the Protein
IEF cell (Bio-Rad), starting at 250 V and progressively increas-
ing the voltage to 10,000 V. After focusing the strips for at least
60,000 Vh, they were incubated for 10 min with equilibration
buffer (50 mM Tris–HCl pH 8.8, 6 M urea, 30% glycerol and 2%
SDS) plus 2% DTT, and with 2.5% iodoacetamide for a further
10 min. The second dimension was run on 10% SDS-PAGE
gels. After imaging the BODIPY-FL fluorescence (see below),
total protein staining was performed with SYPRO Ruby
(Invitrogen), following the manufacturers' instructions. The
images of the different fluorophores were obtained using a
Kodak Image Station 4000MM with excitation/emission filters
set at 470/535 nm for BODIPY-FL and 430/600 nm for SYPRO
Ruby.
2.4. Gel analysis
Images were analyzed with PDQuest 2-D gel analysis software.
An initial analysis was performed using RFS images. Four
biological replicates for each condition (normoxia, hypoxia,
hypoxia with reoxygenation) were matched in a single gel set
and quantified, and spots were selected when the fluorescence
signal was at least two-fold higher in hypoxic versus normoxic
conditions in at least two replicates. For several spots, no
signal was detected in the normoxic conditions, or it was
much lower than in hypoxia. A quantitative analysis was
performed on the remaining spots, calculating the mean
hypoxia:normoxia ratio in each experiment, and significant
differences were determined using a repeated measures
ANOVA test.
Images of the total protein signal for each gel were matched
in a separate gel set and quantified. The spots selected from the
RFS analysis were manually matched to their corresponding
total protein signal spots, and only those where the amount of
total protein remained constant were finally selected for
identification.
2.5. In-gel protein digestion and sample preparation
Spots of interest were excised manually from SYPRO
Ruby-stained gels, deposited in 96-well plates and processed
automatically in a Proteineer DP (Bruker Daltonics, Bremen,
Germany). A digestion protocol described previously was used
[28], with minor variations. The gel plugs were first washedwith 50 mM ammonium bicarbonate and then with acetoni-
trile (ACN), prior to reduction with 10 mM DTT in 25 mM
ammonium bicarbonate solution. Alkylation was carried out
with 55 mM iodoacetamide in 50 mM ammonium bicarbonate
solution, after which the gel pieces were rinsed with 50 mM
ammonium bicarbonate and then ACN, before they were dried
under a stream of nitrogen. Modified porcine trypsin (se-
quencing grade; Promega, Madison WI) was added at a final
concentration of 16 ng/μl in a 50 mM ammonium bicarbonate
solution with 25% ACN and the protein was digested at 37 °C
for 6 h. The reaction was stopped by adding 0.5% TFA to
extract the peptides. The tryptic peptides eluted were dried by
speed-vacuum centrifugation and resuspended in 4 μl of
MALDI solution (33% 2-propanol, 16.7% ACN and 0.5% TFA).
A 0.8 μl aliquot of each peptide mixture was deposited onto a
386 well OptiTOF™ Plate (Applied Biosystems, Framingham,
MA, USA) and dried at RT. A 0.8 μl aliquot of the matrix
solution (3 mg/mL CHCA in MALDI solution) was then
deposited onto the dried digest and the mixture was again
dried at RT.
2.6. MALDI peptide mass fingerprinting, MS/MS analysis
and database searching
For MALDI-TOF/TOF analysis, samples were acquired auto-
matically in an ABi 4800 MALDI TOF/TOF mass spectrometer
(Applied Biosystems, Framingham, MA, USA) in positive ion
reflector mode (the ion acceleration voltage was 25 kV to MS
acquisition and 1 kV to MS/MS) and the spectra obtained were
stored in the ABi 4000 Series Explorer Spot Set Manager.
Peptide mass fingerprinting (PMF) and MS/MS fragment ion
spectra were smoothed and corrected to the zero baseline
using routines embedded in the ABi 4000 Series Explorer
Software v3.6. Each PMF spectrum was internally calibrated
using the mass signals of the trypsin autolysis ions in order to
achieve a typical mass measurement accuracy of <25 ppm.
Known trypsin and keratin mass signals were removed from
the peak list, as were potential sodium and potassium
adducts (+21 Da and +39 Da). GPS Explorer v4.9 was used to
enter the combined PMF and MS/MS data into MASCOT
software v.2.2.04 (Matrix Science, London, UK) to search the
non-redundant Uniprot/SwissProt protein database (Uniprot/
Swiss-Prot, release 57.15, 02-Mar-2010: 515,203 sequences,
181,334,896 residues), restricting the search to human pro-
teins. The following search parameters were used: enzyme,
trypsin; 1 allowed missed cleavage; carbamidomethyl cyste-
ine as a fixed modification; oxidation of methionine as a
variable modification; mass tolerance set to ±25 ppm for
precursors and to ±0.3 Da for MS/MS fragment ions. The
confidence interval for protein identification was set to ≥95%
(p<0.05) and only peptides with an individual ion score
above the identity threshold were considered to be correctly
identified.
2.7. Redox biotin switch
For each sample, 250 μg of protein extracts blocked with IAM
was precipitated with acetone, resuspended in 500 μl of TENS
buffer with 2.5 mM DTT, and incubated for 10 min at RT.
Samples were then precipitated with acetone, resuspended
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pyridyldithio)propionamide (Biotin-HPDP, Pierce) and incu-
bated for 1 h at RT. After further precipitation with acetone,
the samples were resuspended in 500 μl neutralization buffer
(20 mM HEPES pH 7.7, 100 mM NaCl, 1 mM EDTA, 0.5% Triton
X-100). At this point an aliquot (50 μl) of each sample was
separated as the input fraction, while the remaining sample
was mixed with NeutrAvidin Plus UltraLink Resin (Pierce)
pre-equilibrated with equilibration buffer (20 mM HEPES pHFig. 1 – Schematic outline of the methodologies used. In all cases
thiol. Two steps are common to all methods: reduced thiols are b
with DTT. In RFS, fluorophore labeling was performed and oxidi
protein was detected by Sypro Ruby staining of the gel and diffe
analysis. In the NEM switch, newly reduced cysteine residues w
total protein was detected by Sypro Ruby staining. Previously se
cysteines were detected by LC–MS/MS. In the biotin switch, new
captured with an avidin-conjugated resin. After elution, individu7.7, 100 mM NaCl, 1 mM EDTA) and incubated for 1 h at RT.
The resin was then washed three times with wash buffer
(20 mM HEPES pH 7.7, 600 mM NaCl, 1 mM EDTA, 0.5% Triton
X-100) and the retained proteins were incubated for 20 min at
37 °C with elution buffer (20 mM HEPES pH 7.7, 100 mM NaCl,
1 mM EDTA, 100 mM 2-mercaptoethanol). Eluted samples and
15 μl of the input fraction were analyzed in Western blots
probed with antibodies against the following proteins: LDH-B
(ProteinTech), Hsp90 (Santa Cruz Biotechnology), Hsc70,, reversibly oxidized protein thiols are switched for a labeled
locked by reaction with IAM and oxidized thiols are reduced
zed cysteine residues were detected by 2-DE analysis. Total
rentially oxidized spots were selected by 2-DE differential
ere labeled with NEM, the sample was separated by 2-DE and
lected spots were excised from the gel and NEM-derivatized
ly reduced cysteines were labeled with biotin-HPDP and
al oxidized proteins were detected with specific antibodies.
AB
Fig. 2 – SDS-PAGE analysis of the general pattern of protein
cysteine oxidation determined using the Redox Fluorescence
Switch method. A) Endothelial cells were treated with 0.5%
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and PHD2 (Bethyl).
2.8. Identification of oxidized cysteine residues (NEM
switch)
Samples from cells subjected to normoxia and hypoxia were
processed in parallel to those subjected to RFS, employing a
similar procedure but using 400 μM NEM instead of the
fluorophore. After precipitation with acetone, the samples
were separated by 2-DE. Images of the RFS samples were used
as controls of oxidation and all gels were stained with SYPRO
Ruby to detect total protein. The spots of interest were excised
manually from the hypoxic sample and digested as described
above.
LC–MS/MS analysis was performed with a linear LTQ-Velos
linear ion trap apparatus equipped with a microESI ion source
(ThermoFisher, San Jose, CA). Each extract was diluted to a
final volume of 40 μL with 1% formic acid and the samples
were loaded onto a chromatography system equipped with a
C18 preconcentration cartridge (Agilent Technologies, Barcelona,
Spain) connected to a 10 cm long, 150 μm i.d. Vydac C18 column
(Vydac, IL, USA). Separation was performed at 1 μL/min in a
30 min acetonitrile gradient from0 to 40% (solventA: 0.1% formic
acid, solvent B: acetonitrile plus 0.1% formic acid). The HPLC
system consisted of an Agilent 1200 capillary pump, a binary
pump and a thermostated microinjector.
The LTQ-Velos apparatus was operated in the positive ion
mode with a spray voltage of 2 kV. The scan range of each full
MS was m/z 400–2000, and the maximum ion times set for the
MS and MS/MS experiments were 10 and 100 ms, respectively.
Spectrometry was performed in a targeted mode, acquiring a
full scan followed by a list of MS/MS experiments. Precursor
ions for the MS/MS experiments were selected after in silico
tryptic digestion of the target protein, using NEM and IAM
as variable modifications for cysteine, and oxidation as a
variable modification for methionine. The number of targeted
MS/MS experiments per cycle was reduced to less than 25
transitions by excluding non-cysteine-containing peptides. In
some cases peptides with missed cleavages or oxidized
methionine were excluded.
The MS/MS fragmentation spectra were searched using
Proteome Discoverer v1.3 (ThermoFisher, San Jose, CA) to
identify NEM- and IAM-derived peptides. The following
parameters were used in the database search: peptide mass
tolerance, 2 Da; fragment tolerance, 0.8 Da; enzyme, trypsin;
up to one missed cleavage permitted; dynamic modifications
were CAM (+57 Da) and NEM (+125 Da) for cysteines and
methionine oxidation (+16 Da). The database search used was
limited to include only the targeted proteins identified in this
study. The spectra were filtered using 1% FDR and all
identifications were validated manually. NEM derivatives
were confirmed by manual comparison of their MS/MS
spectra with the corresponding CAM derivatives.O2 for 2 h (Hp), 0.5% O2 for 2 h followed by 30 min of
reoxygenation (RO), or 2 mM diamide for 10 min (D).
Normoxic samples (Nx) were used as controls. B) Cells were
treated as above and RFS was performed without DTT. The
images are representative of at least four biological
replicates.3. Results
We sought to determine whether exposure of endothelial cells
to acute hypoxia and subsequent reoxygenation induced aglobal change in the oxidation state of protein cysteines. We
used a “redox fluorescent switch” (RFS) method that tags
reversibly oxidized cysteines with a fluorescent label, similar
to the fluorescence switch approach that we previously used
to study protein S-nitrosothiols [29]. This RFS method is based
on three successive chemical steps (Fig. 1): i) blocking of free
thiols; ii) reduction of oxidized cysteines with dithiothreitol
(DTT); and iii) labeling of the newly-formed free thiols with a
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method we employed diamide, a general non-specific oxidant.
We subjected EA.hy926 cells (an established model human
endothelial cell line [33]) to acute hypoxia (2 h at 0.5% O2), or to
acute hypoxia followed by 30 min reoxygenation. HIFα subunits
began to accumulate after 2 h in hypoxic conditions, although
to a lesser degree than after longer treatments, indicating that
the HIF-induced transcription program is not fully operative
following such acute oxygendeprivation (Supplementary Fig. 1).
When the samples were resolved by SDS-PAGE (Fig. 2A), a
moderate increase in cysteine oxidation was evident in
response to hypoxia, which was more pronounced in specific
bands and that differed from the general oxidation pattern
produced by diamide. Moreover, this effect was partially
reversed when cells were reoxygenated. Indeed, the fluores-
cence signal corresponding to oxidized cysteines was lost
when DTT was omitted (Fig. 2B), showing the specificity of
the technique.
To determine which proteins exhibit differential cysteine
oxidation during acute hypoxia, we separated protein extracts
subjected to RFS by two-dimensional electrophoresis. The
strength of the signal from the derivatizing probe used in the
RFS method, BODIPY-FL (green, upper panels in Fig. 3),
provides a measure of the extent of cysteine oxidation. The
RFS signal from cells subjected to hypoxia revealed an overall
pattern similar to that seen in normoxic cells, althoughFig. 3 – 2-DE analysis of oxidized cysteines labeled using the Redo
as in Fig. 2, loaded onto 17 cm IPG strips (pH 4–7L) and separated
cysteines. Red signal corresponds to Sypro Ruby staining for totadifferences in a number of spots were observed. Most of
these differences reflected an increase in oxidation during
hypoxia, which was reversed upon reoxygenation (Fig. 4).
Diamide treatment increased the number of spots and the
intensity ofmany of these, consistent with the general cysteine
oxidation induced by this reagent.
The Sypro Ruby signal (red, middle panels in Fig. 3)
corresponds to the total protein in each spot and indicates
that there were no significant differences between treatments.
Merging of both signals (lower panels in Fig. 3) demonstrated a
significant overlap of the signals corresponding to the same
spots, whichwas due to the use of a neutral and relatively small
probe for RFS, rather than a charged probe that displaces the
spots of derivatized proteins [29]. As expected, the pattern for
each signal differed given that only proteins bearing oxidized
cysteines are derivatized, and these represent only a small
fraction of the proteins in the cell extracts. A stronger similarity
was observed between signal patterns after diamide treatment
due to the relatively non-specific oxidation of protein cysteines
induced by this agent.
Spots displaying differential cysteine oxidation were fur-
ther analyzed with 2-DE-analysis software, comparing RFS
signals in gels from four experimental replicates of the cell
extracts maintained in normoxic and hypoxic conditions, or
subjected to hypoxia–reoxygenation. Spots were selected
when the signal in hypoxic conditions was at least 2-foldx Fluorescence Switchmethod. Endothelial cells were treated
by 2-DE. Green signal corresponds to RFS, showing oxidized
l protein.
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spots, qualitative difference was clear, as there was no RFS
signal in the normoxia gel for some of the replicates or, when
present, it was more than 7-fold smaller (Table 1). For other
spots, the RFS spot was clear in most of the replicate gels of
hypoxia samples, and a statistical analysis was performed
(see Experimental procedures), selecting those spots with a p
value of less than 0.05 (Table 1). The selected RFS spots were
matched to the corresponding total protein spots in the same
gels, ensuring that they displayed a constant total protein
signal (Fig. 4). These spots were manually excised from the
gels and digested, and the peptides obtained were analyzed by
MALDI-TOF/TOF (Supplementary Fig. 2). Twelve different
proteins were identified from these spots (Table 1) and
although Hsp90α and Hsp90β were detected in the same
spot, the remaining proteins were identified as single or
multiple spots (Supplementary Fig. 2). In addition, 78 kDa
glucose-regulate protein (Grp78), was identified from a RFS
spot localized in three replicates of normoxia and hypoxia
gels, with a mean ratio of 15.5±1.05, but with a p value of 0.08,
thus considered to be non significant.
The oxidation of individual proteins was confirmed using a
“redox biotin switch”, in which oxidized cysteines were
derivatized with a biotin moiety. Biotinylated proteins were
then captured with an avidin resin, allowing individual
proteins to be analyzed in Western blots (Fig. 1). Using
extracts from endothelial cells subjected to the same treat-
ments, this technique was employed to analyze cysteineTable 1 – Proteins differentially oxidized in endothelial cells su
Uniprot ID Protein definition # of
spots a
M
S
Nx Hp
Qualitative analysis Minimal
ratio b
CPNS1_HUMAN Calpain small subunit 1 0 4
SPSY_HUMAN Spermine synthase 1 4 7.4
HS105_HUMAN Heat shock protein 105
kDa
0 3
LDHB_HUMAN L-lactate dehydrogenase
B chain
0 4
1433Z_HUMAN 14-3-3 protein zeta/delta 2 4 63
1433T_HUMAN 14-3-3 protein theta 2 4 7.9
1433B_HUMAN 14-3-3 protein beta/alpha 2 3 61
Quantitative analysis Mean
ratio c
p
HS90A_HUMANd Heat shock protein HSP
90-alpha
2 2 2.5±0.4 0.03
HS90B_HUMANd Heat shock protein HSP
90-beta
TGM2_HUMAN Protein-glutamine
gammaglutamyltransferase2
2 3 7.2±2.4 0.04
HSP7C_HUMAN Heat shock cognate 71
kDa protein
4 4 3.1±1.3 0.04
ACTN4_HUMAN Alpha-actinin-4 3 4 3.5±2.0 0.01
a Number of replicates in which the spot is detected. Nx, normoxia; Hp,
b Minimal value obtained for the ratio (RFS signal in Hp/RFS signal in Nx
c Mean±standard deviation of the ratios (RFS signal in Hp/RFS signal in N
d Both proteins were identified in the same spot.oxidation in some of the proteins identified: lactate de-
hydrogenase B (LDH-B), heat shock protein 90 (Hsp90:),
transglutaminase 2 (Tgm2) and Hsc70 (Fig. 5). These results
confirmed the specific oxidation of these proteins in hypoxia,
which was reversed after reoxygenation. Interestingly, the
proteins behaved differently when the cells were challenged
with diamide, and while oxidation of most of them increased,
LDH-B remained in a reduced state. This observation supports
the view that hypoxia promotes the oxidation of specific
proteins that are not oxidized in other circumstances.
Additionally, we included analysis of PHD2 oxydation, as it is
the main protein controlling HIF-1α stability and its activity is
inhibited by H2O2 [34,35]. However, we found that there is no
differential oxidation between normoxia and hypoxia, further
supporting that oxidation in hypoxia is limited to a particular
set of proteins.
In order to confirm the results in primary endothelial cells,
we subjected HUVEC cultures to the same treatments we had
performed on EA.hy926 cells, obtaining similar results. RFS with
SDS-PAGE showed that there is an increase in cysteine oxidation
after acute hypoxia, revertedwith reoxygenation (Fig. 6A). Redox
biotin switch with Western blots against LDH B, Hsp90 and
calpain small subunit 1 (CPNS1) showed also increased oxida-
tion of these proteins in hypoxia (Fig. 6B). PHD2 oxidation was
not affected in hypoxia and LDH B was not oxidized with
diamide, confirming the results obtained with the cell line.
Tests with standards were performed and showed that
peptides derivatizedwith BODIPY FLN-(2-aminoethyl)maleimidebjected to hypoxia.
ascot
core
Mascot
expect.
MM (Da)
theoretical
Theoretical
pI
Matched
peptides
%
coverage
581 1.60E−54 28,469 5.05 12 45
420 2.00E−38 41,698 4.87 9 24
596 5.10E−56 97,716 5.28 25 27
567 4.00E−53 36,900 5.71 20 42
862 1.30E−82 27,899 4.73 24 70
509 2.60E−47 28,032 4.68 18 42
837 4.00E−80 28,179 4.76 26 74
641 1.60E−60 85,006 4.94 28 36
433 1.00E−39 83,554 4.97 25 17
907 4.00E−87 78,420 5.11 31 51
1110 2.00E−107 71,082 5.37 35 49
1010 2.00E−97 105,245 5.27 45 49
hypoxia.
) of replicate(s) in which a spot was found in normoxia.
x) in individual experiments.
1 2
3RFS
Total
protein
1: HSP90 2: TGM2 3: GRP78
HypoxiaNormoxia Reox
RFS
Total
protein
SPSY
12
3RFS
Total
protein
14-3-3proteins: 1: theta 2: zeta/delta 3: beta/alpha
HypoxiaNormoxia Reox
HSC70
LDHB
CPNS1
2
1
1: HSP105 2: ACTN4
Fig. 4 – Detailed 2-DE images showing spots that were differentially oxidized in hypoxic conditions (labeled with arrows).
Endothelial cells were treated as in Fig. 2, loaded onto 17 cm IPG strips (pH 4–7L) and separated by 2-DE. RFS detect oxidized
cysteines, and total protein was stained with Sypro Ruby. Names of proteins are as in Table 1.
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underivatized peptides (data not shown). The LC–IT-MS/MS
spectra of BODIPY derivatives did not display the classic pattern
of sequential b andy fragments, and theywere largely dominated
byaneutral lossof oneor twoHF (hydrogen fluoride) units [36]. As
a result, the LC–IT-MS/MS spectra of peptides derivatized with
BODIPY FLN-(2-aminoethyl)maleimide contained little structural
information regarding the peptide. Therefore, RFS derivatized
proteins could not be analyzed in LC–IT-MS/MS experiments to
identify the cysteine residues modified.
To overcome this problem, we used a different “redox
switch” procedure designed to more accurately identify cyste-
ine residues after peptide fragmentation analysis by MS/MS, a
procedure similar to that previously used to analyze individual
reversibly oxidized proteins [37]. Accordingly, oxidized cyste-
ines were labeled with N-ethylmaleimide (NEM), a reagentcompatible with peptide sequencing by MS/MS (Fig. 1). As NEM
derivatives cannot be monitored by fluorescence, the same
samples were also subjected to RFS, and both derivatized
extracts were analyzed in parallel 2-DE gels. We excised the
spots that were differentially oxidized in the RFS samples from
the hypoxic NEM gels. The identity of the proteins was
confirmed by MALDI-TOF/TOF, and the tryptic extracts were
subjected to targeted LC–MS/MS to detect and sequence
NEM-derivatized peptides. A total of eight peptides were
positively identified as NEM derivatives and from these, five
oxidized cysteines were identified in five distinct proteins
(Table 2). The peptides with NEM-derivatized cysteines were
further validated by a more detailed comparison of the mass
spectra with the CAM-derivatized homologue (Fig. 7 and
Supplementary Fig. 3). Remarkably, all five cysteines detected
as NEM derivatives were also detected as CAM derivatives
AFig. 5 – Redox biotin switch showing oxidation of individual
proteins. Endothelial cells were treated with 0.5% O2 for 2 h
(Hp), 0.5% O2 for 2 h followed by 30 min of reoxygenation
(RO), or 2 mM diamide for 10 min (D). Normoxic samples (Nx)
were used as controls. After the redox biotin switch, an
aliquot was separated (input) and after avidin purification,
the eluted samples and the input samples were analyzed in
Western blots with antibodies for the indicated proteins. The
images are representative of at least three biological
replicates.
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forms of these fiveproteins, consistentwith the potential role of
reversible cysteine oxidation in signal transduction.B
Fig. 6 – RFS and biotin switch analysis in primary endothelial
cells. HUVEC were treated with 0.5% O2 for 2 h (Hp), 0.5% O2
for 2 h followed by 30 min of reoxygenation (RO), or 2 mM
diamide for 10 min (D). Normoxic samples (Nx) were used as
controls. A) SDS-PAGE showing RFS (oxidized cysteines) and
Sypro Ruby (total protein) signals. B) Oxidation of individual
proteins, showed by redox biotin switch and Western blot
with antibodies for the indicated proteins, performed as in
Fig. 5. The images are representative of at least three
biological replicates.4. Discussion
We have developed a proteomic method using fluorescence
derivatization and electrophoresis to analyze reversible oxi-
dative cysteine modifications, which we have named “redox
fluorescence switch” (RFS). Negative and positive controls
demonstrated the validity of this method in detecting such
modifications: a low background signal was detected when
DTT was omitted from the reaction, while the signal was
clearly enhanced in cells treated with diamide, a powerful
cysteine oxidant.
When coupled with SDS-PAGE, the RFS technique allowed
us to compare protein thiol oxidation in several samples,
demonstrating its utility to screen the global protein thiol
status in different physiological or cell conditions. We used
this approach to evaluate the global oxidation in endothelial
cells subjected to acute hypoxia (2 h at 0.5% O2). In these
conditions, we observed an increase in protein cysteine
oxidation, which was partially lost when the cells were
reoxygenated with ambient air. This result is consistent with
recent studies using novel protein fluorescent sensors that
respond specifically to cysteine oxidation, such as HSP-FRET
and RoGFP, in which acute hypoxia (either hypoxia alone or
hypoxic ischemia) increased cysteine oxidation in cultured
cells, an effect that was reversed by reoxygenation [24,38,39].
However, our method is a global detection method to study
endogenous protein cysteine oxidation rather than one using
specific proteins that act as specialized probes, as in these
earlier studies.By coupling RFS to 2-DE, we analyzed differential cysteine
oxidation in individual protein spots, identifying the proteins
thatwere further oxidized in hypoxic conditions. This approach
offers two novel advantages over a previously described
method used to detect S-nitrosylated proteins [29]: i) the use of
BODIPY-FL as the labeling fluorophore increases the accuracy
with which cysteine oxidation and the total protein signals
from individual protein spots are matched; ii) the use of
iodoacetamide as a blocking reagent, rather than maleimide,
enhances IEF resolution and reduces horizontal streaking [15].
In expression proteomics, DIGE technology reduces gel-to-gel
variation by running samples and standards labeled with
different fluorophores in the same gel. However, when analyz-
ing post-translational modifications, such as cysteine oxida-
tion, differences in the oxidation signal of a spot may reflect a
difference in the ratio of oxidized protein in that spot or
alternatively, a difference in the amount protein. Thus, running
each sample in a different gel allowed us to control for the
Table 2 – List of NEM-derivatized peptides identified by targeted LC–MS/MS of spots corresponding to oxidized proteins.
These NEM derivatives indicate the position of oxidized cysteines in the protein. In all cases we identified both the IAM and
NEM derivatives of the same peptides, indicating the coexistence of both the reduced and oxidized forms of the protein.
Uniprot
accession
number
Uniprot ID Protein
length
Peptide identified Cys
residue
number
Peptide
modification
Charge Precursor
[M+H]+
Number
of
spectra
Max.
XCorr
P08238 HS90B_HUMAN 724 C*LELFSELAEDKENYK 412 NEM 2 2057.1 7 4.99
IAM 2 1989.4 3 3.41
C*LELFSELAEDK 412 NEM 2 1522.7 3 3.83
IAM 2 1454.8 2 3.86
P63104 1433Z_HUMAN 245 DIC*NDVLSLLEK 94 NEM 2 743.5 4 3.84
P27348 1433T_HUMAN 245 SIC*TTVLELLDK 94 NEM 2 1458.3 2 2.26
IAM 2 1390.7 11 3.82
P04632 CPNS1_HUMAN 268 YSDESGNmDFDNFISC*LVR 232 NEM 2 2352.1 2 3.29
IAM 2 2283.9 14 5.04
YSDESGNmDFDNFISC*LVRLDA
MFRAFK
232 NEM 3 3416.4 1 2.48
P11142 HSP7C_HUMAN 646 ILDKC*NEIINWLDK 574 NEM 3 1840.2 2 3.59
IAM 3 1771.9 2 2.76
C*NEIINWLDK 574 NEM 2 1371.4 10 3.26
IAM 2 1303.9 9 3.62
C* — cysteine derivatized with either NEM or IAM.
m — oxidized methionine.
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Fig. 7 – Comparison of MS/MS spectra from the CAM (top) and NEM (bottom) derivatized peptide sequence DIC*NDVLSLLEK
(1433Z_HUMAN). Signals corresponding to the y sequence dominated both spectra. The m/z values interpreted as the
fragments from y3 to y9 coincided in both spectra. However, the intense fragments corresponding to the derivatized cysteine
(y101+ and y102+) were shifted by 68 Da, a value that coincided with the expected mass difference between NEM (125 Da) and CAM
(57 Da).
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each protein spot.
Several studies seeking to establish a catalog of putative
targets for cysteine oxidation have described proteins that are
differentially oxidized after treating cells with strong oxidizing
reagents such as diamide [30,32]. We used diamide as a positive
control, while focusing on changes induced in more physiolog-
ical contexts inwhich oxidative stress is not induced andwhere
differential protein oxidation may modulate signal transduc-
tion pathways or produce specific adaptations. We identified
several proteins that were oxidized in response to acute
hypoxia (Table 1), demonstrating the validity of the RFSmethod
for this type of analysis. Indeed,weobserved LDH-B oxidation in
response to hypoxia but not after diamide treatment, indicating
that hypoxia may indeed induce a specific pattern of protein
oxidation.
Using complementary derivatization techniques, we con-
firmed the validity of the RFS method and circumvented some
of its limitations. The “redox biotin switch” allowed us to label
oxidized cysteines with a biotin moiety and to subsequently
purify the oxidized proteins. Using this approach, we confirmed
the oxidation in hypoxia of several of the identified proteins,
corroborating the results of the RFS approach. Interestingly, this
finding demonstrates the specificity of thiol oxidation of LDH-B
in hypoxia when compared with oxidation by diamide, consis-
tent with a previous study that reported no alterations in LDH
catalytic activity following diamide treatment [40].
Attempts to detect fluorophore-labeled peptides from
spots on RFS 2-DE gels using either MALDI-TOF/TOF or
ESI-MS/MS were unsuccessful, probably due to the chemical
characteristics of the BODIPY-FL moiety. This problem was
successfully resolved using an alternative methodology,
whereby oxidized cysteines were labeled with NEM, which is
a smaller reagent that does not interfere with MS detection.
As proteinsmigrated to the same position in parallel 2-DE gels
after both the RFS and the “NEM switch”, we used this
approach to identify oxidized Cys residues in the spots
detected by RFS (Table 2). Our findings further confirm the
utility of RFS, and provide important information regarding the
oxidative modifications of these proteins and their putative
functional relevance.
In the Supplementary Table 1 we have compiled structural
and functional information on the proteins identified as
oxidation targets in hypoxia. At least four of these proteins
were previously shown to be functionally regulated by different
thiol oxidative modifications (see Supplementary Table 1):
Hsp90 [41,42], transglutaminase-2 [43–46], Hsc70 [47] and
LDH-B [48,49]. As some of these proteins have been previously
implicated in the hypoxia response, their functional modula-
tion by oxidationmay constitute an acute responsemechanism
contributing to HIF activation, or to early events independent of
the HIF pathway.
PHD2 has a direct role in the response to hypoxia by
promoting HIF-α degradation. It has been reported that H2O2
addition to cells stabilizes HIF-1α [34], and purified PHD2 treated
with H2O2 has a decreased activity, an effect dependent on the
presence of two cysteine residues [35]. Thus, ROS produced in
hypoxia could oxidize these cysteine residues, which would
contribute to PHD2 inhibition and HIF activation. However,
we have not found differential oxidation under hypoxiaconditions, arguing against a direct effect, at least in
endothelial cells.
Hypoxia enhances the oxidation of three heat shock proteins.
Hsp90 binds to and stabilizes HIF-α subunits, protecting them
from degradation via the pVHL-independent RACK1-dependent
pathway [50–52]. We previously reported that S-nitrosylation of
Cys 597 inhibits Hsp90 activity [41] and here we observed a
moderate increase in Hsp90 cysteine oxidation, although a
different Cys residue was identified as the site of modification.
Thus, the functional relevance of Hsp90 cysteine oxidation in
HIF-α stabilization remains unclear. As the effects of Hsp90 on
other proteins are inhibited in a ROS-dependent manner in
hypoxic conditions, such as in the case of the hERG K+ channel
[53], the oxidation observed may be functionally related to
specialized proteins not involved in the HIF pathway. Hsc70 is a
member of the Hsp70 family, a type of chaperones for which a
selective role in degrading HIF-1α but not HIF-2α has been
described [54]. Since both HIFα subunits are expressed in
endothelial cells, oxidation of this chaperone may be an
influential event. In addition, Hsp105 has been reported to
inhibit some activities of theHsp70 family.More detailed studies
of the relative oxidation of the individual Hsp proteins will be
necessary to fully determine its functional consequences.
Calpain protease activity participates in the proteasome-
independent cleavage of HIF-α subunits and increased calpain
activity has been described following acute hypoxia [55,56]. We
observed increased oxidation of a calpain regulatory subunit in
acute hypoxia. Although this finding suggests that oxidation
may regulate this pathway, the functional consequences of the
modification of this specific subunit remain unknown.
Cell adaptation to hypoxia involves the inhibition of protein
synthesis via mTOR inactivation. This process is mediated by
activating the mTOR inhibitor, TSC1/2, which is normally
inhibited by the binding of 14-3-3 proteins. Hypoxia induces
REDD1 expression viaHIF, and as REDD1 binds to and sequesters
14-3-3 from complexes with TSC2, TSC2 can inactivate mTOR
[57–59].Moreover, oxidationof 14-3-3 inhibits its interactionwith
other proteins [60]. It is therefore tempting to speculate that the
acute oxidation of a conserved Cys residue in several 14-3-3
isoforms inhibits its binding to TSC2, anticipating the effect of a
HIF-induced gene and advancing the inhibition of mTOR.
Similar acute effects may be hypothesized for lactate
dehydrogenase B (LDH-B) oxidation in terms of the metabolic
adaptation to hypoxia. LDH isoforms catalyze the conversion
between pyruvate and lactate, linked with the NADH/NAD+
redox pair. In hypoxia, activation of glycolysis and inhibition
of NADH consumption via mitochondrial oxidative phosphor-
ylation require an increased rate of pyruvate to lactate
conversion and NAD+ regeneration. This is achieved by the
HIF-dependent induction of LDH-A [61,62], the gene encoding
the LDHM chain (named after its strong expression in skeletal
muscle), which favors the conversion of pyruvate to lactate
[63]. By contrast, the H chain (highly expressed in heart)
is better adapted to aerobic metabolism and favors the
conversion of lactate to pyruvate [63]. While the catalytic
centers are very similar, the amino acid composition of both
chains produces variations in the pKa of the catalytic
histidine, which accounts for the differential activity [64].
Cys 164 of the H chain (LDH-B) has been historically
described as a reactive cysteine. While enzyme inactivation
5460 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 4 9 – 5 4 6 2has been reported when this residue is modified (reviewed in
[65]), more detailed studies using a small modifier, methyl
methanethiosulfonate, demonstrated that such modifica-
tion alters its catalytic activity, making it more similar to the
M chain [48,49]. Reversible oxidation by small modifiers may
thus provide a mechanism for acute regulation of LDH
activity in hypoxia, before gene responses mediated by the
HIF pathway are established, promoting the conversion of
pyruvate to lactate.5. Conclusions
We show here that RFS is a useful proteomic approach to detect
reversible oxidation of cysteine residues in cells subjected to a
physiological treatment that promotes ROS-induced cell signal-
ing. Using complementary switch protocols, oxidation of indi-
vidual proteins can be studied in greater detail, and oxidized
cysteine residues can be identified. Cysteine oxidation of several
proteins is enhanced in endothelial cells subjected to acute
hypoxia, although these proteins do not necessarily coincide
with those that are altered in response to a non-specific
oxidant stimulus. The identification of some of these pro-
teins provides an important basis for further studies into the
functional impact of these modifications on the acute cell
responses to hypoxia.
Supplementary data to this article can be found online at
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Within the last twenty years the view on reactive oxygen species (ROS) has changed; they are no longer
only considered to be harmful but also necessary for cellular communication and homeostasis in dif-
ferent organisms ranging from bacteria to mammals. In the latter, ROS were shown to modulate diverse
physiological processes including the regulation of growth factor signaling, the hypoxic response, in-
ﬂammation and the immune response. During the last 60–100 years the life style, at least in the Western
world, has changed enormously. This became obvious with an increase in caloric intake, decreased en-
ergy expenditure as well as the appearance of alcoholism and smoking; These changes were shown to
contribute to generation of ROS which are, at least in part, associated with the occurrence of several
chronic diseases like adiposity, atherosclerosis, type II diabetes, and cancer. In this review we discuss
aspects and problems on the role of intracellular ROS formation and nutrition with the link to diseases
and their problematic therapeutical issues.
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The research within the last twenty years on chemically re-
active molecules containing oxygen, commonly called reactive
oxygen species (ROS), has shown that these molecules are im-
portant for cellular communication and homeostasis in different
organisms ranging from bacteria to mammals. Thereby, ROS were
shown to modulate diverse physiological processes including the
regulation of growth factor signaling, the hypoxic response, in-
ﬂammation and the immune response in mammalian cells. ROS
are often simply called “free radicals” because their majority is
characterized by at least one unpaired electron in their outer or-
bitals; however, peroxides like hydrogen peroxide may also give
rise to the formation of oxygen radicals and are therefore also
considered as ROS. Frequently the incomplete reduction of oxygen
by one electron producing superoxide anion (O2
·−) is the ﬁrst step
for the formation of most other ROS [1,2].
The action of ROS is usually balanced by the antioxidative ca-
pacity of a cell or organism and a disturbance of this balance in
favor of a prooxidant state is commonly referred to as oxidative
stress. Oxidative stress is usually coupled to harmful effects due to
the primary chemical reactions of ROS with lipids and proteins. In
this respect, diseases frequently associated with a Western life-
style and nutritional regime like type II diabetes, cardiovascular
diseases or cancer were found to be associated with a deregulated
ROS formation [3–7]. Hence, it appears to be of special interest
that production of ROS due to nutrition may affect signaling
pathways and the pathogenesis of these diseases. In the current
review we aim to summarize some aspects on the role of ROS,
nutrition, intracellular ROS formation, and the link to diseases.Fig. 1. ROS generation in cells. ROS can be generated in response to various stimuli
among them diets or radiation which is supported by the action(s) of enzyme
(s) located in different intracellular compartments. ETC, electron transport chain;2. Cellular sources of ROS
A number of studies within the last decade indicated that
overnutrition-induced ROS formation and oxidative stress con-
tribute to the development of metabolic disorders, in particular to
insulin resistance, as well as to cardiovascular diseases, and cancer
[8–12].
In mammalian cells ROS can be generated in different cellular
compartments such as membranes, cytoplasm, mitochondria, en-
doplasmic reticulum (ER), lysosomes, and peroxisomes (Fig.1). In
the following we will give only a short summary because the role
of each compartment in ROS formation has been discussed else-
where in excellent detail [13].
2.1. Plasma membranes and ROS production
The prototypic NADPH oxidase was found in phagocytes loca-
lized in the plasma membrane and phagosomes [14]. It is com-
posed of gp91phox and the smaller subunit p22phox forming the
ﬂavocytochrome b558 [15,16] which is the catalytic core of the
NADPH oxidase generating O2
·−. Several homologs of gp91phox –now termed NOX2-named NOX1-5, and the more distantly related
DUOX1/2 (dual oxidases) were found [17–19]. NOX2 is mainly
expressed in polymorphonuclear cells, macrophages and en-
dothelial cells, but its expression was also veriﬁed in other cell
types including cells from the CNS, smooth muscle cells, ﬁbro-
blasts, cardiomyocytes, skeletal muscle, hepatocytes, and
hematopoietic stem cells [20] (Table 1).
NOX1 is highly expressed in the colon epithelia [21] and was
also detected in lower abundance in smooth muscle cells, en-
dothelial cells, uterus, placenta, pancreatic islet beta cells and
other cell types [22,23]; it is mainly localized in the plasma
membrane of caveolae, but also in early endosomes or nucleus
[24,25].
NOX3 has long been considered to be expressed in fetal tissues,
but is it now also found in the inner ear, HepG2 cells, the mouse
macrophage cell line RAW264.7, and in murine lung endothelium
[26] (Table 1).
NOX4 is widely expressed in many tissues, especially in the
kidney [27], but also in most other tissues and cells including
endothelial cells, smooth muscle cells, ﬁbroblasts and hepatocytes
[25,28–30]. In contrast to most other NOXes, NOX4 is mainly lo-
calized in the endoplasmic reticulum as well as in the outer
membrane of the nucleus [31,32]. Finally, NOX5 expression has
been detected in testis, prostate, spleen, lymph nodes, but also in
endothelial and smooth muscle cells [26] and its mainly localized
in the endoplasmic reticulum of the cell [33] (Table 1).
The two DUOX1/2 proteins are highly expressed in the thyroid,
but also in lung epithelium and gastrointestinal tract [34–36];
mainly in the endoplasmic reticulum and plasma membrane [32].
Most NOXes as well as the two DUOX members require cyto-
solic subunits for full activation. In the case of NOX2 these are the
cytosolic subunits p40phox, p47phox, p67phox as well as the
small monomeric GTPase Rac [16]. NOX1 and NOX3 can be regu-
lated by NOXO1 (p67phox homolog) and NOXA1 (p47phox
Table 1
Overview of the NOX family members (see text for details and references)
Name Subcellular
localization
Expression# Cofactors
NOX1 Caveolae membrane Colon epithelia p22phox
NOXO1Smooth muscle cells
Endothelial cellsEndosomes
Uterus NOXA1
PlacentaNucleus p47phox(?)
Pancreatic islet beta cells RAC 1
NOX2 Plasma membrane Neutrophils p22phox
Macrophages
Endothelial cells p40phox
Central nervous system
Smooth muscle cells p47phox
Fibroblasts
Phagosomes Cardiomyocytes p67phox
Skeletal muscle
Hepatocytes RAC 1/2
Hematopoietic stem cells
NOX3 Fetal tissues p22phox
NOXO1Inner ear
Hepatoblastoma cell line
HepG2
NOXA1
Murine Macrophage cell line
RAW264.7
P47phox(?)
Murine lung endothelium RAC 1
NOX4 Endoplasmic
reticulum
Kidney p22phox
Endothelial cells
Smooth muscle cells RAC 1(?)Outer nucleus
membrane Fibroblasts
Hepatocytes
NOX5a Endoplasmic
reticulum
Testis Ca2þ
Prostate
Spleen Calmodulin
Lymph nodes
Endothelial cells
Smooth muscle cells
DUOX1/2 Endoplasmic
reticulum
Thyroid Ca2þ
Plasma membrane Lung epithelium DUOX1/2
Gastrointestinal tract
a NOX5 is not present in rodents.
# Most relevant expression listed with no claim to completeness.
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and DUOXA2, respectively [26,32]. NOX4 activity seems to be in-
dependent of regulatory subunits, though a role for Rac is dis-
cussed [26] and it is mainly regulated at the expression level. In
addition to regulatory proteins, activation of NOX5 and DUOX1/2
requires calcium [17,33] and in case with NOX5 also calmodulin
[37] (Table 1). Most generated ROS in non-phagocytic cells are
mainly considered to act as second messenger molecules in several
processes including responses to nutrition [26].
2.2. Mitochondria and ROS production
Mitochondria are well known to be major ROS producers [38]
and the fraction of oxygen that is used for ROS production varies
and ranges from 0.15% to 4% [39]. Interestingly, in females mi-
tochondria produce less ROS than in males; a difference which can
be seen also in the induced levels of antioxidant enzymes in fe-
males which is largely due to the action of estrogens [40]. The
electron transport chain (ETC) within mitochondria constitutes animportant source of O2
·− formation primarily due to leaking elec-
trons from complex I (NADH-CoQ reductase) and complex III (cy-
tochrome c reductase). Thereby complex I generates O2
·− only
within the matrix, while complex III can contribute to O2
−· forma-
tion also in the intermembrane space [41]. In addition to the ETC,
also the acetyl-CoA generating enzyme pyruvate dehydrogenase
(PDH) and the Krebs cycle enzyme α-ketoglutarate dehydrogenase
(KGDH) can be sources of O2
·− [42–46]. Moreover, it was shown that
the redox enzyme p66Shc is involved in the direct reduction of
oxygen to H2O2 in the intermembrane space by using reducing
equivalents through the oxidation of cytochrome C [47].
2.3. The endoplasmic reticulum (ER) and ROS production
The endoplasmic reticulum is a place with a high rate of ROS
generation. On the one hand ER-localized ROS can be a byproduct
of ER-localized oxygenases and oxidases during oxidative protein
folding-among them endoplasmic oxidoreductin 1 (ERO1) as the
most prominent one [13,48]. On the other hand there are also ER
localized NADPH oxidases such as NOX4, NOX5, and DUOX1/2
which can contribute to ROS generation in the ER [31,33]. In ad-
dition, there is a crosstalk between enzymes of the protein folding
machinery and NADPH oxidases due to a described interaction
between PDI and NOX1/NOX4 as well as an interaction between
calmodulin and NOX5 [37,49]. Further, ER localized iron deposits
may also contribute to the pool of ROS by the formation of OH via
a Fenton reaction [50].
2.4. Lysosomes and ROS production
Lysosomes are important organelles involved in degradation of
intracellular and extracellular materials which interlinks them
with phagocytosis, endocytosis and autophagy. To operate the
degradative acidic hydrolases require a pH of about 4.8. To gen-
erate this pH, lysosomes appear to contain a redox chain which
similar to the mitochondrial ETC contributes to proton distribu-
tion. As a byproduct ROS are generated. Thereby, reduction of O2 in
three steps can give rise to OH generation [51]. Since lysosomes
are degrading iron- and copper containing macromolecules they
accumulate iron and copper. Due to the acidic and reducing lyso-
somal environment iron is mainly in the divalent, thus redox ac-
tive, state whereas lysosomal copper is usually complexed with
various thiols and is thus likely not redox-active [52]. Hence, the
presence of divalent iron further fosters generation of OH by
Fenton reactions which may affect lysosomal membrane integrity
[52].
2.5. Peroxisomes and ROS production
Peroxisomes participate in several metabolic processes, in-
cluding long-chain fatty acid β-oxidation, the oxidative part of the
pentose phosphate pathway, phospholipid biosynthesis, purine,
and polyamine metabolism as well as amino acid and polyamine
oxidation [53]. Many of the enzymes operating in these pathways
are ﬂavin-dependent oxidases [53] which produce H2O2 as a result
of their activity [54]. The major process forming H2O2 is β–oxida-
tion of fatty acids whereas a peroxisomal xanthine oxidase ap-
pears to provide not only H2O2 but also O2
·− [54]. Since H2O2 can
give rise to formation of other ROS which could damage the cells,
it needs to be degraded into per se non-reactive substances. This is
done by the enzyme catalase which converts H2O2 into O2 and H2O
[55].
2.6. Detrimental action of ROS
The harmful action of ROS is primarily due to their ability to
Fig. 2. Interrelation between ROS in signaling and cell damage. ROS generated in
cells by speciﬁc action of various enzymes appear to have a more critical role in
signaling than ROS generated as by-products of intracellular processes or due to
external toxic stimuli. ETC, electron transport chain. PDH, pyruvate dehydrogenase;
KGDH, α-ketoglutarate dehydrogenase.
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lipids (Fig. 2). Among the ROS, OH are known to mainly damage
DNA by reacting with all four bases whereas 1O2 selectively attacks
guanine [56]; O2
·− and H2O2 contribute indirectly to DNA damage
by forming OH and lipid peroxides which contribute to formation
of DNA adducts [57]. Again, most protein damage is exerted due to
the action of OH at the protein polypeptide backbone [58]; as a
consequence, further radicals such as peroxyl, alkylperoxide, or
alkoxyl radicals are formed [59].
It appears that mitochondrial DNA is more susceptible to DNAFig. 3. ROS-regulated signaling pathways. Simpliﬁed diagram representing major ROS
negatively; see text for further explanations. ROS necessary for regulation of signaling pa
the changes in cellular metabolic activity leading to altered ROS production.
DAG, diacylglycerol; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kina
bound protein 2; HIF-1α, hypoxia-inducible factor-1α; IκB, inhibitor of NF-κB; IKK, IκB
phosphatase/dual speciﬁcity protein phosphatase-6; PHD, prolyl hydroxylase; PI3K, phos
kinase B; PKC, protein kinase C; PTEN, phosphatase and tensin homolog deleted on chr
kinase; SOS, son of sevenless; Shc, SHC-transforming protein; Src, sarcoma.
ETC, electron transport chain; NF-κB, nuclear factor kappa B; NOX, NADPH oxidase subu
superoxide dismutase; TCA, tricarboxylic acid.damage than nuclear DNA since it lacks histones, has only a lim-
ited repair capacity, and is ultimately exposed to mitochondrial
ROS [60]. In particular the displacement loop (D-loop) in mi-
tochondrial DNA is known as mutational hotspot and associated
with hepatocellular carcinoma [61], ovarian cancer [62], breast
cancer [63], colorectal cancer [64] and melanoma [65].
Moreover, ROS can also inﬂuence epigenetic modiﬁcations (for
review see [66]). For example, ROS can affect DNA methylation
[67] by downregulating the expression of O-6-methylguanine-
DNA methyltransferase and MLH1 (mutL homolog 1) [5]. In addi-
tion, it has been speculated that oxidative stress may also be in-
volved in the oxidation of 5-methylcytosines to 5-hydroxy-me-
thylcytosine [68]. Moreover, ROS-mediated formation of 8-oxodG
adjacent to a cytosine may prevent methylation of the latter [69].3. ROS-dependent regulation of signaling pathways
3.1. Kinase signaling and ROS
The action of ROS in various signaling networks is connected to
their physiological role but also to diseases [70–73]. Various sti-
muli, among them nutrients like fatty acids, growth factors, hor-
mones, coagulation factors, cytokines, and hypoxia were shown to
act at least partially via regulated ROS generation (Fig. 2). Thus,
aberrant generation or even degradation of ROS may limit the
signaling function of these stimuli often affecting the mitogen-
activated protein kinases (MAPK) and/or phosphatidylinositol
3-kinases (PI3K)/Akt cascades. ROS also affect pathways like pro-
tein kinase C (PKC), Wnt/β-catenin, Hedgehog, Notch [71, 74–76] in
several ways [77], and many excellent reviews have covered the
details [78,79]. We will thus concentrate only on some principlesregulated signaling pathways. ROS can inﬂuence the pathways either positively or
thways are mostly generated through speciﬁc enzymatic reactions as well as due to
se; GP, G-protein; GPCR, G-protein coupled receptor; Grb2, growth factor receptor-
kinase; MEK, MAPK/ERK kinase; MKP3, mitogen-activated protein (MAP) kinase
phatidylinositol 3-kinases; PI3P, phosphatidylinositol 3-phosphate; PKB/Akt, protein
omosome 10; Raf, ras attachement factor; Ras, Rat sarcoma; RTK, receptor tyrosine
nit; PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor; SOD,
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3.2. MAPK signaling
ROS are known to be able to activate the ERK (extracellular
signal-regulated kinase) and JNK (c-Jun NH2-terminal kinase)
MAPK cascades. Thereby they are supposed to cause autopho-
sphorylation of the epidermal growth factor receptor (EGFR) or
PDGFR in a ligand-dependent manner [80]. In addition, oxidative
modiﬁcation of Ras, a major component of the ERK1/2 cascade, at
Cys118 [81] inhibits GDP/GTP exchange, and activates Ras and the
whole cascade. Since MEK1/2 (MAPK/ERK kinase 1/2) inhibitors
can suppress ROS-mediated ERK1/2 activation [82] ROS might act
indirectly at the level of MEK1/2 or by antagonizing phosphatases
(see below) like mitogen-activated protein kinase phosphatase
(MKP3) [83] (Fig. 3).
3.3. PI3K/Akt signaling
In addition to MAPK pathway activation, growth factor protein
tyrosine kinase receptors including EGFR or PDGFR are also known
to stimulate the protein kinase B (PKB/Akt) pathway [84]; ROS,
especially H2O2 were found to activate PKB/Akt. In addition, the
tumor suppressor PTEN (phosphatase and tensin homolog deleted
on chromosome 10), a counter regulator of PKB/Akt activation was
found to be inactivated by ROS-dependent oxidation of Cys124
[85] thus enhancing PKB/Akt activation. Moreover, loss of PTEN
also causes depletion of antioxidant enzymes [86] (Fig. 3).
3.4. PKC signaling
Three major PKC subfamilies are distinguished; (i) conventional
PKC isoforms (cPKCs; α, with alternatively spliced βI/βII isoforms,
and γ); (ii) the so called novel PKCs (nPKCs, with isoforms δ, θ, ε,
and η), and (iii) atypical PKCs (aPKC; with isoforms Mζ, and ι/λ).
The cPKCs require diacylglycerol and calcium for their activity
while nPKCs can be activated by diacylglycerol independent of
calcium; aPKCs do neither require calcium nor diacylglycerol. All
are potentially susceptible to redox modiﬁcations due to their
content in cysteine residues. Indeed, some proteinkinase C (PKC)
isoforms like α, βI, and γ of cPKC, δ and ɛ of nPKC, and Mζ of aPKC,
were activated upon treatment of cells with H2O2 [87] and further
evidence points to ROS-dependent changes in a conserved cy-
steine-rich region in PKCα binding diacylglycerol [88]. However, it
appeared that the redox-dependent activation of PKC can also be
communicated in an indirect manner. In fact, the activation of
PKCδ by H2O2 was not mediated by cysteine modiﬁcation. Inter-
estingly, the H2O2-dependent increase in PKCδ activity was caused
by the tyrosine kinase Lck (a member of the Src family) which
phosphorylated a tyrosine residue between the regulatory and
catalytic domain [89]. Overall, the existence of various PKC iso-
forms with the option of a direct or indirect redox-dependent
regulation adds another layer of complexity to the understanding
of PKC regulation. This may in particular be important for those
PKCs involved in metabolic regulation; in particular isoform θ in
skeletal muscle and δ in liver can be activated by fatty acid me-
tabolites such as fatty acyl CoA and diacylglycerol. As a con-
sequence this can lead to inhibitory serine phosphorylation of
insulin receptor substrates and an attenuation of insulin signaling
[90] (Fig. 3).
3.5. Protein tyrosine phosphatases
Oxidation of catalytic cysteine residues and inactivation of
protein tyrosine phosphatases (PTP) is another ROS-dependent
regulatory mechanism of action [91]. Extracellular ligand-stimulated ROS and signal-independent ROS production can cause
PTP oxidation. In addition to classical PTPs dephosphorylating
phosphotyrosine, also dual-speciﬁcity phosphatases like MAPK
phosphatases can be inactivated by ROS-dependent oxidation [91]
(Fig. 3).4. Transcription factors and ROS
Transcription factors are among the ROS targets which can
positively or negatively respond to nutrients by changing gene
expression. Thereby the transcription factors nuclear factor kappa
B (NF-κB), nuclear factor erythroid-2-related factor-2 (Nrf2), as
well as hypoxia-inducible factor-1α (HIF-1α) and hypoxia-in-
ducible factor-2α (HIF-2α) appear to integrate the responses to
different primary stimuli at the level of ROS signaling. [92,93]
(Fig. 3). Activation/inhibition of these transcription factors can be
crucial for adaptation, survival and progression of diseases like
inﬂammation, type II diabetes, or cancer.
4.1. NF-κB signaling
The activation of NF-κB is closely linked with ROS generation
during inﬂammation and obesity [94]. ROS were found to mediate
inhibitor of NF-κBα (IκBα) kinase (IKKα and IKKβ) phosphorylation
and release of free NF-κB dimers [95]. Tumor necrosis factor α
(TNFα), a bona ﬁde NF-κB activator, was shown to mediate a redox-
dependent activation of protein kinase A [96] which subsequently
phosphorylated Ser276 on RelA (v-rel avian reticuloendotheliosis
viral oncogene homolog A). By contrast, the NF-κB member p50
was found to have reduced DNA binding activity when oxidized at
Cys62 [97,98].
4.2. Nrf2 signaling
The Nrf2 and its partner Keap1 (Kelch-like ECH-associated
protein (1) are considered as the major transcriptional regulators
in the response and defense against oxidative stress [99,100]. The
regulation of this dimer is primarily achieved by the sulfhydryl
groups within Keap1 which act as sensors for electrophiles and
oxidants [101]. In the absence of ROS binding of Keap1 promotes
proteasomal degradation of Nrf2. In the presence of ROS, cysteine
residues in Keap1, with Cys151 being the most critical, become
oxidized leading to a conformational change of Keap1, which
prevents its binding to Nrf2. In addition to oxidation, ROS can
contribute to dephosphorylation of Keap1 at Tyr141 which con-
tributes to Keap1 degradation [102]. As an overall consequence,
Nrf2 is no longer degraded and can be transported to the nucleus.
Moreover, oxidation of Cys183 in Nrf2 inhibits binding of the nu-
clear export protein CRM1 and thus promotes nuclear presence. In
the nucleus, Nrf2 heterodimerizes with a small Maf protein to
activate genes of the antioxidant response such as NAD(P)H:qui-
none oxidoreductase 1, glutathione S-transferases, cysteine-glu-
tamate exchange transporter, and multidrug resistance-associated
protein.
Interestingly, Nrf2 activating substances like quercetin, genis-
tein, curcumin and sulforaphane are often components of plants,
fruits and vegetables; therapeutics such as oltipraz, auranoﬁn and
acetaminophen; environmental agents like paraquat, and metals
as well as endogenous substances like hydrogen peroxide, NO, or
4-hydroxynonenal also activate Nrf2 signaling [103]. This some-
how may imply that an activation of the Nrf2 pathway may be of
therapeutical beneﬁt. However, Keap1 knockout mice die shortly
after birth. This ﬁnding and the rescue of this lethal phenotype in
Keap1/Nrf2 double knockout mice [104] suggests that excessive
Nrf2 activity may be detrimental for normal life. Indeed, this was
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Nrf2 pathway was beneﬁcial for tumor survival [105].
4.3. HIFα signaling
ROS play an important role in HIF signaling (for review see
[106]). Both HIF-1α and HIF-2α can be modiﬁed by ROS in a direct
and indirect manner. Direct regulation requires presence of redox
factor-1 (Ref-1) and affects transactivation of HIF-1α at Cys800 and
of HIF-2α at Cys848 [107] as well as recruitment of coactivators
such as steroid receptor coactivator-1 and transcription inter-
mediary factor 2. Another direct redox effect is oxidation of the Cys
present in the DNA-binding domain of HIF-2α, but not HIF-1α
[108]. The indirect effects of ROS are mediated via regulation of
prolyl hydroxylases (PHD), asparagine hydroxylases, redox-sensi-
tive kinases, and phosphatases (for review see [3,109]). The PHDs
hydroxylate HIF-1α and HIF-2α at critical proline residues thereby
inducing HIF degradation under normoxia. The PHDs belong to a
family of oxygen, Fe2þ , 2-oxoglutarate, and ascorbate dependent
dioxygenases (reviewed by [110]) which need a radical cycling
system to regenerate the iron after each catalytic cycle [111]. Even
though ascorbate is a key agent in the regeneration of iron, glu-
tathione could substitute it in mice deﬁcient in vitamin C synth-
esis, pointing to the importance of thiol oxidation/reduction cy-
cles. In line, a pair of cysteine residues in one of the PHDs was
described to modulate its redox sensitivity [112], again high-
lighting the possible involvement of thiol oxidation in regulating
PHD activity, though in endothelial cells subjected to hypoxia, no
variation in PHD cysteine oxidation was observed [113].
Both, HIF-1α and HIF-2α could be prevented from hydroxyla-
tion and degradation by increasing ROS generation from ER-loca-
lized NOX4 or addition of hydrogen peroxide to cells [114].
Moreover, ROS generated at the Qo site of the mitochondrial
complex III affected HIF-1α and HIF-2α regulation [115,116].
Thereby mitochondrial ROS seemed to act upstream of prolyl hy-
droxylases in regulating HIF-1α and HIF-2α [117]. From the ROS
formed, hydrogen peroxide seems to be of major importance for
HIF regulation since overexpression of glutathione peroxidase or
catalase, but not superoxide dismutase 1 or 2, prevented the hy-
poxic stabilization of HIF-1α [115,116,118]. Together, ROS appear to
constitute an important link for HIF regulation especially under
certain metabolic regimes or diseases like cancer which are asso-
ciated with altered mitochondrial activity [119].
In addition, HIFα signaling is known to undergo a crosstalk with
both PI3K/Akt and MAPK cascades where ROS and NOX enzymes
act as activators (reviewed by [120]). In line, antioxidants or NOX
inhibitors blocked signaling via PI3K/Akt to HIF-1α [121]. In ad-
dition, a number of ROS inducing substances like angiotensin-II
[122], prostaglandin E2 [123], shock waves [124], thrombin [121]
or chromium (VI) [125] contribute to HIF-1α induction via ERK1/2
which also can phosphorylate HIF-1α [120]. Further, p38 MAPKs
and the p38 upstream kinases MKK3 and MKK6 [126] were shown
to be involved in the induction of HIF-1α by thrombin [121] and
chromium (VI) [125]. In addition, these NADPH oxidases activating
substances can also induce HIF-1α mRNA levels in several cell
types [127–130]. In line, HIF-1α is a direct target gene of NFκB
[131–135], and ROS derived from NOXes or direct application of
H2O2 regulates NFκB–dependent HIF-1α transcription
[132,136,137].
Taken together, ROS are important regulators of the HIF system
and the crosstalk between ROS and HIF is an important patho-
physiological link for a wide variety of disorders.
5. Hypoxia and ROS, a paradoxical and complex relationship
Paradoxically an increased availability of lipids andcarbohydrates which is typical for a Western diet will also increase
the demand on energy synthesis in form of ATP; i.e provision of
these substances will activate usage of the mitochondrial electron
transport chain and oxygen [138]. As a result of an acute hypoxic
event a superoxide burst can occur [139]; however, hypoxia per se
seems to affect ROS production with subsequent consequences for
metabolic activity. In addition to mitochondria [119], several other
sources have been proposed to be involved in the modulation of
ROS levels under hypoxia, such as NADPH oxidases [140], or xan-
thine oxidase [141].
The variability of ROS production in response to changes in the
ambient oxygen partial pressure has been linked with the activa-
tion of the HIF α-subunits. Although controversial data exist, there
is evidence for a feedback regulation between ROS production and
the HIF pathway. However, it appears that the molecular links
between ROS, the complexes involved in oxidative phosphoryla-
tion (OXPHOS), and responses to hypoxia through the HIF pathway
are complex, less direct and may involve cell speciﬁc factors
[142,143]. This is indicated by the fact that most of the interven-
tions (if not all) on OXPHOS complexes alter not only ROS pro-
duction but also other activities, especially oxygen consumption,
oxygen redistribution [144], or metabolites taking part in the HIF-α
degrading PHD reaction such as 2-oxoglutarate or succinate (see
above). In addition to this, several molecular approaches including
overexpression of antioxidant enzymes showed a link between HIF
activation and ROS formation which was independent of the cel-
lular oxygen consumption [115–118].
Vice versa, adaptation to hypoxia through the HIF pathway has
also an effect on ROS production. Both, NOX2 and NOX4 NADPH
oxidases are HIF1 target genes [114,145] and are involved in
maintaining angiogenesis, cellular proliferation, and hypoxia-in-
duced pulmonary hypertension [114], as well as in metabolic
diseases [146,147]. In mitochondria, several HIF-dependent me-
chanisms have been described that actively contribute to reduce
OXPHOS activity under hypoxia and which have been shown (in
more or less detail) to reduce mitochondrial ROS production: re-
duction of pyruvate entry into the TCA cycle through enhanced
expression of PDK1 [148,149], PDK3 [150] or PDK4 [151,152], re-
duction of complex I activity through upregulation of NDUFA4L2
expression [153], and reduction of the activity of iron-sulfur
clusters-containing proteins (among them OXPHOS complexes) by
enhanced expression of miR-210, which represses the iron-sulfur
cluster assembly proteins ISCU1/2 [154].
In addition, HIF-1α and HIF-2α are able to affect mitochondrial
ROS production also in a negative manner. Thereby HIF-1 regulates
the hypoxic switch from COX4-1 to COX4-2 in cytochrome c oxi-
dase at complex IV, and the mitochondrial protease LON which
degrades COX4-1 [155]. In line, HIF-1α-dependent upregulation of
the tumor suppressor REDD1 decreases ROS production while loss
of REDD1 increases mitochondrial ROS [156]. HIF-2α was found to
be involved in the regulation of the SOD2 gene [157]. Together,
these mechanisms are part of a negative feedback loop for reg-
ulation of HIF-1α and HIF-2α.
Another mechanism by which hypoxic responses can be
mediated through ROS production is reversible protein cysteine
oxidation. Indeed, the recent use of a redox proteomic method, by
which reversibly oxidized protein cysteines are speciﬁcally labeled
[158], has helped to identify a number of proteins speciﬁcally
oxidized in cardiac mitochondria from mice subjected to ischemia/
reperfusion or from endothelial cells subjected to acute hypoxia
[113,159]. Thus, the identiﬁcation of reversibly oxidized proteins
by a ﬂuorescent labeling and LC-MS/MS-based approach provides
the option to explore more closely the links between acute or
chronic adaptations to hypoxia and ROS generation.
Together, it is obvious that an intricate interplay between hy-
poxia and ROS production exists and that this involves feed-
Fig. 4. Nutrients modulate ROS generation. Nutrients (free fatty acids, glucose,
amino acids) stimulate ROS production by increasing the postprandial metabolic
rate, especially in mitochondria. Further, nutrients affect ROS via signal cascades
and transcription factors that regulate expression of antioxidant/ROS-generating
enzymes.
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However, the detailed mechanisms, the timing of the responses as
well as the cell-type speciﬁc factors involved in these regulations
need still further investigations before they are completely
understood.6. Dietary fashion, ROS, and diseases
In Western societies, a signiﬁcant part of the day is spent in the
postprandial state. Postprandial oxidative stress is characterized
by an increased susceptibility of the organism towards oxidative
damage after consumption of a meal rich in lipids, proteins and/or
carbohydrates (Fig.4). Evolution of dietary patterns and lifestyle in
most developed countries support the evidence that there is a
direct relationship between diet, lifestyle and risk of certain dis-
eases including cancer; up to 35% of risk is estimated to be asso-
ciated with diet [160]. The postprandial state is characterized by
persistent substrate abundance in the circulation. Increased sub-
strate availability (like glucose), leads to an increased insulin re-
lease and also to an increment in oxidative stress as, for example, a
higher production of reactive oxygen species (ROS) [161]. The
permanent availability of oxidizable substrates at rest leads to an
enhanced mitochondrial membrane potential which, in turn, leads
to a diminished velocity in oxidative phosphorylation and, thus, a
higher possibility for electrons to “leak” from the respiratory chain
directly to molecular oxygen, resulting in ROS generation [162]
(Fig. 4). In turn, the diminished substrate utilization is accom-
panied by an increment in NADH, in both the cytosol and in mi-
tochondria. NADþ and NADH values are kept relatively constant
within a cell, and the ratio between them is considered to be a
marker of the metabolic status [163]. As such, high levels ofcellular nutrient metabolites result in ROS production and oxida-
tive stress as well as the development and progression of diseases
like obesity, non-alcoholic fatty liver diseases (NAFLD), type II
diabetes, atherosclerosis or cancer which are increasing, rapidly
reaching epidemic proportions.
In addition to the direct effect on ROS production, mainly via
the ETC, although data on NADPH oxidases also exist, nutrients
have long-term indirect effects on ROS levels via regulation of
gene expression. Thereby peroxisome proliferator-activated re-
ceptors (PPAR), liver X receptors, and sterol response element-
binding proteins, contribute to fatty acid-induced transcription
[164]. In particular PPARγ was found to promote elimination of
ROS; in a murine model of type 2 diabetes, PPARγ activation ex-
erted an antioxidant effect in vivo [165] and decreased expression
of PPARγ in morbidly obese persons was associated with the de-
crease of Cu/ZnSOD and glutaredoxin activities and an increase in
the concentration of free fatty acids after a fat meal [166]. These
features as well as the link between PPARγ, HIF-1α and activated
fatty acid uptake and glycerolipid synthesis seem to be important
for cardiac contractile dysfunction. Indeed, deletion of HIF-1α in
the heart of mice prevented hypertrophy-induced PPARγ activa-
tion, metabolic reprogramming, and contractile dysfunction [167].
In addition, fatty acids and glucose may modify the activity of
transcription factors like NF-κB, and HIF-1α [74,164] which have
antioxidant as well as ROS-generating enzyme coding genes as
targets. Therefore, transcription factors like NF-κB or HIF-1 can
respond to a macronutrient-dependent burst in ROS as well as to
the macronutrient-mediated regulation of intracellular signaling
pathways like PKC or PKB. Overall, the short-term action of mac-
ronutrients may increase ROS, but they may also cause increased
ROS scavenging via their long-term action on transcription factors.
6.1. Diets and oxidative stress
High-fat diets (HFDs) typically contain about 32–60% of calories
from fat and are commonly used to induce obesity in rodents
[168,169]. A HFD is associated with body weight increase, fat de-
position throughout various organs, a marked insulin resistance
and development of a hypoxic status in the fat depositing organs.
Before a signiﬁcant peripheral fat deposition occurs, HFDs typically
increase liver fat levels as well as hepatic insulin resistance, ele-
vation of ROS and oxidative stress [170]. In addition, the hypoxic
status becomes evident already after three days of feeding a HFD
in white adipocytes. Subsequently, HIF-1α induction contributes to
an off-set of the chronic adipose tissue inﬂammatory response
[171]. Importantly, the source of dietary fat can modify the “phe-
notype”; e.g. in comparison to fat from butter, polyunsaturated fats
present in olive and ﬁsh oil increase liver fat oxidation, reduce
liver triglyceride accumulation and liver cholesterol levels, re-
spectively [172] as well as induce expression of pro-inﬂammatory
genes [173].
An excess intake of reﬁned carbohydrates is associated with
increased weight gain, hypertriglyceridemia, ROS production and
insulin resistance in humans and animal models [174,175]. Usually,
rodent chow diets contain only 4% sucrose and less than 0.5% of
free fructose with most carbohydrates as both digestible starch
and non-digestible ﬁber from grain sources. In contrast, low-fat
puriﬁed diets can contain higher levels of sucrose and this will
depend heavily on the formula being used. It is possible to modify
puriﬁed diets by manipulating only the carbohydrates while the
essential nutrients remain at recommended levels to promote a
metabolic syndrome and to have different oxidative stress levels.
A methionine and choline-deﬁcient (MCD) diet rapidly induces
hepatic macrovesicular steatosis in rodents and leads to in-
ﬂammation, ﬁbrosis and cancer [176,177]. The MCD diet also
contains sucrose, which induces de novo lipogenesis and
Fig. 5. ROS generation and nutrient availability. Under nutrient-deﬁcient condi-
tions, as well as in the presence of nutrient excess ROS formation is above the
physiological threshold. As such, these conditions may be considered as patholo-
gical situations, with abnormally high ROS generation.
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hepatic fat accumulation, fructose was more effective than glucose
in inducing hepatocellular injury in mice fed MCD diets for 21 days
[178]. A choline-deﬁcient diet alone induces only steatosis, in-
ﬂammation and ﬁbrosis within 10 weeks [179,180], but not a
marked hepatitis, cirrhosis or hepatocellular carcinoma. A choline-
deﬁcient L-amino acid-deﬁned diet leads to the development of
typical non-alcoholic steatohepatitis (NASH), with lobular in-
ﬂammation and ﬁbrosis, a basis onwhich further hepatocarcinoma
develops [181].
6.2. Metabolic reprogramming and ROS generation
Several studies are consistent with the idea that an increased
caloric intake and/or obesity are associated with a pro-oxidant
environment and increased oxidative damage [8–12] (Fig. 5). In
line, both protein carbonylation and lipid peroxidation were in-
creased in white adipose tissue and liver of animals with high-
nutrient feeding induced obesity [182]. Increased ROS production
was shown in mitochondria isolated from skeletal muscle, kidney,
liver and adipose tissue from obese HFD fed animals [183–186]. In
addition, NADPH oxidases have also been described to contribute
to elevated ROS levels and to be upregulated in the liver in several
animal models of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis [187,188] where animals were treated with an
“high-fat” or “hypercholesterolemic” diet. Interestingly, female
mice lacking the NADPH oxidase subunit p47phox are protected
against high fat diet induced obesity [189]. Similar results have
been obtained in NOX2-deﬁcient mice [190] while NOX4 deﬁcient
mice were reported to be more obese and to have hepatic steatosis
and whole body insulin resistance [191]. The role of NOX2 in in-
sulin resistance was also corroborated in skeletal muscle. Here, a
long-term HFD increased NOX2 expression, superoxide produc-
tion, and impaired insulin signaling in skeletal muscle of wild-type
mice; these effects were not occurring in NOX2-deﬁcient mice. Cell
culture experiments with C2C12 myotubes revealed a key role for
H2O2 in mediating insulin resistance since down-regulation of
NOX2 by shRNA prevented insulin resistance induced by high
glucose or palmitate [192].
Further, increased mitochondrial ROS were found to be in-
volved in short-term HFD-induced insulin resistance in white
adipose tissue. Consuming a high-fat diet for one week impaired
insulin signaling, increased c-Jun NH2-terminal kinase phosphor-
ylation and mitochondrial ROS formation. Overexpression of hu-
man catalase in the mitochondria of these mice attenuatedmitochondrial ROS formation, inﬂammation, and maintained in-
sulin signaling. Thus, elevated mitochondrial ROS formation can
contribute to HFD-induced insulin resistance in white adipose
tissue [193]. Moreover, HIF transcription factors were shown to be
induced by NOX4-derived ROS [132,194] and lipid load [106,195].
Thus, HIFs and NOXes appear to be involved in insulin resistance,
metabolic dysfunction and inﬂammation [171,196,197] and thus
might play an important role in the concert of redox related pro-
cesses promoting the development of steatohepatitis, obesity and
type II diabetes, and aging-related diseases. Aging tissues exhibit
higher rates of ROS generation, genetic instability, and inﬂamma-
tion and in some cases telomere shortening which is accelerated
during diabetes [198,199].
Conditions of reduced glucose supply activate metabolic re-
programming that switches cells to metabolize fatty acids and
amino acids through the TCA cycle and OXPHOS; this elevates the
risk of mitochondrial oxidative damage, when compared only to
the metabolization of glucose via glycolysis (Fig. 5). Exposure of
cells in culture to free fatty acids increases ROS, suggesting that an
elevated concentration of fatty acids in the circulation may provide
an additional source of excess OXPHOS substrates through in-
creased fatty acid oxidation [200]. However, studies performed
with obese animals that develop diabetes, have shown a state of
metabolic inefﬁciency where an increase in cardiac fatty acid uti-
lization is associated with enhanced mitochondrial oxygen con-
sumption but a lower cardiac contractile capacity [201–203].
Moreover, these hearts exhibit limited ATP generation associated
with fatty acid-induced mitochondrial uncoupling and are unable
to modulate their substrate utilization in response to insulin and
fatty acid supply [201,204]. These ﬁndings suggest that mi-
tochondrial dysfunction in response to diets may arise from lipo-
toxicity or oxidative stress [205,206] rather than from changes in
glucose concentrations [204,206]. This view is supported by a
study indicating that ROS are also involved in obesity-induced
autophagy. Interestingly HFD fed transgenic mice with cardiac
overexpression of catalase did not display ROS production and
showed suppressed autophagy in the heart. In addition, the HFD
compromised myocardial geometry and function like hypertrophy,
enlarged left ventricular end systolic and diastolic diameters,
fractional shortening, cardiomyocyte contractile capacity and in-
tracellular Ca2þ were attenuated by catalase. On the molecular
level these HFD-mediated effects in the heart seemed to be
transmitted by an IKKβ-AMPK-dependent pathway which could be
inhibited by catalase [207].
By contrast, the metabolism in cancer cells is a strong example
how glucose deprivation and altered mitochondrial function con-
tribute to massive ROS production [208]. Energy production in
cancer cells is abnormally dependent on glycolysis classically best
known the “Warburg effect”. Moreover, the rapid proliferating
status dictates an increased biosynthesis which is dependent on
the availability of building blocks and reducing equivalents [209].
Therefore, cancer cells may be considered to be in a perpetually
“hungry” state. NOX1 seems to be involved in regulation of the
Warburg effect and metabolic remodeling of hepatic tumor cells
towards a sustained production of building blocks required to
maintain a high proliferative rate [210].
Moreover, cancer cells often proliferate in a hypoxic milieu,
where the adaptation is largely dependent on HIF transcription
factors regulated by NOX, and the transcriptional activation of
genes involved in various metabolic pathways, among them car-
bohydrate and fatty acid metabolism. Thereby, the role of hypoxia
and HIFs, especially HIF-1 as regulator of carbohydrate metabolism
is well established. In this respect, HIFs respond to enhanced levels
of insulin [211–213] and regulate almost every gene which is in-
volved in glucose uptake, glycogen synthesis, and glycolysis
[142,214]. Reciprocally, gluconeogenesis in liver is reduced under
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coneogenic enzyme PCK1 [215]. Moreover, lipid metabolism, in
particular in liver, appears to be more regulated by HIF-2 [216]. In
addition to the direct involvement of the HIF proteins as powerful
regulators of metabolism, recent ﬁndings indicated a cross-talk
between the insulin signaling pathway and hypoxia signaling at
the level of the HIF-regulating proline hydroxylases in liver. In
particular PHD3 was found to have a key role since its acute de-
letion improved insulin sensitivity and ameliorated diabetes by
speciﬁcally stabilizing HIF-2α [217].
Moreover, a vast majority of endogenously derived fatty acids
are synthesized in the cytosol from acetyl-CoA through a large
polyfunctional fatty acid synthetase encoded by the FASN gene.
Both the cytosolic form of acetyl-CoA synthase and FASN itself can
be induced by hypoxia [218]. However, hypoxic induction of FASN
appears to be an indirect HIF effect involving ﬁrst HIF-dependent
up-regulation of SREBP1 and an action of SREBP1 on the promoter
of FASN [218]. Further, hypoxia and the Ras regulated MAPK
pathway were also shown to regulate elongation and desaturation
of fatty acids for lipogenesis [219]. In addition to the role of hy-
poxia/HIF-1-dependent regulation of lipid metabolism, there exist
also a number of hypoxia mediated, but HIF1α-independent al-
terations of lipid metabolites and associated enzymes. For ex-
ample, a recent metabolomics approach showed that enzymatic
steps in fatty acid synthesis and the de novo synthesis of phos-
phatidylethanolamine and phosphatidylcholine were modiﬁed in
a HIF1α-dependent fashion whereas palmitate, stearate, phos-
pholipase D3 and platelet activating factor 16 were regulated in a
HIF-independent manner [220]. Overall, these ﬁndings help to
understand why an increased lipid content is a common feature of
hypoxic cancer cells [142]
Although stabilization of HIF-1α contributes to a decrease in
oxidative phosphorylation, and an initial increase in ROS produc-
tion, likely via NOX4, it also initiates a later counteracting adaptive
response e.g. by switching complex IV subunits or by increasing
the mitochondrial manganese superoxide dismutase content
[143]. These features may be important for the survival of meta-
static cancer cells since it was described that colonization of lungs
with cancer cells is dependent on reduced ROS due to HIF-1-
mediated metabolic reprogramming [221].
In line, the up-regulation of the antioxidant capacity in some
subsets of cancer stem cells appears to be associated with re-
sistance to therapy [222]. This makes exogenous agents, which are
able to modulate the susceptibility of cancer cells to oxidative
insults, interesting for anticancer strategies [223] and may, at least
in part, explain why antioxidant supplementation in cancer pa-
tients is not necessarily beneﬁcial (see below).
Recent ﬁndings from experiments where the mitochondria
targeted redox cycler mitoquinone was able to induce an autop-
hagic growth arrest in breast cancer cells associated with en-
hanced ROS levels and the initiation of an antioxidant response
underline this. Interestingly, a further knockdown of Nrf2 in these
cells potentiated the autophagy [224]. In line, more recent data
indicate that high ROS can cause autophagy, but that autophagy is
able to trigger an antioxidant feedback response by linking au-
tophagy related gene 7 (Atg7) with Keap1 and Nrf2 [225]. Overall,
this is in line with ﬁndings that a forced activation of Nrf2 has a
pro-carcinogenic function (see above) and why antioxidants are
not simply protective against cancer (see below).
Moreover, inactivating mutations in genes that promote au-
tophagy have been described in several human cancers, as well as
activation of genes that block autophagy [226]. Hyperactivation of
the Ser/Thr kinase mammalian target of rapamycin complex 1
(mTORC1) has been shown to promote breast cancer progression
through increasing autophagy [227] and aberrant mTORC1 sig-
naling has been frequently detected among common humancancers [228]. Thereby mTORC1 integrates the activation of kinase
complexes like receptor tyrosine kinases (RTKs), the PI3K, and the
mitogen activated protein kinase (MAPK) pathways which are ROS
sensitive and dictates the balance between the energetic and
anabolic demands of rapidly proliferating cancer cells [229]; hence
linking autophagy with ROS, cancer and nutrition.
6.3. Antioxidative therapeutic strategies: rather harmful than
beneﬁcial?
The association of ROS with various diseases like athero-
sclerosis, type II diabetes or cancer is known for more than three
decades [5,6,71,230] and accordingly this led to the believe that an
antioxidant supplementation would have beneﬁcial therapeutic
effects. Indeed, the ﬁrst observations were promising and an ‘an-
tioxidant hype’ emerged throughout the world. As a result, high
doses of antioxidants were examined in hundreds of studies
among them about a dozen of large randomized trials where
various combinations of the best known antioxidants except
polyphenols (so called ‘traditional antioxidants’) were included
[231]. More than 10 large-scale trials have been completed (for
review see [232]). The outcome was enigmatic. There was no
corroboration of the data derived from non-human models as well
as from observational epidemiologic studies. In particular, meta-
analyses of randomized controlled trials including tens of thou-
sands subjects found no overall association between the con-
sumption of antioxidant supplements and cancer risk [233] (for
detailed review see [232]). This ‘antioxidant paradox’ [234] is not
only limited to cancer but also reported for type II diabetes and
cardiovascular diseases [235,236].
So far it is not known why the antioxidants did not exert the
expected protective effects. The wrong type, dose, combination,
and/or duration of exposure may explain some but not all. Indeed,
in almost all large-scale trials high doses of each antioxidant were
used either alone or in limited combinations. In addition, me-
chanisms of actions have been neglected; some antioxidants in-
cluding vitamin E, vitamin C, and quercetin, can act as prooxidants
at high concentrations. Indeed, meta-analyses of the vitamin E
dose and total mortality indicated that vitamin E at high doses
Z400 IU/day) may be associated with increased mortality due to
the prooxidant effects of vitamin E at these concentrations [237].
Moreover, β–carotene can act as prooxidant when given to smo-
kers [238,239]. In line, quercetin at concentrations in the range of
1–40 mM reacts with ROS and chelates metal ions whereas at
concentrations higher than 40 mM it increases oxidative stress
[240]. Thus, antioxidant therapy may be improved if patients
would be tested for subclinical deﬁciencies of antioxidants before
such a therapy is initiated. In addition, the large clinical trials did
not test for compliance like the EPIC Norfolk clinical trial in which
certain antioxidant levels were measured in plasma and where
signiﬁcant improvement of various parameters could be reported.
For example, parental administration of vitamin C was highly
beneﬁcial in many different disease conditions [241].
However, the beneﬁcial effects of antioxidant-rich food at least
with respect to cancer are widely reported [242–244]; but these
beneﬁts are achieved by the diet itself and not by supplementation
[245]. Moreover, the dietary intake involves low doses of various
antioxidants and not high doses of a single antioxidant. In line,
while high doses of single antioxidants were shown to be harmful
in smokers, two antioxidant-rich diets were found to be safe in a
randomised controlled trial in male smokers [246]. Overall, this
suggests that antioxidant therapies are not hopeless but to ﬁnd an
optimal way more research on ROS, antioxidants and nutrition in
line with large multicenter trials are necessary.
A. Görlach et al. / Redox Biology 6 (2015) 372–385 3817. Conclusion
ROS have likely evolved together with the appearance of oxy-
gen on earth and the evolution of aerobic living cells. At the same
time aerobic living cells developed systems allowing to use ROS in
signaling and to protect themselves from their harmful effects.
Within these systems components need to be maintained and
provision of certain substances through the diet is a prerequisite.
Although the human genome seems to be quite stable for the last
ten thousand years (spontaneous mutation rate is appr. 0.5% per
million years [247]), dietary fashion, food amount and composition
has changed within the last 60–100 years; at least in the Western
world. In addition to the increase in the caloric intake, also the
decreased energy expenditure as well as alcoholism and smoking
contribute to generation of more ROS than needed. As a con-
sequence the antioxidant capability is confronted with various
problems and not always able to maintain redox homeostasis,
which is, at least in part, associated with the occurrence of several
chronic diseases like adiposity, atherosclerosis, type II diabetes,
and cancer. In addition, the little or no beneﬁt evidence from the
large scale studies with antioxidant supplementation demands to
further improve the knowledge about the interconnection of ROS
with nutrition and diseases indicating that the associated health
problems are not yet solved.Conﬂict of interest statement
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Control over the Na,K-ATPase function plays a central role in adaptation of the organisms
to hypoxic and anoxic conditions. As the enzyme itself does not possess O2 binding
sites its “oxygen-sensitivity” is mediated by a variety of redox-sensitive modifications
including S-glutathionylation, S-nitrosylation, and redox-sensitive phosphorylation. This
is an overview of the current knowledge on the plethora of molecular mechanisms
tuning the activity of the ATP-consuming Na,K-ATPase to the cellular metabolic
activity. Recent findings suggest that oxygen-derived free radicals and H2O2, NO,
and oxidized glutathione are the signaling messengers that make the Na,K-ATPase
“oxygen-sensitive.” This very ancient signaling pathway targeting thiols of all three
subunits of the Na,K-ATPase as well as redox-sensitive kinases sustains the enzyme
activity at the “optimal” level avoiding terminal ATP depletion and maintaining the
transmembrane ion gradients in cells of anoxia-tolerant species. We acknowledge the
complexity of the underlying processes as we characterize the sources of reactive
oxygen and nitrogen species production in hypoxic cells, and identify their targets, the
reactive thiol groups which, upon modification, impact the enzyme activity. Structured
accordingly, this review presents a summary on (i) the sources of free radical production
in hypoxic cells, (ii) localization of regulatory thiols within the Na,K-ATPase and the role
reversible thiol modifications play in responses of the enzyme to a variety of stimuli
(hypoxia, receptors’ activation) (iii) redox-sensitive regulatory phosphorylation, and (iv) the
role of fine modulation of the Na,K-ATPase function in survival success under hypoxic
conditions. The co-authors attempted to cover all the contradictions and standing
hypotheses in the field and propose the possible future developments in this dynamic
area of research, the importance of which is hard to overestimate. Better understanding
of the processes underlying successful adaptation strategies will make it possible to
harness them and use for treatment of patients with stroke and myocardial infarction,
sleep apnoea and high altitude pulmonary oedema, and those undergoing surgical
interventions associated with the interruption of blood perfusion.
Keywords: Sodium-Potassium-Exchanging ATPase, redox regulation, thiols, hypoxia, S-glutathionylation,
S-nitrosylation
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INTRODUCTION. OXYGEN, AND OXYGEN
SENSING FROM EVOLUTIONARY AND
MODERN PERSPECTIVES
Oxygen, Redox State, Ions, Energy, and
Na,K-ATPase
Sustaining of life is a process requiring high energy costs.
Energy production in living systems utilizes transmembrane
electrochemical gradients, those for ions and redox equivalents.
No gradients can be sustained without a membrane, so
membranes are the key elements of any living cell since the
first proto-cell, the last universal common ancestor (LUCA),
that existed more than 3 billion years ago on our planet (Sousa
et al., 2013). As life evolved, more specialized compartments
were formed within cells, each surrounded by its ownmembrane.
Modern plasma membrane uses the energy of ATP produced
by aerobic or anaerobic pathways to generate transmembrane
Na+/K+ and Ca2+ gradients. One member of the P-type ATPases
family, Na,K-ATPase, transforms the energy of phosphate bonds
within the ATP to the energy of transmembrane Na/K gradient
that is used to support the excitability of neurons and myocytes,
control of intracellular Ca2+ levels and pH, intake of amino
acids and fuel, and for sensing and signaling (Blanco andMercer,
1998; Therien and Blostein, 2000; Blanco, 2005; Geering, 2006;
Toyoshima et al., 2011; Reinhard et al., 2013; Shattock et al.,
2015). It uses 1 ATP molecule to exchange 3 intracellular Na+
ions for 2 extracellular K+ ions per cycle. The number of
cycles varies between 1500 and 10,000 per min (Liang et al.,
2007) and the corresponding energy expenditure ranges between
20% of total energy consumption in non-excitable cells to
75% in excitable tissues under hypoxic conditions (Buck and
Hochachka, 1993; Erecinska and Silver, 2001). Being a major
sink for ATP under hypoxic conditions, Na,K-ATPase is capable
of “sensing” the changes in O2 availability and adjusting its
activity to the rates of ATP production (Bogdanova et al., 2006).
This review summarizes the progress in our understanding of
the mechanisms utilized by the Na,K-ATPase for “O2 sensing.”
Recent developments in of the field of free radical biology and
medicine have provided decisive clues for dissection of these
mechanisms and the role that protein thiols play in it.
Reactive Oxygen (ROS) and Nitrogen (RNS)
Species As Signal Messengers
Oxygen is a key component of the cell energy production
machinery driving Cambrian explosion ∼500 Mio years ago. It
plays a role of the final acceptor of the mitochondrial electron
transport chain (ETC), which is coupled to ATP production
by the H+-dependent reversible mitochondrial ATPase in the
mitochondrial oxidative phosphorylation (OXPHOS) system.
Many other metabolic reactions in the cell also use oxygen as a
necessary component. Thus, cells have developed systems that
can sense fluctuations in oxygen concentration and perform
different adaptations, and there are several links between hypoxia
sensing and redox reactions that we briefly explore here.
Oxygen produces reactive oxygen species (ROS) by successive
one-electron reductions (Figure 1). Superoxide anion (O•−2 ) is
the first ROS formed from O2; its half-life is as short as 2 ×
105 M−1s−1 (Kalyanaraman, 2013), what makes O•−2 particularly
difficult to detect. It is not a powerful oxidant, and its effect
on protein thiols is mainly limited to disruption of iron-sulfur
clusters; in this regard, mitochondrial aconitase inactivation has
been a classical hallmark ofmitochondrial superoxide production
(Fridovich, 1995; Hausladen and Fridovich, 1996). It dismutates
spontaneously or by the action of cytosolic or mitochondrial
superoxide dismutases (Cu,Zn-SOD or Mn-SOD respectively),
producing a reduced form, hydrogen peroxide (H2O2), and
an oxidized form, water (H2O). Hydrogen peroxide half-life
is quite greater than that of its predecessor, 103–104 M−1s−1
(Kalyanaraman, 2013), it can cross biological membranes and
oxidize thiols within Cys residues in proteins. The latter
capacity has been a useful tool for nature to design molecular
sensors of H2O2; likewise several laboratories have developed
different fluorescent proteins capable of detecting H2O2 through
reversible oxidation of critical, sensitive thiols in their structure
(Hanson et al., 2004; Belousov et al., 2006; Ermakova et al.,
2014). All together, these features make H2O2 the most easily
detectable ROS and the best known. A one-electron reduction
of hydrogen peroxide forms hydroxyl radical (•OH), a reaction
that can be catalyzed by the oxidation of Fe2+ into Fe3+ in
the so-called Fenton reaction (Kalyanaraman, 2013). •OH is the
most reactive and probably the most toxic free radical due to
the initiation of radical chain reactions. It is worth mentioning
the very fast reaction of superoxide with nitric oxide (NO•) to
form peroxynitrite (ONOO−), with a rate comparable to that of
diffusion, 4–6 × 109 M−1s−1 (Kalyanaraman, 2013). Although
peroxynitrite (one of the reactive nitrogen species, RNS) is well
known as an inducer of tyrosine nitration, it is a peroxide and as
such it is a very effective two-electron oxidant of thiols.
ROS/RNS and Hypoxia
Since ROS are chemical derivatives of O2, hypoxia would lower
the production of ROS due to the law of mass action, i.e., as
there is a lower oxygen concentration, one would expect to
observe a decrease in ROS production. However, cell systems
are often more complicated than the basic chemical systems
in a test tube with multiple players and reactions involved
in production and scavenging of ROS and RNS. Apart of
thermodynamic and kinetic restrains, compartmentalization
within the cell and species/cell type-specific settings affect the
capacity of electron donors to react with the oxygen molecules
and time course of these reactions. Indeed, there has been a
long-standing controversy in the field, as there are a number of
observations reporting lower ROS production in hypoxia (Hagen
et al., 2003; Acker et al., 2006; Chua et al., 2010; Fernandez-
Aguera et al., 2015) but also the opposite (Chandel et al.,
1998, 2000; Guzy and Schumacker, 2006), what has been called
the paradoxical ROS increase in hypoxia (Turrens, 2003; Guzy
and Schumacker, 2006). This controversy emerged from the
differences in experimental design including timing of hypoxic
exposure prior to ROS detection, cell type, tissue or organism,
as well as from the methodological diversity in ROS detection.
For example, two groups detecting O•−2 in cells using superoxide-
sensing probe (dihydroethidium) and microscopy reported the
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FIGURE 1 | Schematic representation of reactions in which reactive oxygen and nitrogen species are formed. Shown in blue are the half-life for each
species and in brackets the concentration range for each species in biological systems, and in green the enzymes catalyzing the corresponding reactions: dual
oxidizes (DOUXes), superoxide dismutases (SOD). Under the arrows are the rate constants for the reactions shown. Myoglobin (Mb) and hemoglobin (Hb) are shown
as sinks for NO.
opposing findings (Quintero et al., 2006; Chua et al., 2010).
The only decisive difference was the time of hypoxic exposure.
Detection of O•−2 in cells following 3 h of hypoxia showed no
changes in superoxide levels compared to the normoxic control
(Chua et al., 2010), while facilitation of O•−2 production was
observed during the first hour of hypoxia (Quintero et al., 2006).
A recent report reconciled this apparent controversy, as it showed
that production of mitochondrial superoxide is upregulated
exclusively during the first minutes of hypoxia and its production
decreases afterwards, in what has been called a superoxide burst
in hypoxia (Hernansanz-Agustin et al., 2014).
Several sources have been proposed to be the origin of
ROS in hypoxia. One of the first enzymes implicated in ROS
generation in hypoxia was NADPH oxidase, which plays a role
in hypoxic pulmonary vasoconstriction (HPV) (Marshall et al.,
1996). Together with this, xanthine oxidase was also shown to
produce ROS in hypoxia in neurons, contributing to cell death in
ischemic conditions (Abramov et al., 2007).
Last but not least, mitochondria-derived ROS have been
also shown to increase in hypoxia (Chandel et al., 1998,
2000; Hernansanz-Agustin et al., 2014), are necessary for
ROS production by NADPH oxidase in hypoxic pulmonary
vasoconstriction (Moreno et al., 2014) and are prior to the
xanthine oxidase-derived ROS (Abramov et al., 2007). The
source of electron leakage giving rise to an excessive production
of O•−2 remains a matter of intensive investigation. Listed
below are some considerations regarding the causes and
possible mechanisms of hypoxia-inducible O•−2 burst in the
mitochondria.
ROS and RNS Production in Hypoxic
Mitochondria
Mitochondrial electron transport chain (mtETC) consists of four
protein complexes within the mitochondrial inner membrane.
Complexes I and II oxidize electron carriers NADH and
FADH2, and transfer the electrons to complex III by means of
ubiquinone. Complex III reduces cytochrome c, which transports
the electrons to complex IV and reduces O2 to H2O. These
activities of complexes I, III, and IV are coupled to the pumping
of H+ across the mitochondrial inner membrane, thus creating
an electrochemical gradient. The oxidative phosphorylation
system (OXPHOS) includes a fifth complex, complex V or
ATP synthase that transforms the energy of proton gradient to
phosphorylation of ADP to ATP (Mitchell, 1961; Mitchell and
Moyle, 1967).
It is suggested that ROS generation occurs mainly at the level
of complex I, but also at complex III (Turrens, 2003; Murphy,
2009; Drose and Brandt, 2012). FMN group within complex I
oxidizes NADH into NAD+ and transfers electrons to a series
of Fe-S clusters which, in turn, reduce ubiquinone into ubiquinol
(Berrisford and Sazanov, 2009; Hunte et al., 2010; Zickermann
et al., 2015) in the so-called forward electron transport. On
the other hand, at high mitochondrial transmembrane potential
19mt or in the presence of the complex II substrate succinate,
complex I can accept electrons from ubiquinol and reduce NAD+
into NADH at the level of flavin mononucleotide FMN, together
with the intrusion of H+ in a process called reverse electron
transport (RET) (Vinogradov and Grivennikova, 2005, 2016;
Drose and Brandt, 2012). In both forward and reverse transport
there is a leakage of electrons giving rise to O•−2 production.
Inhibitors targeting the ubiquinone-binding site (e.g., rotenone;
Pryde and Hirst, 2011) increase the leakage in the forward
transport, but inhibit it in RET. It is also reported in the presence
of high concentrations of succinate, condition associated with
progression of ischemia-reperfusion injury (Drose and Brandt,
2012; Chouchani et al., 2014). RET also takes place at elevated
19mt (Korshunov et al., 1997; Drose and Brandt, 2012). O•−2
produced by complex I will be released toward the mitochondrial
matrix where it is dismutated by Mn-SOD (SOD2) to H2O2.
The latter is further detoxified by GSH-Glutaredoxin2 system
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within the matrix (Drose et al., 2014). Complex III can also
give rise to O•−2 production along with oxidation of ubiquinol
to ubiquinone known as Q cycle (Boveris et al., 1976; Cadenas
et al., 1977). This process includes formation of semiquinone as
an intermediate step (Trumpower, 1990), and this step becomes
rate-limiting at high 19mt or in the presence of the complex
III-Qi site inhibitor Antimycin A. In case of electron leakage
from complex III O•−2 is accumulating within the intermembrane
space. After dismutation by Cu,Zn-SOD (SOD1) the resulting
H2O2 is extruded from themitochondria into the cytosol through
porin (Drose et al., 2014) and then detoxified by catalase and
GSH/glutaredoxin 2 systems. Free radicals and H2O2 originating
from these two complexes most likely serve as local signaling
messengers.
Evidence obtained using transgenic animal models suggest
different mitochondrial complexes of the mtETC are involved
in generation of superoxide anion participating in redox
signaling. Knocking down Rieske iron-sulfur protein (RISP)
within the complex III indicates the key role of electron
transport by this complex for HIF-1α stabilization under
hypoxic conditions (Brunelle et al., 2005; Guzy et al., 2005;
Mansfield et al., 2005). Silencing of the NDUFS2 protein
expression within complex I compromised hypoxia-induced ROS
production and arterial chemoreception in vivo (Fernandez-
Aguera et al., 2015). However, none of these studies explained
the paradox of ROS production in hypoxia or addressed the
mechanism of their production. Our recent data point to the
key roles of complex I deactivation and Na+/Ca2+ exchange
through the mitochondrial Na+/Ca2+ exchanger in the hypoxic
superoxide production (Hernansanz-Agustín et al., manuscript
submitted).
CO, H2S, and NO production are most likely supported
within the mitochondria by heme oxygenase 1 (Ryter et al.,
2006), mitochondrial NO synthase (Ghafourifar and Sen, 2007),
and 3-mercaptopyruvate sulfurtransferase (Li et al., 2011).
All gasses were shown to protect tissues from irreversible
suppression of respiratory capacity of mitochondria during
ischemia-reperfusion injury (Elrod et al., 2007). In addition to
blocking complex III H2S is also capable of direct binding to
the heme group of complex IV (Cooper and Brown, 2008).
Supplementation of H2S has been shown to inhibit HIF-1α
stabilization in hypoxic, but not in anoxic conditions, which
is probably related to its capacity of inhibiting mitochondrial
respiration (Kai et al., 2012). Systemic administration of sulfide
was shown to sustain hibernation state (Blackstone et al.,
2005). Nitrite causes inhibition of complex I by S-nitrosylation
(reviewed inMartinez-Ruiz et al., 2011) and decreases free radical
generation in tissues exposed to ischemia-reperfusion (Shiva
et al., 2007).
Genetic adaptation to hypoxia via stabilization of the alpha
subunit of hypoxia-inducible factors (HIF1α and HIF2α), has
been suggested to require mitochondrial ETC O•−2 production
(Chandel et al., 1998, 2000). However, how ROS act over
HIFα subunits or its degrading enzymes, the prolyl-hydroxylases
(EGLNs), is still unknown (Kaelin and Ratcliffe, 2008). More
recently, mitochondrial complex I and ROS production have
been shown to play a key role in acute oxygen sensing by carotid
body (Fernandez-Aguera et al., 2015). Such increase in ROS
production depolarizes glomus cells through inhibition of K+
channels and increase of cytosolic Ca2+ by extracellular Ca2+
influx. Both stabilization of HIF-α subunits and inhibition of
K+ channels could be influenced by ROS through oxidation
of thiols. Indeed, redox balance is also modified in hypoxia
since ROS reversibly oxidize thiols in the cytosolic compartment
of cells which, in turn, could have a role in cell signaling
and survival during hypoxia (Izquierdo-Alvarez et al., 2012).
Superoxide anion generation by mitochondria upon decrease
in oxygenation below “normoxic values” as well as decline in
NO production by neuronal and inducible NO synthases that
have low affinity for O2 (Kd 2–5 kPa; Dweik, 2005) result in
an increase in oxidized glutathione in hypoxic heart tissues
of animals that are hypoxia-sensitive, but not in hypoxia-
resistant ones (Petrushanko et al., 2012; Yakushev et al., 2012).
Oxidized glutathione joins the reactions of non-enzymatic dithiol
exchange in which S-glutathionylated adducts of thiol residues
are formed in multiple proteins including the Na,K-ATPase. For
mitochondrial ROS/RNS to be regulators of the Na,K-ATPase
function under hypoxic conditions, the ROS generators should
be co-localized with the ATPase. The existence of membrane-
bound pool of mitochondria has been confirmed (Westermann,
2015). However, the role of ROS and RNS produced by the
mitochondria in control of the Na,K-ATPase activity, amplifying
and complementing the signals generated as NADPH oxidases,
xanthine oxidase and other free radical generators, awaits further
investigation.
Therefore, mitochondria-derived ROS produced in the first
minutes of hypoxia (Hernansanz-Agustin et al., 2014), may be
a primary and necessary event in redox signaling in hypoxia,
leading to the activation of multiple redox processes. All these
events converge to targeted thiol oxidation and development of
acute adaptive response (Izquierdo-Alvarez et al., 2012).
Both mitochondria and Na,K-ATPase are corner-stones in
control of metabolic state of hypoxic tissue. The intimate relation
between them remains to be unraveled as it does not seem to be
limited to the production and consumption of ATP alone.
VERSATILITY OF OXYGEN SENSING.
MULTIPLE SIGNALS-MULTIPLE
TARGETS—MULTIPLE
RESPONSES—MULTIPLE OUTCOMES
Changes in O2 availability occurring in the course if evolution
trigger multiple responses in every cell of any living organism
on this planet (Holland, 2006). These responses are species-
and cell type-specific. Diversity in responses matches the oxygen
levels in the tissue under normoxic conditions (Bogdanova
et al., 2006) and is associated with adaptations some species
developed to survive hypoxic periods (Hochachka et al., 1999).
A single protein, such as the Na,K-ATPase, may demonstrate
essential hypoxia-insensitivity (Yakushev et al., 2012), maintain
maximal activity within a narrow window of O2 concentrations
(Petrushanko et al., 2007), or show linear dose-dependence of
O2 concentration in the environment (Bogdanova et al., 2005;
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Yakushev et al., 2012) depending on the species and cell type.
These responses also vary depending on the duration and severity
of hypoxia (Dada et al., 2003; Fuller et al., 2003; Bogdanova et al.,
2006; Petrushanko et al., 2007, 2015; Yakushev et al., 2012).
Patterns of response correlate with the changes in ROS/RNS
and NO production in the cells and the corresponding shifts
in redox state. Apart of the regulatory thiols within the Na,K-
ATPase changes in the enzyme activity are in part mediated
by its phosphorylation by multiple redox-sensitive kinases
and phosphatases (Devarie-Baez et al., 2016). These versatile
signaling messengers as well as the variability in free radical
scavenging systems make responses to hypoxia dependent
on location of free radical generators and speciation of the
messengers (free radical- and gaseous-based). The mechanisms
of oxygen-inducible regulation are largely restricted to the
oxidative modifications of thiols (formation of mixed di-thiols
with glutathione, sulfide or other protein thiols, S-nitrosylation,
or proline/threonine carbonylation (Yan et al., 2013). These
changes occur in multiple proteins at the same time. Fine-
tuning of protein complexes is accomplished translating into the
protection against hypoxia or reperfusion injury at the tissue and
organism levels (Yan, 2014).
OXYGEN AND REDOX-SENSITIVITY OF
THE NA,K-ATPase
Na,K-ATPase and Its Thiols
Sodium potassium pump is formed by the 100–113 kDa catalytic
α subunit, the regulatory obligatory 55 kDa β subunit and the
tissue-specific regulatory proteins of 7–11 kDa belonging to the
FXYD family (Figure 2A; Blanco and Mercer, 1998; Blanco,
2005; Geering, 2006; Toyoshima et al., 2011). Furthermore,
Na,K-ATPase serves as a “docking station” for multiple other
proteins of those other ion transporters, receptors, cytoskeletal
proteins andmembers of signaling proteins are known (Reinhard
et al., 2013). Each Na,K-ATPase subunit type contains cysteine
residues. The only reduced thiol within the beta subunit is
localized at the edge to the membrane surface, diving into
and out of the membrane during the pumping cycle (White
et al., 2009; Bibert et al., 2011). Muscle-specific FXYD subunit
pospholemman (PLM) has two thiols (Bibert et al., 2011). The
catalytic α subunit is the largest of the three subunits, forms the
ATP binding site and binding sites for ions and transport pore,
and has 23–24 thiols depending on the isoform (Bogdanova et al.,
2006). Several of these thiols are considered to be the targets
of regulatory reversible thiol modifications. These modifications
make the Na,K-ATPase function extremely sensitive to the
changes in redox state and oxygen availability (chronic and acute
hypoxia).
Irreversible Oxidation of Thiols
Oxidative stress represents an imbalance between an augmented
production of pro-oxidative equivalents (mostly ROS and RNS)
and/or their detoxification rate by the so-called antioxidant
systems (Sies, 2015). Under these circumstances oxidants attack
reduced protein thiols turning them into sulfinic or sulfonic
acids. Irreversible oxidation induced in the Na,K-ATPase isolated
from kidneys by its exposure to 20mMH2O2 results in a decrease
in Vmax to a half and inability to form oligomeric complexes
(Kurella et al., 1999). Sensitivity to oxidation varied for the Na,K-
ATPase isozymes, those from the heart and the brain (astrocytes)
formed by the α2 isoform of the catalytic subunit being more
susceptible for oxidation than the ubiquitously expressed α1
isozyme (Xie et al., 1995). ATP was protecting the enzyme from
irreversible oxidation (Xu et al., 1997). Depletion of cytoplasmic
and mitochondrial GSH or exposure of cerebellar granule cells
to hyperoxia also caused suppression of the enzyme activity
associated with massive free radical burst (Petrushanko et al.,
2006, 2007).
As reviewed below terminal irreversible oxidation of the
enzyme has two more consequences. It makes the regulatory
thiols inaccessible for reversible thiol modifications and therefore
renders the enzyme insensitive to redox changes and alterations
in oxygen levels (Petrushanko et al., 2012). Irreversible oxidation
primes the proteins to degradation (Thevenod and Friedmann,
1999). In the lungs severe hypoxia (1.5 kPa) promotes
ubiquitination and lysosomal degradation of the alpha1-isozyme
of the Na,K-ATPase by phosphorylation of the catalytic subunit
at Ser18 by PKCzeta (redox-sensitive kinase containing cysteine
clusters; Dada et al., 2003, 2007; Dada and Sznajder, 2003).
S-nitrosylation of Thiols
S-nitrosylation (and S-nitrosation, for nomenclature see
Heinrich et al., 2013) is a common thiol modification in
biological systems (Martinez-Ruiz and Lamas, 2004; Martinez-
Ruiz et al., 2013). Nitric oxide is unable to directly interact with
reduced thiols. Several mechanisms have been described for
nitrosothiol formation, which do not require the presence of
specific enzymes that catalyze these reactions (Martinez-Ruiz
et al., 2013).
Direct reaction of NO to nitrosylate a cysteine thiyl radical
(P-S•) whenever the latter has been formed.
P-S• + •NO → P-S-NO (1)
This is a fast reaction may compete with NO binding to the
heme of soluble guanylate cyclase sGC heme (Madej et al., 2008;
reviewed in Smith and Marletta, 2012). However, its biological
significance is limited to those proteins in which the thiyl radical
could be formed when NO is being produced.
NO autooxidation can also lead to S-nitrosylation, via the
formation of N2O3:
2 NO + O2 → 2 NO2 (2)
NO2 + NO→ N2O3 (3)
N2O3 + RSH→ RSNO+H
+
+NO−2 (4)
The rate-limiting reaction is the formation of NO2, so it requires
a very high NO concentration for producing a significant amount
of S-nitrosylation. This high NO concentration can be achieved
in the proximity of NO sources, mainly NOS. Indeed, the reaction
is 30-fold faster in hydrophobic environments (Moller et al.,
2007), suggestion that it can be favored in regions close to cell
membranes, where NOS enzymes localize.
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FIGURE 2 | Schematic representation of localization S-glutathionylated cysteine residues in α (in blue), β (in yellow), and phospholemman (FXYD, in
cyan) subunits (A). Regulatory S-glutathionylation sites are shown in red. Basal S-glutathionylation is shown in green. ATP binding site is highlighted in red. Blue
rectangle depicts ouabain binding site. Stars highlight the Cys residues with differences in pK between the α1 and α2 isoform (for details see Table 1). (B) Shows
schematically the cavities with trapped S-glutathionylated Cys residues inaccessible for de-glutathionylation without detergents and representing “redox memory.”
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Transnitrosylation in reactions involving modified cysteine
residues, including S-nitrosoglutathione, has emerged as an
effective and regulated mechanism forming this modifications
(Nakamura and Lipton, 2013; Kohr et al., 2014):
RSNO + R’SH→ RSH+ R’SNO (trans− nitrosylation,
nitrosylated glutathione may be involved) (5)
Interaction of peroxynitrite with cysteine thiol residues does
not give S-nitrosylated products directly but causes oxidation of
thiols to sulfenic acid that in turn can form mixed disulfides,
in particular with glutathione (see S-glutathionylation below;
Alvarez and Radi, 2003):
RS− + ONOOH→ RSOH+NO−2
RSO− + GSH→ RSSG+OH− (6)
Denitrosylation mainly involves two mechanisms (Smith
and Marletta, 2012). GSNO concentration is controlled by
enzymatically-catalyzed NADH (for GSNO reductase (GSNOR)
or NADPH-dependent (carbonyl reductase 1, CBR1) reduction
to GSH. Since trans-nitrosylation of thiols involves GSNO
(reaction 5), this process may be considered as rate-limiting in
S-nitrosylation of proteins. This is true for the Na,K-ATPase,
as increase in the levels of GSNO induces the second trans-
nitrosylation step and formation of S-glutathionylated adducts
of the α (Li et al., 2001; Petrushanko et al., 2015) and β (Liu
et al., 2013) subunits of the enzyme. Thioredoxin catalyzes
denitrosylation of multiple targets by trans-nitrosylation of its
active cysteines Cys32 and 35.
Hypoxia alters the number of S-nitrosylated cysteines in
numerous proteins. In endothelial cells with high levels of
eNOS (NOSIII) multiple targets get S-nitrosylated under hypoxic
conditions. This NO synthase has high affinity to O2 (Kd 0.29
kPa, Dweik, 2005) and can therefore support NO production
at low O2 levels. At the same time in heart tissue, where NOSI
and NOSII with low O2 affinity are dominating (Kd 23–35
kPa, Dweik, 2005) hypoxia is associated with rapid cessation
of NO production and decrease in S-nitrosylation of cysteine
residues of the α subunit of the Na,K-ATPase (Yakushev et al.,
2012). NO and S-nitrosylation were shown to protect thiols
from irreversible oxidation and S-glutathionylation, and allow
the enzyme to maintain high activity in the brain and heart
(Petrushanko et al., 2007; Yakushev et al., 2012). Irreversible
oxidationmakes regulatory thiols inaccessible for S-nitrosylation.
This may explain the fact that the sensitivity of the Na,K-ATPase
to NO was lost in a mouse model of amyotrophic lateral sclerosis
(Ellis et al., 2003).
S-glutathionylation of Thiols: Chemistry
S-glutathionylation (also referred to as S-glutathiolation), the
formation of a mixed disulfide between a protein cysteine and
that of glutathione. This thiol modification is produced in a
number of chemical reactions (Klatt and Lamas, 2000; Dalle-
Donne et al., 2007, 2008; Martinez-Ruiz and Lamas, 2007; Mieyal
et al., 2008; Bachi et al., 2013).
Reactions resulting in formation of S-glutathionylated protein
adducts include classical thiol disulfide exchange (reaction 7) that
does not require any catalysis, and several mechanisms requiring
prior oxidative modification of the thiol residues (either the
protein thiol or cysteine residue of GSH, reactions 8–13).
P-S− + GSSG→ P-SSG+ GS− (7)
Reactions priming thiols to S-glutathionylation include prior
formation of thiyl radicals with O2 as an electron acceptor
(reactions 8–9), oxidation of thiols to sulphenic acid (reaction
10–11) or to nitrosothiol (reactions 12–13)
P− S• + GS− +O2 → P-SSG+O
•−
2 (8)
P− S− + GS• +O2 → P-SSG+O
•−
2
(catalyzed by glutaredoxin) (9)
P-SOH + GSH→ P-SSG+H2O (10)
P-SH + GSOH→ P-SSG+H2O (11)
P-SNO + GSH→ P-SSG+HNO (12)
P-SH + GSNO→ P-SSG+HNO (13)
S-glutathionylation of thiols in hypoxic cells is triggered by a
local shift in GSSG/GSH ratio toward more GSSG (Petrushanko
et al., 2012; Yakushev et al., 2012). On the other hand, oxidative
stress following superoxide anion burst in hypoxic mitochondria,
will promote oxidation of thiols to sulfenic acid priming them to
S-glutathionylation via reaction 10.
Reversibility of S-glutathionylation is supported.
Glutaredoxin1 and 2 may catalyze de-glutathionylation or
glutathionylation reactions depending on the redox environment
(NAD(P)H:NAD(P), GSH:GSSG, NO availability; Mieyal et al.,
2008). Not all thiols in the proteins are accessible for S-
glutathionylation. Whereas glutaredoxin1 is active in the cytosol
and inter-membrane space, whereas glutaredoxin 2 is localized
in the mitochondrial matrix, controlling the state of protein
thiols in these compartments (Allen and Mieyal, 2012). Further
enzymes capable to catalyze de-glutathionylation reaction
include sulfiredoxin (Lei et al., 2008), glutathione transferase P
(Townsend et al., 2009), and glutathione transferase omega 1
(Menon and Board, 2013).
Not all thiols are equally accessible for S-glutathionylation.
Specific conditions that have to be fulfilled for the thiol to become
glutathionylated are discussed below.
Localization of the Groups Favoring Glutathionylation
The likelihood for a given thiol to undergo S-glutathionylation
is defined by several factors: (i) dissociation constant pKa of a
thiol (ii) microenvironment (amino acid composition in vicinity
to the cysteine residue), (iii) accessibility of the group and steric
restrictions, and (iv) redox potential of a thiol (Nagy, 2013).
Nucleophilic substitution reaction in which S-glutathionylated
adduct is formed involves interaction of a thiolate anion with a
GSSG molecule (Allen and Mieyal, 2012). Thiol therefore has to
be deprotonated to join this reaction. The average pKa ofmajority
of cysteine residues is 8.5. Thus, probability of deprotonation
of cysteine residues under physiological conditions is relatively
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low making S-glutathionylation selective (Dalle-Donne et al.,
2009). Reduction in pKa of distinct thiols is supported by the
positive charge of three flanking amino acids such as arginine,
lysine, or histidine (Allen and Mieyal, 2012; Sun et al., 2013;
Zhao et al., 2015). Proximity of negatively charged amino acids
to a thiol on the contrary compromises interaction with GSSG.
Protein sequence analysis for the α1 subunit of the Na,K-ATPase
revealed that cysteines 204, 452, 599, and 698 (corresponding
to the Cys 206, 454, 601, and 700 in Figure 2) are prone to
S-glutathionylation (Mitkevich et al., 2016).
Steric restriction and localization of cysteine residue within
the protein sequence are yet other parameters that should be
taken into consideration when predicting S-glutathionylation
sites (Pineda-Molina et al., 2001). Hydrophilicity of GSSG
suggests that the residues should be exposed to aqueous phase as
the reaction with GSSG occurs. Furthermore, the exposed surface
of thiol should be sufficient for docking of GSSG to form mixed
dithiols (Sun et al., 2013). “Basal S-glutathionylation” of cysteines
that are buried within the protein, but are S-glutathionylated,
represents a special case and is discussed below.
Further restrictions limiting the number of S-glutathionylated
residues are related to the redox state of a thiol. For most proteins
GSH:GSSG ratio should decrease from 100:1 to 1:1 to achieve
S-glutathionylation of 50% of thiols (Allen and Mieyal, 2012).
Very few proteins, such as c-Jun may be glutathionylated within
physiological range of half-cell redox potential for GSH:GSSG
couple (Klatt et al., 1999; Allen and Mieyal, 2012). Na,K-ATPase
is one of these few proteins as interaction of the cysteine residues
within its catalytic α subunit with GSSG can be observed as
GSSG reaches 150 µM levels in the presence of 1.5 mM GSH
(Petrushanko et al., 2012; Yakushev et al., 2012).
S-glutathionylation and Targets in the
Na,K-ATPase
Alpha Subunit of the Enzyme
Cysteines of all three types of subunits forming Na,K-ATPase
undergo S-glutathionylation. Catalytic α subunit contains 23 or
more (depending on the isoform) cysteine residues (Figure 2A).
Fifteen out of 23 Cys residues of the α1 isoform are
localized within the cytosolic loops and are easily accessible
for interaction with cytosolic GSSG. Out of seven cysteine
residues of the regulatory β subunit 6 are forming S-S bonds
with each other and only one remaining cysteine possesses
a thiol accessible for S-glutathionylation (White et al., 2009).
Tissue-specific FXYD subunits also contain 1–2 cysteines of
which at least one undergoes S-glutathionylation (Bibert et al.,
2011).
Regulatory S-glutathionylation Cysteine residues that were
found S-glutathionylated within the α1 subunit isolated from
duck salt gland were classified as targets for regulatory or
basal S-glutathionylation (Petrushanko et al., 2012). Whereas
basal S-glutathionylation is not associated with the changes
in the enzyme hydrolytic activity, binding of glutathione to
the regulatory cysteine residues causes the enzyme’s complete
inactivation that can be reversed upon de-glutathionylation
(Petrushanko et al., 2012; Yakushev et al., 2012). Regulatory S-
glutathionylation could be accomplished by incubation of the
purified enzyme or membrane fraction with GSSG indicating
that regulatory thiols were accessible for classical thiol disulfide
exchange (reaction 5). Similar response was obtained for the
α1 subunit within the broad range of tissues and cell type (cell
line, salt gland, kidneys, heart tissue) and species (duck, rabbit,
pig, mouse, rat, Spalax mole rat, trout, and human; Petrushanko
et al., 2012, 2015; Yakushev et al., 2012; Juel, 2014; Xianyu et al.,
2014; Juel et al., 2015; Mitkevich et al., 2016). Apart of α1, S-
glutathionylation of the α2 isozyme was shown in heart and
skeletal muscle. Moreover, α2 isozyme appeared to be more
sensitive to GSSG-inducible inhibition in rat heart (Petrushanko
et al., 2012; Xianyu et al., 2014; Juel, 2016). This observation
is in agreement with the report of Xie on exceptionally high
susceptibility of the α2 subunit to oxidation (Xie et al., 1995)
and suggests that Cys residue(s) within this isoform are more
accessible for oxidation (e.g., Cys 579 in Table 1). As can be seen
from the Table 1, microenvironment for two cysteine residues
(Cys 206 and 579) within the cytosolic loops of the α2 subunit
favors S-glutathionylation as non-charged amino acids present
in the α1 isoform are substituted by positively charged ones
facilitating thereby deprotonation of the thiols. Furthermore, α2
subunit harbors the extra cysteine (Cys 236) in the actuator
domain and lacks the Cys458 (present in the α1). Thus, although
the number of cysteines does not differ between the α1 and
α2 subunits, their location, pK and the ability to become S-
glutathionylated show clear isoform-specificity.
Localization of the sites of regulatory S-glutathionylation was
identified by means of mass spectrometry (Petrushanko et al.,
2012). Three of them, Cys 454, 456, and 459 are proximal
to the ATP binding site whereas Cys 244 is localized in
the small cytosolic loop that may approach the ATP binding
pocket in E2 conformation (Bogdanova et al., 2006). Binding of
glutathione to the regulatory sites displaces adenine nucleotides
from interaction with the enzyme (Petrushanko et al., 2012). In
turn, GSSG cannot block the enzyme’s hydrolytic activity in the
presence of ATP or ADP (Petrushanko et al., 2012; Xianyu et al.,
2014). ATP was showing maximal “protective effect” compared
to the other nucleotides (Xianyu et al., 2014). Interaction with
ATP (but not with the other nucleotides) brings the nucleotide-
binding domain of the α subunit closer to the phosphorylation
domain (E1-closed state) shielding thiols of the small and large
cytosolic loops from attack by GSSG or oxidants (Petrushanko
et al., 2014) and making them less prone to irreversible oxidation
(Xie et al., 1995; Xu et al., 1997).
Increase in S-glutathionylation of the α subunit was
triggered by hypoxia associated with mild oxidative stress
and modest ATP depletion in rat heart and SC1 cell line
derived from mouse fibroblasts (Petrushanko et al., 2012, 2015;
Yakushev et al., 2012). Inhibition of the Na,K-ATPase and
induction of S-glutathionylation could be mimicked by the
modulation of intracellular redox state by exposure of cells
to glutathione derivatives et-GSH, GSNO, GSSG, or depletion
of the intracellular GSH (Petrushanko et al., 2006, 2015). S-
glutathionylation of the α subunit cannot be sustained under
anoxic conditions. This thiol modification is induced by 0.2% O2
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TABLE 1 | Analysis of flanking amino acids’ composition of selected thiols in the α1 and α2 subunits (rat sequences).
Number
of Cys
Sequence
fragment
Substitutions
α1-> α2
Comments
206 α1
α2
NGCKV
HGCKV
.****
N->H Asp-> His (neutral to positive in α2)
236 α1
α2
NIAFF
NICFF
**.**
A->C Cys present in α2 and missing in α 1 isoform
458 α1
α2
EVCCGS
ELSCGS
*:.***
V->L
C->S
Cys missing in the α2 isoform and present in α 1 Val->Leu (neutral)
513 α1
α2
DRCSS
DRCST
****:
S->T Neutral substitutions
551 α1
α2
GFCHL
GFCQL
***:*
H->Q His->Gln (positive to neutral in α2)
579 α1
α2
NLCFV
KLCFV
:****
N->K Asp->Lys (neutral to positive in α2)
932 α1
α2
VICKT
IICKT
:****
V->I Neutral exchange
Data shown in the table are obtained as a result of sequence alignment (Clustal O(1.2.1)) for the Na,K-ATPase α1(P06685) and α2 (P06686) subunits’ sequences for rat (Rattus
norvegicus), published in UniProt-Knowledgebase (Swiss-Prot collection of sequences, http://www.uniprot.org/uniprot). Included into the table are the amino acids flanking the cysteine
residues for which the isoform-specific differences (substitution, omission) have been observed. Asterisks stand for the conserved amino acids whereas dots and semicolon indicate
the substitutions. Cysteines are color-coded in blue and the substituted amino acids in yellow.
but less pronounced at 0.05% O2 in mouse fibroblast-derived cell
line (Petrushanko et al., 2015).
Basal S-glutationylation of the α subunit
Basal S-glutathionylation of the α subunit of the Na,K-ATPase
is not associated with the changes in the enzyme function.
15 cysteine residues facing the cytosol are accessible for S-
glutathionylation. Treatment of the cell lysates, membrane
fractions or purified active Na,K-ATPase preparations with
reducing agents (e.g., by Dithiotreitol or Tris(2-carboethyl)-
phosphine, TCEP) could not completely remove glutathione
bound to the α subunit’s thiols (Mitkevich et al., 2016).
Complete de-glutathionylation could only be achieved under
conditions supporting partial denaturation of the protein (8
M urea and 8% SDS). De-glutathionylation of the cysteines
inaccessible for reducing agents in the protein retaining its
native structure was associated with substantial loss of the
enzyme activity due to unfolding. The only chance these Cys
residues shielded from GSSG and reducing agents have to
acquire S-glutathionylation is before the folding was completed
(Figure 2B). This implies that S-glutathionylation of certain
Cys residues is a co-translational rather than post-translational
modification and it may be required for correct protein
folding. Detailed analysis of the X-ray structures of the
porcine α1 subunit-containing enzyme (PBD codes: 3B8E, 3KDP,
3WGU, 3WGV, 4HYT) revealed a number of isolated cavities
with unresolved electron density next to the Cys residues
(numbering as in Figure 2B) Cys 206–Cys 244; Cys 454–Cys
458–Cys 459; Cys 700–Cys 369, Cys 601 (Mitkevich et al.,
2016).
These regions of relatively high residual electron density that
cannot be explained by the presence of water are sufficient in size
to home glutathione. However, so far no X-ray structures of the
actual catalytic subunit with S-glutathionylated cysteine adduct
was reported. Detection of glutathionylated residues in crystal
structures of proteins is not impossible (Srinivasan et al., 2014),
but much less common that detection of these modifications by
means of mass spectrometry. One of the technical approaches
to use for identification of S-glutathionylated cysteine residues is
tracking for glutathione localisation using analysis of unresolved
density next to the cysteine residues. This approach was used
for identification of glutathione bound to the ABC transporter
Atm1 (Srinivasan et al., 2014). In each cavity of the α subunit
only one Cys residue was reported to be S-glutathionylated (basal
type of S-glutathionylation, Figure 2B, Mitkevich et al., 2016).
These findings imply that Cys454 is located in a cavity and, hence,
cannot be a regulatory thiol as suggested earlier (Petrushanko
et al., 2012). Its basal S-glutathionylation will contribute to the
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protein folding instead. Out of the Cys206-Cys244 couple Cys
206 is capable of basal S-glutathionylation whereas Cys 244
carries a regulatory thiol group. In contrast to regulatory S-
glutathionylation observed within minutes after the drop in O2
availability, increase in basal S-glutathionylation is only observed
after 72 h of hypoxic exposure (Mitkevich et al., 2016). This
kinetics correlate with the onset of de novo protein synthesis
rather than acute alterations in thiol state.
Moreover, as this modification is retained during the life-span
of a protein it represents “redoxmemory” that reflects the cellular
redox state at the moment of synthesis of this molecule. Thus,
this “redox memory” may represent the process of adaptation to
the alterations in redox state occurring in particular in response
to deoxygenation. The fact that basal S-glutathionylation levels
differ in muscle fibers being higher in oxidative fibers compared
to the glycolytic fiber type suggests that it is likely to be associated
with the metabolic state of the tissue (Juel, 2014).
S-glutathionylation of Beta Subunit
A single reduced thiol group in β subunit of the Na,K-ATPase,
Cys 46 (Figure 2A), is the one that may undergo reversible post-
translational modifications. S-glutathionylation of this cysteine
residue was reported for all three muscle types (skeletal, smooth,
and heart muscles; Figtree et al., 2009; Liu et al., 2013; Juel et al.,
2015). Since interaction of glutathione with Cys 46 results in
down-regulation of the enzyme function this residue is a site of
regulatory S-glutathionylation (Figtree et al., 2009). Inhibitory
effect is achieved due to the weakening of the interaction between
α and β subunits upon S-glutathionylation (Figtree et al., 2009).
S-glutathionylation of β subunit does not inactivate the enzyme
completely (Figtree et al., 2009). Unfortunately, the studies in
which S-glutathionylation of the β subunit was detected were not
presenting the information on the degree of S-glutathionylation
of the α subunit, making it impossible to discriminate between
the impacts of these two processes into the enzyme activity
regulation (Liu et al., 2013).
In contrast to the regulatory cysteines of the catalytic α
subunit that are readily interacting with GSSG Cys 46 does
not join reaction of classical thiol disulfide exchange with
GSSG (Petrushanko et al., 2012). This may be attributed to
the localization of this Cys residue. According to the X-ray
structure it is buried within the membrane in E2 2K+Pi
conformation (Ogawa et al., 2009) and is only accessible for
S-glutathionylation in E1ATP and E1Na(3) conformation (Liu
et al., 2012). Furthermore, Cys 46 may become accessible or S-
glutathionylation upon the loss of association between the α and
β subunits (Garcia et al., 2015). Ouabain stabilizes the enzyme
in E2 conformation and compromises S-glutathionylation of
β subunit (Liu et al., 2012). De-glutathionylation can be
achieved by treatment of the S-glutathionylated enzyme with
Glutaredoxin.
Localization of the regulatory cysteine defines conditions
required for its S-glutathionylation. It only occurs in the
presence of peroxynitrite and hence involves reactions 12
and 13. Physiological and pathophysiological role of this
form of regulatory thiol modification in the heart has been
intensively investigated. Stimulation of O•−2 production by
NADPH oxidases, that co-localize and co-immunoprecipitate
with the Na,K-ATPase, induces S-glutathionylation of the β
subunit at Cys46 (Liu et al., 2013). The stimulation of NADPH
oxidases could be triggered by their phosphorylation by PKC
produced upon activation of β1/β2 adrenoceptors or treatment
of the myocardium with angiotensin II. Furthermore, increase
in S-glutathionylation of the β subunit was reported in the
infarcted area in sheep heart (Figtree et al., 2009). Similar effect
was achieved by exposure of cardiomyocytes to the activator
of adenylate cyclase forskolin and the following activation of
PKCǫ (White et al., 2010) or direct administration of ONOO-
(Figtree et al., 2009). Scavenging of O•−2 using superoxide
dismutase on the contrary abolishes S-glutathionylation of the β
subunit. Similar effect may be achieved by the stimulation of sGC
that interfered with phosphorylation and activation of NADPH
oxidases (Chia et al., 2015). Activation of β3 adrenoreceptor is a
physiological stimulus decreasing S-glutathionylation of the Cys
46 (Bundgaard et al., 2010). These differential responses are easily
explained based on the chemistry of S-glutathionylation of thiols.
Deoxygenation is associated with suppression in production of
NO by NOS1 and NOS2 as well as in reduction of activity of
NADPH oxidases Kd of which for O2 is within 2 kPa range. Thus,
decrease in O2 levels below this threshold reduces production
of peroxynitrite and decreases S-glutathionylation of Cys 46 in
β subunit. Uncoupling of oxidative phosphorylation and O•−2
burst in the mitochondria on the contrary will facilitate GSSG
production in the cytosol and induce S-glutathionylation of
regulatory cysteines within the cytosolic loops of the catalytic α
subunit.
S-glutathionylation of FXYD Subunits
Tissue-specific FXYD proteins associate with Na,K-ATPase αβ
complex stabilizing it and modulating the enzyme activity
(Geering, 2006). These modulatory subunits also contain 1 or
2 cysteine residues that undergo reversible thiol modifications.
Most of the information on the role of these modifications in
control of Na,K-ATPase function was obtained for the cardiac-
specific FXYD1 subunit also known as phospholemman (PLM).
It contains 2 Cys residues (C1 corresponding to Cys40 and C2
corresponding to Cys42 in human FXYD1 protein, Figure 2A),
and S-glutathionylation of the C2 was shown to correlate
reciprocally with the availability of glutathionylated form of the β
subunit (Bibert et al., 2011). Localization of C2 and mechanisms
of induction of S-glutathionylation of PLM are most likely shared
with the β subunit of the Na,K-ATPase and involve peroxynitrite.
Interaction of PLM with glutathione may be triggered by
forskolin and prevented by exposure to superoxide dismutase.
De-glutathionylation is also catalyzed by glutaredoxin1 or
treatment with DTT. Thus, both PLM and β subunits lack
cysteines that are not accessible for de-glutathionylation (redox
memory). Physiological stimuli increasing the level of PLM S-
glutathionylation include angiotensin II and infarction (Bibert
et al., 2011).
The importance of the amino acids flanking the cysteine
residue in control of accessibility of it for S-glutathionylation
was emphasized as the amount of glutathionylated adducts was
compared for several members of FXYD family. C2 cysteines
Frontiers in Physiology | www.frontiersin.org 10 August 2016 | Volume 7 | Article 314
Bogdanova et al. Responses of Na,K-ATPase to Hypoxia
were found to be prone to S-glutathionylation in FXYD2 (renal)
and FXYD7 (brain-derived) (Geering, 2006; Bibert et al., 2011).
Phospholemman (PLM, FXYD1) interacts with both catalytic
and regulatory subunits of the Na,K-ATPase. Thus, interaction
between α and β subunits and the enzyme function is affected by
S-glutathionylation of the FXYD1. Furthermore, the reciprocal
regulation of S-glutathionylation of the β and FXYD subunits
suggests that FXYD may reverse the inhibitory action mediated
by binding of glutathione to the regulatory β subunit on the
Na,K-ATPase. It remains unclear if glutathione is transferred
from the Cys46 on to the β subunit to the C2 residue in
reaction of thiol disulfide exchange of the FXYD protein or if S-
glutathionylation of the FXYD protein makes Cys46 inaccessible
for S-glutathionylation.
H2S and the Na,K-ATPase
Hypoxic exposure was shown to cause a rapid increase in H2S
levels in a number of cells including chemoreceptory glomus
cells (Peng et al., 2010; Olson, 2015; Yuan et al., 2015). Direct
interaction of H2S with the Na,K-ATPase has not been reported.
However, exposure of renal tubular epithelial cells to H2S
causes internalization of the Na,K-ATPase in complex with other
proteins. This inhibitory response of the pump is triggered by
sulfhydrolation of cysteines 797 and 798 at the epidermal growth
factor receptos (EGFRs) (Ge et al., 2014).
COORDINATED REGULATION OF
REDOX-SENSITIVE PROTEIN NETWORKS
BY REVERSIBLE THIOL MODIFICATIONS
S-glutathionylation and S-nitrosylation are altering the function
of numerous proteins that form redox sensitive networks
(Sun et al., 2006; Dalle-Donne et al., 2009). Protein clusters
forming these networks are the ones controlling metabolism,
ion transport, cell fate and cycle, adaptation, and others. This
type of free radical-based signaling is of key importance in
responses to hypoxia and reoxygenation mediating acute and
long-term tissue-specific coordination of function of multiple
proteins. S-glutathionylation of the α subunit of the Na,K-
ATPase occurs among with alterations in thiol state of other
proteins. The most obvious protein partners that undergo S-
glutathionylation are the adjacent β and FXYD subunits. Thiol
disulfide exchange in which PLMmost likely acquires glutathione
from the Cys 46 subunit of the β subunit is suggested to cause
dissociation of the FXYD subunit of from the Na,K-ATPase
as it does not co-precipitate with the α subunit (Bibert et al.,
2011). As PLM is a regulatory subunit that is shared between the
Na,K-ATPase and the Na/Ca exchanger, it was suggested that S-
glutathionylation as well as its redox-sensitive phosphorylation
of it impacts activity of both transporters (Silverman et al.,
2005; Cheung et al., 2007; Zhang et al., 2011). Calcium handling
in the heart is intimately linked to the Na+ levels (Shattock
et al., 2015) and, hence to the activity of the α2 isozyme of the
Na,K-ATPase that is particularly prone to inhibition by GSSG
(James et al., 1999; Petrushanko et al., 2012). Apart of the Na/Ca
exchanger reversible thiol modifications are known to control
the activity of L-type Ca2+ channel, RyR2 ryanodine receptors,
SERCA2a Ca2+ pump and multiple other ion transporters (Sun
et al., 2006; Bull et al., 2008; Lancel et al., 2009; Donoso et al.,
2011).
These coordinated redox-driven changes in activity of
multiple ion transporters may support cytoprotection and
survival of the cell/tissue/organism or promote death under
hypoxic conditions (see Section Regulation of the Na,K-ATPase
Activity by Cardiotonic Steroids).
OXYGEN-SENSITIVE PHOSPHORYLATION
Regulatory phosphorylation is known to control the activity,
sensitivity to the cardiotonic steroids, and availability of
the Na,K-ATPase on the plasma membrane. Changes in
phosphorylation state of the enzyme were reported in response
to hypoxic challenge and for a long time believed to be the only
mechanism involved in “channel arrest” response of the Na,K-
ATPase in hibernating animals (MacDonald and Storey, 1999;
Ramnanan and Storey, 2006; McMullen and Storey, 2008). At
present “channel arrest” responses seem to be more versatile,
and yet triggered by a single mechanism of regulation, in this
case not only the Na,K-ATPase itself, but also the redox-sensitive
kinases, namely, reversible thiol modifications of regulatory
cysteine residues or action of gasotransmitters. Phosphorylation
sites at the α, β and FXYD subunits are schematically presented
in Figure 3.
Protein Kinase C (PKC)
Hypoxic exposure of alveolar epithelial cells was shown to trigger
actively controlled internalization of the Na,K-ATPase in the
form of clathrin-coated vesicles (Dada et al., 2003). This process
was induced by phosphorylation of the α subunit of the Na,K-
ATPase by at atypical PKC isozyme.
Novel and classical PKC isoforms are also capable to alter
activity of the Na,K-ATPase in various cell types. Classical
(conventional α, β1 and β2, and γ isoforms) and novel isoforms
PKC δ, ε, η, θ, and µ may be activated diacylglycerol (DAG),
phorbol esthers and phosphatidylserine and are sensitive to
the changes in Ca2+ in the cell. Atypical PKCι and ξ retain
the sensitivity to phosphatidylserine but are Ca2+-insensitive
(Figure 3; Newton, 1995; Parker and Murray-Rust, 2004).
Catalytic core of PKC contains critical cysteine-rich motifs
that are conserved in all PKC isozymes making all proteins of this
class redox-sensitive (Newton, 1995). This motif is duplicated in
classical and novel PKC isoforms, whereas in atypical PKCs only
one repeat is found. Oxidation of these cysteines causes transient
activation of the enzyme but makes it unable to interact with
DAG and phorbol esters making it Ca2+- and DAG-insensitive
(Gopalakrishna and Anderson, 1989). S-glutathionylation of
these regulatory thiols is inactivating α, βI, βII, γ, δ, ε, and ζ
isoforms of PKC. Formation of glutathionylated adducts occurs
within physiological range of GSH concentrations (0.5–10 mM)
and results in the enzyme inactivation (Ward et al., 1998, 2000;
Chu et al., 2001). In addition, PKC may undergo S-nitrosylation
that was shown to suppress activity of PKCα (Choi et al., 2011).
Depletion of intracellular GSH by exposure to conjugating agent
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FIGURE 3 | Schematic representation of the multiple pathways involved in regulatory phosphorylation of the Na,K-ATPase under hypoxic conditions.
The following abbreviations were used in the scheme: cyclic adenosine and guanosine monophosphates (cGMP and cAMP), protein kinases C, A, and G (PKC, PKA,
PKG), cardiotonic steroids (CTS), Src kinase family (SFK), AMP-activated protein kinase (AMPK), phospholipase C (PLC), diacylglycerol (DAG), inositol 3-phosphate
(IP3), ubiquitin (Ub), NKA (Na,K-ATPase), adaptor protein 2 (AP-2).
diethylmaleimide or inhibition of de novo GSH production by
L-buthionine-S,R-sulfoximine results in reduction in activity
of conventional PKC isoforms (α, βI, and βII) by 35–50%,
along activation of the novel isoforms (δ and ε) (Domenicotti
et al., 2000). This response of the PKCs to the changes
in redox state will induce endocytosis of the Na,K-ATPase
(Figure 3).
PKC phosphorylates the catalytic α1 subunit at Ser11 and
18 (rat sequence) at the N-terminus of the protein that forms
the actuator domain. Ser18 that is considered as a major
phosphorylation site is available for phosphorylation in the
E2 conformation (Feschenko and Sweadner, 1997). In the E1
conformation the N-terminus is translocated approaching the
small cytosolic loop that shields the phosphorylation site from
interaction with the kinase (Feschenko et al., 1997; Segall et al.,
2003). The analogs of Ser18 and Ser11 are missing in the α2
isoform of the catalytic subunit (compare sequences A24639 for
α1 and B24639 for α2 subunit in PubMed protein sequence
library http://www.ncbi.nlm.nih.gov) making this isozyme PKC-
insensitive. Phosphorylation efficiency may also vary depending
on the PKC isoform. Conventional isoforms are more efficient
in phosphorylation of the α1 isoform of the pump isolated from
rat retinal cells than the novel isoforms δ and ε (Kazanietz
et al., 2001). Phosphorylation of the α subunit by PKC may have
stimulatory of inhibitory effects on the Na,K-ATPase depending
on the cell type (Therien and Blostein, 2000). It is suggested
that phosphorylation modulates interaction of the enzyme with
other proteins or trigger its internalization (Feschenko and
Sweadner, 1997). For example, activation of the atypical isoforms
of PKC ξ triggers internalization of the Na,K-ATPase in alveolar
epithelial cells under hypoxic conditions (Dada and Sznajder,
2003). This effect is initiated by the free radical burst in the
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mitochondria that is followed by the activation by the 5′-
AMP-activated protein kinase (AMPK) that is phosphorylated at
Thr172. The activated AMPK phosphorylates PKCξ at Thr410
and its translocation to the plasma membrane (Gusarova et al.,
2009). Upon translocation PKC phosphorylates Na,K-ATPase
at the Ser18 residue in the N-terminus of the α1 subunit.
Endocytosis of the α1-containing isozyme of the ATPase is
precluded by ubiquitination of the lysine residues next to the
Ser18 (Dada et al., 2007; Lecuona et al., 2007). Ubiquitination
makes the enzyme recognizable for the mu2 subunit of the
adaptor protein that binds to the Tyr527 of the α1 subunit
initiating its endocytosis in clathrin-coated vesicle is initiated
with the following degradation of the Na,K-ATPase (Chen et al.,
2006; Lecuona et al., 2007).
PLM is one more target of phosphorylation by PKCǫ at Ser36
and Ser 68. Phosphorylation it stimulated by Ca2+ and is NO-
dependent (Pavlovic et al., 2013). Ischemia was associated with
facilitation of phosphorylation of PLM, its de-attachment from
the αβ complex and increase in the Na,K-ATPase hydrolytic
activity in sarcoplasmic membrane fraction (Fuller et al., 2003,
2009).
Protein Kinase G (PKG)
Hypoxia and reoxygenation result in the alterations in NO, CO,
and H2S production (see above). All gasotransmitters are capable
of activation of sGC that in turn triggers activation of cGMP-
dependent protein kinase PKC (PKG) (Therien and Blostein,
2000; Chen et al., 2015). Similar to that for PKC, phosphorylation
by PKG was reported to have diverse effects on the Na,K-ATPase
activity (Therien and Blostein, 2000). It remains unclear if PKG
can directly access the phosphorylation site within the α subunit,
as it could only be phosphorylated in the presence of detergents
in the purified protein preparation (Fotis et al., 1999; Beltowski
et al., 2003). However, treatment of yolk-free homogenates of
Xenopus oocytes with cGMP results in phosphorylation and
activation of the Na,K-ATPase in the absence of detergents
(Fotis et al., 1999). It may reflect the indirect action of PKG
on the ATPase via the suppression of dephosphorylation. Yet
one more report on the activation of the α2/3 isozymes of the
Na,K-ATPase in the central nervous system involves activation
of cGMP-PKG pathway following the stimulation with glutamate
(Munhoz et al., 2005; Scavone et al., 2005). On the other hand,
supplementation of NO donors was shown to inhibit the Na,K-
ATPase in nonpigmented epithelial cells of porcine eyes that is
associated with activation of PKG (Shahidullah and Delamere,
2006). This effect involves PKG-driven activation of src-family
kinases (Shahidullah et al., 2014).
Apart of the alterations in the enzyme activity, stimulation
of the cGMP-PKG pathway may affect binding of cardiotonic
steroids to the Na,K-ATPase. Increases the sensitivity of the
renotubular Na,K-ATPase to marinobufagenin triggered by atrial
natriuretic peptide is mediated by the cGMP-PKG signaling
cascade (Fedorova et al., 2012).
Protein Kinase A (PKA)
Cyclic AMP-sensitive protein kinase (PKA) is a redox-
sensitive enzyme containing regulatory thiols (Brennan et al.,
2006). In the absence of cAMP the enzyme exists in the
inactive tetrameric state and the regulatory Cys199 within the
C subunits is inaccessible for regulatory S-glutathionylation
(Humphries et al., 2002). Binding of glutathione to this cysteine
residue inactivates the kinase and enhances dephosphorylation
(Humphries et al., 2005). Vector of the changes in activity of
PKA in response to deoxygenation is very much dependent
on the cell type and on the activity of G-protein coupled
receptors signaling via cAMP-PKA transduction pathway
(Jiang et al., 2011).
PKA phosphorylates the catalytic α subunit at Ser938 (rat
α1 sequence) within the cytosolic M8-M9 loop. This loop may
interact with the M10, C-terminus and the third Na+ binding
site. In line with that phosphorylation at Ser938 decreases affinity
of this Na+ binding site to Na+ and thereby suppresses the
enzyme function (Einholm et al., 2016).
In the purified Na,K-ATPase protein preparation this target
is accessible for phosphorylation in the presence of detergent
(Feschenko and Sweadner, 1994; Lutz et al., 1996). In intact COS
cells phosphorylation of the α subunit at Ser943 is triggered
by β-adrenergic stimulation with the following inhibition of
hydrolytic and transport activity of the Na,K-ATPase (Cheng
et al., 1997).
Activation of cAMP-PKA-dependent pathways in NRK-52E
and L6 cell lines may suppress activity of PKC and reduce
phosphorylation of the Na,K-ATPase at the PKC binding sites
(Feschenko et al., 2000). This cross-talk may result from the close
proximity of the PKG binding site to that of PKC (Kruger et al.,
2003).
Along with PKC, PKA may catalyze phosphorylation of PLM
at Ser68 (Fuller et al., 2004, 2009) in response to ischemia or β
adrenergic stimulation (Despa et al., 2005) causing release of the
inhibitory action of association of the FXYD1 subunit with the
Na,K-ATPase.
REGULATION OF THE NA,K-ATPASE
ACTIVITY BY CARDIOTONIC STEROIDS
Cardenolides and bufadienolides are the two classes of
endogenous cardiotonic steroids that serve as hormones
selectively interacting with Na,K-ATPase. These compounds are
produced by midbrain and adrenocortical cells, and released
into the circulation in sub-micromolar concentrations in
response to various stimuli such as angiotensin II, acetylcholine,
vasopressin, catecholamines, and hypoxic exposure (Bagrov
et al., 2009). Interaction of these very low doses of endogenous
inhibitors with the Na,K-ATPase does not compromise the
transmembrane Na+ gradients, but induces activation of Src
kinase and formation of protein complex in which Src kinase and
Na,K-ATPase associate with epidermal growth factor receptor
(EGRF) and initiate several signaling cascades (Li and Xie, 2009).
Signaling modalities depend on the type of cardiotonic steroid
and its dose (Dvela et al., 2007). At the molecular level these
differences in physiological action of cardenolide ouabain and
bufadienolide marinobufagenin are reflected by the specific
pattern of conformational changes unique for each steroid
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upon binding to the purified Na,K-ATPase enzyme (Klimanova
et al., 2015). Affinity of the Na,K-ATPase to ouabain is maximal
in E2P conformation (in this conformation binding constant
for ouabain exceeds that for marinobufagenin by 17-fold),
whereas marinobufagenin does not discriminate between
the E1 and E2 conformations when binding to the enzyme
(Klimanova et al., 2015).
Notably, substitution of Cys 244 by Ala makes cells ouabain-
intolerant (Shi et al., 2000). This cysteine is a target of regulatory
S-glutathionylation (Petrushanko et al., 2012). Furthermore,
binding of cardiotonic steroids fixes the enzyme in distinct
conformation depending on the type of cardiotonic steroids
(Klimanova et al., 2015). Thus, binding of cardiotonic steroids
may alter susceptibility of cysteine residues to S-glutathionylation
and, vice versa, reversible thiol modifications may possibly alter
sensitivity of the enzyme to cardiotonic steroids. This hypothesis
awaits further investigations.
Local (renal) or systemic reduction in oxygen availability was
shown to trigger release of cardiotonic steroids (bufadienolides or
endogenous ouabain) into the circulation in rodents and humans
(Zhao et al., 1995; Bagrov et al., 1998; De Angelis and Haupert,
1998; Tian et al., 2010). Apart of the induction of cytoprotective
signaling pathway, endocytosis of Na,K-ATPase will support
reduction of ATP consumption by hypoxic tissue (De Angelis
and Haupert, 1998). Protective effect of distinct cardiotonic
steroids (low doses oleandrin for the brain and ouabain or
the heart) was reported for the brain and heart exposed
to ischemia-reperfusion (Pasdois et al., 2007; Van Kanegan
et al., 2014). Binding of ouabain in low doses to the ATPase
protects from toxicity of other cardiotonic steroids (Nesher
et al., 2010). Whereas micormolar doses of cardiotonic steroids
trigger Ca2+ overload and promote apoptosis (Winnicka et al.,
2007), nanomolar doses of some of these compounds stimulate
proliferation (Winnicka et al., 2010). This anti-apoptotic action
may be reflect the changes in affinity of the Na,K-ATPase-ouabain
complex to other proteins interacting with the Na,K-ATPase
such as PKC, BAX, and Bcl-2 (Lauf et al., 2015). Release of
them from the enzyme into the cytosol protects the cells from
apoptosis.
On the other hand endogenous ouabain andmarinobufagenin
act as powerful vasoconstrictors actively participating in
development of hypertension (Bagrov and Fedorova, 1998),
and have a potential to cause Ca2+ overload secondary to the
inhibition of the Na+ extrusion from hypoxic tissue (Schwinger
et al., 1999). At the moment, we clearly know too little about
the mechanisms of cytoprotection by cardiotonic steroids to use
them effectively as therapeutic agents avoiding deadly side-effects
(Washam et al., 2015).
THE ROLE OF ACUTE REGULATION OF
THE NA,K-ATPase IN ADAPTATION OR
IRREPARABLE DAMAGE AT LOW O2
LEVELS
As shown above, the capacity of the Na,K-ATPase to sense
and respond to the changes in oxygen availability is immensely
diverse withmultiple signaling cascades implicated in fine-tuning
of the enzyme’s activity apart and before terminal ATP depletion
is reached. The choice of signaling mechanism as well as the
resulting vector and amplitude of the change in the Na,K-
ATPase activity depends on the cell type, severity and duration
of hypoxia, and is rather species-specific. Strictly speaking, we
cannot refer to Na,K-ATPase as the “oxygen-sensitive” protein
as all the processes involved in its responding to hypoxia are
mediated by secondary products of O2 transformation to either
gaseous messengers or products of O2 reduction.
Several types of response to hypoxia include (i) inhibition
by thiol modifications (ii) modulation of the enzyme
function/availability at the membrane due to the changes
in phosphorylation, and (iii) interaction with nanomolar doses
of endogenous cardiotonic steroids.
Diversity of regulatory pathways allows for fine dose-
dependent regulation of the enzyme within minutes after the
alteration in O2 availability. Based on the current knowledge
the following scheme of responses may be suggested (Figure 4).
Following gradual deoxygenation NO availability in cells
expressing NOS1 and NOS2 becomes limited whereas O•−2
production by NADPH oxidases is maintained while pO2
is above 2–3 kPa (Kd for NOXes ∼ 2 kPa) (Pacher et al.,
2007). This is not the case for tissues in which NOS3 isoform
of NO synthase with high affinity for O2 prevails (such
as vascular endothelial cells). These conditions most likely
favor S-glutathionylation of β subunit that is associated with
activation of superoxide production by NOXes (White et al.,
2009) and α subunits of the Na,K-ATPase due to the gradual
accumulation of GSSG (Petrushanko et al., 2012). Further
decrease in oxygenation to 1–2 kPa supports uncoupling of
electron transfer and triggers mitochondrial O•−2 production
and accumulation of H2O2 in the cytosol. Oxidation of GSSG
becomes more pronounced and complete inactivation of the
enzyme may be achieved as soon as ATP levels decrease below
50 µM (Petrushanko et al., 2012). Further decrease in O2 to
0.2 kPa reduces S-glutathionylation and renders regulatory
thiols within the α subunit oxidized to sulfinic and sulfonic
acid making the enzyme insensitive to the changes in GSSG
and ONOO− (Petrushanko et al., 2015). Phosphorylation may
support or reduce the probability of complete reversible
inactivation by S-glutathionylation of the regulatory
cysteines by shifting the equilibrium between the E1 and
E2 conformation of the enzyme (see Section Oxygen-Sensitive
Phosphorylation).
Survival under hypoxic conditions implies that Na+ uptake
particularly high in excitable tissues is balanced with equally
efficient extrusion of Na+ by the pump (Hylland et al., 1997;
Nilsson, 2001). Inhibition of the Na,K-ATPase is deadly when
not synchronized with the closing of the cation channels
and cessation of activity of the animal (channel arrest) (Buck
and Hochachka, 1993; Hochachka et al., 1996; Hylland et al.,
1997; Silver et al., 1997; Nilsson, 2001; Ross et al., 2006;
Wilkie et al., 2008; Dave et al., 2009). If the Na,K-ATPase
is suppressed and the channels are not “arrested,” survival is
limited to the time of Na+/K+ gradients dissipation in the
brain and in the heart (Hylland et al., 1996, 1997; Silver
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FIGURE 4 | Schematic representation of O2-induced regulation of activity and abundance of Na,K-ATPase in majority of cells and tissues (for details
see the Section The role of acute regulation of the Na,K-ATPase in adaptation or irreparable damage at low O2 of levels of the review).
et al., 1997; Nilsson, 2001). It is tempting to assume that
the alterations in free radical production and reversible thiol
modifications are involved in the simultaneous regulation of
multiple ion transporting systems coupling their activity to
the mitochondrial function and ATP availability. However,
data providing direct support for this hypothesis are currently
missing.
The pilot studies suggest that preservation of redox state in
hypoxic heart is sufficient to maintain the Na,K-ATPase activity
in Spalax mole rate and trout supporting activity of both species
under conditions of critical O2 shortage for at least 20 min
(Yakushev et al., 2012). S-nitrosylation of the regulatory cysteine
residues in the α subunit may also prevent S-glutathionylation
and the enzyme inactivation by GSSG in myocardial membranes
(Petrushanko et al., 2012). Whether this is the case for some
or all anoxia-tolerant species (e.g., Hylland et al., 1997; Nilsson,
2001; Ross et al., 2006; Dave et al., 2009), remains to be
clarified.
Maintenance of the transmembrane Na+ gradients does
not only support neuronal function and heart contractility.
It also regulates intracellular Ca2+ by controlling the activity
of Na/Ca exchanger and that of voltage-gated Ca2+ channels.
Ca2+ transport pathways are by themselves targets regulated by
reversible thiol modifications in hypoxic cells (Lehotsky et al.,
2002; Wang and Zheng, 2010).
Recent data revealed the existence of intimate link between the
activity of the Na,K-ATPase and the gene expression in hypoxic
cells and tissues. Two factors that were recently suggested to
impact the gene expression under hypoxic conditions include
the shift in transmembrane Na/K gradients (Koltsova et al.,
2014) and the alteration in HIF1α levels upon binding of
the nanomolar concentrations of cardiotonic steroids to their
binding site within the Na,K-ATPase (Zhang et al., 2008; Cao
et al., 2014). Decrease in HIF1α in hypoxic cells (1% O2)
in the presence of <50 nM ouabain is not caused by its
degradation but rather by a drop in protein synthesis (Zhang
et al., 2008), most likely at the level of translation (Cao et al.,
2014). Alterations of HIF1α availability by cardiac glycosides
contributes to the modulation of long-term hypoxic responses
of the organism. For example digoxin treatment prevents
remodeling of pulmonary vasculature underlying development
of hypoxic pulmonary hypertension (Abud et al., 2012). It is
known that signaling cascades initiated by binding of low doses
of cardiotonic steroids to the Na,K-ATPase include modulation
of intracellular Ca2+ levels and free radical production as well
as activation of several kinases. Molecular mechanisms linking
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these processes to the regulation of HIF1α translation remain
unclear.
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Aging is associated with progressive white
adipose tissue (WAT) enlargement initiated early
in life, but the molecular mechanisms involved
remain unknown. Here we show that mitochondrial
complex IV (CIV) activity and assembly are
already repressed in white adipocytes of middle-
aged mice and involve a HIF1A-dependent decline
of essential CIV components such as COX5B. At
the molecular level, HIF1A binds to the Cox5b
proximal promoter and represses its expression.
Silencing of Cox5b decreased fatty acid oxidation
and promoted intracellular lipid accumulation.
Moreover, local in vivo Cox5b silencing in WAT of
young mice increased the size of adipocytes,
whereas restoration of COX5B expression in
aging mice counteracted adipocyte enlargement.
An age-dependent reduction in COX5B gene
expression was also found in human visceral adi-
pose tissue. Collectively, our findings establish a
pivotal role for CIV dysfunction in progressive
white adipocyte enlargement during aging, which
can be restored to alleviate age-dependent WAT
expansion.Cell Repo
This is an open access article under the CC BY-NINTRODUCTION
With a steadily increasing incidence, obesity has become the
leading medical disorder of the 21st Century. In particular, the
middle-aged population appears to be prone to obesity (Ng
et al., 2014; Ogden et al., 2013; van Harmelen et al., 2003).
Although the reasons for this remain largely enigmatic, several
factors are strongly implicated in the development of obesity,
such as sedentary lifestyle and poor dietary habits. Genetic
factors have also been suggested to control age-dependent
obesity. For example, hypothalamic pro-opiomelanocortin
neurons, which are involved in the regulation of food intake,
are progressively silenced during aging (Yang et al., 2012).
Most of the knowledge on fat development stems from experi-
mental studies in which white adipose tissue (WAT) expansion
occurs rapidly upon high-fat diet (HFD) feeding. The mecha-
nisms involved in progressive WAT expansion during aging,
however, remain mostly unidentified. Because obesity at a later
age predisposes to life-threatening conditions such as insulin
resistance, type 2 diabetes, and cardiovascular disease, under-
standing the causal molecular mechanisms of age-related
obesity may provide a strategy for treating these disorders.
One of the hallmarks of aging is the functional dysregulation of
mitochondria (Lo´pez-Otı´n et al., 2013), which constitute the
central metabolic hub in many cell types and are the gateway
to aerobic metabolism. Mitochondrial oxidative phosphorylation
is governed by the electron transport chain (ETC). Oxygen is therts 16, 2991–3002, September 13, 2016 ª 2016 The Authors. 2991
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
final electron acceptor in the ETC, and cytochrome c oxidase
(complex IV [CIV]), the terminal enzyme of the ETC, reduces it
to H2O after which energy is produced in the form of ATP by
the action of ATP synthase (Saraste, 1999). In mature white ad-
ipocytes, mitochondria have a central role in many processes,
such as ensuring energy generation through fatty acid b-oxida-
tion in the mitochondrial matrix (Kusminski and Scherer, 2012;
Villarroya et al., 2009). Aside from ATP production, mitochondria
generate the necessary metabolic intermediates for lipid synthe-
sis, thereby determining lipogenic potential (Kusminski and
Scherer, 2012). Moreover, mitochondrial activity in WAT is
associated with the release of several adipokines, including
adiponectin (Kim et al., 2007; Koh et al., 2007; Kusminski and
Scherer, 2012).
Aging has also been associated with increased adiposity early
in the lives of mice and humans (Gargiulo et al., 2014; Kuk et al.,
2009). However, it is unclear whether mitochondrial dysfunction
in WAT contributes to age-related adipocyte enlargement and
whether it can be restored to counteract age-dependent WAT
expansion. Here we report that adipocytes of early middle-
aged mice already exhibit mitochondrial dysfunction, which is
largely associated with a decline of mitochondrial CIV activity
and assembly. This decline in CIV activity involves a hypoxia-
inducible factor 1A (HIF1A)-dependent reduction of CIV compo-
nents, including cytochrome c oxidase subunit Vb (Cox5b).
Silencing of Cox5b is sufficient to promote a global decline of
CIV assembly, as well as decreased fat oxidation, and contrib-
utes to adipocyte enlargement during aging. Conversely, in vivo
restoration of COX5B expression counteracts age-dependent
white adipocyte enlargement. Collectively, our findings highlight
the potential of targeting mitochondrial CIV to reverse adipocyte
expansion during aging.
RESULTS
Selective Reduction of White Adipocyte Mitochondrial
CIV Activity during Age-Dependent Obesity
During aging, mouse body weight progressively increased from
31.7 ± 1.2 g (in 3- to 5-month-old mice) to 43.3 ± 3.7 g (8- to
11-month-old mice), indicating that molecular mechanisms
involved in age-dependent body weight gain are initiated early
in life. We therefore focused the study on those initiating events
of obesity in early middle-aged mice rather than in older mice.
Throughout this work, 3- to 5-month-old mice are called
‘‘young’’ mice and 8- to 11-month-old mice are termed ‘‘aging’’
mice. We used the term ‘‘aging’’ instead of ‘‘aged’’ or ‘‘old’’ in
this context to denote the process of progressively getting
older. Age-dependent weight gain was accompanied by a sig-
nificant increase in the size of adipocytes from epididymal WAT
(eWAT) (Figures 1A, 1B, and S1), a visceral WAT depot with a
remarkable expansion capacity during aging and a major risk
factor for metabolic disease (Rosen and Spiegelman, 2014).
To investigate the molecular mechanisms underlying age-
dependent WAT enlargement, we focused on mitochondria
because of their emerging fundamental role in white adipocyte
biology (Bournat and Brown, 2010; Kusminski and Scherer,
2012; Rosen and Spiegelman, 2014; Villarroya et al., 2009)
and in aging (Lo´pez-Otı´n et al., 2013). Although mitochondrial2992 Cell Reports 16, 2991–3002, September 13, 2016content of eWAT adipocytes was similar between young and
aging mice (Figure 1C), the oxygen consumption rate (OCR)
and ATP turnover were significantly lower in eWAT of aging
mice (Figures 1D and 1E). More detailed mitochondrial activity
analysis revealed a significant decline of CIV activity in aging
white adipocytes, whereas complex I, II, I+III, and II+III activities
remained unchanged (Figure 1F). Furthermore, western blot
analysis showed that the protein levels of representative CIV
subunits, such as COX5B, NDUFA4, and mt-CO1, were signif-
icantly lower in aging than in young adipocytes (Figures 1G and
1H). By contrast, protein expression levels of NADH dehydro-
genase (ubiquinone) 1 alpha subcomplex 9 (NDUFA9; complex
I), succinate dehydrogenase complex, subunit A, flavoprotein
(Fp) (SDHA; complex II), ubiquinol-cytochrome c reductase
core protein 1 (UQCRC1; complex III), and mitochondrial
voltage-dependent anion channel 1 (VDAC1) were not signifi-
cantly changed (Figures 1G and 1H). These data show that
while mitochondrial oxygen consumption is reduced in aging
eWAT, not all mitochondrial complexes are equally affected
during this process, and mitochondrial CIV is specifically
repressed.
HIF1A Promotes Age-Dependent eWAT Expansion and a
Reduction of CIV Expression
To investigate the molecular mechanisms involved in age-
dependent regulation of mitochondrial CIV and adipocyte
enlargement, we focused on HIF1A because previous studies
have demonstrated its activation in aged tissues (Gomes et al.,
2013; Gonza´lez-Rodrı´guez et al., 2012). Although these studies
were performed at later stages during the lifespan of the mouse,
we wondered whether HIF1A is already expressed in WAT of
aging mice (8- to 11-month-old mice). Western blot analysis
confirmed that the steady-state levels of HIF1A in eWAT were
higher in aging than in young mice (Figure 2A), and this was
not seen in other tissues, such as brown adipose tissue or liver
(Figure S2A). We therefore questioned whether HIF1A could
drive age-dependent white adipocyte enlargement. To do this,
we generated mice with global or adipocyte-restricted Hif1a
gene deficiency using transgenic mice expressing ubiquitin-
Cre-ERT2 (Hif1aDUbq) or adiponectin-Cre-ERT2 (Hif1aDAdipo),
respectively (Figures S2B and S2F). Aging Hif1aDUbq and
Hif1aDAdipo mice gained significantly less body weight (Figures
S2D, S2E, S2G, and S2H) and had smaller eWAT adipocytes
(Figures 2B, 2C, and S2C) under normal dietary conditions
than aging control mice, suggesting that adipocyte HIF1A drives
age-dependent obesity.
Given that HIF1A functions as a transcription factor that can
also be involved in gene repression (Eltzschig et al., 2005;
Gordan et al., 2007; Krishnan et al., 2012), we next evaluated
the possibility that the expression of nuclear-encoded CIV
gene transcripts was repressed in aging adipocytes in a
HIF1A-dependent manner. By RT-PCR analysis, we found
that the levels of Cox5b, Cox6a, Cox6c, and Cox8a mRNA
were all significantly lower in aging adipocytes than in young
adipocytes, whereas the mRNA expression level of other
CIV subunits was unaffected (Figure S2I). In addition, only
Cox5b and Cox8a mRNA levels were restored in Hif1a-defi-
cient adipocytes (Figure 2D). Only a few CIV genes were
Figure 1. Mitochondrial CIV Activity Is Spe-
cifically Decreased during Age-Dependent
Obesity in White Adipocytes
(A and B) Average adipocyte area (A) and adipocyte
size frequency (B) distribution in young mice (n = 7)
and aging mice (n = 5).
(C) Mitochondrial content in isolated white adipo-
cytes of young mice (n = 4) and aging mice (n = 5).
(D) Mitochondrial OCR in eWAT from young mice
(n = 6) and aging mice (n = 7). OCR was measured
after sequential addition of glutamate and malate
(Glut + Mal, State 4), ADP (Glut + Mal, State 3),
succinate (Glut + Mal + Succ, State 3), and oligo-
mycin (Glut + Mal + Succ, State 4).
(E)Mitochondrial OCRcoupled to ATP synthesis (or
ATP turnover) in eWAT from young mice (n = 6) and
aging mice (n = 7).
(F) Activities of the indicated mitochondrial ETC
complexes were measured in isolated white
adipocytes of young mice (n = 6) and aging mice
(n = 10).
(G and H) Western blot analysis (G) and quantifi-
cation of the indicatedmitochondrial subunits (H) in
isolated white adipocytes of young mice (n = 12)
and aging mice (n = 10). Protein expression was
normalized to VDAC1.
In bar graphs, values represent mean ± SEM (error
bars). In box and whiskers plots, vertical lines
connect the minimum and the maximum values.
Statistical significance was assessed with a
two-tailed t test (*p < 0.05; **p < 0.01; ***p < 0.001;
NS, not significant). See also Figure S1.affected by aging, which was surprising because our analysis
of protein content of other representative subunits, such as
NDUFA4 or mt-CO1 (Figures 1G and 1H), indicated a more
global repression in aging adipocytes. The protein content of
NDUFA4 and mt-CO1 was restored by Hif1a deletion (Fig-
ure 2E), suggesting that HIF1A-dependent repression of
Cox5b and Cox8a mRNAs could lead to reduced protein con-
tent of other mitochondrial CIV subunits in aging adipocytes.
In this respect, it has been previously shown in a macrophage
cell line that Cox5b silencing is sufficient to promote global
CIV dysfunction by reducing the protein stability of other CIVCell Reportscomponents (Galati et al., 2009). To
test whether COX5B and COX8A control
CIV stability in adipocytes, we silenced
both in 3T3-L1 cells (Figure 3A) and
found reduced protein levels of the mito-
chondrial CIV subunits NDUFA4 and
mt-CO1 (Figure 3B). Moreover, silencing
of Cox5b resulted in a profound decline
of both CIV activity and CIV assembly
(Figures 3C and 3D). The ability of
COX5B to regulate CIV stability was
dose dependent, because silencing
Cox5b by 90% (as occurred in clone
#2) resulted in a stronger inhibition of
CIV assembly and activity than that
observed when Cox5b was reduced by60%–70% (as occurred in clone #1) (Figures 3C and 3D). In
addition, robust silencing of Cox8a mRNA (90%–95%)
reduced mitochondrial CIV activity and assembly, but to a
lesser extent than that observed for Cox5b silencing (Figures
3C and 3D). In agreement with these data, CIV assembly
was also reduced in aging adipocytes (Figures 3E and 3F).
Collectively, these data show a global decline of CIV in aging
white adipocytes that is characterized by repression of CIV
activity and assembly. This CIV dysfunction could be initiated
by repressing Cox5b, as well as Cox8a, through HIF1A stabiliza-
tion during WAT expansion.16, 2991–3002, September 13, 2016 2993
Figure 2. HIF1A Promotes Age-Dependent
Complex IV Decline Associated with eWAT
Expansion
(A) Representative western blot analysis and
quantification of HIF1A in eWAT from young and
aging mice.
(B) Average adipocyte size in Hif1aDAdipo mice (n =
6) andHif1afloxed control mice (n = 8) at the age of 8–
10 months.
(C) Adipocyte area frequency distribution analysis
in Hif1aDAdipo mice (n = 6) and control mice (n = 8) at
the age of 8–10 months.
(D) mRNA expression levels of Cox5b, Cox8a,
Cox6c, and Cox6a1 in isolated adipocytes of Hi-
f1aDAdipo mice (n = 6) and Hif1afloxed control mice
(n = 5) at the age of 8–10 months.
(E) Western blot analysis of CIV subunits (COX5B,
NDUFA4, and mt-CO1) in isolated adipocytes of
Hif1aDUbq mice and control mice (control).
In bar graphs, values represent mean ± SEM (error
bars). In box and whiskers plots, vertical lines
connect the minimum and the maximum values.
Statistical significance was assessed with a two-
tailed t test (*p < 0.05; **p < 0.01; ***p < 0.001; NS,
not significant). See also Figure S2.HIF1A Binds the Cox5b Proximal Promoter
We next examined the molecular link between HIF1A and CIV
gene expression, focusing our analysis on Cox5b and Cox8a.
Previous studies have reported a HIF1A-dependent repression
of some genes following the binding of HIF1A to their DNA regu-
latory regions (Eltzschig et al., 2005; Krishnan et al., 2012). We
therefore first assessed the presence of HIF1A binding activity
in the DNA regulatory regions of Cox5b and Cox8a (Dhar et al.,
2008). Sequence analysis revealed potential HIF1A binding sites
from 93 to 97 positions (Figure 4A) and from 760 to 756
positions (Figure S3A) of murine Cox5b and Cox8a DNA regula-
tory regions, respectively. Chromatin immunoprecipitation
(ChIP) using an anti-HIF1A antibody confirmed the binding of
HIF1A to the Cox5b proximal promoter region in 3T3-L1 cells
exposed to hypoxia (Figure 4B). Moreover, binding of HIF1A
was specific to this region, because it was not detected with
oligonucleotides directed to amplify a distal region of the
Cox5b promoter or the Cox8a proximal promoter (Figures 4A,
4B, S3A, and S3B). Consistent with HIF1A binding to this region,
expression of Cox5bmRNA was significantly reduced in 3T3-L1
cells under hypoxia (Figure 4C), whereas the mRNA of the prolyl
hydroxylase domain enzyme 3 (Phd3), a well-characterized HIF-
inducible gene, was increased (Figure S3C). To validate the role
of HIF1A in Cox5b gene repression, we used Hif1a-deficient
murine embryonic fibroblasts (MEFs). We first confirmed that
repression of Cox5b gene expression occurred in wild-type
MEF exposed to hypoxia (Figure 4D), whereas Phd3 expression2994 Cell Reports 16, 2991–3002, September 13, 2016was elevated (Figure S3D). Moreover,
activation of the HIF pathway with
dimethyloxaloylglycine (DMOG), a com-
petitive inhibitor of prolyl hydroxylase
oxygen sensors, reduced Cox5b gene
expression in MEF (Figure 4E). As ex-pected, Cox5b gene repression by hypoxia or DMOG treatment
was markedly attenuated in Hif1a-deficient MEF (Figures 4D
and 4E), strongly suggesting that HIF1A acts as a transcriptional
repressor of Cox5b. As a positive control, the expression of
Phd3 was less evident in Hif1a-deficient MEF (Figures S3D
and S3E).
Overall, these data indicate thatCox5b repression is a primary
event that occurs upon HIF1A stabilization in aging adipocytes.
We therefore further explored the role of CIV in the control of
adipocyte size during aging by modifying white adipocyte
COX5B expression.
Mitochondrial CIV Inhibition through Silencing of Cox5b
Promotes Intracellular Lipid Accumulation and White
Adipocyte Enlargement
We next determined whether COX5B-dependent mitochondrial
CIV repression controls lipid accumulation and age-dependent
adipocyte size enlargement. To evaluate intracellular lipid accu-
mulation, 3T3-L1-shCOX5B (small hairpin COX5B RNA) cells
and control cells were stained with Nile red and intracellular
lipids were measured by flow cytometry. Lipid content was
higher in 3T3-L1-shCOX5B cells than in control cells (Figures
5A and S4A), suggesting that a reduction in CIV activity
by Cox5b silencing is sufficient to promote lipid storage. To
confirm this finding, 3T3-L1-shSCR (small hairpin scrambled
RNA) control cells were treated with sodium azide, a well-es-
tablished pharmacological inhibitor of CIV. Azide treatment
Figure 3. Comparative Analysis of Cox5b and
Cox8a Silencing Effects on CIV Activity and
Assembly
(A) Left panel: mRNA expression of Cox5b in 3T3-
L1-shCOX5B cells using two shRNA sequences:
clone 1 (#1) and clone 2 (#2) relative to 3T3-L1-
shSCR control cells (n = 4 independent experi-
ments). Right panel: mRNA expression of Cox8a
in 3T3-L1-shCOX8A cells using two shRNA se-
quences: clone 1 (#1) and clone 2 (#2) relative to
3T3-L1-pLKO control cells (n = 3 independent
experiments).
(B) Western blot analysis of the indicated mito-
chondrial ETC subunits in 3T3-L1-shCOX5B and
3T3-L1-shCOX8A cells and their respective
controls.
(C) CIV activity in 3T3-L1-shCOX5B cells and 3T3-
L1-shCOX8A cells and their respective controls.
(D) Blue native-PAGE western blot analysis showing
mitochondrial complexes and super-complexes in
3T3-L1-shCOX5B and 3T3-L1-shCOX8A cells
and their respective controls. UQCRC2 or mt-CO1
antibody was used to identify complex III or IV
assembly.
(E and F) Representative images (E) and quantifica-
tion (F) of blue native-PAGE analysis of mitochon-
drial complex III and IV assembly using UQCRC2 or
mt-CO1, respectively, in isolated adipocytes of
young mice (n = 8) and aging mice (n = 8).
In bar graphs, values represent mean ± SEM (error
bars). Statistical significance was assessed with a
two-tailed t test (*p < 0.05; **p < 0.01; ***p < 0.001;
NS, not significant).also increased the Nile red signal intensity in 3T3-L1-shSCR
control cells (Figure 5A). Because increased fat accumulation
has been associated with reduced fatty acid oxidation (Kusmin-
ski and Scherer, 2012; Vernochet et al., 2012), we also
measured fatty acid oxidation in Cox5b-silenced cells. Both
3T3-L1-shCOX5B cells and azide-treated 3T3-L1-shSCR cells
presented significantly reduced fatty acid oxidation when
compared with control cells (Figure 5B). Furthermore, consis-
tent with aging adipocytes, Cox5b silencing in 3T3-L1 cells
reduced oxygen consumption and ATP turnover (Figures 5C,
5D, S4B, and S4C). Collectively, these data suggest that
repression of Cox5b leads to the attenuation of mitochondrial
CIV activity, which is sufficient to reduce fatty acid oxidation
and promote intracellular lipid accumulation.
We next asked whether Cox5b silencing in young mice would
promote white adipocyte enlargement in vivo. We therefore in-
jected lentiviral shCOX5B particles into the right eWAT depot
of young wild-type mice, while the left contralateral eWAT depot
remained uninjected and served as an internal control (Fig-
ure 6A). An identical protocol was used for control shSCR parti-
cles (Figure 6A). Injection of shCOX5B particles significantlyCell Reportreduced the ratio of Cox5b mRNA levels
in the injected to non-injected eWAT depot
when compared with shSCR mice (Fig-
ure 6B), which was concomitant with a
significant increase in the adipocyte sizeratio (Figure 6C). Moreover, analysis of adipocyte size distribu-
tion revealed that shCOX5B-injected eWAT depots contained a
greater proportion of large adipocytes and a smaller proportion
of small adipocytes than shSCR-injected depots (Figure 6D).
No significant differences were found in the contralateral non-in-
jected depots (Figure S5A). Thus, the reduction of COX5B
expression in the eWAT of young mice drives white adipocyte
enlargement, indicating that Cox5b repression is an important
determinant of eWAT adipocyte size.
In vivo COX5B Restoration Attenuates Adipocyte Size
Enlargement in Aging Mice
These findings prompted us to evaluate whether restoration of
COX5B expression could be exploited as a potential molecular
target to prevent age-dependent adipocyte enlargement. To
do this, we first validated that overexpression of COX5B protein
is sufficient to increase mitochondrial CIV activity. Ectopic over-
expression of COX5B protein in HEK293T cells (Figure S5B)
increased mitochondrial CIV activity (Figure S5C). Next, lentiviral
particles overexpressing COX5B were injected into the right
eWAT depot of aging mice, while the left contralateral viscerals 16, 2991–3002, September 13, 2016 2995
Figure 4. HIF1A Binds to theCox5b Proximal
Promoter
(A) Schematic representation of the mouse Cox5b
gene and its promoter region, indicating the posi-
tion of the HIF1A binding site in bold.
(B) ChIP assay to assess the relative HIF1A binding
activity to themouseCox5b proximal promoter and
distal region in 3T3-L1 cells exposed to normoxia
or hypoxia 0.5% for 18–20 hr (n = 7 independent
experiments). A representative gel showing DNA
amplified in the ChIP assays is shown in the lower
panel.
(C) Cox5b mRNA expression levels in 3T3-L1 cells
exposed to normoxia or hypoxia 0.5% for 72 hr
(n = 4 independent experiments).
(D) Cox5b mRNA expression levels in control or
Hif1afl/fl MEF exposed to normoxia or hypoxia
0.5% for 48 hr (n = 4 independent experiments).
(E) Cox5b mRNA expression levels in control or
Hif1afl/fl MEF under normoxia or 48 hr after 0.5 mM
DMOG treatment (n = 4 independent experiments).
In bar graphs, values represent mean ± SEM (error
bars). Statistical significance was assessed with a
two-tailed t test (*p < 0.05; **p < 0.01). See also
Figure S3.eWAT depot remained uninjected (Figure 6E). An identical
protocol was used for control empty vector particles (Figure 6E).
Injection of COX5B-expressing lentiviral particles significantly
increased the ratio of Cox5b mRNA levels in the injected to
non-injected eWAT depot when compared with empty vector
mice (Figure 6F) and significantly decreased the adipocyte size
(Figure 6G). Adipocyte size distribution analysis revealed a
greater proportion of small adipocytes and a reduced proportion
of large adipocytes in COX5B-injected eWAT depots when
compared with the empty vector-injected eWAT depots (Fig-
ure 6H), whereas no significant differences were observed in
the corresponding non-injected contralateral eWAT depots
(Figure S5D).
These in vivo data demonstrate that restoring COX5B expres-
sion in visceral eWAT is sufficient to attenuate adipocyte
enlargement in aging mice, underscoring the relevance of
COX5B to control age-dependent adipocyte size.2996 Cell Reports 16, 2991–3002, September 13, 2016Human WAT COX5B Expression
Correlates Negatively with Age and
Serves as a Prognostic Factor for
Weight Loss after Bariatric Surgery
Finally, to explore the potential relevance
of our findings in humans, we measured
COX5B expression in human visceral adi-
pose tissue (VAT) during aging in a cohort
of subjects with a range of adiposity
(anthropometric and clinical parameters
are described in the Experimental Proced-
ures section). We found that COX5B
mRNA levels correlated negatively with
age in this cohort (Figure 7A), which per-
sisted after controlling for BMI in multiple
linear regression analysis (Figure 7B).Expression of the mitochondrial marker VDAC1 was not associ-
ated with age in this cohort (Figures 7C and 7D), suggesting that
the decrease in COX5B expression was not attributable to an
overall decrease in the expression ofmitochondrial components.
Thus, the expression of COX5B is highly vulnerable to visceral
WAT aging, not only in mice but also in human VAT.
We also investigated the clinical value of our findings. Post-
bariatric surgery weight reduction shows great disparities
among individuals (Lutfi et al., 2006; Maggard et al., 2005), and
age has been shown to be a prognostic factor (Scozzari et al.,
2012). We therefore asked whetherCOX5B in WATmight predict
long-term weight loss in humans after bariatric surgery. We
found that subcutaneous white adipose tissue (SAT) COX5B
levels negatively correlated with BMI 1 year after bariatric
surgery (Figure 7E), whereas VDAC1 showed the opposite
trend (Figure 7F). Patients with higher COX5B levels had a lower
BMI 1 year after bariatric surgery (Figure 7E), underlining the
Figure 5. Mitochondrial CIV Inhibition and
Cox5b Silencing Results in Intracellular Lipid
Storage In Vitro and Decreases Mitochon-
drial Respiration
(A) Nile red fluorescence intensity in 3T3-L1-
shCOX5B #2 cells, 3T3-L1-shSCR control cells,
and 3T3-L1-shSCR control cells treated with 5 mM
azide. A representative experiment out of seven
independent experiments is shown.
(B) Fatty acid oxidation in 3T3-L1-shCOX5B #2
cells (n = 6), 3T3-L1-shSCR control cells (n = 5), and
3T3-L1-shSCR control cells treated with 5 mM
azide (n = 6).
(C) Mitochondrial OCR in 3T3-L1-shCOX5B #2
cells, 3T3-L1-shSCR control cells, and 3T3-L1-
shSCR control cells treated with 5mMazide (n = 6).
(D) ATP turnover in 3T3-L1-shCOX5B #2 cells, 3T3-
L1-shSCR control cells, and 3T3-L1-shSCR control
cells treated with 5 mM azide (n = 6).
In bar graphs, values represent mean ± SEM (error
bars). Statistical significance was assessed with a
two-tailed t test (*p < 0.05; **p < 0.01; ***p < 0.001).
See also Figure S4.translational relevance and clinical value of COX5B measure-
ments in SAT. Moreover, SAT samples can be gathered using
a minimally invasive biopsy technique (Campbell et al., 2009),
which also supports the clinical relevance of measuring COX5B.
Overall, our data show that repression of mitochondrial CIV
activity is an early sign of age-dependent mitochondrial dysfunc-
tion in white adipocytes that drivesWAT expansion during aging.
Moreover, these data highlight the potential of CIV restoration to
prevent increased adipocyte size enlargement during aging.
DISCUSSION
Aging is associated with increased adiposity early in life (Gar-
giulo et al., 2014; Kuk et al., 2009), suggesting that the molecular
mechanisms underlying age-dependent WAT expansion should
be initiated at an early stage of the lifetime. This is in contrast to
other molecular alterations associated with aging, which are
usually studied in very old mice (22- to 30-month-old mice)
(Gomes et al., 2013; Houtkooper et al., 2011). Our study shows
that mitochondrial CIV activity is specifically compromised in
white adipocytes in early phases during aging (8- to 11-month-
old mice), although the activity of other mitochondrial com-
plexes, as well as mitochondrial content, are unaltered. There-
fore, our study identifies WAT CIV dysfunction as an early sign
of aging in white adipocytes that manifests in middle-aged
mice, which leads to progressive age-dependent body weight
gain during the lifetime.
Previous studies have demonstrated that mitochondrial activ-
ity is globally repressed in more severe models of obesity.
Accordingly, mice subjected to HFD and mice with altered leptin
signaling, such as ob/ob and db/db mice, show a significant
decline in mitochondrial content in WAT (Choo et al., 2006;
Rong et al., 2007; Sutherland et al., 2008; Valerio et al., 2006).
It is possible that these settings, which are different from age-dependent obesity, have specific features that provoke global
mitochondrial dysfunction in white adipocytes. The reasons for
these differences are unclear, but one possible explanation is
the excessive nutrient supply in HFD models. Several studies
have shown that high levels of nutrients, including free fatty
acids, lead to global mitochondrial dysfunction through diverse
mechanisms, including oxidative stress and production of in-
flammatory cytokines (Gao et al., 2010; Kusminski and Scherer,
2012; Sutherland et al., 2008; Valerio et al., 2006). It is therefore
conceivable that global mitochondrial dysfunction, including a
decrease in mitochondrial content, is a general response to a
pathological WAT scenario that is more characterized by nutrient
overload. Presumably, this nutrient surplus occurs to a lesser de-
gree, or maybe absent, during age-dependent WAT expansion.
Along this line, human studies have shown that mitochondrial
content is not consistently repressed in obese subjects (Kaaman
et al., 2007; Lindinger et al., 2010; Yin et al., 2014). Lindinger et al.
(2010) described a trend for reduced mtDNA content in diabetic
obese patients but not in non-diabetic obese patients. In this re-
gard, our present data in human VAT show that the expression of
the mitochondrial marker VDAC1 is not affected during aging,
whereas the expression of COX5B is significantly repressed,
indicating that aging can promote specific mitochondrial alter-
ations in VAT. Furthermore, we show the prognostic potential
of COX5B measurements in WAT, because patients with higher
COX5B levels have lower BMI 1 year after bariatric surgery.
These data are in accordance with a study showing that younger
patients experienced a significantly greater and prolonged BMI
decrease after surgery (Scozzari et al., 2012).
Previous studies have detected hypoxia in WAT under normal
dietary conditions, based on pimonidazole staining (Hosogai
et al., 2007; Lee et al., 2011; Ye et al., 2007). These data might
explain the basal HIF1A expression observed in WAT of young
mice (Figure 2A) (Krishnan et al., 2012; Lee et al., 2014; YinCell Reports 16, 2991–3002, September 13, 2016 2997
Figure 6. Opposing Effects of In Vivo
Silencing and Restoration of Cox5b Expres-
sion in eWAT
(A) Schematic representation of eWAT injection of
shSCR and shCOX5B lentiviral particles in mice.
(B) Ratio of Cox5b mRNA expression levels in in-
jected to non-injected eWAT depots of shCOX5B
mice (n = 4) and shSCR mice (n = 4). Fold change
relative to shSCR is shown.
(C) Ratio of average adipocyte size in injected to
non-injected eWAT depot of shCOX5B mice (n = 4)
and shSCR mice (n = 4). Fold change relative to
shSCR is shown.
(D) Adipocyte area frequency distribution analysis
in shCOX5B (n = 4) and shSCR (n = 4) injected
depots.
(E) Schematic representation of eWAT injection of
COX5B and empty vector lentiviral particles in
mice.
(F) Ratio of Cox5b mRNA expression in injected to
non-injected eWAT depot of COX5B mice (n = 4)
and empty vector mice (n = 5). Fold change relative
to empty vector is shown.
(G) Ratio of average adipocyte size in injected to
non-injected eWAT depots of COX5B mice (n = 4)
and empty vector mice (n = 4). Fold change relative
to empty vector is shown.
(H) Adipocyte area frequency distribution analysis
in COX5B (n = 4) and empty vector (n = 4) injected
depots.
In bar graphs, values represent mean ± SEM (error
bars). Statistical significance was assessed with a
two-tailed t test (*p < 0.05; **p < 0.01). See also
Figure S5.et al., 2009), which drives CIV repression and subsequent fat
accumulation during aging. This latter contention is in line with
a previous study showing that adipocyte-restricted inactivation
of Arnt, a transcription factor with multiple partners, including
HIF1A, counteracts age-dependent body weight gain (Lee
et al., 2011). In addition, adipocyte-restricted Hif1a gene inacti-
vation counteracts pathological WAT expansion in HFD-fed
mice (Jiang et al., 2011; Krishnan et al., 2012; Lee et al., 2011,
2014). Regarding the molecular mechanisms executed by
HIF1A leading to age-dependent white adipocyte enlargement,
we found that HIF1A represses Cox5b and Cox8a gene expres-
sion. Previous studies have reported HIF1A-dependent gene
repression associated with the binding of HIF1A to DNA regula-
tory regions of target genes (Eltzschig et al., 2005; Krishnan et al.,
2012). In the present study, we found that hypoxia inducesHIF1A
binding to the Cox5b proximal promoter, which was associated2998 Cell Reports 16, 2991–3002, September 13, 2016with Cox5b repression. This promoter re-
gion has been previously shown to sustain
Cox5b gene expression through NRF1
transcription factors (Dhar et al., 2008),
suggesting that HIF1A could interfere
with its basal activity. By contrast,
although we acknowledge that HIF1A-
dependent Cox8a repression can poten-
tially cooperate with Cox5b to reduceCIV activity in aging adipocytes, we did not find HIF1A binding
activity at the Cox8a proximal promoter, suggesting that HIF1A
could drive Cox8a repression by indirect mechanisms, as
described for other target genes repressed by HIF1A (Chan
et al., 2009). Our analysis also shows that Cox6a and Cox6c
expression in white adipocytes declined during age-dependent
body weight gain but was not restored upon Hif1a deletion in
aging adipocytes, suggesting that their regulation is executed
by other hypoxia-dependent pathways (Sena and Chandel,
2012) or as a consequence of fat accumulation (Lee et al.,
2014). A previous study has shown that HIF1A induces a
COX4.2/COX4.1 switch to protect cells against hypoxia-induced
reactive oxygen species (ROS) by optimizing respiration effi-
ciency (Fukuda et al., 2007). However, we have not found evi-
dence of this metabolic adaptation in aging WAT, suggesting
that perhaps this switch is not operative in white adipocytes or
Figure 7. Age-Dependent Repression of COX5B Gene Expression in Human VAT and COX5B as a Prognostic Factor in Bariatric Surgery
(A–D) Boxplots showing log COX5B (A) or VDAC (C) gene expression in human VAT with increasing age quartiles (see Experimental Procedures); vertical lines
connect the minimum and the maximum values (n = 24). Linear correlation analysis of the association between COX5B (B) or VDAC (D) gene expression in human
VAT and age. Results remained significant after adjusting for Deuremberg-calculated fat mass instead of BMI.
(E and F) Linear correlation analysis of the association between COX5B (E) or VDAC (F) gene expression in human subcutaneous white adipose tissue (SAT) and
BMI 1 year after bariatric surgery (n = 31).
Differences in human gene expression across age quartiles were evaluated with one-way ANOVA (*p < 0.05; NS, not significant). Linear association between gene
expression and age or BMI was evaluated with Spearman’s rank test.
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it requires a more robust activation of HIF1A than that observed
in aging adipocytes in vivo. Collectively, our data suggest that
HIF1A-dependent repression of Cox5b expression can be
considered a primary event, leading to a more global CIV decline
because of the central role of COX5B in CIV stability, and further
establish a molecular link between HIF1A and CIV, wherein
HIF1A acts as a global repressor of CIV expression in white
adipocytes.
Adipocyte-restricted inactivation and overexpression of key
genes involved in mitochondrial biogenesis and activity is funda-
mental to better understand the role ofmitochondria in adipocyte
biology. It has been hypothesized that inactivation of these
genes would reduce mitochondrial activity, leading to intracel-
lular accumulation of lipids that cannot be oxidized (Kusminski
et al., 2012; Vernochet et al., 2012, 2014). For example, reduced
adipocyte mitochondrial activity and increased adipocyte size
was detected in mice with adipose tissue-restricted overexpres-
sion of mitoNEET, an iron-sulfur protein that inhibits mitochon-
drial iron transport into the matrix and lowers the rate of b-oxida-
tion (Kusminski et al., 2012). However, other studies have shown
that adipocyte-restricted inactivation of the mitochondrial tran-
scription factor A (TFAM), which is essential for maintenance of
mtDNA, does not lead to increased adiposity because of an
unanticipated compensatory response leading to increased
mitochondrial oxygen consumption and uncoupling (Vernochet
et al., 2012). Moreover, a second mouse model in which Tfam
was inactivated in adipose tissue to a greater extent revealed a
profound and global dysfunction of mitochondria, resulting in
adipocyte death and subsequent lipodystrophy (Vernochet
et al., 2014). In contrast to these studies, our data indicate that
mitochondrial CIV dysfunction through Cox5b repression is suf-
ficient to drive intracellular lipid accumulation. Our data suggest
that a decline in COX5B protein content cannot be followed by
compensatory mitochondrial overactivation or adipocyte death
and culminates in enhanced adipocyte lipid content. Therefore,
it is possible that during age-dependent body weight gain,
repression of Cox5b guarantees enhanced lipid storage without
these secondary compensatory effects on mitochondrial activity
or adipocyte death.
In summary, our data establish mitochondrial CIV, and partic-
ularly COX5B, as a vulnerable mitochondrial component during
visceral WAT aging in mice and humans. Cox5b repression is
mediated by the HIF1A pathway and is sufficient to promote
age-dependent white adipocyte enlargement. Moreover, our
findings highlight the potential of COX5B restoration in visceral
WAT to counteract age-dependent adipocyte expansion.EXPERIMENTAL PROCEDURES
White Adipocyte Isolation
Epididymal fat pads were removed, minced, and digested using collagenase
type II (Calbiochem) at 37C for 1 hr in Krebs-Ringer-HEPES-bicarbonate
(KRH) buffer supplemented with BSA (3.5%; Roche). The digested tissue
was filtered through a 100 mm cell strainer (BD Falcon), and the floating adipo-
cytes were recovered and used for RNA or protein extraction.
Mitochondrial Content
Relative concentrations of nuclear DNA and mtDNA were determined by
RT-PCR. In brief, DNA was isolated from adipocytes using UltraPure phenol:3000 Cell Reports 16, 2991–3002, September 13, 2016chlorofom:isoamyl alcohol (25:24:1; Invitrogen) after proteinase K (Ambion)
digestion at 56C overnight. Nuclear DNA and mtDNA were measured using
a Power SYBRGreen PCRMaster Mix kit (Applied Biosystems). The amplifica-
tion data were analyzed using StepOne Software v.2.0 (Applied Biosystems).
The following primer sets were used: Genomic Hprt: forward 50-TGGGAGGC
CATCACATTGT-30; reverse 50-TCCAGCAGGTCAGCAAAGAA-30. Genomic
mt-Co1: forward 50-GCTAGCCGCAGGCATTACTATAC-30; reverse 50-GCG
GGATCAAAGAAAGTTGTG-30.
Viral Injection In Vivo
Micewere anesthetized by isoflurane (Abbott) before dissection of the skin and
body wall. The lentiviral preparation (1 3 107–8 plaque-forming units in a
volume of 100 ml) was injected into the right eWAT depot distributed in four
to six injections of 20–25 ml (each mouse was injected with 100–150 ml of
lentiviral preparation). The left contralateral eWAT depot remained uninjected
and served as an internal control. Separate mice were injected with different
lentiviral particles. Mice injected with virus containing small hairpin RNA
(shRNA) against Cox5b were sacrificed 2–3 weeks after surgery, and the tis-
sues of interest were removed. Mice injected with virus containing overex-
pressing COX5B were sacrificed 5–6 weeks after surgery, and the tissues of
interest were removed. Mice were randomly allocated to the treatment groups
(shSCR group versus shCOX5B group, as well as empty vector group versus
COX5B group).
Histological Analysis
Adipose tissue from eWAT depots was isolated and fixed for at least 24 hr in
4%–10% formaldehyde before embedding in paraffin. Sections (5–7 mm; Leica
RM2135 microtome) were subjected to standard H&E staining and analyzed
using CellD Olympus software (Olympus). At least 200 adipocytes per mouse
were analyzed for adipocyte surface area measurement. For adipocyte size
quantification in eWAT of injected or non-injected mice, Hif1aDAdipo or control
mice, and young or aging mice, the investigator was blinded to the group
allocation.
Statistical Analysis
Data are expressed as mean ± SEM (error bars). In box and whiskers
plots, vertical lines connect the minimum and the maximum values. All
statistical analyses were performed using GraphPad Prism software, and
differences between groups with similar variances were analyzed with a
two-tailed t test. When variances of the groups were significantly different, a
two-tailed t test with Welch’s correction was used. Differences between
variances of the groups were analyzed with the Fisher test (F-test). A p value
lower than 0.05 was considered significant: *p < 0.05, **p < 0.01, and ***p <
0.001. Differences in human gene expression factors across age quartiles
were evaluated using one-way ANOVA. Linear association between gene
expression factors and age was evaluated using Spearman’s rank test.
A multiple linear regression analysis in a stepwise procedure was used to
adjust for BMI. Deuremberg-calculated fat mass was evaluated using the
following formula: percent fat mass = 1.2 3 (BMI) + 0.23 3 (age (years)) 
10.8 3 (sex)  5.4, where sex = 0 in women and sex = 1 in men.
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Abstract
Significance: In the immune system, nitric oxide (NO) has been mainly associated with antibacterial defenses
exerted through oxidative, nitrosative, and nitrative stress and signal transduction through cyclic GMP-de-
pendent mechanisms. However, S-nitrosylation is emerging as a post-translational modification (PTM) involved
in NO-mediated cell signaling. Recent Advances: Precise roles for S-nitrosylation in signaling pathways have
been described both for innate and adaptive immunity. Denitrosylation may protect macrophages from their
own S-nitrosylation, while maintaining nitrosative stress compartmentalized in the phagosomes. Nitrosothiols
have also been shown to be beneficial in experimental models of autoimmune diseases, mainly through their role
in modulating T-cell differentiation and function. Critical Issues: Relationship between S-nitrosylation, other
thiol redox PTMs, and other NO-signaling pathways has not been always taken into account, particularly in the
context of immune responses. Methods for assaying S-nitrosylation in individual proteins and proteomic ap-
proaches to study the S-nitrosoproteome are constantly being improved, which helps to move this field forward.
Future Directions: Integrated studies of signaling pathways in the immune system should consider whether S-
nitrosylation/denitrosylation processes are among the PTMs influencing the activity of key signaling and
adaptor proteins. Studies in pathophysiological scenarios will also be of interest to put these mechanisms into
broader contexts. Interventions modulating nitrosothiol levels in autoimmune disease could be investigated with
a view to developing new therapies. Antioxid. Redox Signal. 18, 288–308.
Introduction
Since the recognition of nitric oxide (NO) as a secondmessenger in vertebrate cardiovascular and nervous
systems, a classical signaling pathway has been established in
which NO produced by nitric oxide synthase (NOS) stimulates
soluble guanylate cyclase activation, cyclic GMP (cGMP) pro-
duction, and cGMP-activated protein kinases (cGKs or PKGs).
In addition, a less-classical pathway involves the inhibition of
mitochondrial cytochrome c oxidase (complex IV of the elec-
tron transport chain), which has a profound influence on cell
metabolism and homeostasis. Apart from these modes of ac-
tion, several nonclassical mechanisms have been described,
which includeNOproduction fromother sources such as nitrite
anion (NO2
- ) and the covalent post-translational modification
(PTM) of proteins provoked by the so-called reactive nitrogen
species (RNS), a series of chemical species derived from reac-
tions ofNOwith other smallmolecules [reviewed in Ref. (106)].
Among the PTMs induced by RNS, S-nitrosylation [also
called S-nitrosation: see (42, 75, 108) for a discussion of the
terminology] has emerged as an important signaling pathway
related to NO production, with some particularities in terms
of specificity that have been discussed elsewhere (30, 64, 90,
106, 108). It consists in the formation of a nitrosothiol (RSNO,
also called thionitrite) at a protein cysteine thiol (RSH), which
can potentially be achieved through several possible chemical
mechanisms (41, 56, 64). Different structural motifs may
confer specificity to particular cysteine residues in protein
chains (32, 102), suggesting that these distinct pathways
may coexist in any given biochemical environment. As NO
itself is rarely a direct S-nitrosylating agent (unless it reacts
with a thyil radical in the protein cysteine), most of these
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mechanisms proceed through formation of RNS. Other im-
portant parameters driving the specificity of S-nitrosylation
signaling are subcellular compartmentalization and the
proximity to or interaction with NOS, as well as the presence
of denitrosylases and the recently described transnitrosylase
activities (12, 30, 88, 106, 108, 124, 166, 190).
S-nitrosylation is one of several oxidative PTMs produced at
cysteine thiols, such as formation of sulfenic, sulfinic, or sulfonic
acid, of protein intra- or intermolecular disulfide bridges, or of
mixed disulfides with low molecular mass thiols (S-thiolation,
termed S-glutathionylation when formed with glutathione
[GSH]). The relationships among them are complex, including
shared and differential roles in cell signaling and nitroxidative
stress (75, 109). In particular, S-nitrosylation has been shown to
induce disulfide bridges, and especially S-glutathionylation
(5, 109, 183). Indeed, this should be taken into account when
studying the effect of NO donors and nitrosothiols, as they can
produce different types of modifications (106, 109). For exam-
ple, S-nitrosoglutathione (GSNO) is not only a nitrosylating
agent but also a glutathionylating agent (106, 147, 183).
We review here several recently uncovered aspects of the
role of S-nitrosylation in themammalian immune system. One
of them is the influence of S-nitrosylation in toll-like receptor
(TLR) activation and signaling, through the modification of
several proteins and pathways that are mainly involved in
innate immunity, a good example of which is surfactant
protein D (SP-D) modification in the alveolar system. Un-
derstanding the mechanisms that protect macrophages
against their own unbalanced S-nitrosylation when they
are activated through pathways that induce high NO and
RNS production also reflects the implication of nitrosothiol
in innate immunity. NF-kB activation is modulated by S-
nitrosylation at many points of its pathway, which is common
to innate and adaptive immunity. As such, we discuss this in a
middle chapter, together with other proteins and pathways
that are S-nitrosylated and that fulfill diverse roles in the
immune system. In adaptive immunity, most studies dealing
with the role of S-nitrosylation have been conducted on T
cells. S-nitrosylation has been described to take part in specific
signaling pathways during T-cell activation, while it inhibits
T-cell development in the thymus. Finally, we review studies
that have described a role for S-nitrosylation and NO pro-
duction in the differentiation and function of the T-helper cell
subsets involved in chronic inflammatory diseases of auto-
immune origin, for which treatments with nitrosothiols have
been shown to be beneficial in many cases.
In recent years, S-nitrosylation has been shown to play an
important role in the plant immune response, sharing given
mechanisms with animals [for recent references, see Refs. (100,
196)], even though the existence of NOS has yet to be confirmed
in plants (47).While it would certainly be interesting to compare
this response in both kingdoms, this is beyond the scope of this
review. So is the effect of S-nitrosylation on themicrobes that are
attacked by the immune system, for example, those engulfed by
phagocytic cells, which is covered in another review in this
Forum (91a), and in another recent review covering several
chemical mechanisms that depend on ROS and RNS (186).
Nitrosothiols in Innate Immunity
An early defense against infectious agents requires the
participation of innate immune responses, a set of cellular and
biochemical mechanisms representing the organism’s first
line of defense to pathogens. Physical and chemical barriers
(e.g., the respiratory epithelial mucosa and compounds with
antimicrobial activity), cytokines, and phagocytic cells (e.g.,
neutrophils andmacrophages) are themain effectors of innate
immunity. Among the mechanisms by which phagocytes
exert their functions, recent attention has been given to TLRs,
a family of transmembrane proteins that recognize microbe-
derived molecules, many of which are bacterial wall constit-
uents. TLRs increase phagocytosis and cytokine production
mainly through the NF-kB signaling pathway. Ligand bind-
ing to the TLR induces the association of the adaptor MyD88
to its cytoplasmic domain, the recruitment of interleukin-1
receptor (IL-1R)-associated kinase (IRAK) and TRAF-6, and
the ensuing activation of IjB-kinase (IKK), which in turn ac-
tivates NF-jB by inhibiting IjB. This enhances the production
of the proinflammatory cytokines tumor necrosis factor
(TNF)-a, IL-1b, and IL-12 and the expression of adhesion
molecules in activated endothelial cells, which favors the re-
cruitment of leukocytes to inflammatory foci.
Role of SP-D S-nitrosylation in TLR activation
Pulmonary surfactant was initially described as a complex
of lipids and proteins that reduces the surface tension at the
air–liquid interface in the alveoli, thus avoiding atelectasis or
collapsed lung. However, recent studies indicate that a sur-
factant also plays an active role in the innate immune response
(89, 157, 188). Four surfactant proteins have been described
that belong to the family of collagen-like lectins or collectins:
surfactant protein A (SP-A), B (SP-B), C (SP-C), and D (SP-D).
The N-terminal domain of the SP-D monomer contains
two key Cys residues (Cys15 and Cys20), a collagen-like do-
main, a neck region formed by a short a-helix, and a C-type
carbohydrate-recognition domain (CRD) through which it
interacts with anionic phospholipids and complex carbohy-
drates present in pathogens in a Ca2 + -dependent manner (27,
136, 157). It is worth noting that the SP-D monomer does not
seem to be biologically active, but rather the monomers in-
teract through their collagen-like domains to form trimers,
which can oligomerize into a dodecamer through their N-
terminal domains, forming a cruciform structure (27, 136).
This new structure is also able to participate in higher orders
of multimerization (27).
SP-A and SP-D have a pathogen-dependent proin-
flammatory function (49), yet conversely, in a noninflamma-
tory scenario, these collectins can bind to the signal inhibitory
regulatory protein a (SIRP-a) via their CRD, leading to the ac-
tivation of SHP-1 and inhibition of p38 mitogen-activated pro-
tein kinase (MAPK), and thereby suppressing the synthesis of
proinflammatory mediators. However, SP-A and SP-D interact
with pathogens or apoptotic cells through the CRD, allowing
the collagen-like domain at the N-terminus to be presented to
calreticulin/CD91, and therefore triggering a proinflammatory
response through p38 activation. Thus, SP-A and SP-D can act
as both anti-inflammatory and proinflammatory molecules
depending on the environmentwithin the lung (49). SP-D hides
itsN-terminalwithin the dodecamer structure, so its quaternary
structure might be crucial for its immunomodulatory function.
Indeed, oligomerization of SP-D (where disulfide bridges form
between Cys15 and Cys20) has been demonstrated to be critical
for their dual inflammatory role (17, 63, 194).
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Recently, S-nitrosylation of Cys15 and Cys20 has been
shown to play a pivotal role in oligomerization (7, 57), re-
viewed in Ref. (6). This modification disassembles the dode-
camer into trimers, producing macrophage chemotaxis and
triggering a proinflammatory response by activating calreti-
culin/CD91-dependent p38 (57). Under certain conditions,
such as in the presence of pathogen or under nitrosative stress,
S-nitrosylation of SP-D coulddrive the switch between anti- and
proinflammatory activity. As mentioned above, dodecameric
SP-D would act as an anti-inflammatory molecule in basal
conditions. Alternatively, S-nitrosylation of SP-D disassembles
the oligomer into trimers, with the N-terminal domain exposed
and ready to interact with calreticulin/CD91, promoting the
proinflammatory cascade (6, 57) (Fig. 1).
In models of acute lung injury, such as an 8-day exposure to
bleomycin, SP-D S-nitrosylation is reduced by 80% in inducible
nitric oxide synthase (iNOS) knockout mice, suggesting that
this modification is mostly produced by iNOS activity (57).
Thus, since iNOS is expressed in inflammatory scenarios, S-
nitrosylation of SP-Dwould produce positive proinflammatory
feedback (57).
Some questions still require further study. The oligo-
meric form of SP-D can bind to TLR4 (132) and inhibit the
TLR4-dependent proinflammatory response (194). Thus, it
would be of interest to determine whether S-nitrosylation
of SP-D might allow TLR4 receptors to dimerize, activating
and promoting p38-dependent synthesis of proinflam-
matory mediators. Likewise, it remains unknown whether
S-nitrosylation of Cys15/Cys20 in SP-D is necessary for
its interaction with calreticulin/CD91. Finally, it would
be very interesting to assess if other oxidative modifica-
tions of these Cys residues might have a similar functional
relevance.
Macrophage activation and self-protection
by denitrosylases
Macrophage activation by proinflammatory cytokines
(such as interferon-c [IFN-c], produced by other immune cells)
or lipopolysaccharide (LPS) (from the bacterial walls) upre-
gulates iNOS transcription, which produces a burst of NO.
This NO acts as a part of the antimicrobial armory of these
cells, and among other effects (186), it may inactivate through
S-nitrosylation essential proteins of phagocytosed cells (146).
A murine cell line, RAW 264.7, has frequently been used as
a model of macrophage induction to study the role of S-
nitrosylation. Early studies showed that when these cells were
activated by LPS and IFN-c, the amount of S-nitrosothiols in
cell extracts clearly increases, mainly in the protein fraction
(36), which was subsequently confirmed in the same cells (54,
199) and in the J774 macrophage cell line (37). In RAW 264.7
cells, when the intracellular levels of nitrosothiols have been
measured after either the treatment of cells with exogenous
transnitrosylating agents or the endogenous induction of
iNOS, it seems clear that endogenous iNOS induction pro-
duces relatively lower amounts of nitrosothiols, even though
considerable amounts of iNOS-derived NO are produced
(nitrosothiols are estimated at about 0.02% of the nitrite gen-
erated) (199, 200). It is worth noting that in J774 cells, bacterial
infection was recently reported to reduce the nitrosothiol
content of activated macrophages, a process dependent on
genes thought to detoxify NO in such bacteria, namely norB
FIG. 1. S-nitrosylation modulates the quaternary structure and function of surfactant protein D (SP-D). The SP-D
dodecamer binds to signal inhibitory regulatory protein a (SIRP-a) and inhibits p38 mitogen-activated protein kinase (MAPK)
activation via SHP-1, and it also binds toll-like receptor 4 (TLR4), thereby avoiding its dimerization and subsequent acti-
vation. Upon S-nitrosylation, SP-D dodecamers disassemble into trimers, which bind to CD-91/calreticulin, a process that
activates p38 MAPK and triggers a proinflammatory response. Dodecamer disassembly might allow TLR4 dimerization and
downstream activation of NF-jB (To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars).
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(Neisseria meningitidis, meningococcus) and flavohemoglobin,
Hmp (Salmonella enterica and Escherichia coli) (92).
Despite producing large amounts of NO, activated macro-
phagesmay protect themselves against their ownproduction of
such toxic levels of NO and related RNS. It is now clear that
denitrosylases may participate in this protection by acting on
nitrosothiols in proteins and low-molecular-mass thiols, such as
GSH. Two main denitrosylases have been described, which are
related to redox pathways: GSH coupled to GSNO reductase
(GSNOR) (76, 96); and thioredoxin (Trx), coupled to Trx re-
ductase and NADPH (168) [reviewed in Ref. (12); Fig. 2].
GSNOR (also known as GSH-dependent formaldehyde
dehydrogenase) breaks GSNO, and it has been shown to re-
duce protein S-nitrosylation levels, at least in a subset of
proteins whose S-nitrosylation would be in equilibrium with
GSH modification (96). Mice with a targeted deletion of
GSNOR suffer increased S-nitrosylation and mortality after
endotoxic shock induced by LPS, revealing a role in the reg-
ulation of innate immunity (98). In a recent report, a GSNOR
inhibitor profoundly affected the expression of a number of
proteins in activated macrophages (45). By using quantitative
general proteomics (i.e., directed at the general proteome and
not identifying S-nitrosylated proteins), it has been shown
that several inflammatory mediators are downregulated
when GSNOR is inhibited, including iNOS, cyclooxygenase-2
(COX-2), and osteopontin, whereas targets of the Nrf2 tran-
scription factor were upregulated, like heme oxygenase-1 and
glutamate–cysteine ligase modulatory subunit. These results
suggest that a feedback cycle might finely tune the presence
and activity of iNOS, in which Nrf2 may also be implicated
(45). Another protein susceptible of regulation by deni-
trosylation is histone deacetylase 2 (HDAC2). HDAC2 is in-
activated through S-nitrosylation in alveolar macrophages
from chronic obstructive pulmonary disease, which confers
cell resistance to corticosteroid treatment. In this setting, GSH
treatment and induction of Nrf2 restoredHDAC2 activity and
corticosteroid sensitivity, although this GSH- and Nrf2-
dependentmechanismof denitrosylationwas not identified (99).
The role of Trx in denitrosylating particular proteins has
been studied in detail for some proteins such as caspase-3 (11,
13) aswell as using proteomic approaches (see below). It is not
clear if there is an increase in denitrosylation activity during
macrophage activation, or if the basal denitrosylation activity is
sufficient to cope with the increased RNS produced by iNOS
induction. Negative feedback regulators of NOS-dependent
S-nitrosylation have been postulated; for example, the Trx-
interacting protein (Txnip) that inhibits Trx denitrosylation is in
turn inhibited by increased NO levels. Thus, Trx denitrosyla-
tion activity is increased when NO is produced (43). In addi-
tion, Trx itself is a target of S-nitrosylation at several residues,
whose specificity is different in the reduced and oxidized forms
(10), and it can act also as a transnitrosylase (118, 189, 190)
[reviewed inRef. (159)]. Therefore,more detailed studies on the
different roles of Trx in the regulation of S-nitrosylation in
macrophages will be necessary to address this issue.
Further protection could arise through the precise subcel-
lular localization of iNOS in the activated macrophages. Early
reports showed that in primary macrophages, iNOS localizes
in vesicles that could translocate to phagosomes (178). Each of
the three NOS isoforms bears different structural features at
the N- and C-termini that influence their subcellular location.
Cysteine palmitoylation at the N-terminus of iNOS has been
shown to be needed for vesicle association and correct traf-
ficking of the protein through the Golgi apparatus to apical
positions in polarized cells, which is needed for the vectorial
synthesis and release of NO (125, 126). However, to our
knowledge, this has not been studied in macrophages. The
four C-terminal amino acids in iNOS, which become inserted
FIG. 2. Macrophages protect
themselves from inducible
nitric oxide synthase (iNOS)-
induced S-nitrosylation. Pro-
inflammatory stimuli, such as
interferon-c (IFN-c) and lipo-
polysaccharide (LPS), trigger
iNOS expression. This iNOS
associates with vesicles
through the Golgi, and it
may be recruited to phago-
somes where it produces
large amounts of NO that can
S-nitrosylate protein targets
in a phagocyted cell, such as
a bacterium. Thioredoxin
(Trx) and glutathione (GSH)/
S-nitrosoglutathione reduc-
tase (GSNOR) may denitro-
sylate macrophage proteins
that become modified (To see
this illustration in color, the
reader is referred to the web
version of this article at
www.liebertpub.com/ars).
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within PDZ domains, are also needed for its apical localiza-
tion in polarized cells (51, 127). Likewise, in macrophages, the
iNOS C-terminus interacts with the PDZ domains of the cy-
toskeleton scaffolding protein EBP50, which directs iNOS to
the phagosomes (29). Interestingly, the EBP50 gene is induced
in parallel to iNOS, and its recruitment is impaired in Myco-
bacterium tuberculosis-infected phagosomes, which explains
the previously observed exclusion of iNOS from these pha-
gosomes (29, 116).
Macrophage activation, particularly in the murine cell line
RAW 264.7, has been frequently used as a model for the study
of the S-nitrosoproteome, illustrating the sensitivity of the
proteomic methods employed to identify S-nitrosylated pro-
teins. By 2001, more than 100 S-nitrosylated proteins had
been described [see Table S1 in Ref. (167)], all studied on an
individual basis. The original biotin-switch technique (BST)
described by Jaffrey et al. (74) opened the way to study the
S-nitrosoproteome, by describing a method that allowed de-
rivatized S-nitrosylated proteins to be purified, and employ-
ing emergent proteomic techniques to identify the purified
subproteome. However, one study concluded that such
methodology only detected S-nitrosylated proteins when
RAW 264.7 cells were treated with at least 100lM extracel-
lular S-nitroso-l-cysteine, which gave an intracellular S-
nitrosothiol concentration of around 500 nmol/mg protein
(201), well above that produced by endogenous iNOS acti-
vation by proinflammatory cytokines (around 100 pmol/mg
protein) (36, 54, 199). We obtained similar results, as we were
able to detect and identify S-nitrosylated proteins in endo-
thelial cells treatedwith extracellular S-nitroso-l-cysteine (107,
111), but we did not detect S-nitrosylation differences in RAW
264.7 cells after cytokine-dependent induction and activation
of iNOS [results published in Ref. (174), Fig. 3]. However,
another study reported an increase in the S-nitrosylated pro-
tein signal using the BST, identifying up to 15 proteins modi-
fied after cytokine treatment of RAW 264.7 cells (48).
The use of fluorescent derivatization instead of biotin la-
beling, coupled to two-dimensional electrophoresis (2-DE),
has increased the sensitivity of proteomic techniques to study
the S-nitrosoproteome. Although the depth of the proteome
has not been increased (i.e., the number of identified proteins
is not much higher), this approach implies that the starting
material may be 20-fold less (174). However, when applied to
RAW 264.7 cells activated with LPS/IFN-c, we were only able
to detect differentially S-nitrosylated proteins when we in-
cluded auranofin, an inhibitor of the Trx pathway, thereby
identifying putative targets denitrosylated by this path-
way (174). A two-fluorophore scheme for derivatizing S-
nitrosothiols has also been used to detect an overall increase
in S-nitrosylation in cytokine-stimulated RAW 264.7 cells,
mixing samples from nonactivated and activated cells in the
same 2-DE (152). Compared to a one-fluorophore one-sample-
per-gel scheme (174), this approach has two problems: first,
each fluorophore signal has a different normalization pa-
rameter; and second, the amount of total protein in each spot
from each sample is not analyzed, and thus the variations in
the S-nitrosylation signal for a spot may simply be due to a
change in protein abundance [reviewed in Ref. (73)].
Development ofmore sensitive proteomicmethodswill help
to study the S-nitrosoproteome associated with macrophage
activation and the role of the protection mechanisms. These
advances may come from both general improvements in pro-
teomic techniques, such as the use of more powerful mass
spectrometers, as well as through the development of im-
proved protocols and techniques for the specific detection of
this modification. Recent advances in the application of quan-
titative second-generation proteomics (based on large-scale
identification of peptides by tandem mass spectrometry),
coupled to improved derivatization and purification of S-ni-
trosylated peptides, could produce advances in the field, even
in the detection of S-nitrosylated proteins under basal condi-
tions (32, 44). In the RAW 264.7 cell model of cytokine
FIG. 3. The biotin-switch technique (BST) is not sensitive
enough to detect endogenous S-nitrosylation produced by
iNOS activation in macrophages. (A) Murine macrophage
cell line RAW 264.7 was treated with LPS and IFN-c, and
with auranofin, producing iNOS that was detected in west-
ern blots and NO measured as extracellular nitrite with the
Griess reagent. (B) Cell extracts were subjected to the BST,
blotted, and detected with avidin. Although there is a clear
increase in iNOS-derived NO production after LPS + IFN-c
activation, differences in S-nitrosylation are only observed
when the Trx pathway is inhibited with auranofin. Reprinted
by permission from Tello et al. (174).
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activation, two methods have recently been applied that use
stable isotope labeling in culture or label-free spectral counting,
coupled to the purification of derivatized S-nitrosylated pep-
tides. Through thesemethods, 17 or 27 proteinswere described
that were S-nitrosylated after cytokine activation (198, 203).
More detailed studies on the S-nitrosoproteome of macro-
phages during activation, combined with studies into the role
of S-nitrosylation in particular proteins, could shed light on
the mechanisms that could be operating in self-protection
(such as denitrosylation and subcellular localization), as well
as on the interaction with phagocytosed cells.
S-Nitrosylation in Innate and Adaptive Immunity
NF-kB pathway and S-nitrosylation
NF-jB is a heterodimeric transcription factor, usually
comprised of a p50 and p65 subunit, which controls the ex-
pression of many genes involved in innate and adaptive im-
mune responses, including proinflammatory cytokines and
adhesion receptors. The activation of NF-jB itself is controlled
by a tightly regulated protein cascade. In the basal state, the
p50–p65 heterodimer is bound to the inhibitor of NF-jB (IjB),
which maintains the transcription factor inactivated. IjB
phosphorylation by the IKK complex (IKKa, IKKb, and IKKc)
promotes IjB degradation by the 26S proteasome and the
subsequent liberation, translocation into the nucleus, and
DNA binding of NF-jB (50). Distinct stimuli trigger NF-jB
activation (e.g., TNF-a, IFN-c, IL-1b, or LPS) through a series
of pathways that converge on the activation of the IKK com-
plex (66).
NO from exogenous sources or endogenous iNOS ex-
pression can modulate the promoter and DNA-binding ac-
tivity of NF-jB in cells. Indeed, some elements of the
activation pathway of NF-jB, including the subunits of the
transcription factor itself, have been shown to be modified
by S-nitrosylation (Fig. 4).
The p50 subunit of NF-jB is S-nitrosylated at a cysteine
residue located in its DNA-binding domain, which inhibits its
binding to DNA, and thereby decreases the proinflammatory
response (104). Interestingly, S-glutathionylation of the same
cysteine residue also inactivates its DNA binding (137), a
modification likely to be induced by GSNO (86). Likewise,
p65 can also be S-nitrosylated, producing similar conse-
quences, and so nitrosylation of both NF-jB subunits results
in its inactivation (81). IKKb has also been shown to be S-
nitrosylated at Cys179, a modification capable of modulating
kinase function independently of phosphorylation, since
IKKb activity is abrogated after S-nitrosylation after TNF-a
activation (145).
Other elements upstream of NF-jB activation are also
S-nitrosylated. Treatment of the nonreceptor protein tyrosine
kinase p60Src (Src) with nitrosothiol results in Src activation
through autophosphorylation at Tyr416 and the formation
of multimers, an action presumably exerted through S-
nitrosylation at Cys498 and/or the formation of disulfide
bridges between Src monomers (3, 5, 142). Furthermore, in the
TLR-dependent pathway of NF-jB activation, S-nitrosylation
of MyD88 disrupts its binding to the upstream Toll/IL-1R
adaptor protein (TIRAP), but not to the downstream IRAK-1,
which might influence the delayed development of the acute
immune response (70).
CD40 is a member of the TNF receptor (TNFR) family
that when stimulated by CD40L activates the NF-jB pathway
(20). S-nitrosylation of the CD40 extracellular domain occurs in
quiescent macrophages and monocytes, whereas denitrosyla-
tion is produced after activation by CD40L (52). This
FIG. 4. The NF-jB activation
pathway is regulated by S-
nitrosylation. S-nitrosylation
of the p50 and p65 subunits of
NF-jB causes the inhibition of
its binding to DNA. Upstream
inhibition of the IjB-kinase
(IKK) complex’s kinase activity
is induced by S-nitrosylation of
the IKKb subunit, abrogating
NF-jB activation. S-nitrosylation
of CD40 inhibits binding and
activation by CD40L. MyD88
S-nitrosylation disrupts binding
to its upstream partner toll/
interleukin-1 receptor adaptor
protein (TIRAP), which might
serve to delay the development
of the immune response. On
the other hand, S-nitrosylation
of Src may activate NF-jB (To
see this illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars).
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modification blocks CD40 signal transduction, such that CD40
denitrosylation could be a prerequisite for macrophage activa-
tion via the CD40 pathway (52). Indeed, CD40 denitrosylation
was observed in mice injected with LPS and in monocytes from
patients suffering severe sepsis or septic shock (52).
It is worth noting that the iNOS gene promoter itself con-
tains NF-jB response elements, and that this transcription
factor is important for iNOS expression (81). Thus, it is feasible
that negative feedback onto S-nitrosylation-dependent NF-jB
inactivation should be taken into account. In this mechanism,
inactivation of IKK/NF-jB by S-nitrosylation could down-
regulate iNOS expression and the associated S-nitrosylation
activity, an effect reinforced by the fact that iNOS itself is
susceptible to inactivation by S-nitrosylation (117, 163). As a
result, NF-jB activation may be equilibrated in cells, and the
levels of NF-jB-induced cytokines and endothelial adhesion
molecules (vascular cell adhesion protein 1, intercellular ad-
hesion molecule 1, and E- and P-selectins) sustained for leu-
kocyte extravasation and function.
As shown by several groups, S-nitrosylation can affect the
NF-jB activation pathway at several points, from the up-
stream molecules to the transcription factor itself. Although
most of the described S-nitrosylation targets (MyD88, CD40,
IKKb, p50, and p65) inhibit the pathway, the modification of
SP-D and Src may activate it. Hence, further studies should
discriminate how these different modifications are integrated
in the regulation of NF-kB.
S-nitrosylation of other relevant proteins and pathways
S100A8 expression is induced by inflammatory mediators
of oxidative stress in macrophages, microvascular endothelial
cells, fibroblast, and keratinocytes. It has chemotactic-, anti-
microbial-, apoptosis-inducing and growth-inhibitory prop-
erties (143). S-nitrosylation of S100A8 at Cys41 could be
important in the resolution of inflammation given that this
modification suppresses mast cell degranulation and mast-
cell-mediated inflammation in the microcirculation (95). In-
teractions between S100A8 and NO produced by endothelial
cells may also alter endothelial cell–leukocyte interactions in
the microcirculation (95).
C-Jun N-terminal kinase ( JNK) belongs to the MAPK
family, and it is the terminal kinase in a pathway composed
byMEKK1 andMKK4/7. Phosphorylation of JNK allows it to
activate target proteins such as c-Jun, a component of the AP-1
transcription factor. This pathway is involved in many dif-
ferent cell activities, including apoptosis, survival, and pro-
liferation. In macrophages activated by IFN-c, when NO is
produced, the activity of JNK is inhibited by a redox mecha-
nism compatible with S-nitrosylation and dependent on
Cys116 (134). This effect is independent of its upstream
partners and of antagonistic stimuli (134), and it may be me-
diated by the disruption of the interaction between JNK and c-
Jun (135). Interestingly, this cysteine residue is only conserved
among the JNK subgroup ofMAPK, which suggests a specific
role for this mechanism that could participate in resolving the
inflammatory response (60). As in the case of the NF-jB
pathway, more complex regulation could occur, as c-Jun
DNA-binding activity is also inhibited by NO-dependent S-
glutathionylation at a critical Cys residue (85), althoughwe do
not know of any study specifically assessing S-nitrosylation of
that residue.
During the inflammatory process, COX-2, a key enzyme in
prostaglandin synthesis, is activated over a similar time
course to iNOS, and crosstalk between these enzymes was
suspected as iNOS-derived NO had been shown to activate
COX (151). In microglia and activated macrophages, iNOS
has been shown to bind and S-nitrosylate COX-2, increasing
its activity (83). Interestingly, COX-2 S-nitrosylation depends
on direct interaction with iNOS, which provides a potential
target for the pharmacological control of this pathway (83),
stressing the role of S-nitrosylation as a short-range signaling
mechanism (106, 110). Indeed, a similar functional interaction
with neuronal NOS has been observed in the context of
NMDA neurotoxicity (175). Additional synergistic regulation
of the COX-2 pathway includes S-nitrosylation of cytosolic
phospholipase A2a (cPLA2a), the rate-limiting enzyme up-
stream of COX, as COX-2 induces the iNOS-dependent
cPLA2a S-nitrosylation that activates this enzyme (192).
Adaptive Immunity: Nitrosothiols in T-Cell-Mediated
Immune Responses
A role for S-nitrosylation in T-cell activation
In the immune system, helper T lymphocytes orchestrate
the responses to pathogenic agents, secreting cytokines whose
function is to coordinate the action of leukocytes and
immune-associated cells. To fulfill the multiple demands on
their effector functions, T lymphocytes proliferate and dif-
ferentiate in response to the action of T-cell receptor (TCR)-
mediated recognition of pathogen-derived antigenic peptides
on antigen-presenting cells (APCs) (162). These cognate in-
teractions result in the phosphorylation-dependent activation
of signaling pathways initiated from the TCR (112). Besides
the importance of protein phosphorylation on key Tyr and
Ser/Thr residues in the activation of signal transduction cas-
cades initiated from the TCR, there is increasing evidence
indicating that protein S-nitrosylation and its redox switch by
denitrosylation are also PTMs able to take part in the regu-
lation of T-cell activation.
T-cell lines and primary T lymphocytes produce NO in
response to TCR engagement with CD3 antibodies, super-
antigens, or antigenic peptides on APCs (69, 165). Despite
some controversies regarding the source of NO and the ex-
pression of NOS isoforms in immune cells of human origin
(155), it has been reported that mouse and human T lym-
phocytes can express iNOS upon viral infection and in re-
sponse to proinflammatory cytokines, or other environmental
factors (25, 87, 119). Nevertheless, the rapid onset of NO
production observed in T cells upon TCR engagement sug-
gests the participation of constitutive rather than inducible
NOS. In this regard, human T lymphocytes express endo-
thelial NOS (eNOS), assessed bymRNA and protein detection
(122, 144, 156), and although mouse T lymphocytes do not
appear to express eNOS mRNA (46), its expression can be in-
duced in murine T lymphocytes upon CD3 stimulation (23).
Hence, species differences or conditioning by factors such as
stimulation, or the origin andheterogeneity of cell samples,may
distort the results of experimental studies.
We reported that eNOS-derived NO is synthesized by T
lymphocytes during antigen-specific interactions with APCs
(69). eNOS is rapidly activated on the Golgi complex by
phosphorylation at Ser1179 due to the combined action of
PI3K/AKT signaling and Ca2 + fluxes. As a consequence, it is
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translocated toward the immune synapse (69), a specialized
intercellular domain where the TCR accumulates along with
signaling and cytoskeletal molecules, and adhesion receptors,
which are organized to regulate the activation of T cells
(34). As a result, early and late TCR-mediated signal trans-
duction events are affected, as eNOS-derived NO increases
the phosphorylation/activation of the TCR CD3f chain and
the adaptor kinase ZAP-70. Moreover, eNOS-derived NO
also activates the MAPK ERK-1 and ERK-2 through the
compartmentalized S-nitrosylation of N-Ras at Cys118 on
the Golgi complex, which facilitates its activation by conver-
sion of GDP- to GTP-bound N-Ras (68) (Fig. 5). Moreover,
using a specific S-nitrosocysteine antibody, we found that
S-nitrosylation is mainly compartmentalized near the Golgi
complex, where active eNOS localizes (68), and a similar
compartmentalization of S-nitrosylation near the foci of NOS
activation has been observed in other cell systems (71). This
localization can be explained by the requirement of high
NO concentrations to produce S-nitrosylation in comparison
with other NO reactions, and it has been postulated as a
mechanism for specific S-nitrosylation of proteins interact-
ing or co-localizing with NOS isoforms, suggesting that
S-nitrosylation is a short-range or proximity-based NO sig-
naling event (30, 106, 110). We showed that although T cells
express both K-Ras and N-Ras (which have the same con-
served Cys residue that can be S-nitrosylated), only N-Ras
FIG. 5. Model of endothelial nitric oxide synthase (eNOS) activation of N-Ras on the Golgi complex of antigen-
stimulated T cells. The figure schematically depicts the possible compartmentalized signaling through which T-cell receptor
(TCR) stimulation may lead to the selective S-nitrosylation and activation of N-Ras on the Golgi complex. Engagement of the
TCR by antigens results in the phosphorylation of the CD3f chain and the recruitment of the adapter kinase ZAP-70. This
kinase in turn phosphorylates LAT and PI3K, leading to activation of PLC-c and Akt, respectively. PLC-c activation produces
diacylglycerol (DAG) in the plasma membrane and inositol 1,4,5-triphosphate (IP3) in the cytosol. IP3 release liberates Ca2 +
from internal stores, which binds to calmodulin-associated eNOS and induces the translocation of RasGRP1 to the Golgi,
where the levels of DAG are high. Simultaneously, active Akt can phosphorylate eNOS on Ser1177. As a result, eNOS might be
fully activated to synthesize NO and S-nitrosylate inactive (GDP-bound) N-Ras on Cys118 (small red arrow). This would
weaken its interaction with GDP, thereby facilitating RasGRP1-mediated GDP-GTP exchange on the Golgi complex (large red
arrow) (To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars).
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is S-nitrosylated due to its localization on the Golgi apparatus
(68), suggesting that specific targets sensitive to regulation
may be S-nitrosylated at the immune synapse.
Our findings also suggest that eNOS-dependent S-
nitrosylation of N-Ras on Cys118 may foster activation-
induced cell death (AICD), a protective mechanism to avoid
the potentially deleterious effects of overactivated T cells (68).
Similarly, other authors have found that treatment with
GSNO stimulates apoptosis in the human promyelomonocy-
tic cell line THP-1, and that mutation of Ras on Cys118 al-
most abrogates apoptosis, further suggesting a role of Ras
S-nitrosylation in cell death (177). Events leading to apoptosis
are activated in the mitochondria through the intrinsic path-
way, or in the case of AICD, they are triggered by death re-
ceptors such as TNFR and CD95/Fas, a member of the TNFR
family that binds to the CD95L/Fas ligand. During AICD,
CD95L interacts with the Fas-associated death domain
(FADD) and recruits procaspase-8, which is proteolytically
activated and released to the cytosol (15).
Although the TNFR may produce antiapoptotic effects
through the activation of NF-jB, binding of soluble TNF-a
and the formation of dead-inducing signaling complexes as-
sociated with the cytoplasmic tail of TNFRmay also represent
a mechanism to sensitize T cells to AICD. In this regard, ni-
trosative stress confers to TNF-a the capacity to promote ap-
optosis in Jurkat T cells by blocking IjBa degradation and the
translocation of NF-jB to the nucleus (105). However, rather
than inducing apoptosis, low-to-moderate concentrations of
NO have been shown to protect T cells from cell death (97).
Caspases are the best-known targets through which NO
exerts its antiapoptotic effects. All caspases contain an es-
sential Cys within their active centers that is sensitive to S-
nitrosylation, and S-nitrosylation of caspase-1, 3, and 9 is
correlated with their enzymatic inhibition in vitro (31, 101).
However, studies carried out in Jurkat T cells suggest that
rather than inhibiting caspase-3 enzymatic activity, NO at-
tenuates its proteolysis to the active form through both the
mitochondrial pathway, by interfering with the Apaf-1/
caspase-9 apoptosome assembly, and the CD95 death recep-
tor pathway, by S-nitrosylation of caspase-1 and 8 (31, 197).
Another S-nitrosylation-dependent mechanism bywhich cells
may be protected from apoptosis involves Bcl-2. In the human
lung epithelial cancer cell line NCI-H460, endogenous NO
produced in response to proapoptotic stimuli inhibits Bcl-2
degradation by S-nitrosylation at Cys158 and 229 (9).
Nevertheless, in some cell systems, neither caspase nor Bcl-2
S-nitrosylation may be sufficient to fully rescue cells from
AICD. In this regard, it has been reported that Ras/MEK/
ERK activation promotes intrinsic apoptosis pathways in
T cells through the phosphorylation and mitochondrial tar-
geting of the orphan nuclear receptor Nur77. Although in
cancer cells Nur77 can bind to Bcl-2 at mitochondria and
convert this antiapoptotic factor into a proapoptotic mediator,
in T cells, Nur77 exerts its actions through an unknown Bcl-2-
independent mechanism (180). Whether eNOS-mediated N-
Ras S-nitrosylation on the Golgi complex of T cells may also
favor apoptosis through an AICD-independent mechanism,
involving ERK-mediated Nur77 phosphorylation/activation,
merits further investigation.
There is increasing evidence of a possible role for deni-
trosylation in T-cell activation. Initial studies on the role of
redox maintenance in T cells indicated that GSH is important
for proliferation and apoptosis, although it only weakly in-
fluences early activation events such as IL-2R expression (114,
153, 164). On the other hand, intracellular GSH levels enable
activation of NF-kB inMolt-4 T cells (115), whereas in Jurkat T
cells, NO inhibits NF-kB activation through S-nitrosylation of
IKKb at Cys179 (145). Hence, reducing environments main-
tained by GSH could be required to counteract the inhibitory
effects exerted by NO-dependent S-nitrosylation on the
proinflammatory transcription factor NF-kB. However, GSH
is not the only reducing or denitrosylating agent involved in
T-cell activation. Trx-maintained reducing microenviron-
ments facilitate the proliferation of T lymphocytes during
antigen-specific interactions with dendritic cells (DCs), and
they buffer apoptosis in primary T lymphocytes and Jurkat T
cells (4, 72). Trxs are expressed in primary T lymphocytes and
T-cell lines, mainly upon mitogenic stimulation in the former
(150, 169, 187), and Trx is particularly prominent in T lym-
phocytes of the intestinal lamina propria. These cells ex-
pressed more Trx than peripheral blood T cells (PBTs), and
they produce more proinflammatory cytokines in response to
activation stimuli (161). Moreover, in experimental studies,
cytokine expression and endogenous Trx in activated PBTs
increase after pretreatment with recombinant Trx. The im-
portance recently attributed to Trx as a cellular enzymatic
system with denitrosylase activity (11, 12, 168) suggests that
its expression in T lymphocytes of the lamina propria may be
important in intestinal microenvironments as a specialized
first line of defense against harmful pathogens, and that this
activity may be regulated by S-nitrosylation.
S-nitrosylation/denitrosylation in T-cell development
During the development of immature T cells into CD4 +
and CD8+ subsets in the thymus, autoreactive CD4 +CD8 +
double-positive thymocytes must be removed by negative
selection, where apoptosis is induced when the TCR strongly
recognizes MHC-presented self-antigens (160). The mecha-
nisms of apoptosis involved in negative selection in the thy-
mus are not well characterized, although it is known that it
differs from that observed in peripheral T lymphocytes, which
mainly proceeds through AICD (133). High levels of NO are
considered important proapoptotic stimuli that can play de-
cisive roles in T-cell selection in the thymus: TCR-stimulated
CD4 +CD8+ thymocytes are highly sensitive to NO-mediated
apoptosis, whereas CD4 +CD8 - and CD4-CD8 + thymocytes
are rather resistant (38). This possibility is supported by
findings showing that increased NO synthesis by iNOS fos-
ters negative selection of CD3-stimulated double-positive
thymocytes (170).
In terms of the mechanisms by which iNOS may regu-
late negative selection, high levels of NO from S-nitroso-N-
acetylpenicillamine have been seen to increase thymocyte
apoptosis via caspase-1 and p53. Moreover, thymocytes from
either caspase-1- or p53-null mice are more resistant to NO-
induced apoptosis, supporting the hypothesis that both
caspase-1 and p53may transmit proapoptotic signals induced
by NO (53, 202). In fact, it has been proposed that NO in-
creases Bax, but reduces Bcl-2 expression through p53 (53).
How the p53/Bax/Bcl-2 axis regulates caspase-1 activation
in thymocytes is a subject of active research. Strikingly, re-
cent studies indicate that S-nitrosylation/denitrosylation is
required for T-cell development. In the thymus of GSNOR-
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deficient mice, there is increased S-nitrosylation (with
GAPDH one of the major proteins identified), apoptosis, and
concomitant reduction of CD4 + thymocytes, a situation that
was normalized in the thymus from iNOS and GSNOR
double knockout mice (195). DCs of the corticomedullary
junction and medulla constitutively express iNOS in the
thymus, and this expression is upregulated after their in-
teraction with thymocytes activated with auto- or alloanti-
gens (2, 170). Hence, NO from thymic stromal DCs may be
an important secondary signal associated to TCR-mediated
apoptosis, and its effects on negative selection may take
place through S-nitrosylation, which can be counteracted by
the denitrosylase activity of GSNOR (Fig. 6). Interestingly,
recent studies carried out in macrophages and neuroblas-
toma cells indicate that iNOS-derived NO S-nitrosylates
GAPDH, and that once S-nitrosylated, GAPDH can trans-
locate to the nucleus after interacting with the E3-ubiquitin
ligase Siah1, where it activates the acetyl transferase activity
of p300/CBP and induces apoptosis by increasing p53 ex-
pression (62, 158). Further work will be required to find
out whether S-nitrosylation/denitrosylation exchange on
GAPDH actually regulates p53-mediated apoptosis during
T-cell development.
By contrast, there is evidence that the selection of CD8 +
and CD4+ T lymphocytes is no different in iNOS-deficient
andwild-type animals (173), suggesting that the denitrosylase
activity of GSNOR during T-cell development may pre-
dominate over the S-nitrosylation activity of iNOS. It remains
unclear how CD4+ maturation is selectively regulated by
GSNOR. One possibility is that thymocytes ongoing CD4+
maturation may be more sensitive to S-nitrosylation-mediated
apoptosis than CD8+ thymocytes. If so,MHC class II-restricted
signals from DCs may upregulate GSNOR expression/
activation in thymocytes undergoing CD4 + maturation, pref-
erentially counteracting the proapoptotic actions of iNOS-
derived S-nitrosylation in those cells. Furthermore, iNOS-in-
dependent S-nitrosylation may also be important for T-cell
development. In this regard, it has been reported that mouse
FIG. 6. Hypothetical S-nitrosylation/denitrosylation mechanisms in T-cell development. (A) Local high extracellular
levels of NO produced by iNOS from corticomedullar and medullar dendritic cells (DCs) in the thymus promote S-
nitrosylation in thymocytes, fostering negative selection of CD4 +CD8+ double-positive thymocytes. Protein S-nitrosylation in
thymocytes may induce apoptosis by increasing p53 expression. The iNOS-derived NO may promote apoptosis through the
S-nitrosylation of GAPDH. S-nitrosylated GAPDH can bind to Siah1 and translocate to the nucleus, where it increases the
acetyltransferase activity of p300/CBP and the ensuing synthesis of p53, which can in turn activate caspase-1 through a still-
to-be determined mechanism. (B) Through denitrosylation, upregulated GSNOR expression or activity in thymocytes on-
going CD4 + maturation may counteract the proapoptotic actions of protein S-nitrosylation mediated by iNOS-derived NO
from DCs. (C) Low levels of NO generated in thymocytes by constitutive NOS (cNOS) during their cognate interactions with
iNOS-nonexpressing DCs and macrophages (antigen-presenting cells [APC]) may protect thymocytes from cell death by S-
nitrosylation of caspase-1 (To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars).
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thymocytes can express constitutive NOS as well as iNOS,
and produce low levels of Ca2 + -induced NO, even in the
presence of iNOS-inducing stimuli such as LPS and proin-
flammatory cytokines (19, 28, 185). It is yet to be seen whether
the antiapoptotic actions of caspase S-nitrosylation generated
by NO from constitutive NOS might also play an important
role in modulating apoptosis during thymocyte maturation.
NO and nitrosothiols in T-cell differentiation
and autoimmunity
Naive CD4 + T lymphocytes recognize antigens in periph-
eral lymphoid organs, provoking the expansion and differ-
entiation of antigen-specific lymphocytes into subsets of
effector cells that can be distinguished on the basis of the
cytokines they produce. Chronic inflammatory diseases are
often dominated by Th1, Th2, and Th17 cells and modulated
by regulatory T cells (Tregs) (94). The most important differ-
entiation-inducing stimuli for Th1, Th2, and Th17 cells are IL-
12, IL-4, and IL-6/IL-23, respectively. The main function of
Th1 and Th17 cells is to activate cellular immunity: Th1 cells
produce IFN-c and TNF-a, whereas Th17 cells produce IL-17
and IL-22. On the other hand, Th2 cells regulate humoral
immune responses typically synthesizing IL-4, IL-5, IL-6, and
IL-10, whereas Tregs mainly produce IL-10 and have been
implicated in the generation of tolerance to exacerbated in-
flammatory responses (94).
The regulation of cytokines by NO has received consider-
able attention, because it might be relevant in the selection of
adaptive immune responses and the management of auto-
immune chronic inflammation (Table 1). The first solid evi-
dence of a role for NO in T-cell differentiation came from a
seminal study carried out in iNOS-deficient Balb/c mice,
which generated Th1 responses upon Leishmania major infec-
tion instead of the characteristic Th2 polarization associated
with control Balb/c mice (182). Later studies demonstrated
that high NO concentrations promoted Th2 differentiation by
suppressing IL-12 synthesis in activated macrophages (67).
Since then, iNOS has been associated with the incidence and
severity of many chronic inflammatory diseases, such as
rheumatoid arthritis (113, 121), systemic lupus erythematosus
(123), experimental autoimmune uveitis (EAU) (172), experi-
mental autoimmune encephalomyelitis (EAE) (184), and
asthma (58).
Th1 Differentiation. Several reports support the hypoth-
esis that nitrosothiols may be behind the actions of NO in Th1
differentiation. In a murine model of autoimmune hepatitis
induced by concanavalin-A activation of Fas-regulated apo-
ptosis (148, 176), high levels of NO from NO-aspirin (NCX-
4016) or from a NO derivative of ursodeoxycholic acid (NCX-
1000) reduced Th1 responses by inhibiting the caspases in-
volved in the processing and production of Th1 cytokines (39,
40). This effect was reverted when cell lysates were treated
with DTT or HgCl2, which are able to reduce oxidized cys-
teines (including S-nitrosothiols), suggesting that the inhibi-
tory effect of NO on caspase activity could be achieved via the
S-nitrosylation of essential cysteine residues within their cat-
alytic site (39).
Moreover, Trx induction in T lymphocytes increased
production of Th1 cytokines by stimulating IFN-g gene ex-
pression (79). Therefore, it seems likely that high levels of
NO generated by iNOS may prevent overexpansion of Th1
cells by S-nitrosylation of key transcriptional and post-
transcriptional regulators of Th1 pathways. By contrast,
low concentrations of NO stimulate T cells to express IL12-
Rb2 and promote Th1 differentiation via cGMP (130).
Nevertheless, since Th1 cells are more sensitive to apoptosis
induced by high concentrations of NO than Th2 cells (149),
and low-to-moderate concentrations of NO can exert S-
nitrosylation-mediated antiapoptotic effects, the influence of
NO from constitutive NOS may improve Th1 viability and
influence the Th1/Th2 balance. Indeed, it has been reported
that Ras/MAPK signaling also plays an important role in T-
cell differentiation: strong signals from the antigen-engaged
TCR sustain ERK activation and favor Th1 differentiation,
whereas weak and transient TCR-mediated activation of
ERKs preferentially induces Th2 differentiation, a conse-
quence of increased Jak-1, STAT-6, and GATA-3 activation
(193). A possible role for NO in Ras/ERK-mediated Th1/Th2
differentiation is supported by eNOS and NO donors regu-
lating ERK activity through Ras S-nitrosylation (68, 91).
Nevertheless, a recent study analyzing eNOS-deficient
C57BL/6 mice infected with L. major clearly showed that
eNOS does not play any role in the selection of the Th1/Th2
immune response to infection, although it enhanced granu-
locyte infiltration into lesions (46). However, it remains
possible that the actions of eNOS-derived NO in human and
mouse T-cell differentiation could be species specific (see
above).
Uveitis represents a group of sight-threatening intraocular
inflammatory diseases, including Behc¸et’s disease, birdshot
retinochoroidopathy, sympathetic ophthalmia, Vogt-Koyanagi-
Harada’s disease, and ocular sarcoidosis, which may have an
autoimmune etiology (131). EAU can be induced in suscep-
tible rodent species by immunization with the retinal protein,
interphotoreceptor retinoid-binding protein (IRBP) (181).
GSNO treatment ameliorates the disease due to its ability to
inhibit retinal expression of Th1 cytokines and T-cell prolif-
eration (61). In an earlier report, administration of IL-12 to
these animals protected them from disease due to apoptotic
deletion of detrimental T cells, inducing IFN-c overproduc-
tion and iNOS-derived NO (172). While not specifically as-
sessed, these results suggest that Th1 cells could be the subset
of detrimental T cells depleted. More recent work indicates
that uveitis is also associated with Th17 response (24, 181),
although we have not found reports of nitrosothiols partici-
pation in Th17-dependent uveitis.
Th17 Differentiation. Multiple sclerosis (MS) is a common
inflammatory disease of the central nervous system (CNS)
characterized by the instability and disruption of myelin, the
death of oligodendrocytes and axonal damage (80). A murine
EAE model of MS involves the induction of a neuroin-
flammatory disease by immunization with antigens derived
from myelin protein. This animal model is associated with
impaired integrity of the blood–brain barrier, upregulation of
adhesion molecules, and the invasion of vascular inflamma-
tory cells into the CNS.
In the recent years, increasing importance has been given to
Th17 cells as mediators of EAE, and NO has emerged as a
possible regulator of Th17 proliferation and function. NO
inhibits the proliferation and function of polarized Th17 cells,
and EAE is more severe in iNOS-deficient mice than in wild-
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type controls (128). Moreover, GSNO attenuates EAE, pro-
tecting myelin by restricting mononuclear cell infiltration and
inhibiting proinflammatory mediator expression (TNF-b,
IFN-c, and IL-1b), as well as by reducing IL-17 production
through the inactivation of STAT-3 and the reduction of RORc
expression, two essential transcription factors for Th17 cell
differentiation and function (139).
In EAE mice, differences in the S-nitrosoproteome have
been described by comparative biotin-switch and western
blot analysis, affecting cytoskeletal components (neurofila-
ment proteins, tubulin, and b-actin), metabolic enzymes
(GAPDH and neuronal-specific enolase), ion-channel-related
proteins (glutamate receptor NR2A), and myelin proteins
(2¢,3¢-cyclic nucleotide 3¢-phosphodiesterase) (14). Such find-
ings argue in favor of a neuroprotective role of iNOS-derived
NO in EAE, possibly through S-nitrosylation of specific
targets in Th17 cells. Nevertheless, since most of the S-
nitrosylated proteins identified in the aforementioned study
are abundant cellular proteins, in-depth screening with more
sensitive proteomic approaches would be required in EAE-
infiltrated T cells to search for key S-nitrosylation targets that
may influence Th17 differentiation and function. Conversely,
the participation of NO in the etiopathology of EAE is not
an exclusive hallmark of iNOS. In EAE studies with eNOS-
deficient mice, eNOS-derived NO appears to favor the re-
cruitment of T lymphocytes to the CNS, whereas it attenuates
EAE exacerbation. Thus, eNOS fulfills proinflammatory and
neuroprotective roles during the course of the disease (191).
Whether this latter effect involves protein S-nitrosylation re-
mains to be investigated.
Th2 and Tregs. The preferential role for oxidative stress
and superoxide in the differentiation toward Th2 phenotypes
has recently been highlighted (23, 84). There is also evidence
indicating that nitrosothiols may be important for Th2 dif-
ferentiation and function. Treatment of human bronchial ep-
ithelial cells with NO reversibly suppresses proliferation of
activated Th2 cells in atopic asthma (35). Moreover, S-ni-
trosylated proteins are substantially reduced in asthmatic
patients, correlating fairly well with the increased GSNOR
levels in their bronchoalveolar fluids (140). These findings are
supported by studies carried out in an experimental mouse
model of asthma, in which mice deficient in the expression of
GSNOR were protected against hypersensitivity to the spe-
cific allergen and against hyper-reactivity to bronchocon-
strictors by increasing the levels of iNOS-derived S-
nitrosylated proteins in the lungs, an effect reverted by
treatment with NOS inhibitors (141). Furthermore, proteomic
studies of T lymphocytes have shown that Trx and other re-
dox control proteins are increased in T cells from asthmatic
patients with respect to healthy controls (77).
Several types of Tregs have been implicated in the gener-
ation of tolerance to exacerbated inflammatory responses.
These include natural and adaptive CD4+ CD25+ , Foxp3 +
Tregs. Natural Tregs develop in the thymus, whereas adap-
tive Tregs can be generated by repetitive antigen presentation
to naive CD4 +CD25- T cells by immature or tolerogenic DCs
(22, 78, 179). Although recent studies have clearly shown that
NO can negatively regulate classical Treg differentiation by
inhibiting Foxp3 expression, supposedly through a cGMP-
dependent mechanism (16, 93), several lines of evidence do
not exclude a role for iNOS-derived NO and S-nitrosylation in
the function of Tregs. First, in response to autoantigens, Tregs
secrete IFN-c and induce iNOS-derived NO production by
APCs. The APC-derived NO suppresses the proliferation of
pathogenic T cells, thereby inhibiting the course of autoim-
mune diseases (8, 21, 171). Second, DCs expressing a kinase-
defective dominant-negative form of Ikappa B kinase-2
(dnIKK2) show an impaired allostimulatory ability to upre-
gulate MHC-II antigens and costimulatory molecules in re-
sponse to either LPS or CD40 engagement (2). Naivemurine T
cells stimulated with antigen-loaded immature dnIKK2 DCs
differentiate into CD4 +CD25 - Tregs (dnIKK2-Tregs). These
Tregs express iNOS, and have the ability to inhibit naive and
preactivated T-cell responses in vitro (1). Finally, recent
studies demonstrated the existence of a population of Tregs
(NO-Treg) generated by NO in a cGMP-independent man-
ner via p53-mediated expression of antiapoptotic genes and
local secretion of IL-2 (129). NO-Tregs are a subset of T lym-
phocytes induced by NO together with TcR-mediated acti-
vation. They are CD4+CD25 + , Foxp3- , GITR + , and CD27 + ,
and they have a Th2 phenotype that suppresses CD4 +CD25 -
effector T cells, exerting their activities in an IL-10-dependent
manner. Nonetheless, there is still no consistent evidence
that NO-involved Treg functions may take place through
S-nitrosylation, beyond a recent report indicating that
Tregs express high levels of Trx-1, which may confer resis-
tance to the characteristic oxidative stress of inflammatory
foci (120).
Collectively, these diverse lines of evidence suggest that
NO can regulate T-cell differentiation and function through a
variety of mechanisms, some of them involving the partici-
pation of S-nitrosylation, which provides benefits in the
course of chronic inflammatory diseases, presumably by
disturbing the differentiation and/or function of Th1, Th2,
and/or Th17 cells, while the effects on Tregs remain un-
known.
S-Nitrosylation as a Therapeutic Agent in Chronic
Inflammatory Diseases
Crohn’s disease is a chronic inflammatory disease of the
gastrointestinal tract, which is probably caused by an imbal-
ance between proinflammatory and anti-inflammatory me-
diators, and is associated with a permeability disorder of the
mucosal barrier (26, 138) (Table 1). A murine model of the
disease has been obtained by expressing the herpes simplex
virus thymidine kinase (HSV-Tk) gene under the control of the
astroglial-specific promoter for glial fibrillary acid protein
(GFAP). Ganciclovir administration provokes enteric glial
ablation in this model, leading to intestinal inflammation and
an apparent disruption of the intestinal epithelial monolayer
(18). In these mice, GSNO was implicated in promoting the
function of the mucosal barrier (154). At low concentrations,
and unlike GSH or GSSG, GSNO reduced the intestinal per-
meability caused by enteric glial cell ablation, and it protected
these transgenic mice from intestinal inflammation. ZO-1 is a
protein implicated in the formation of tight junctions, and its
interaction with actin might directly regulate barrier integrity
and permeability. ZO-1 expression increased after exposure to
GSNO exposure, a possible means by which GSNO might
help maintain mucosal barrier function. This protein may also
be regulated by GSNO through PTMs, since ZO-1 protein has
a cysteine in a transnitrosylation consensus motif situated in
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the C-terminal actin-binding region (154). Future studies
might elucidate the mechanisms involved.
Mannose-binding lectin (MBL) is a complement-activating
protein involved in innate immune defense. MBL deficit or
dysfunction is associated with autoimmune diseases such
as lupus erythematosus and rheumatoid arthritis (55, 82). S-
nitrosylated MBL was detected in synovial fluid of rheuma-
toid arthritis patients (59, 65), and there is evidence of the
potential harmful effects that S-nitrosylation of MBL might
provoke in such patients, including impaired function (man-
nan binding, complement deposition, bacterial opsonization,
agglutination and phagocytosis, and induction of apoptosis)
and increased anti-MBL autoantibody generation (59). Given
the possible conformational changes in the MBL structure
after S-nitrosylation of one or some of its cysteines, it would be
of interest to further investigate these potential changes and
which cysteine residues might be modified.
Inhaled NO has been used therapeutically in the treat-
ment of acute lung injury, a poorly understood inflamma-
tory syndrome with a significant influence on public health
(33). Nevertheless, NO might be not so efficient in treating
this disease, since its use may increase the formation of
deleterious RNS. By studying lung inflammation in a
mouse model of LPS-induced airway injury, it was recently
shown that inhalation of ethyl nitrite (ENO), a gas that
fosters S-nitrosylation, may decrease lung inflammation
and injury in mice by inhibiting epithelial activation in the
airways (103). S-nitrosylation homeostasis in the lung was
disrupted on LPS treatment, which reduced S-nitrosylation
levels and increased NF-jB activation, which was pre-
vented by pretreatment with the S-nitrosylating agent ENO
(103).
In conjunction, the findings that managing the levels of
S-nitrosylation may be useful in treating those chronic in-
flammatory diseases in which S-nitrosylation homeostasis
is altered considerably are promising. In this regard, S-
nitrosylating/denitrosylating agents may represent thera-
peutic tools for the prevention and/or treatment of this group
of diseases. Thus, it is reasonable to expect that in the coming
years, these tools could be further developed into more effi-
cient treatments.
Conclusions
S-nitrosylation is increasingly being considered as a
signaling mechanism in many cells and systems. In the
immune system, several signaling pathways are modulated
by this oxidative PTM in the regulation of T-helper cell re-
sponses during adaptive immunity, as well as in the innate
immunity mediated by phagocytes. Indeed, self-protection
mechanisms of macrophages, specialized cells that use NO
and RNS production as antimicrobial weapons, have begun
to be uncovered. Further work will be required to study
these issues in more detail within broader contexts, both
from the molecular and pathophysiological points of view,
which will benefit from methodological improvements to
analyze and quantify the S-nitrosoproteome. There is ac-
cumulating evidence of the positive role for nitrosothiols
and S-nitrosylation in T-cell regulation, demonstrating
beneficial effects in autoimmune disease models, which
certainly could be further explored and potentially trans-
lated to improve disease treatment.
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Specificity in S-Nitrosylation:
A Short-Range Mechanism for NO Signaling?
Antonio Martı´nez-Ruiz,1 Ineˆs M. Arau´jo,2,3 Alicia Izquierdo-A´lvarez,1
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Abstract
Significance: Nitric oxide (NO) classical and less classical signaling mechanisms (through interaction with sol-
uble guanylate cyclase and cytochrome c oxidase, respectively) operate through direct binding of NO to protein
metal centers, and rely on diffusibility of the NO molecule. S-Nitrosylation, a covalent post-translational
modification of protein cysteines, has emerged as a paradigm of nonclassical NO signaling. Recent Advances:
Several nonenzymatic mechanisms for S-nitrosylation formation and destruction have been described. Enzy-
matic mechanisms for transnitrosylation and denitrosylation have been also studied as regulators of the mod-
ification of specific subsets of proteins. The advancement of modification-specific proteomic methodologies has
allowed progress in the study of diverse S-nitrosoproteomes, raising clues and questions about the parameters
for determining the protein specificity of the modification. Critical Issues: We propose that S-nitrosylation is
mainly a short-range mechanism of NO signaling, exerted in a relatively limited range of action around the NO
sources, and tightly related to the very controlled regulation of subcellular localization of nitric oxide synthases.
We review the nonenzymatic and enzymatic mechanisms that support this concept, as well as physiological
examples of mammalian systems that illustrate well the precise compartmentalization of S-nitrosylation. Future
Directions: Individual and proteomic studies of protein S-nitrosylation-based signaling should take into account
the subcellular localization in order to gain further insight into the functional role of this modification in
(patho)physiological settings. Antioxid. Redox Signal. 00, 000–000.
Introduction
Nitric oxide (NO) is clearly recognized as a signalingmolecule in different pathways. A hallmark in this rec-
ognition came from the identification of NO as the endothe-
lial-derived relaxing factor (EDRF), a factor produced by
endothelial cells that induced vascular relaxation by operat-
ing on smoothmuscle cells (52, 68). It was the firstmammalian
gas molecule discovered as a second messenger in a signaling
pathway that included its production from L-arginine by a
family of nitric oxide synthases (NOSs), and generation of
cyclic GMP (cGMP) after the activation of soluble guanylate
cyclase (sGC) by NO binding through a high-affinity metal
coordination bond (26, 127). This may be considered as the
‘‘classical’’ mechanism of NO signaling (103, 106), and it in-
cludes a clear example of paracrine signaling, as NO pro-
duced in endothelial cells reacts with sGC located in smooth
muscle cells, taking advantage of its ability to diffuse across
biological membranes. In a similar way, NO produced in one
neuron diffuses and acts upon surrounding neurons. Another
well-established but ‘‘less classical’’ signaling mechanism of
NO operates through the inhibition of cytochrome c oxidase,
the complex IV of the oxidative phosphorylation system. Both
signaling mechanisms rely on direct binding of NO to protein
1Servicio de Inmunologı´a, Hospital Universitario de La Princesa, Instituto de Investigacio´n Sanitaria Princesa (IP), Madrid, Spain.
2Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, and 3IBB-Institute for Biotechnology and Bioengi-
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metal centers through coordination chemistry (reviewed in
Refs. 103–106).
In addition, several ‘‘nonclassical’’ nitric oxide signaling
mechanisms have been described, which rely mainly on co-
valent post-translational protein modification by a series of
reactive nitrogen species (RNS) derived from the reaction of
NO with other small molecules, including free radicals. Tyr-
osine nitration is associated with formation of peroxynitrite
(ONOO - ) and nitrogen dioxide (NO2), and is considered
mainly as an irreversible modification that can impact on
some signaling pathways (69, 124, 133, 145). Cysteine residues
can be oxidized following RNS formation: ONOO - induces
formation of oxygenated forms (sulfenic acid, - SOH; sulfinic
acid, - SO2H; sulfonic acid, - SO3H), and S-glutathionylation
and other forms of S-thiolation are induced both by ONOO-
and nitrosothiol formation (3, 103, 105, 106, 111, 134, 157, 163).
S-Nitrosylation (also called S-nitrosation; see Refs. 42, 73,
104 for a discussion of the terminology) has emerged as one of
the main mechanisms of nonclassical NO signaling. It implies
the formation of a nitrosothiol (or thionitrite, R-S-N =O) at a
cysteine residue, a subtle modification that has been shown to
alter the functionality of a number of proteins. There are
several reviews that highlight the particular characteristics of
S-nitrosylation supporting its relevance as a mechanism of
redox signaling related to NO production, as well as its im-
plications in (patho)physiology in several species (35, 44, 61,
73, 83, 90, 104, 105, 141, 160). At least for some proteins, it has
been shown that S-nitrosylation leads to disulfide formation
(including S-glutathionylation), so it could be considered as
an intermediate to such more stable modifications (reviewed
in Refs. 73, 103, 105). For each case, detailed studies could
establish if the different PTMs may have the same or differ-
ent functional consequences, but it seems clear that this pos-
sibility has be integrated when studying signaling by
S-nitrosylation.
Our aim is to review the factors that confer specificity to S-
nitrosylation in order to be considered a signaling mecha-
nism, with the proposal that its signaling function is exerted
mainly in the short range, close to the NO producing sources
(mainly NOS enzymes), and thus very dependent on their
precise subcellular localization (Fig. 1). In addition, we pro-
vide some examples in which this short-range signaling oc-
curs in the context of specific human and mammalian cell
systems.
Biochemistry of S-Nitrosylation Specificity
Nonenzymatic biochemistry of S-nitrosylation formation
Several biochemical mechanisms have been postulated for
nitrosothiol formation without requiring the presence of en-
zymes to catalyze it. Direct reaction of NO with cysteine res-
idues is only relevant when the thiyl radical (P-S) has been
formed,
P-S þ NO/P-S-NO
which is relatively rare. This poses a substantial difference
with classical and less classical NO signaling mechanisms,
which are based on the direct reaction of NO with target
proteins, and in which specificity relies on structural deter-
minants that favor NO binding to particular metal centers.
In the case of S-nitrosylation, the formation of other RNS is
required, as the result of the reaction of NO with other
species.
Reactions of NO with O2 form a series of nitrogen oxides,
with different oxidation states for the N atoms; among them,
N2O3 is considered as a main nitrosating agent producing
nitrite and a nitrosothiol:
N2O3þRSH/RSNOþHþ þNO2
However, the implication of N2O3 as a relevant nitrosating
agent in biochemical environments has been challenged,
mainly because its formation depends on the reaction of NO
and O2, also called NO auto-oxidation
2 NOþO2/2 NO2
NO2þNO/N2O3
and the reaction rate for its formation in water has been
estimated as Rate= k [NO]2 [O2] with k being around 2–5· 106
M- 2 s - 1, consistent with the rate-limiting formation of NO2
(11, 48, 165). Kinetic models integrating these reactions with
the formation of other RNS have shown that N2O3 formation
would not be very important at the NO concentrations esti-
mated for biological systems (82, 87).
However, two facts can be considered that argue in favor
of the relevance of this mechanism in localized cellular
FIG. 1. Short-range and long-range NO signaling. Clas-
sical NO signaling, such as sGC activation, can be exerted at
a relatively long distance from NO sources (NOS enzymes),
even if NO concentration diminishes while targets are farther
from the NOS. We postulate that S-nitrosylation of target
proteins (TP) is essentially a short-range mechanism, limited
to a tiny sphere around NOS. Among other factors described
in the text, RNS formation requires higher NO concentra-
tions, which are easier to achieve in the NOS surroundings
(this is more clear in interacting proteins, IP), and deni-
trosylases such as Trx or GSNOR with GSH can narrow the
range of action by reducing target protein S-nitrosylation.
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environments. First, the reaction rate is very sensitive to the
concentrations of the reactants, particularly NO. In a cell
system where reactants concentrations are not in equilibrium,
NO concentration would be much higher in a relatively small
virtual sphere surrounding the NOS enzymes, allowing for
faster formation of N2O3 and thiol S-nitrosylation. Second, it
has been shown that in hydrophobic environments such as
biological membranes, the same third-order rate law is ob-
served, but the rate constant is increased up to 300 times (97,
113, 114); even with this rate acceleration, the overall NO fate
would not be affected, but the reaction would be relevant
enough to produce localized nitrosating species in membrane
regions (114), where NOS enzymes localize due to their
membrane binding structures.
An alternative mechanism for S-nitrosylation by nitrogen
oxides involves the thiyl formation by NO2 and subsequent
reaction with NO (76):
NO2þRSH/R-S þNO2 þHþ
NOþR-S/RSNO
Again, the rate limiting step is the formation of NO2, and it
also requires an additional NO molecule, so the same con-
siderations for the localized formation of N2O3 apply to this
mechanism.
Metal-catalyzed formation of nitrosothiols has been de-
scribed, mainly explained by a mechanism involving a one-
electron oxidation of NO by oxidized transition metals, such
as Fe3 + or Cu2 + ; the nitrosonium (NO+ ) formed could ni-
trosate a thiol in the proximity of such catalytic center (it is a
relatively unstable species):
Me(nþ 1)þ þNO/Men-NOþ
Men-NOþ þRSH/RSNOþMenþHþ
This mechanism has been shown to take part in specific
proteins, where it can be considered as an enzymatic ‘‘ni-
trosylase’’ mechanism, such as in auto-nitrosylation of he-
moglobin and other globins, and in S-nitrosoglutathione
(GSNO) formation by ceruloplasmin or cytochrome c (re-
viewed in Refs. 5, 23, 53).
Recently, another pathway for S-nitrosylation formation
has been described that could operate through generation of
dinitrosyl-iron complexes (DNIC) fromNO (20), and evidence
has been found that DNIC can be a main form of NO in cells
(62). This pathwaywill certainly deserve further investigation
to assess the possible physiological role of these complexes as
catalyzers of S-nitrosylation, and to test whether they are
modified by subcellular localization.
Transnitrosylation
The nitroso group can be easily transferred between thiol
groups, in a reversible reaction called transnitrosylation (or
transnitrosation):
RSNOþR¢SH/RSHþR¢SNO
Transnitrosylation among low-molecular-mass (LMM) thiols
and protein thiols has been studied for a long time. LMM
nitrosothiols, and especially GSNO (as the main intracellular
LMM thiol is glutathione) can be considered as putative
S-nitrosylation vectors in cells that could transmit the S-ni-
trosylation signal from the nitrosothiol-producing foci to po-
tential protein targets. A recent study that analyzed the
structural features of confirmed protein S-nitrosylation sites
in the literature has postulated that a subset of proteins and
residues could be specifically transnitrosylated by GSNO
(101). However, the reaction of GSNO with protein thiols is
more complicated, as it can also form a mixed disulfide by
S-glutathionylation (reviewed in Refs. 80, 103, 105, 111), most
probably with formation of nitroxyl (HNO):
PSHþGSNO/PSNOþGSH
PSHþGSNO/PSSGþHNO
Thus it would be interesting to compare the structural fea-
tures regulating the balance between these reactions.
Several groups have recently described transnitrosylation
reactions between proteins. These include protein–protein
interaction determinants as specificity factors, as is the case
in other enzymatic post-translational modifications used in
signal transduction, such as phosphorylation. Each of the
described transnitrosylases may have a restricted or broader
range of target proteins and residues that can be preferentially
S-nitrosylated due to their specific interactions. The nitroso
group is transferred by equilibrium reactions and thus the
thermodynamic comparison between both reactions (which
can also be described with the redox potentials) has also to be
considered. Recent reviews have thoroughly covered protein–
protein transnitrosylation (5, 119), so we will just briefly de-
scribe the most relevant transnitrosylases.
Early studies on S-nitrosylated hemoglobin (SNO-Hb) re-
ported that it was able to release NO to the blood flow causing
an increase in blood pressure (50, 75, 142). Hb presents a heme
group in each of its four subunits with a central iron atom,
where O2 binds. When O2 concentration is low, NO binds to
the iron; by an auto-S-nitrosylation reaction, this NOmoiety is
transferred to Cys93, and Hb suffers a conformational change
from relaxed to tense structure. A clue for the export of theNO
moiety came from the description of transnitrosylation from
SNO-Hb to the most abundant protein in red blood cells, the
Anion Exchanger 1 (AE1) (128). SNO-Hb interacts withAE1 in
the erythrocyte membrane, promoting its transnitrosylation;
subsequently the NO moiety leaves AE1 and diffuses into
vessels (128). However, how this NO moiety is transferred
from AE1 protein to vessels remains unclear.
Caspase-3 inactivation by S-nitrosylation of an active site
Cys (Cys163) is reverted during Fas-induced signaling (100).
The thioredoxin (Trx) system was described as a caspase-3
activator by denitrosylation via two different biochemical
mechanisms (112). The first one implies thiol reduction in a
‘‘classical’’ way bymeans of its two active site Cys (Cys32 and
Cys35) (8, 86). The second one is a transference of the NO
moiety from caspase-3 to Trx by transnitrosylation of Cys32 in
Trx. S-Nitrosylation of nonactive Cys has also been described,
particularly Cys62, Cys69, and Cys73, in conditions where
active site cysteines were oxidized (54, 59, 166). A recent
study, using C32S and C35S mutants, demonstrated that Trx
S-nitrosylated in Cys73 is able to transnitrosylate many cel-
lular targets including caspase-3 (112, 166, 168). Interestingly,
when Trx is S-nitrosylated in Cys73, the disulfide bond in the
active site C32–C35 is not reduced by Trx reductase; both
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enzymes are then uncoupled, which can be a mechanism to
prevent the denitrosylase activity of Trx while promoting its
transnitrosylase activity (59). Figure 2 summarizes the trans-
nitrosylation and denitrosylation mechanisms involved in
caspase-3 activation and inhibition in physiological and stress
conditions.
Recently, S-nitrosylation of XIAP, one of the most impor-
tant caspase-3/7/9 inhibitory proteins, was described in
neurons (120, 155). As a consequence of this nitrosylation, the
E3 ubiquitin ligase activity of XIAP is decreased and caspase
degradation is inhibited, favoring apoptosis. This process is
especially important in neurodegenerative diseases such as
Alzheimer (AD), Parkinson (PD), and Huntington (HD) dis-
eases, where a high content of SNO-XIAP was observed,
suggesting that this reaction contributes to neuronal damage
in these diseases. Interestingly, caspase-3 is able to transni-
trosylate XIAP in pathophysiological situations of nitrosative
stress or excitotoxicity, promoting apoptosis both by the
protease activity of caspase-3 and impairing its degradation
by inhibition of XIAP (120, 155).
In AD, amyloid-b peptide oligomerization provokes an
increase in NO production, which leads to S-nitrosylation of
Cdk5 (132). SNO-Cdk5 transnitrosylates dynamin related
protein 1 (Drp1) in Cys644 (28). This reaction causes a mito-
chondrial fission hyperactivation as well as a compromise in
mitochondrial bioenergetics which, in synaptic structures,
could lead to synaptic loss (28, 159).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
also implicated in transnitrosylation processes. GAPDH is S-
nitrosylated in its Cys150 residue; S-nitrosylated GAPDH
interacts with Siah1, and it is translocated to the nucleus
due to Siah1 nuclear localization signal (56). Once in the nu-
cleus, SNO-GAPDH transnitrosylates proteins such as SIRT1,
HDAC2, andDNA-PK, affectingmetabolic pathways, normal
aging processes, chromatin remodeling in neuronal develop-
ment, or neurodegeneration (81, 121).
Transnitrosylation has been involved in the formation of
pulmonary arterial hypertension (PAH). Mice chronically
treated with N-acetylcysteine (NAC) or its S-nitrosylated
form, S-nitroso-N-acetylcysteine (SNOAC), developed PAH,
mimicking the effects of chronic hypoxia (126). This study
showed that NAC needs to be converted to SNOAC and that
activation of the HIF-dependent hypoxia response through
transnitrosylation of particular proteins in the canonical HIF
activation pathway (such as pVHL) could be among the mo-
lecular mechanisms responsible for this effect (126).
Denitrosylases
Removal of the nitroso group is another important aspect
of S-nitrosylation signaling. It is generally accepted that
S-nitrosylation is a labile modification, and that the levels of
cellular nitrosothiols are low, due to a rapid turnover. Deni-
trosylation was firstly conceived as an unregulated and
spontaneous process, and several nonenzymatic mechanisms
of denitrosylation have been described that could potentially
act in vivo. These include reactions mediated by nucleophilic
compounds, transition metal ions, reactive oxygen species
(ROS), and ascorbate (reviewed in Ref. 147).
Accumulating evidence shows that several enzymes can
catalyze denitrosylation in vitro (14, 64, 77, 143, 154) and
in vivo (16, 95) (reviewed in Refs. 5, 17). These enzymes may
contribute to spacially limit the action of S-nitrosylation
events, helping to keep their precise subcellular localization
close to NO sources. They also may help to protect cells
from ‘‘excessive’’ S-nitrosylation, as, for example, when
inducible nitric oxide synthase (iNOS) is induced in im-
mune cells in order to attack pathogens (reviewed in Ref.
60). In addition, they provide another mechanism of spec-
ificity and regulation since these enzymes may act over
defined sets of substrate proteins. This is more important in
examples of tightly regulated denitrosylation that may ac-
tivate precise signals, such as the case of Fas-induced cas-
pase-3 denitrosylation (100), which can be mediated by Trx
(16), or receptor-regulated endothelial nitric oxide synthase
(eNOS) activation (37).
Two main enzymatic mechanisms of denitrosylation
have emerged in recent studies, GSNO reductase and the
thioredoxin system. GSNO reductase (GSNOR) is an evolu-
tionary conserved enzyme system previously known as al-
cohol dehydrogenase class III. GSH can react with a protein
nitrosothiol leading to either transnitrosylation and subse-
quent generation of S-nitrosoglutathione (GSNO) or glu-
tathionylation of the protein, in both cases with subsequent
FIG. 2. Summary of trans-
nitrosylation reactions be-
tween Trx, caspase-3, and
XIAP that leads to caspase-3
activity regulation, including
Cys residues that undergo S-
nitrosylation. The active site of
Trx denitrosylases caspase-3 in
normal conditions, producing
HNO and its own disulfide,
which is reduced back by Trx
reductase (TR). When its active
site Cys is oxidized, Trx S-
nitrosylated in Cys73 is able to
transnitrosylate caspase-3 in
Cys163. S-nitrosylated caspase-
3 may also transnitrosylate its
inhibitor XIAP, leading to a
release of caspase-3.
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release of the NO group from the protein thiol. This is
supported by the observation that addition of GSH to SNO-
proteins leads to their denitrosylation (125). GSNOR mainly
catalyzes the denitrosylation of GSNO towards GSSG, uti-
lizing NADH as an electron donor. The cycle is completed as
GSSG is reduced by glutathione reductase and NADPH. Al-
though GSNOR does not directly act on protein nitrosothiols,
an equilibrium between GSNO and SNO-proteins is main-
tained by transnitrosylation, since GSNOR-knockout mice
showed increased levels of both GSNO and SNO-proteins
after nitrosothiol addition or lipopolysaccharide (LPS) treat-
ment (95, 96).
GSNOR participates in signal transduction through G
protein-coupled receptors (GPCRs) and, in particular, b2-
adrenergic receptor (b2-AR). Upon agonist stimulation, GPCR
kinases (GRKs) 2 and 3 are recruited to the plasmamembrane
by interaction with Gbc subunits and phosphorylate the b2-
AR at the cytoplasmic tail (Fig. 3). This allows b-arrestin 2 to
be transiently recruited by the activated receptor and driven
to clathrin-coated pits where, after its dissociation, the re-
ceptor internalizes and becomes desensitized (reviewed in
Ref. 135). Both GRK2 and b-arrestin 2 S-nitrosylations are
controlled by GSNOR since both augment in GSNOR-
knockout mice. S-Nitrosylation at GRK2 Cys340 decreased its
kinase activity, b-arrestin 2 interaction and b2-AR internaliza-
tion and desensitization (164). On the other hand, binding of
b-arrestin 2 to the clathrin pit is promoted by S-nitrosylation,
which in turn increases b2-AR internalization (123). This dif-
ferential regulation of GPCR signaling by S-nitrosylation
suggests that local denitrosylation of particular elements be-
comes important for cell signaling. GSNOR has been linked
with the development and protection against several diseases.
S-Nitrosylation of O6-alkylguanine-DNA alkyl transferase
(AGT) in the liver of GSNOR - /- mice after LPS or diethylni-
trosamine treatment promoted decreased capability of DNA
repair, thus increasing hepatocellular carcinoma incidence
(162). On the other hand, GSNORdeficiency protected against
myocardial infarction (89).
The other best known denitrosylase is the thioredoxin (Trx)
system. While GSNOR denitrosylates SNO-proteins indi-
rectly through GSNO formation, Trx system has been shown
to denitrosylate them directly. As mentioned above, un-
coupled Trx can act as a transnitrosylase when its Cys73 is
S-nitrosylated, after disulfide formation between catalytic
Cys32 and Cys35; however, for its denitrosylase function it
uses the catalytic center with both Cys32 and Cys35 in their
reduced state (167). Trx establishes a disulfide bridge with the
substrate SNO-protein allowing the release of the NO (in the
form of HNO) (16). An intramolecular disulfide bond is then
formed between Cys32 and Cys35, substituting the intermo-
lecular disulfide. Thioredoxin reductase (TR) is in charge of
restoring the reduced state of these Cys through a NADPH–
dependent reduction of the Trx intramolecular disulfide.
Trx1 was identified as the caspase-3 constitutive and cy-
tosolic denitrosylase since inhibition of Trx1 or TR1 produced
increased amounts of SNO-caspase-3 (16). On the other hand,
Trx2 was identified as a denitrosylase of mitochondrial cas-
pase-3 upon Fas ligand stimulation, a process required for its
activation and, therefore, for apoptotic cell death (16). Fur-
thermore, the Trx-interacting protein (Txnip) has been shown
to inhibit denitrosylate activity of Trx, since it increases SNO-
protein levels (43).
Proteomic analyses have helped to highlight Trx as a de-
nitrosylase. In cytokine-activated macrophages where iNOS
is induced, we used a ‘‘fluorescence switch’’ technique to label
S-nitrosylated proteins, identifying eleven proteins that were
differentially S-nitrosylated when the thioredoxin reductase
was inhibited with auranofin (152). Benhar et al. used a
quantitative LC-MS/MS approach to identify proteins that
were denitrosylated when they added Trx/TR to cell extracts
that had been nitrosylated in vitro (18). Interestingly, Trx
targets of transnitrosylase activity could be differentiated
from those of denitrosylation, providing specificity to the
search of Trx substrates in the context of S-nitrosylation (168).
Denitrosylation has emerged as a relevant mechanism by
which functional relevance of S-nitrosylation is regulated.
FIG. 3. Agonist-stimulated
internalization of b2-AR is
regulated by S-nitrosylation.
After agonist (epinephrine)
stimulation, b2-AR stimulates
separation of a from b and
c subunits of the G protein.
The two latter subunits
bind reduced GRK2, which
phosphorylates b2-AR. S-
Nitrosylation of GRK2 pre-
vents its binding to b and c
subunits. Once phosphory-
lated, b2-AR recruits b-arrestin
which becomes S-nitrosylated
and subsequently binds to
AP2 and clathrin, thus allow-
ing internalization. If b-
arrestin is not S-nitrosylated,
internalization of b2-AR be-
comes attenuated.
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Study of the dynamic equilibrium between nitrosothiol gen-
eration and its removal, as well as the enzymes implicated
will provide more accurate knowledge of S-nitrosylation
regulation in vivo and their connection with diseases.
Regulation of S-Nitrosylation by Subcellular
Localization of eNOS
Despite some evidence indicating a possible role for the
compartmentalization of iNOS and short-range actions of
high levels of NO in protein S-nitrosylation—for instance, in
the S-nitrosylation of matrix metalloproteinase 9 (MMP-9) at
the leading edge of migrating cells, and chloride intracellular
channel 4 (CLIC4) during its nuclear translocation in macro-
phages (58, 99)—eNOS and neuronal nitric oxide synthase
(nNOS) are the prototypic NOS whose dependence between
localization and S-nitrosylation has been more extensively
studied (70, 151).
In cells, eNOS traffics between the plasma membrane and
the cytoplasmic face of the Golgi apparatus by means of both
specific interaction with proteins involved in vesicle traf-
ficking and a cycle of palmitoylation/depalmitoylation on
Cys15/Cys26, two amino acid residues whose mutations do
not affect the catalytic activity of the enzyme itself but de-
crease NO production in cells due to alteration of eNOS lo-
calization (36, 94, 122, 146). A large body of work indicates
that the confinement of eNOS in cell compartments and its
proximity or binding to target proteins may lead to selective
S-nitrosylation.
eNOS at the plasma membrane
Several studies have shown that preferential localization of
eNOS at the plasma membrane produces higher levels of NO
and S-nitrosylation in this region than in the Golgi apparatus.
At the plasma membrane, eNOS is retained in its low active
state associated to caveolin-1 in caveolae, and it is fully acti-
vated after dissociation from caveolin-1 by Ca2 +/calmodulin
binding and kinase-mediated phosphorylation on key serine
residues (Ser1177, Ser635, and Ser617); among them, phos-
phorylation of Ser1177 by Akt is particularly remarkable as
the most constant sign of eNOS activation (36, 46). In contrast,
the association of eNOS with the actin cytoskeleton by means
of its interaction with NOS-interacting protein (NOSIP) or its
trafficking towards the Golgi complex by binding to NOS
traffic inducer (NOSTRIN) can reduce eNOS activity, moving
the enzyme away from plasma membrane-associated signals
of activation (122). eNOS activity can also be negatively reg-
ulated through auto-S-nitrosylation on Cys94 and Cys99, a
negative feedback mechanism that affects NO synthesis by
impairing substrate binding and/or electron transfer at the
eNOS dimeric interface (36). Studies carried out with both
plasmamembrane-restricted eNOS and a cytoplasmic mutant
deficient in myristoylation on Gly2—which alters its mem-
brane binding and inhibits further palmitoylation—clearly
show thatmembrane localization is required for S-nitrosylation
(37, 38). Since eNOS can be reversibly S-nitrosylated, com-
partmentalized S-nitrosylation of eNOS might be favored, for
instance, by environments devoid of denitrosylases such as
thioredoxin or GSNOR. However, complementary studies
carried out with compartment-targeted iNOS constructs
and calcium-independent eNOS showed no differences be-
tween the activities of these mutants irrespectively of their
subcellular localization (32, 72, 131), suggesting that the lev-
els of NO produced are the most important factors for lo-
calized S-nitrosylation and that, in the case of constitutive/
regulatable NOS, proximity to the upstream signaling
pathways—Ca2 +/calmodulin and Ser/Thr kinases—may
explain the differences in NO production and S-nitrosylation
observed between membrane cell compartments.
In addition to auto-S-nitrosylation of eNOS, other proteins
involved in what can be called the ‘‘eNOS system’’ are targets
of S-nitrosylation, which can alter the system activity. The
eNOS-binding protein caveolin-1 is constitutively S-ni-
trosylated in endothelial cells (117), although if this can reg-
ulate eNOS localization and activity has not been described,
to our knowledge. The chaperone Hsp90 also interacts with
eNOS, increasing its affinity for calmodulin and Akt, and thus
its activity (51, 149). We have shown that Hsp90 can be
S-nitrosylated in Cys597 (107), an amino acid residue located
in the region of interaction with eNOS (40). This modification
inhibits the ATPase activity of Hsp90, and its ability to acti-
vate eNOS, representing an additional S-nitrosylation-based
feedback mechanism modulating eNOS activity. It is worth
noting that the binding of Hsp90 to NOS is not an exclusive
hallmark of eNOS since both nNOS and iNOS can also be
activated by binding to Hsp90 (129, 169). Whether nNOS
and/or iNOS may also S-nitrosylate Hsp90 in the context of a
negative regulatory feedback loop of NOS activation, and
whether their subcellular localization is actually important for
Hsp90 S-nitrosylation deserves further research.
An increasing number of proteins S-nitrosylated by eNOS
at the plasma membrane have been identified over the last
years. eNOS can interact with the GTPase dynamin-2, in-
creasing receptor-mediated endocytosis through S-nitrosylation
of Cys607, a modification that fosters dynamin oligomeriza-
tion and GTPase-dependent vesicle scission from the plasma
membrane (25, 158). Interestingly, a recent report suggested a
role for eNOS and dynamin-2 in the immune-escape of ur-
opathogenic strains of Escherichia coli (161). The study shows
that E. coli invasion of bladder epithelial cells in recurrent
urinary tract infections is facilitated by endocytosis mediated
by eNOS-dependent S-nitrosylation of dynamin-2. It would
be important to address if this is a general mechanism of es-
cape for those microorganisms infecting hosts through NO-
producing specialized barriers. b-Arrestin is also regulated by
eNOS-dependent S-nitrosylation; it forms a complex with
eNOS that translocates to GPCRs upon agonist binding, re-
sulting in eNOS activation and b-arrestin S-nitrosylation
(123). Once b-arrestin is S-nitrosylated, eNOS dissociates from
the complex, and stimulated GPCRs can internalize by asso-
ciation with the clathrin-b-arrestin endocytic machinery (123).
b-Catenin, an essential component of adherens junctions—
intercellular structures controlling permeability on epithelial
and endothelial monolayers—is also a target of S-nitrosylation
by eNOS. Stimulation of endothelial cells with VEGF induces
eNOS-dependent S-nitrosylation of b-catenin on Cys619, an
important amino acid residue for the interaction with VE-
cadherin and the preservation of the permeability cell barrier
(153). Up to our knowledge, it is not clear yet if there is a direct
interaction between eNOS and b-catenin. H-Ras, a Ras iso-
form localized both at the plasma membrane and the Golgi
complex, has recently been added to the list of proteins that
can be activated at the plasmamembrane by eNOS-dependent
S-nitrosylation. In endothelial cells, bradykinin stimulation
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induces preferential activation of H-Ras at the plasma mem-
brane through a mechanism independent of Src activation
which involves S-nitrosylation of H-Ras on Cys118 (15).
N-Ethylmaleimide-sensitive fusion protein (NSF), a SNARE
regulator involved in vesicular trafficking and exocytosis of
platelet a-granules and Weibel-Palade bodies from endothe-
lial cells, is also S-nitrosylated by eNOS as demonstrated
using NOS inhibitors and eNOS-deficient cells (109, 116).
S-Nitrosylation of NSF reduces granule exocytosis by stabi-
lizing SNARE complexes in vesicles. The possible role played
by the compartmentalized activity of eNOS on NSF S-
nitrosylation has been studied, trying to discriminate the ef-
fects of Golgi and plasma membrane localization. Whereas a
recent study with eNOS directed to either plasma membrane
or Golgi found that eNOS induces higher levels of NSF
S-nitrosylation at the plasma membrane (131), imaging anal-
ysis from previous studies carried out with wild-type eNOS-
transfected COS-7 cells clearly showed that in response to
ATP eNOS produced NO mainly on the Golgi complex, a
compartment in which most of eNOS and S-nitrosylated
proteins are concentrated (71). In this regard, NSF trafficking
may play an important role in a cellular model of pulmonary
arterial hypertension induced with the pirrolizidine alkaloid
MCTP, which induces megalocytosis of pulmonary arterial
endothelial cells (117, 118). These studies show that MCTP
disrupts vesicular trafficking in endothelial cells, mislocaliz-
ing eNOS in the cytoplasm accompanied by loss of NO from
caveolae and reduced S-nitrosylation and localization of NSF
on the Golgi. Whether reduced NSF S-nitrosylation in MCTP-
induced aberrant trafficking is the consequence of eNOS
dysfunction at the plasma membrane, the Golgi complex, or
both remains an open question.
eNOS on the Golgi
Several studies have also shown that eNOS localiza-
tion on the Golgi complex is functional and contributes to
S-nitrosylation of Golgi-localized proteins (70). Although the
mechanisms involved in eNOS localization on the Golgi
complex are not fully understood, it is clear that palmitoyla-
tion on Cys15/Cys26 andNOSTRIN binding to eNOS play an
important role. In this regard, a recent study shows that ac-
tivation of the transcription factor STAT-3 by the adhesion
molecule PCAM-1 induces NOSTRIN expression and the
traffic of eNOS from the plasmamembrane towards the Golgi
complex (110). The role of subcellular localization on eNOS
activation has been studied by transfecting protein versions
with different localization signals. Transfection in COS-7 cells
showed that cis-Golgi-targeted eNOS was less sensitive to
activation by Ca2 +/calmodulin but more easily activated by
Akt-mediated phosphorylation on Ser1179, when compared
to the protein localized on the plasma membrane (45). Similar
cell transfection studies performed in eNOS-deficient endo-
thelial cells showed that on the Golgi complex eNOSmay also
result less sensitive to Akt activation but resistant to choles-
terol and LDL inhibition, releasing lower amounts of NO than
at the plasma membrane (170). Altogether, these reports
suggest that compartmentalized activity of eNOS on theGolgi
complex may be cell-type specific and/or that low to mod-
erate levels of NO would be enough to S-nitrosylate Golgi
resident proteins near eNOS, either due to an enhanced se-
lectivity for S-nitrosylation, or to decreased denitrosylation.
A recent proteomic study combining biotin-switch assay
and mass spectrometry has identified nine Golgi-resident
proteins S-nitrosylated in Golgi membranes isolated from
rat livers (136). Among those, the authors focused on the
study of extracellular matrix metalloproteinase inducer
(EMPRIN)—a member of the immunoglobulin superfamily
involved in invasion and metastasis—and Golgi phospho-
protein 3 (GOLPH3), a potential oncogene involved in protein
glycosylation and mTOR regulation. Both proteins interacted
with eNOS and co-localized with it on the Golgi of endothe-
lial cells, increasing their S-nitrosylation upon activation
with the Ca2 + ionophore ionomycin and also in pathophysi-
ological conditions such as cirrhosis (136).
In T cells, S-nitrosylation is mainly compartmentalized
near the Golgi complex, where active eNOS localizes. In this
compartment, eNOS S-nitrosylates N-Ras at Cys118, fostering
the conversion of GDP- to GTP-bound N-Ras, and the con-
sequent activation of the MAPKs ERK-1 and ERK-2 (67). In-
terestingly, although T cells express both K-Ras and N-Ras
(which share the same conserved Cys residue sensitive to
S-nitrosylation), only N-Ras becomes S-nitrosylated due to its
preferential localization on the Golgi, suggesting that prox-
imity of eNOS-derived NO to N-Ras is an important deter-
minant of S-nitrosylation and MAPK activation (Fig. 4).
MAPK phosphatase 7 (MKP7)—a negative regulator of the
MAPK JNK3—is S-nitrosylated by eNOS on Cys244 in re-
sponse to SDF-1, a CXC chemokine with proangiogenic
properties on endothelial cells (130). S-Nitrosylation reduces
the phosphatase activity of MKP7, increasing JNK3 activity,
and thus endothelial cell migration. Although there is no ev-
idence of compartmentalized S-nitrosylation of MKP7, since
the Golgi complex plays an important role in the regulation
of MAPK pathways (19), it would be interesting to explore
whether eNOS-mediated MKP7 S-nitrosylation may take
place on the Golgi.
Nitric Oxide Synthases and the Heart:
Role of Localized S-Nitrosylation
Very early since the characterization of eNOS in endothelial
cells, it was clear that this isoform was expressed in cardio-
myocytes and that NO could play a role as a regulator of
cardiac rhythm and inotropic responses (108, 139). It is now
accepted that the heart expresses both eNOS and nNOS, the
former in endothelial and endocardial cells, the latter in ner-
vous tissue and autonomic ganglia, and both in cardiomyo-
cytes. In addition, iNOS may be expressed upon exposure of
endothelial cells or cardiomyocytes to cytokines or proin-
flammatory stimuli (9, 12). A significant discovery which
shifted the view of the role of NO in the heart was related to
the topological confinement of NO signaling, whereby eNOS,
localized in caveolae, mainly directed its action towards the
inhibition of b-adrenergic-induced inotropy. In contrast,
nNOS, which is targeted to sarcoplasmic reticulum, stimu-
lates calcium release via the ryanodine receptor (RyR) with
an opposite effect on contractility (13). Both classical and
nonclassical modes of signaling (103) have been demon-
strated for NOwithin the heart. The classical cGMP-mediated
pathway is responsible for several important actions of NO
related to regulation of contractility and inhibition of cardiac
remodeling (see Ref. 55 for review). Elevation of cGMP levels
encompasses the activation of cGMP-dependent protein
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kinases (PKGs) that are important for the regulation of con-
tractility through the inhibition of the L-type Ca2 + channel
(LTCC). Noteworthy, cGMP signaling in cardiomyocytes is
also compartmentalized due to specific subcellular locali-
zation of soluble and particulate guanylate cyclases and of
phosphodiesterase enzymes (PDEs), thus offering another
example of subcellular localization as a major means to
control intracellular signaling. The nonclassical pathway is
inherently related to NO-induced post-translational modifi-
cations of thiols, such as S-nitrosylation and S-glutathionyla-
tion (103, 105, 106). For a comprehensive update on the role of
these PTMs in the cardiovascular system, the readers may
wish to consult recent excellent reviews (102, 138).
eNOS has been shown to localize mainly within the ca-
veolae of sarcolemma and T-tubules, which supports the idea
that NO generated through this isoform exerts its action on
vicinal cell surface receptors that regulate contractility, in-
cluding muscarinic, b-adrenergic, and bradykinin receptors
(57). The global eNOS effect is negative on chronotropy and
inotropy and is counteracted by the action of nNOS, circum-
scribed to the sarcoplasmic reticulum. Interactions of eNOS
and nNOS with other proteins sharing their subcellular lo-
calization, caveolin 3 and the RyR, respectively, are essential
to understanding their action on cardiac function (156).
S-Nitrosylation has been described to involve several proteins
regulating contractility including LTCC, RyR, Kv1.5 channel,
and sarcoplasmic/endoplasmic reticulum Ca2 + -activated
ATPase (SERCA). The ryanodine receptor Ca2 + release
channel (RyR2), together with SERCA2a, are critical compo-
nents of the excitation–contraction coupling molecular ma-
chinery. It has been proposed that the close apposition of
nNOS and RyR2 facilitates S-nitrosylation of the latter, in-
creasing its channel opening probability (88). A similar
mechanism may operate for the S-nitrosylation-induced reg-
ulation of LTCC and SERCA2a which has also been shown to
become activated by NO-induced S-glutathionylation (3).
A deficit of nNOS-mediated S-nitrosylation of RyR2 has
been associated with pathological cardiac responses such as
arrhythmia (49). Other ion channels have also been proposed
to undergo S-nitrosylation: intermediate conductance potas-
sium channel (IK1), late inward Na + current (InaL), slowly
activating delayed rectifier current (Iks), and ATP-sensitive
K + channel (see Ref. 150 for review). Finally, eNOS and vic-
inal scaffolding proteins are themselves potential targets for S-
nitrosylation, at least in endothelial cells (37, 107), resulting in
an autoinhibitory feedback mechanism. Thus, knowledge of
FIG. 4. Compartmentalized S-nitrosylation of N-Ras but not K-Ras in antigen-stimulated T cells. The figure represents
the signaling pathways involved in the selective eNOS-dependent S-nitrosylation and activation of N-Ras on the Golgi
complex. Although K- and N-Ras are both farnesylated, K-Ras is targeted to the plasma membrane (PM) by means of a basic
carboxyl-terminal region of amino acids, whereas N-Ras is mainly localized on the Golgi by palmitoylation, co-localizing
with eNOS. Upon TCR binding to antigen (Ag) on an antigen presenting cell (APC), the TCR complex is phosphorylated on
the CD3n chains, which induces the activation of PLC-c and Akt by recruitment of the tyrosine kinase ZAP-70. PLC-c
increases the cytosolic levels of inositol 1,4,5-triphosphate, releasing Ca2 + from internal stores, which in turn can bind
calmodulin-associated eNOS. On the other hand, Akt can phosphorylate eNOS on Ser1177. As a result of the combined
actions of Ca2 + and phosphorylation, eNOS is activated producing NO on the Golgi, fostering N-Ras activation by
S-nitrosylation on Cys118, an amino acid residue shared by K-Ras but which is not S-nitrosylated in T cells due to K-Ras
localization at a different cell compartment.
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S-nitrosylation modification of cardiac function depicts a
complex scenario which still awaits further clarification
through the employment of animal models and corroboration
by clinical settings where this PTM is specifically addressed.
Short-Range S-Nitrosylation Signaling in the Brain
In neurons, NO is produced essentially by neuronal NO
synthase (nNOS), which can be localized in well-defined
neuronal localizations, such as the presynaptic terminal or the
postsynaptic density, where NOproduction can be coupled to
synaptic transmission, either in an anterograde or retrograde
manner. The best characterized signaling molecule coupled
to NO production by nNOS in the brain is the neurotrans-
mitter glutamate. Glutamate is the main excitatory neuro-
transmitter in the central nervous system, and is recognized
by both ionotropic and metabotropic receptors. The calcium-
permeable ionotropic N-methyl-D-aspartate (NMDA) re-
ceptor was shown to be associated to glutamate-induced
calcium-dependent NO production by nNOS in the brain (21,
47). NMDA receptors are also central to neurodevelopment,
synaptic plasticity, and neurodegeneration. Other ionotropic
glutamate receptors have also been involved in these pro-
cesses, such as AMPA receptors. Overactivation of glutamate
receptors often results in excitotoxicity, a phenomenon caused
by excitatory neurotransmitters that cause a rise in the intra-
cellular calcium concentration induced by receptor activation,
which may trigger cell death pathways (2, 41, 84).
NMDA receptor coupling to nNOS by PSD-95:
Implications for neuronal survival
The participation of NMDA receptors in excitotoxic neu-
ronal death has been extensively studied in the last 30 years,
and NO has been shown to be a participant in this complex
cascade of events. Glutamate release by synapses causes an
increase in the intracellular calcium concentration of the
postsynaptic neurons, and this rise in calcium is usually me-
diated by influx through voltage-dependent calcium chan-
nels, influx by calcium-permeable receptors (such as NMDA
or certain types of AMPA receptors) or by reversal of the
sodium–calcium exchanger (10). Activation of NMDA re-
ceptors by glutamate causes an influx of calcium through the
receptor itself that was shown to be linked to the activation of
nNOS and neuronal death (22). Activation of AMPA receptors
was also linked to NO production by nNOS, resulting in
neurotoxicity (6). NOproduced by nNOS following activation
of NMDA receptors was initially shown to mediate the neu-
rotoxicity of glutamate in cultured neurons (34), and a num-
ber of studies later showed that NO produced by nNOS
during a variety of brain insults is responsible, at least par-
tially, for the neuronal damage (for review, see Refs. 2, 7, 24,
27, 78, 84).
NO is produced rapidly following stimulation of NMDA
receptor, which prompted the investigation of whether a
structural proximity between this glutamate receptor and
nNOS existed. The PDZ domains in PSD-95 mediate a struc-
tural interaction between the NMDA receptor NR2 subunits
and nNOS at the postsynaptic density (31), an area that is rich
in anchoring and scaffolding proteins that help in making
synaptic transmission more efficient (Fig. 5). Another study
showed that uncoupling the NMDA receptor from nNOS by
interfering with PSD-95 resulted in loss of the neurotoxic ef-
fect of NO (137), without loss of calcium influx through the
receptor. Peptide inhibitors such as Tat-NR2B9c that disrupt
the coupling of the NR2 subunits of the NMDA receptor and
PSD-95 provoke a loss of NO production following NMDA
receptor activation (1). Such peptide inhibitors contain a se-
quence similar to the C-terminal of NR2 subunits, which
competes with native NMDA receptors and disrupts the in-
teraction of NMDA receptors and PSD-95.
PSD-95 itself presents sites of competing regulation
which control the targeting of PSD-95 to the postsynaptic
density, on Cys3 and Cys5, which can be both regulated by
S-palmitoylation (increases the localization of PSD-95 at
the postsynaptic density) or by S-nitrosylation (reduces the
clustering of PSD-95 on synapses), supporting a model for
regulation of NMDA receptor activation coupled to NO
FIG. 5. Postsynaptic localization of nNOS and S-
nitrosylation signaling in a glutamatergic synapse. Produc-
tion of NO by nNOS following glutamate release is coupled
to activation of Ca2 + -permeable NMDA receptors (NMDAr),
which are anchored at the postsynaptic density by scaffold-
ing proteins, including PSD-95. PSD-95 binds to NMDAr and
nNOS via PDZ domains, allowing for a close proximity of
permeable NMDAr and nNOS. NO produced in close
proximity to NMDA receptors triggers the S-nitrosylation
of NR2A subunits (SNO-NR2A), which then allow less Ca2 +
in. Activation of NMDAr also triggers the recruitment of
more AMPA receptors (AMPAr) towards the membrane
surface. S-Nitrosylation of stargazin (SNO-stargazin) and
NSF (SNO-NSF) contributes to increase the surface expres-
sion of AMPAr during events of synaptic plasticity following
the activation of NMDAr. On the other hand, S-nitrosylation
of PICK1 facilitates its release from AMPAr after membrane
insertion and also facilitates surface expression of AMPAr.
When these proteins are out of range of NO and are not
S-nitrosylated, PICK1 interacts more strongly with the re-
ceptor while NSF interacts more weakly, allowing the
binding of proteins that facilitate endocytosis of AMPAr.
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production via PSD-95, by controlling the postsynaptic lo-
calization of PSD-95 as well (63).
The close proximity of nNOS and the NMDA receptor
via PSD-95 in the postsynaptic density facilitates the regula-
tory effect of NO also on the NMDA receptor itself (29). The
first reports that NO would affect redox modulatory sites of
the NMDA receptor date back to the 1990s (85, 91, 93). It was
then hypothesized that S-nitrosylation would decrease the
permeability of the receptor, as a neuroprotective feedback
mechanism (92) (Fig. 5). Site-directed mutagenesis studies
later identified Cys399 in the NR2A subunit of the NMDA
receptor that may undergo endogenous S-nitrosylation and
thus regulate the ion channel activity, decreasing calcium in-
flux (30, 79). S-Nitrosylation of NR1 subunits may also occur
on Cys744/Cys798 pair, particularly during hypoxia or stroke
conditions (148), which supports a function for S-nitrosylation
of the NMDA receptor as a way to regulate calcium influx
through the receptor and limit neurotoxicity.
Interestingly, it has been known for a long time that nNOS-
positive neurons are relatively resistant to excitotoxic stimuli
and are spared in several neurodegenerative conditions, such
as Alzheimer disease (66) and Huntington disease (HD) (39).
The selective resistance of nNOS-positive striatal interneurons
inHDwas correlatedwith the fact that such neurons probably
have endogenous S-nitrosylation of their NMDA receptors,
thus becoming less permeable to calcium influx and therefore
less likely to degenerate (171). On the other hand, unlike
nNOS-positive interneurons, striatal medium spiny neurons
do not produce NO and are sensitive to excitotoxic damage
and degenerate more easily. This may render the NMDA re-
ceptor in medium spiny neurons more permeable to calcium,
and thus increase their susceptibility to injury. Furthermore,
in a model of HD, it was observed that PSD-95 and nNOS are
less present in association with the synaptic membrane and
the NMDA receptor in striatal neurons (74), which suggests a
decreased coupling between the receptor andNOproduction.
S-Nitrosylation and synaptic plasticity
Synaptic plasticity underlies the formation of new memo-
ries and learning processes. One form of synaptic plasticity
is the insertion of synaptic AMPA receptors in postsynaptic
sites following activation of NMDA receptors. The increase in
AMPA receptors at the synapse makes the synapse respond
with larger excitatory currents upon synaptic stimulation,
thus making the synapse stronger. Several intracellular pro-
teins are involved in the recruitment of AMPA receptors
to the synaptic membrane, and some may be functionally
S-nitrosylated (4, 115, 151).
Upon glutamatergic stimulation, AMPA receptors mediate
the initial membrane depolarization that allows activation of
NMDA receptors. Activation of NMDA receptors triggers a
set of events that result in long-term changes in the number of
AMPA receptors present in the synaptic membrane (98).
Following activation of NMDA receptors, a number of pro-
teins are responsible for regulating the insertion or removal of
AMPA receptors to the membrane. NSF and Protein Inter-
acting with C Kinase (PICK1) are two regulatory proteins that
interact with AMPA receptors and that are sensitive to S-ni-
trosylation (Fig. 5). NSF is important for membrane fusion
during exocytosis and was shown to be S-nitrosylated (65). In
this study, the authors show that S-nitrosylation of Cys91
increases the association of NSF with GluR2-containing
AMPA receptors, thus driving surface expression of AMPA
receptors (65). Nitrosylation of NSF was later shown to allow
unclustering of PICK1 and delivery of AMPA receptors to the
membrane (144). This mechanism may be responsible for
long-term potentiation dependent on activation of the NMDA
receptor. Stargazin is another protein important for regulation
of AMPA receptor surface expression, and physiological S-
nitrosylation of stargazin at Cys302 in the C-terminal tail eli-
cited byNMDA receptor activation was shown to increase the
presence of AMPA receptors at the membrane surface (140)
(Fig. 5). Interestingly, the uncoupling of NMDA-PSD-95 in-
teraction with Tat-NR2B9c was shown to affect plasticity re-
lated to nociceptive signaling (33), but a similar approach was
not yet described for synaptic plasticity. To date, of the many
proteins involved in regulating AMPA receptor surface ex-
pression, only NSF, PICK1, and stargazin were shown to be
functionally modified by S-nitrosylation following NMDA
receptor activation and postsynaptic NO production by
nNOS, but possibly other proteins may also be controlled by
S-nitrosylation with implications for synaptic plasticity.
Conclusions
Protein S-nitrosylation is generally accepted as a nonclas-
sical mechanism of NO signaling. Although the precise
biochemical pathways leading to its formation are not com-
pletely understood, several of the pathways that have been so
far described point out to the hypothesis that thismodification
is mainly localized close to the NO producing foci, which in
FIG. 6. Integration of several factors affecting short-range
S-nitrosylation signaling. The short-range S-nitrosylation
signaling range of action shadowed in gray (see also Fig. 1)
becomes more complex when other factors are included. In
addition to catalyzed RNS formation that could be exerted
by membranes (not shown), some metal proteins are also
catalyzers of S-nitrosylation formation, expanding the range
of action. Transnitrosylases (including Trx) and other LMM
vectors such as GSNO or DNIC can also selectively extend it
to their targets. On the other hand, denitrosylases such as Trx
or GSNOR, limit the influence of S-nitrosylation in certain
areas and/or in certain protein targets.
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mammals are mainly the NOS enzymes. Examples of sub-
cellular compartmentalization of S-nitrosylation signaling
have been described in neurons and cardiac tissue, where
S-nitrosylated proteins with signaling functions co-localize
with the different NOS isoforms. Similarly, in cells such
as endothelial cells or T lymphocytes, eNOS-dependent S-
nitrosylation is observed in proteins localized at the plasma
membrane or on the Golgi, associated to regulated localiza-
tion and activity of eNOS in these compartments.
A simple model of the short-range signaling exerted by
S-nitrosylation in the NOS proximity is illustrated in Figure 1,
where S-nitrosylation signaling is depicted in a limited
spherical space around NOS. However, consideration of
some of the mechanisms involved in S-nitrosothiol forma-
tion and breakage leads to a more complex picture, in which
S-nitrosylation catalyzers (e.g., specific metal centers, mem-
branes) or S-nitrosylation vectors (such as DNIC, transni-
trosylases) could promote the expansion of the S-nitrosylation
range of action, while the presence of denitrosylases could
restrict it (Fig. 6).
Future studies will confirm, modify or even refute this
hypothesis, but we consider that the subcellular localization
of protein S-nitrosylation needs to be taken into account when
the functional role of this modification is studied. This is im-
portant also in proteomic studies that attempt to identify the
S-nitrosoproteome, even though it poses an additional chal-
lenge to current methodologies.
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Abbreviations Used
AD¼Alzheimer disease
b2-AR¼ b2-adrenergic receptor
eNOS¼ endothelial nitric oxide synthase
GAPDH¼ glyceraldehyde-3-phosphate
dehydrogenase
GPCR¼G protein-coupled receptors
GRK¼GPCR kinase
GSH¼ reduced glutathione
GSNO¼ S-nitrosoglutathione
GSNOR¼ S-nitrosoglutathione reductase
Hb¼hemoglobin
HD¼Huntington disease
iNOS¼ inducible nitric oxide synthase
LMM¼ low molecular mass
LPS¼ lipopolysaccharide
LTCC¼L-type Ca2+ channel
nNOS¼neuronal nitric oxide synthase
NO¼nitric oxide
NOS¼nitric oxide synthase
ONOO-¼peroxynitrite
PTM¼post-translational modification
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
RyR¼ ryanodine receptor
SERCA¼ sarcoplasmic/endoplasmic reticulum
Ca2+-activated ATPase
sGC¼ soluble guanylate cyclase
SNO-protein¼ S-nitrosylated protein
TR¼ thioredoxin reductase
Trx¼ thioredoxin
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